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The next generation sequencing technologies have advanced pharmacogenetics by 
enabling rapid assessment of the entire exome or even whole genome for 
associations between variants or gene regions with drug response. Third generation 
sequencing such as nanopore sequencing overcomes the limitations of short read 
sequencing by offering low capital cost and advantages in deciphering complex 
genes, detecting structural variants, and providing accurate haplotypes. The first aim 
of this thesis was to explore nanopore sequencing for pharmacogenetic 
implementation. The second part of this thesis applied genomic technologies to 
investigate genetic and epigenetic contributors to a rare but serious adverse drug 
reaction. 
At the outset of this thesis, a multiplex assay comprising common and rare genetic 
variants attributed to response variability to clopidogrel and warfarin was developed 
and validated on the nanopore sequencing technology. A one-tube multiplex PCR was 
employed to amplify 15 regions containing 27 variants in seven genes. Use of sample 
barcodes enabled inclusion of 84 samples in one sequencing run to provide a cost-
effective assay. With the relatively error-prone state of the nanopore sequencing 
device and chemistry at the time of study, accuracy of variant genotyping relied 
heavily on the choice of bioinformatic tools and was sequence-dependent. Using 
Albacore v2 as the basecalling tool and nanopolish or Clairvoyante as variant calling 
tools, accuracy of ≥90% was achieved for all variants except one. Nanopolish resulted 
in <90% accuracy only for VKORC1 rs9923231 and Clairvoyante resulted in <90% 
only for CYP2C19*2 rs4244285. Accuracy did not improve by increasing read depth. 
This illustrated that it was possible to develop multiplexed, targeted genotyping 
assays on the nanopore platform, although further improvements in the platform 
may be required to obtain optimal accuracy. 
Nanopore sequencing offers great potential for genotyping complex genes such as 
CYP2D6, which is hindered by the very polymorphic nature of the gene, high 
homology with its pseudogene CYP2D7, and the occurrence of structural variants. 
Therefore, a second goal of this PhD was to establish and apply an effective nanopore 
sequencing method for CYP2D6. DNA amplicons encompassing the CYP2D6 gene 
from seven reference samples of known genotype (Coriell Institute, Camden, NJ, 
iv 
 
USA), and 25 clinical samples from adverse drug reaction cohorts were sequenced 
and analysed over two sequencing runs on the nanopore sequencer. All alleles were 
genotyped and all duplicated alleles were determined accurately. In addition, five 
novel variants, one novel allele, CYP2D6*127, and seven novel subvariants were 
identified in this study. Although the method proved efficient and generally effective, 
it was noteworthy that the presence of a hybrid allele CYP2D6*68 in two of the 
reference samples was undetected by this method.  
Although pharmacogenetic studies have been fruitful in elucidating the response 
variability of a large number of drugs, variation in response to many other drugs 
remains unresolved. An example is angioedema induced by angiotensin converting 
enzyme inhibitor (ACEi-A). This potentially fatal reaction occurs in approximately 
three of 1000 individuals taking the drugs. Genome-wide analysis by whole exome 
sequencing was performed for five DNA samples from participants having this ADR 
and whole genome sequencing was performed on another 15 samples. Initial analysis 
on 15 previously reported variants potentially associated with the ADR did not show 
any significant enrichment in the ACEi-A group compared to population allele 
frequency. Analysis on the whole exome and whole genome datasets only resulted in 
one rare coding variant found to be consistently enriched in both datasets, rs4365 in 
ACE, with allele frequency of 40% in the ACEi-A cohort compared to 3% in the 
population. This synonymous variant is predicted to be benign, and the possible 
significance of this variant to ACEi-A is yet to be elucidated. A number of moderately 
enriched variants were identified, however, no single rare variant with minor allele 
frequency of <1% was found in more than seven of the 15 whole genome sequencing 
datasets. Limited CNV analysis on subsets of samples did not find any variant 
affecting candidate genes. Further understanding of the genetic make-up of this rare 
ADR will likely benefit from collection of more cases and application of different 
approaches including analysis of combined effect of multiple variants, analysis of the 
ADR as complex trait, or more comprehensive analysis of structural variants.  
As attempts to find the genetic variants responsible for ACEi-A did not implicate any 
strong candidates; the potential of epigenetic regulation involvement in this ADR was 
explored by investigating the effect of ACEi on DNA methylation in clinical samples 
and cell culture model. Analysis of existing methylation array data from patient 
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samples with and without ACEi consumption showed a putative differentially 
methylated CpG site on chromosome 10. However, this was not validated in the in 
vitro experiment. Methylation array data from the cell culture experiment resulted in 
several potential CpG sites showing differential methylation, however none of these 
was validated using bisulfite amplicon sequencing. Overall, this work showed little 
evidence of effect of ACEi on DNA methylation, and it seems unlikely that DNA 
methylation change by ACEi is involved in the association of angioedema with the 
drug.  
The work in this thesis applied various approaches and technologies to advance 
knowledge in pharmacogenetics. Nanopore sequencing was shown to be beneficial 
for pharmacogenetic applications and with the continual improvement in accuracy, 
this technology will continue to be a valuable tool, especially in elucidating complex 
structural variants and providing accurate haplotype information. Short read 
sequencing technologies for whole exome or whole genome sequencing are useful 
for interrogation of rare variants; however other approaches might be needed to 
elucidate the basis of potentially complex phenotypes such as ADR. Lastly, studies of 
epigenetic regulation in pharmacogenetics are still limited, and the potential role of 
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Chapter 1 : Introduction 
1.1 Pharmacogenetics/pharmacogenomics 
“Pharmacogenetics” refers to the contribution of genetic factors to variability in drug 
response. It is often used interchangeably with “pharmacogenomics”, which refers to 
genome-wide information (Daly, 2017). Genetic factors associated with drug 
response can affect proteins involved in the absorption, distribution, metabolism, 
and excretion (ADME) of drugs (pharmacokinetics), or drug targets 
(pharmacodynamics) (Roden et al., 2019). 
1.1.1 A brief historical review 
The first studies of modern pharmacogenetics occurred in the 1950s (Meyer, 2004). 
However, the notion of inter-individual differences in response to exogenous 
substances can be traced back to when Pythagoras in 510 B.C. observed that 
ingestion of fava beans induced adverse effects in certain individuals (Nebert, 1999). 
Although the term pharmacogenetics was first coined by Vogel (Vogel, 1959), Arno 
Motulsky is known as the “father of pharmacogenetics”. Motulsky wrote a seminal 
paper in late 1957 recognising the genetic traits of adverse drug reactions (ADR) 
based on several key findings in the earlier years of the decade (Motulsky, 1957). The 
anti-malarial drug primaquine induced acute haemolytic anaemia in a substantial 
proportion of African American soldiers during World War II, but rarely in 
Caucasians (Hockwald et al., 1952). This ADR was later shown to be caused by 
deficiency in glucose-6-phosphate dehydrogenase (G6PD) enzyme activity (Carson 
et al., 1956), which is now known to be caused by variants in the polymorphic G6PD 
gene (Meyer, 2004). Another ADR recognised in that period was prolonged apnoea 
associated with the adjunctive anaesthetic drug succinylcholine (Lehmann & Ryan, 
1956). This ADR was found to be caused by pseudocholinesterase deficiency due to 
variation in the BCHE gene (Kalow & Staron, 1957). Another important 
pharmacogenetics example was the observation of a biomodal pattern in the 
metabolism of isoniazid, an anti-mycobacterium drug, where individuals either 
presented as rapid or slow inactivators of the drug (Evans et al., 1960). This 
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difference in isoniazid acetylation was later found to be associated with genetic 
polymorphism in the N-acetyltransferase (NAT2) gene (Vatsis et al., 1991).  
Following this early period, the pharmacogenetics field advanced further with the 
discovery of several drug metabolising enzymes including the cytochrome P450 
(CYP) monooxygenase in the 1970s to 1980s. Two separate studies in the 1970s 
found that a small proportion of individuals lacked the ability to metabolise 
debrisoquine and sparteine, referred to then as “non-metabolisers”, and through 
family studies, this condition was found to be inherited in an autosomal recessive 
manner (Eichelbaum et al., 1979; Mahgoub et al., 1977). The gene responsible in this 
case was CYP2D6, one of the many members of the CYP enzyme family. 
1.1.2 Cytochrome P450 metabolising enzymes 
The discovery and characterisation of CYP2D6 was followed by identification of other 
important drug metabolising enzymes in this family, including CYP2C19, associated 
with metabolism of mephenytoin and omeprazole (De Morais et al., 1994) and 
CYP2C9 with warfarin and phenytoin (Miners & Birkett, 1998). 
Variability in drug metabolism resulting from variation in CYP genes is one of the 
most widely studied areas of pharmacogenetics (Daly, 2017). The CYP enzyme 
superfamily is grouped into 18 families and 44 subfamilies, with enzymes in the 
CYP1, 2, and 3 families mainly responsible for drug metabolism. CYP3A4/5, CYP2D6, 
CYP2C9, and CYP2C19 are the main enzymes, responsible for metabolism of 
approximately 70% of all drugs (Zanger & Schwab, 2013). Heritable genetic 
polymorphisms leading to diminished or amplified activities of these enzymes are 
present at variable frequencies among different ethnicity groups (Meyer, 2004). 
Known genetic variants in the CYP genes are curated in the PharmVar database 
(www.pharmvar.org) using the star (*) allele nomenclature to define haplotypes. 
Each haplotype is designated by an asterisk (*) followed by a number, and can be 
defined by one or more genetic variants. Assignation of a new star (*) allele requires 
that the haplotype contains at least one nucleotide change (core variant) that affects 
protein structure or function. Some haplotypes share the same core variants but have 
different additional non-functional variations; these are designated as subvariants 
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under the same star (*) alleles (indicated by additional numbering, e.g. *1.002) 
(Gaedigk et al., 2018b). 
The impact of genetic variants in CYP genes depends on the pharmacological context. 
For prodrugs requiring metabolism to their active form, loss of function variants 
result in inadequate bioavailability of the drug and lack of efficacy. In contrast, for 
active drugs, loss of function variants can result in toxic plasma levels and adverse 
reactions (Zanger & Schwab, 2013). The effect of gain of function variants is the 
opposite.  
Common variants in CYP genes have been well-characterised (Gaedigk et al., 2018b) 
and their impacts on the functionality of the enzymes are well understood (Relling & 
Klein, 2011; Whirl-Carrillo et al., 2012). However, common variants are likely to only 
explain a proportion of the variability observed in enzyme activity (Tracy et al., 2016) 
or drug response (Shuldiner et al., 2009), highlighting the significance of rare 
variants (Gordon et al., 2014) or other genetic regulation such as epigenetic 
modification (Fisel et al., 2016) in these genes. In addition, the presence of structural 
variants (SV), gene deletions and duplication is common for CYP2D6, contributing 
greatly to the enzyme activity and making full analysis of the gene notoriously 
difficult. Although less prominent than CYP2D6, recent reports showed that other 
CYP genes might also be affected by SV (Botton et al., 2019; Santos et al., 2018).   
1.1.3  Clinical implementation of pharmacogenetics 
In addition to metabolising enzymes, variations affecting drug response have been 
found in many other genes. Several important early pharmacogenetic findings 
included the discovery of polymorphisms in TPMT in association with the toxicity of 
thiopurine drugs such as azathioprine, mercaptopurine or thioguanine, and the effect 
of polymorphisms in UGT1A1 on response to irinotecan (Meyer, 2004).  
Azathioprine (prodrug of mercaptopurine), mercaptopurine and thioguanine share 
similar pharmacologic action and are used for autoimmune diseases, leukaemia, and 
lymphoma (Liu et al., 2017). These drugs are metabolised by the TPMT enzyme to 
inactive metabolites, limiting the amount of parent drug to be converted into 
thioguanine nucleotides, the active compound. Genetic variations in the TPMT gene 
resulting in diminished enzyme function are therefore associated with higher 
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concentration of the toxic thioguanine nucleotides and can cause serious adverse 
effects (Relling et al., 2019). Association of TPMT with response to thiopurine drugs 
is regarded as one of the actionable pharmacogenetic tests, and testing for genetic 
variation or enzyme activity of TPMT is recommended and routinely performed in 
service laboratories before administration of the related drugs (Weitzel et al., 2018). 
Irinotecan is an anticancer drug used for many solid tumours. The active compound 
of irinotecan, SN-38, is inactivated by glucuronidation by UGT1A1. The UGT1A1 gene 
is highly polymorphic with more than 100 genetic variants. UGT1A1*28, the most 
common variant in Caucasians with minor allele frequency (MAF) of ~30%, reduces 
the enzyme expression by 70%. Individuals having this variant will therefore have 
increased exposure to SN-38 and higher risk of adverse reaction at a normal dose of 
irinotecan (de Man et al., 2018). Various regulatory bodies including the United 
States Food and Drug Administration (FDA) and Health Canada annotate this 
association as an actionable pharmacogenetic test, and the Japanese Pharmaceuticals 
and Medical Devices Agency recommends testing for the UGT1A1 variant before 
irinotecan administration (PharmGKB) (Whirl-Carrillo et al., 2012). However, testing 
for the UGT1A1 variant has not been routine, possibly due to the lack of prospective 
studies evaluating clinical benefits (de Man et al., 2018). 
Currently, approximately 600 drugs have been associated with at least one genetic 
variant in the pharmacogenomics knowledge base (PharmGKB), more than 100 of 
which have a high level of evidence (1A or 1B). More than 200 drug-gene annotations 
have also been labelled as “actionable pharmacogenetics”, “testing required”, or 
“testing recommended” by the FDA. This includes association of genetic variants in 
CYP2C19 with clopidogrel response, CYP2D6 with codeine response, and CYP2C9 and 
VKORC1 with warfarin response (https://www.pharmgkb.org/) (Whirl-Carrillo et 
al., 2012). Moreover, the Clinical Pharmacogenetic Implementation Consortium 
(CPIC) has published more than 20 clinical guidelines aiming to progress the 
implementation of pharmacogenetics in clinical practice 
(https://www.cpiccpgx.org) (Relling & Klein, 2011).  
Curation of pharmacogenetic evidence and availability of guidelines to interpret 
genetic results and direct actions, as available from PharmGKB and CPIC are essential 
in translation of pharmacogenetics into clinical practice (Roden et al., 2019). 
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Although several pharmacogenetic examples have been implemented in clinics such 
as in the case of TPMT, routine implementation of most pharmacogenetic tests still 
faces many barriers. These barriers include the genetic information itself, such as the 
complexity of some genes (CYP2D6, HLA), the presence of rare variants or novel 
variants of unknown function, and in some cases the lack of tools that offer rapid 
turnaround for clinical utility.  Other hurdles recognised are the lack of integration of 
genetic information into health records, unfamiliarity or lack of expertise of 
healthcare providers in interpreting and acting on the pharmacogenetic information, 
as well as economic considerations (Luzum et al., 2017; Roden et al., 2019). 
The CYP2D6 enzyme is responsible for the metabolism of many drugs and the 
CYP2D6 gene is highly polymorphic, contributing to the variability in enzyme activity 
(Gaedigk, 2013). However, implementation of CYP2D6 genotyping in clinical practice 
has been slow, partly due to the challenges in accurate genotyping of the gene. For 
example, in individuals with CYP2D6 heterozygous genotypes together with a gene 
duplication, most assays are not able to identify the duplicated allele and/or the 
number of copies, resulting in ambiguous phenotype assignment (Cavallari et al., 
2019).  
Moreover, most commercially available pharmacogenetic assays only detect 
common variants, while accumulating evidence has pointed out the significance of 
rare variants (Ingelman-Sundberg et al., 2018; Kozyra et al., 2017; Wright et al., 
2018). Studying 146 clinically relevant pharmacogenes in the 1000 Genomes and 
Exome Sequencing Project database, one study found that approximately 92.9% of 
the variation in these genes was rare with a MAF of less than 1%, and these rare 
variants contributed to 30-40% variability in the gene functions (Kozyra et al., 2017). 
This was replicated in another study of 120 pharmacogenes in the 1000 Genomes 
database, also showing that 90% of genetic variants in these genes had MAF of less 
than 0.5% and approximately half of the variants were singletons (Wright et al., 
2018). More importantly, this study showed that 97% of individuals had at least one 
variant with pharmacogenetic relevance (Wright et al., 2018). A report examining 
rare variants in 208 pharmacogenes from more than 60,000 WES datasets showed 
that these rare variants contribute to a significant proportion of unexplained genetic 
variability in drug response. For example, up to 2% of CYP2C9 alleles were reported 
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to have rare variants that disrupt the enzyme function and explain ~18% of the 
genetic variability in CYP2C9 enzyme activity. Also, up to 40% of the deleterious 
variants in ABCC1, the drug transporter gene associated with irinotecan response, 
were rare variants (Ingelman-Sundberg et al., 2018). Notably, variants that are 
considerably rare in one population might be common in others. For example 
CYP2D6*29 is very rare in most populations with MAF <0.1%, but is present in 
African with MAF of 9% (Lauschke et al., 2017). The significance of these rare 
variants highlights the advantage of genome sequencing methods able to detect all 
possible variants.  
1.2 Genomic technologies in pharmacogenetics 
In this section, I will introduce and briefly summarise genomic technologies applied 
during this PhD thesis research. 
As in other fields of genetic medicine, pharmacogenetic studies have been advanced 
by the completion of the human genome project and the introduction of various 
genomic technologies in the past two decades. These days, extensive interrogation 
into the almost entire human DNA sequences, RNA transcriptomes, and epigenetic 
regulations such as DNA methylation has been made possible, in both research and 
clinical settings (Ji et al., 2018).  
Termination chain sequencing or Sanger sequencing, named after the person who 
invented the method (Sanger et al., 1977), has been a key technology in unravelling 
the human genome. A typical modern Sanger sequencing reaction involves DNA 
subjected to polymerase chain reaction (PCR) using dideoxynucleoside 
triphosphates that lack the 3’-hydroxyl group, and cause termination in the cycle 
reaction. Each type of dideoxynucleoside (ddCTP, ddGTP, ddATP, ddTTP) is labelled 
with distinct fluorescent labels. The results are DNA fragments of different length and 
fluorescent labels in the 3’-ends representing each base of a particular DNA sequence. 
Electrophoresis through hair-thin capillaries separates these fragments based on 
size, and a detector reads the fluorescent labels to provide the DNA sequences. The 
high accuracy makes this a long-standing gold standard method which also enabled 
the completion of the human genome project (International Human Genome 
Sequencing Consortium, 2004).  
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However, the human genome project took more than 10 years and millions of dollars 
to complete and it was evident that faster and cheaper methods would be necessary 
to advance genomic research. Various sequencing and non-sequencing methods have 
since been developed. 
1.2.1 SNP array technology and genome wide association study 
Before the completion of the human genome project, a non-sequencing method to 
interrogate hundreds of single nucleotide polymorphisms (SNPs) using a small chip 
was introduced (Wang et al., 1998). This technology has evolved since, and currently 
SNP array technology is capable of detecting millions of SNPs in multiple samples on 
a single chip (Huang & Lin, 2017). Currently, Affymetrix (now ThermoFisher 
Scientific) and Illumina are the main companies producing commonly used SNP 
arrays. The Affymetrix assay applies probes for both alleles of a given SNP. Target 
DNA from a sample will bind to both probes, but more efficiently when the sequence 
is fully complementary to the probe, resulting in higher signal for the given allele. The 
Illumina SNP array relies on single locus-specific probes with sequences 
complementary to the region adjacent to a given SNP. Target DNA hybridises to the 
probes and single base extension with differently labelled nucleotides takes place at 
the SNP site. The hybridised nucleotide will be complementary to the allele present 





Figure 1.1 Principle of SNP array 
(A) Alleles present in the sample, (B) Principle of Affymetrix chip array, (C) Principle 
of Illumina chip array. Figure is reproduced with permission from (Lindgren et al., 
2011). 
 
Since SNP arrays are a relatively affordable method to detect millions of SNPs, this 
technology has been widely used in genome wide association studies (GWAS) to find 
SNPs associated with a certain phenotype, a disease or response to medication. The 
first GWAS study was published in 2002, and reported an association between two 
variants in the lymphotoxin alpha gene, rs909253 and rs1041981, with myocardial 
infarction (Ikegawa, 2012; Ozaki et al., 2002). Several key findings relevant to 
pharmacogenetics discovered or confirmed through GWAS have been reviewed 
(Motsinger-Reif et al., 2013). Among these are associations between clopidogrel 
response and SNPs in the CYP2C19 loci (Shuldiner et al., 2009) and warfarin response 
and SNPs in CYP2C9, VKORC1, and CYP4F2 (Takeuchi et al., 2009). Currently the 
GWAS catalogue (www.ebi.ac.uk/gwas/, accessed 6 December 2019) contains 335 
SNPs associated with “response to drugs”.  
GWAS is advantageous in pharmacogenetics as family or pedigree studies are less 
feasible. Unlike hereditary diseases, where affected individuals in families are easily 
recognised, in a pharmacogenetic study, other family members are less likely to take 
the same medication (Motsinger-Reif et al., 2013). However, one disadvantage of 
GWAS is that SNP arrays usually only include common variants (MAF >1%) and any 
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pharmacogenetic traits with rare causative variants might be missed. Therefore, 
sequencing methods that detect rare as well as common variants are also of value. 
1.2.2 Next generation sequencing 
In the world of sequencing technologies, two papers in 2005 marked the new era of 
next generation sequencing (NGS). Using clonal amplification to parallelise millions 
of reactions in droplets of emulsion combined with sequencing by synthesis based 
on the pyrosequencing method, Margulies et al. introduced the method with the 454 
sequencing instrument, the first NGS machine on the market (Margulies et al., 2005). 
In this paper, 25 megabases (Mb) were sequenced in four hours. In the second paper, 
mate-paired DNA libraries were amplified using emulsion based amplification and 
sequenced by ligation and four-colour imaging to generate 400 basepair (bp) of 
sequence information per second (Shendure et al., 2005).  
Following the 454 sequencer, several NGS technologies entered the market, including 
the Solexa/Illumina sequencing by synthesis platform in 2006, the sequencing by 
oligo ligation detection (SOLiD) by Applied Biosystems (now ThermoFisher 
Scientific) in 2007, and the Personal Genome Machine (PGM) by Ion Torrent (now 
ThermoFisher Scientific) based on hydrogen ion release of pyrosequencing 
reactions, in 2010. All these technologies share the characteristics of massively 
parallel sequencing of short fragments (~100-400 bp) which are the key features of 
second generation sequencing (van Dijk et al., 2014). 454 and SOLiD sequencers have 
since been discontinued and current short read sequencing technologies in the 
market are dominated by Illumina, and to a lesser extent, Ion Torrent technologies. 
These two sequencing platforms were used in this thesis and thus will be briefly 
described.  
Illumina currently offers a range of instruments from the small benchtop iSeq 100 to 
the highest throughput NovaSeq 6000 system. The maximum output of the iSeq 100 
is 1.2 gigabases (Gb) with maximum 4 million reads/run while NovaSeq can generate 
up to 6000 Gb data with 20 billion reads/run (Illumina, 2019b). All these instruments 
rely on the core reversible terminator-based sequencing by synthesis chemistry. The 
DNA sample is randomly fragmented and ligated with adapters at the 5’-and 3’- ends. 
These adapters facilitate the immobilisation of the fragmented DNA by 
10 
 
complementary binding to surface-bound oligo in the flow cell. Here, amplification 
occurs through bridge amplification to generate clusters of identical fragments. The 
DNA sequences are decoded by adding reversible terminator-bound 
deoxyribonucleoside triphosphate (dNTP), primers and DNA polymerase. In each 
sequencing cycle, only one nucleoside is incorporated into the DNA template and a 
digital image is captured. After elimination of the fluorescent-labelled terminator, the 
cycle is repeated (Buermans & den Dunnen, 2014). The images in each cluster are 
translated to DNA sequences (Figure 1.2). This method is accurate, with an error rate 
of 0.1% per nucleotide (Pfeiffer et al., 2018). 
The Ion Torrent sequencing technology also has a range of instruments with various 
throughput capacities: Ion Personal Genome Machine (PGM) system, Ion Proton 
System and Ion GeneStudio system, with throughput from 100 Mb up to 50 Gb, 
depending on the Ion Chip used (www.thermofisher.com). This platform applies 
semiconductor sequencing based on the observation that when DNA polymerase 
incorporates a nucleotide into a strand of DNA, a hydrogen ion is released. The 
hydrogen ion changes the pH of the solution, which is detected by a sensor and 
converted to a voltage signal. Incorporating one known nucleotide at a time (A, G, T, 
or C), the captured signal can be confidently converted into DNA base information 
(Figure 1.3). This method is capable of sequencing longer fragments of DNA (~200 
to 400 bp) and is generally faster than the Illumina technology (Heather & Chain, 
2016). However, the accuracy is compromised when sequencing homopolymer 
strings because the pH change is not completely proportional to the number of 




Figure 1.2 Principle of sequencing by synthesis NGS technology by Illumina 
 
Figure shows (A) template preparation by bridge PCR, and (B) sequencing by synthesis 
and reversible termination reaction. Figure is reproduced with permission from 





Figure 1.3 Principle of semiconductor sequencing by Ion Torrent 
 
Figure shows (A) template preparation by emulsion PCR, and (B) semiconductor 
sequencing. Figure is reproduced with permission from (Goodwin et al., 2016). 
 
1.2.3 Applications of NGS in pharmacogenetics 
NGS technologies have empowered many applications of genomic research including 
pharmacogenetics. Sequencing hundreds of genes through targeted sequencing, 
entire coding regions through whole exome sequencing (WES), and the majority of 
the genome through whole genome sequencing (WGS) are approaches that are all 
now readily available at an ever-decreasing cost.  
Targeted sequencing of genes with well-established pharmacogenetic associations, 
such as genes associated with variability in drug pharmacokinetics or 
pharmacodynamics, is a cost-effective way to detect pharmacogenetic related 
variants, including rare variants. An NGS-based panel of 340 pharmacogenetic 
related genes including coding and adjacent non-coding regions on 150 samples 
uncovered more than 7,000 rare variants with one third of them predicted to be 
affecting protein function (Klein et al., 2019). Another study developed a panel of 100 
pharmacogenes in more than 200 subjects, and reported close to 80% of the subjects 
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had at least one variant affecting medication response (Gulilat et al., 2019). This type 
of application of NGS in pharmacogenetics has been predicted to be most readily 
translated into clinical practice (Giannopoulou et al., 2019). 
Targeting only the coding parts of the genes representing ~3% of the genome, WES 
allows for a focused and cost-effective way to explore variants for uncharacterised 
variability in drug response (Suwinski et al., 2019). Application of WES has been 
beneficial in rare diseases, providing a diagnosis in approximately 25% of the cases, 
and many of the variants found were noted to be novel rare variants (Hartman et al., 
2019; Yang et al., 2014). Some success stories of WES in pharmacogenomics have also 
been reported. A study of 65 drug-induced long QT syndrome cases found rare 
variants in two genes as risk factors for the ADR (Weeke et al., 2014). In addition, 
WES of only eight patients succeeded in finding rare variants in CYP3A4 responsible 
for paclitaxel-induced neuropathy in the Spanish population (Apellániz-Ruiz et al., 
2015). Similarly, WES performed on extreme responders with high and low on-
treatment platelet reactivity on clopidogrel found a novel variant in B4GALT2 gene 
associated with low platelet reactivity (Scott et al., 2016).  
Although WES is very powerful in screening for potentially functional variants, it has 
some recognised limitations. Some important pharmacogenetic variants lie in the 
non-exonic regions; for example, CYP2C19*17 and VKORC1 rs9923231 are located in 
the regulatory regions of the respective genes, and would likely be missed by WES 
(Londin et al., 2014). Use of WGS is therefore required to enable detection of such 
non-exonic variants.  WGS also provides more even coverage of exonic regions than 
WES, as no capture or amplification step is involved. The uniformity in coverage of 
WGS makes it a better tool to evaluate SV such as copy number variants (CNV) 
(Gilissen et al., 2014). However, the vast amount of data generated by WGS does 
create challenges in bioinformatic analysis and data storage (Schwarz et al., 2019).   
Several WGS applications in pharmacogenomics research have been reported. A WGS 
study of 482 individuals focussing on drug ADME and toxicity related genes (n=231) 
found 1012 novel variants in genes predicted to disrupt protein function (Mizzi et al., 
2014).  Another study also utilised WGS to find potentially causative variants in 
linkage disequilibrium to known variants in a range of pharmacogenes (Choi et al., 
2019). The largest WGS study assessing pharmacogenomics to date was in a cohort 
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of 1441 children with asthma, and it reported several variants associated at genome-
wide significance with extreme responders to a bronchodilator medication (Mak et 
al., 2018).  
Short read sequencing has advanced genomic studies in the last two decades; 
however, there are some limitations to this technology. Although variant detection is 
highly reliable in most genomic regions (Laurie et al., 2016), accurate variant 
detection is challenging in regions with high homology, such as when pseudogenes 
are present, or in complex gene regions such as the human leukocyte antigen (HLA) 
locus (Schwarz et al., 2019). Approximately 10% of the human genome is inaccessible 
using this technology (Laurie et al., 2016). This includes regions with high GC content 
and low complexity/simple repeats (Drögemöller et al., 2013). Variant phasing to 
determine haplotype is also challenging using this technology and is usually done 
through computational methods (Snyder et al., 2015). In addition, as NGS relies on 
DNA amplification, this technology cannot directly detect base modifications such as 
DNA methylation (Li et al., 2018). 
In recent years, new sequencing technologies that use entirely different approaches 
to massively parallel sequencing have been developed, referred to as third 
generation sequencing. These new technologies are characterised by long read, real 
time sequencing, without the need for PCR amplification.  
1.2.4 Third generation sequencing (long read sequencing) 
Two major third generation sequencing technologies are currently in the market, 
single molecule real-time (SMRT) sequencing from PacBio Biosciences and nanopore 
sequencing from Oxford Nanopore Technologies (ONT). These technologies offer 
several advantages over previous short read sequencing. With the ability to sequence 
longer DNA molecules, they have potential to overcome the limitations of short read 
sequencing in regions with simple repeats or high homology with other regions. This 
long read capability also enables other previously challenging tasks, such as de novo 
assembly, SV detection, and direct variant phasing. Lastly, sequencing raw DNA/RNA 
strands without amplification opens the opportunity to assess base modification 
such as DNA methylation. 
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Nanopore sequencing technology comes in a unique, portable and highly accessible 
platform. In this thesis, nanopore sequencing technology was explored for 
application in pharmacogenetics and hence will be further described in the next 
sections. 
1.3 Nanopore sequencing  
1.3.1 History of nanopore sequencing 
David Deamer first sketched the concept of nanopore sequencing in his notebook in 
the late 1980s. The note showed a DNA strand being pulled through a pore embedded 
in an electrically charged membrane, and as each base has different properties, it 
disrupts the electric current corresponding to each base, and this signal could be 
translated into base sequence (Deamer et al., 2016) (Figure 1.4). This hypothetical 
concept came into reality after more than two decades of development (Deamer et 
al., 2016). 
 
Figure 1.4  First sketch of the concept of nanopore sequencing 
The sketch by David Deamer dated back in 1989 showed three nucleotides being pulled 
through a pore by electrical voltage and the hypothetical current change induced by 




First trials of nanopore sequencing were done on wild-type α-hemolysin, a pore 
formed by a toxin of Staphylococcus aureus. This pore has a small diameter of 
approximately 2 nm as confirmed by its crystal structure (Song et al., 1996), which is 
suitable to accommodate only a single strand of nucleic acid. Initial experiments 
using pores in a lipid membrane separating two buffer-containing chambers, showed 
promising results. RNA homopolymer - in this case polyuridylic acid (poly[U]) was 
chosen as it had minimal secondary structure . When put in the cis side of the 
membrane, with a positive charge applied to the trans side, depending on the length 
of the polymer, this resulted in a current blockage by 85-100% that lasted for micro 
to milliseconds. Application of other homopolymers, poly[A], poly[C], poly[dT], and 
poly[dC] and synthetic DNA strand also disrupted the current in a similar time scale. 
By using a mixture of single-stranded and double-stranded DNA, this study also 
confirmed that the narrow size of α-hemolysin only passed a single strand DNA, with 
double-stranded DNA remaining on the cis side of the pore (Kasianowicz et al., 1996). 
Further study using an oligomer consisting of 70% cytosine followed by 30% adenine 
demonstrated that the two nucleotides resulted in a different degree of blockage.  
Adenine, a purine, produced a typical 85% blockage, while cytosine, a pyrimidine, 
resulted in a greater blockage of 95%, as well as moving through the pore six times 
faster than adenine. It was surprising that cytosine, being a smaller molecule than 
adenine, would cause greater signal disruption. It appeared that poly[C] passed 
through the pore as a helix which had a greater diameter than poly [A] which exists 
as an extended form (Akeson et al., 1999).  
The feasibility of nanopore sequencing to differentiate DNA nucleotides down to 
single base resolution remained unknown until 2005. A single adenine nucleotide 
inside a strand of poly d(C) could be identified with single base resolution by 
immobilising the DNA strand inside the α-hemolysin pore (Ashkenasy et al., 2005). 
This success was replicated by other reports showing that all four DNA bases could 
be differentiated in an immobilised DNA strand (Stoddart et al., 2010; Stoddart et al., 
2009). 
Despite these early promising results, nanopore sequencing of free flowing DNA 
strands proved challenging, with two main problems identified. First, without 
immobilisation, even the smallest voltage will stream the DNA strand through the 
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pore too fast, so that each base only resided in the detection region of the pore in 1-
10 microseconds time-scale, which was too rapid to achieve the necessary signal to 
noise ratio (Deamer et al., 2016). Strategies to slow down the transport of DNA across 
the pore were later developed, one of which was binding DNA to an enzyme such as 
phi29 DNA polymerase and a blocking polymer. The blocking polymer prevented the 
activation of the phi29 until the complex was captured by nanopores. Upon capture 
by a nanopore, the DNA strand was ratcheted through the pores. This strategy 
enabled sequencing up to 500 DNA molecules through individual nanopores with one 
nucleotide spatial precision (Cherf et al., 2012). 
The other problem lay in the pore itself. Although the diameter of wild-type α-
hemolysin was small enough to allow passage of only single stranded DNA, the 5 nm 
sensing region of this pore accommodated ~12 nucleobases at a time, making signal 
interpretation complicated, because each signal disruption could be attributed to 12 
nucleobases (Deamer et al., 2016). Another nanopore, MspA from Mycobacterium 
smegmatis, with a similar diameter as α-hemolysin, but a sensing region ≤0.6 nm was 
proposed as an alternative. Wild-type MspA could not capture DNA, but modifying 
the pore by replacing negatively charged amino acids with neutral or positively 
charged amino acids allowed it to translocate and characterise DNA molecules 
(Butler et al., 2008).  Combining phi29 and modified MspA, Manrao et al. showed 
these two solutions enabled nanopore sequencing with single nucleotide resolution 
(Manrao et al., 2012).  
1.3.2 Oxford Nanopore Technologies 
Along with the advances of nanopore sequencing technologies in the academic area, 
a spinoff of University of Oxford, ONT, introduced the first commercial nanopore 
sequencing device at Genome Biology and Technology (AGBT) conference in Florida 
in 2012. In April 2014 this device, in the form of a portable sequencer called MinION 
(ONT, Oxford, UK), was available to the research community via the MinION Access 
Program and it became commercially available in May 2015. The MinION is a pocket-
size, portable sequencing device with a flow cell containing 2048 individual pores, 
which can be run by a laptop computer. The high throughput instrument with 48 flow 
cells, PromethION was introduced in 2016, and a benchtop instrument with five flow 
cells and an integrated computer, GridION X5, was introduced in 2017. PromethION 
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has its own type of flow cell, each containing 6000 nanopores, while the GridION uses 
the same flow cell as MinION (Loose, 2017). A mini flow cell, the Flongle, with a price 
of one tenth of the MinION flow cell, was released in 2019. Application of nanopore 
sequencing in pharmacogenetics in this thesis used both MinION and GridION 
platforms (Figure 1.5).  
 
Figure 1.5 The MinION and GridION sequencing platforms 
Figure shows (A) the MinION device with the size that fits in the palm of a hand, 
containing 2048 individual pores in the flow cell, and (B) the GridION sequencer, a 
benchtop platform with capacity for five flow cells, each containing 2048 pores. Figures 
are reproduced from (Lu et al., 2016b) and (ONT, 2019a). 
1.3.3 Principle of ONT nanopore sequencing 
In every sequencing run of MinION or GridION, the MinKNOW software chooses the 
best group of 512 pores to be used, enabling thousands of DNA or RNA strands to be 
sequenced every second. An adapter mix is added to the DNA fragments during 
library preparation. The Y-shaped adapter guides DNA to the pore, and the motor 
protein separates the double stranded DNA and aids streaming of single stranded 
DNA into the pore. The motor protein is essential in controlling the speed of the DNA 
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passing through the pore. As a DNA/RNA strand goes through the pore, current 
deflection takes place which is unique to each base (or groups of bases), and the 
signal is subsequently converted into sequences of DNA or RNA in real time using an 
ONT proprietary algorithm (Lu et al., 2016b) (Figure 1.6). 
Because of this unique reading method, compared with earlier NGS technologies that 
are based on sequencing-by-synthesis or sequencing-by-amplification, nanopore 
sequencing is not limited by the length of DNA. In fact, length of the sequencing reads 
generated is limited only by the length of DNA presented to the pore, and therefore 
depends on the preparation of the DNA rather than the sequencing itself (Jain et al., 
2018). Moreover, compared to other third generation long read sequencers, it offers 
the advantage of portability and almost-zero capital setup costs, with the potential to 
detect methylation, haplotypes, and structural variation (Laver 2015). 
 
Figure 1.6 Principle of ONT nanopore sequencing 
Figure shows (a) nanopore embedded in membrane with ion flow and DNA strand with 
motor protein ligated onto it, (b) motor protein attaches to pores, opens up double 
stranded DNA and streams single stranded DNA into the pores, (c) DNA disrupts the ion 
flow, which generated signals that are recorded to be later translated into DNA 
sequences. Figure is reproduced with permission from (Leggett & Clark, 2017). 
 
1.3.4 Development of ONT sequencing chemistries and flow cells 
ONT sequencing chemistries and devices (flow cells) have been developed 
continuously since they were first launched. Initially, two sequencing chemistries 
were available from ONT, one-directional (1D) and two-directional (2D). As reflected 
by the names, 1D sequencing chemistry sequences only one strand of the DNA, while 
2D sequencing chemistry sequences both the template and complementary strands, 
with the information combined to generate a consensus read. 2D sequencing was 
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achieved by ligating an additional adapter called the hairpin adapter to one end of 
the DNA. A motor protein at the other end drives the template strand through the 
pore until it reaches the hairpin adaptor which then allows the complement strand 
to be pulled through the pore (Jain et al., 2016) (Figure 1.7).  
 
Figure 1.7 ONT 2D sequencing 
Steps of 2D sequencing. (i) open channel, (ii) dsDNA with lead adaptor and hairpin 
adaptor is capture by the pore, (iii) translocation of lead adaptor, followed by (iv) 
template strand, (v) hairpin adaptor, (vi) complement strand and (vii) trailing adaptor. 
(viii) back to open channel. Figure is reproduced with permission from (Jain et al., 
2015). 
 
In general, 2D chemistry offered a more accurate sequencing compared to 1D (Figure 
1.8). The application of nanopore sequencing in this thesis (Chapter 3) was initiated 
using 2D chemistry. In May 2017, 2D chemistry was discontinued and a new 
chemistry enabling two-directional sequencing, 1D2 was introduced. This new 
chemistry was developed for long genomic DNA sequencing and was not compatible 
with amplicon sequencing nor sample barcoding used in this thesis. The 1D 
chemistry, although less accurate, has advantages in simpler library preparation, 





Figure 1.8 Accuracy of 1D vs 2D chemistry  
Figure shows higher accuracy of the 2D chemistry (~95%) compared to 1D (~85%) 
using the R9 flow cell. Figure is reproduced from (ONT, 2016).  
 
The main challenge faced by nanopore sequencing is the accuracy of the generated 
DNA sequence. With the discontinuation of 2D sequencing chemistry, the lower 
accuracy of 1D chemistry has been improved by the development of better flow cells 
and bioinformatic tools.  
The flow cells, which contain a membrane with embedded nanopores, have also been 
updated progressively. The first version available to members of the MinION Access 
Program in 2014 was R6. It was then updated successively to R7, R9, and the latest 
R10 (released in September 2019). The accuracy has improved with each flow cell 
update (Figure 1.9). Moreover, the sequencing speed has also been improved, 
currently at 450 bp/second (Jain et al., 2018). Information on the types of pores used 
in earlier R6 and R7 flowcells was never revealed (Deamer et al., 2016), but the R9.4 
released in mid-2016 used a new material for the pore, the Escherichia coli Curlin 
sigma S-dependent growth subunit G (CsgG) which resulted in improved accuracy, 
especially for 1D chemistry.  This new flow cell achieved 94% accuracy for 2D and 
89% for 1D chemistry (Jain et al., 2017). In earlier pores before the R9, an individual 
signal represented five or six nucleotides in the sensing region of the pore at a given 
time, thus resulting in 2048 or 4096 possible k-mers for the software to differentiate. 
In R9, the signal was mainly attributed to the three middle nucleotides (Rang et al., 
2018). However, this means DNA sequences with consecutive identical bases or 
homopolymers still suffer from inaccuracy (Jain et al., 2018).  To address this, the 
R10 flow cell with two sensing regions in the pore was commercially released in 
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September 2019 to increase the accuracy of homopolymer regions (ONT, 2019d). 
The work with nanopore sequencing in this thesis was conducted before the R10 flow 
cell was available, and was mainly done using R9.4 flow cells.  
 
Figure 1.9 Accuracy of different versions of flow cells 
Figure shows the improving accuracy along with the update of the flow cells. Flow cell 
R9.4 with 1D chemistry resulted in ~90% accuracy.  Figure is reproduced from (ONT, 
2017a).  
 
1.3.5 Development of nanopore sequencing bioinformatics tools. 
The unique, long-read capability of the new platforms required development of 
algorithms able to manage long sequence reads. In addition, various bioinformatics 
tools are needed to convert the raw sequencing reads to lists of variants in a variant 
calling format (VCF) file. These tools have evolved rapidly in recent years, driven by 
both ONT and the research community.  
Basecaller, an algorithm used to translate electrical current signal to DNA sequences 
is one of the main contributors to improved accuracy. The main basecaller in the 
early days of MinION was the cloud-based epi2me software from Metrichor (Lu et al., 
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2016b). The offline command line-based basecaller, Albacore was released in late 
2016 and became the main basecalling tool for approximately two years. Albacore 
was updated frequently, and between January and September 2017 alone, it was 
updated at least 12 times (Rang et al., 2018). A significant change was introduced in 
the second version of Albacore that removed the event-segmentation step (ONT, 
2017b). 
Albacore v1 reads DNA sequences based on “events” or a segmentation of signal, 
corresponding to the dwelling time in the pore, usually 5-6 bases at a time. The 
sequences of events are then converted to DNA bases using a Hidden Markov Model 
(HMM). With the updated and more accurate chemistry, this approach appeared to 
contribute to error. Albacore v2 identified DNA sequences directly from raw data 
rather than events, using a recurrent neural network algorithm, which increased the 
accuracy and speed of basecalling (Figure 1.10). This version was also equipped with 
quality score (q-score) filtering, and by default would bin any reads with a q-score 
<7 to a failed folder (ONT, 2017b).  
 
Figure 1.10 Accuracy comparison between raw basecalling vs event based basecalling 
Figures shows increased accuracy of raw basecalling (Albacore v2) compared to event-




Guppy, another basecaller developed by ONT, was initially used for GridION and 
PromethION, but at the end of 2018 was released to replace Albacore as the main 
basecalling tool for all platforms (ONT, 2018). The main advantage of Guppy over 
Albacore was the upgrade in speed by approximately one magnitude from 105 
bp/second to 106 bp/second  (Wick et al., 2019). Later Guppy versions (after v2.2.2) 
used the flip-flop model (which refers to a process where two states are defined for 
each base), that further increased basecalling accuracy, but at the cost of speed (ONT, 
2018).  
The performance of Guppy has been reported to be comparable to Albacore v2 (Wick 
et al., 2019). Accuracy of consensus reads was better for Guppy when compared with 
Albacore (Q22.8 vs Q21.9), but Albacore has higher raw reads accuracy (Q9.2 vs 
Q8.9). Guppy with the flip-flop model resulted in higher accuracy both for consensus 
reads and raw reads (Q23 and Q9.7) (Wick et al., 2019). Guppy v3.2.1, released in July 
2019, also enabled detection of base modification such as methyl-adenosine and 
methyl-cytosine (ONT, 2019b).  
Earlier versions of basecaller generated DNA sequences in FAST5 formats, requiring 
tools to convert them to the standard FASTQ or FASTA files, such as poretools 
(Loman & Quinlan, 2014) or pore (Watson et al., 2014). Later versions had the option 
to generate FASTQ files, which could be directly used for downstream analysis such 
as alignment to a reference sequence. 
Several alignment/mapping tools have been developed or modified to overcome the 
difficulty in the high error characteristics of nanopore sequencing reads. Earlier 
popular mapping tools  included LAST (Kiełbasa et al., 2011), BWA MEM with its 
“ont2d” mode specifically designed to handle nanopore reads (Li, 2013), marginAlign 
(Jain et al., 2015), and Graphmap (Sovic et al., 2016). More recently developed tools 
include minimap2, which rapidly gained popularity due to its superior speed and 
accuracy (Li, 2018) and NGMLR, another mapping tool designed to improve the 
performance of detecting SV (Sedlazeck et al., 2018).  
Nanopolish is an error correction tool originally developed for genome assembly 
(Quick et al., 2016), which generally increased the accuracy of consensus reads (Wick 
et al., 2019). Nanopolish variant calling function has also been increasingly used (Jain 
et al., 2018; Leija-Salazar et al., 2019; Orsini et al., 2018). The later update of 
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nanopolish included detection of DNA methylation (Simpson et al., 2017). Other 
variant calling tools used for nanopore sequencing include marginCaller (Jain et al., 
2015), VarScan 2 (Euskirchen et al., 2017; Koboldt et al., 2012; Orsini et al., 2018) 
and Clairvoyante (Luo et al., 2019). 
1.3.6 Application of ONT nanopore sequencing 
ONT nanopore sequencing has been used in a wide range of applications. Earlier 
versions of the technology suffered from low yield and high error rates, making it 
challenging for applications that required high accuracy such as variant genotyping 
in human genetics. Instead, earlier applications mainly exploited the unique nature 
of long read sequencing and portability of the technology. The MinION has been 
successfully used to investigate the Ebola virus outbreak in Africa (Quick et al., 2016) 
and Zika virus in Brazil (Quick et al., 2017), and even used in the international space 
station (Castro-Wallace et al., 2017).  
Until recently, only a handful of reports applying this technology to the study of 
pharmacogenetics and human genetics had been published. A preliminary study 
using an earlier version of the MinION on two complex genes of importance to 
pharmacogenetics, HLA and CYPD26, reported inaccurate results (Ammar et al., 
2015). The subsequent introduction of R9 flow cell chemistry led to more promising 
results. For example, the combination of this flow cell with the 2D chemistry enabled 
high resolution and accurate HLA-B typing in New Zealand Māori and Pacific Island 
individuals (Ton et al., 2018). With improving flow cell versions and bioinformatic 
analysis tools, successful applications of 1D chemistry in analysing complex genes 
such as HLA or GBA have also been reported (Graham et al., 2020; Leija-Salazar et al., 
2019; Liu et al., 2018). 
With the increasing sequencing yield, sequencing of human genomes solely on this 
technology platform has been made possible (Beyter et al., 2019; Bowden et al., 2019; 
Jain et al., 2018). Nanopore sequencing was successfully used to phase de novo 
mutations in patient samples (Bowden et al., 2019) and to close several gaps in the 
current human reference genome, GRch38 (Jain et al., 2018). Using 73 flow cells to 
sequence the reference sample NA12878, Bowden et al. reported a consensus 
accuracy above 99.9%, however, substitution and deletion error rates were still high, 
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at 13% and 5%, respectively (Bowden et al., 2019). The recent pre-print on 1817 
Icelanders reported the first large scale and genome-wide SV detection using 
nanopore sequencing. They identified ~23,000 SVs per individual, one third of which 
were rare with MAF<1% (Beyter et al., 2019). The number of SV reported by 
nanopore sequencing was similar to that reported using another long read 
sequencing technology (Audano et al., 2019; Chaisson et al., 2019), and was three 
times higher than the SV findings by short read sequencing (Collins et al., 2019).  
Despite the current limitation in base call accuracy, nanopore sequencing in its 
current state has benefited many aspects of human genetics unattainable by short 
read sequencing. These include accurate and direct phasing of variants (Leija-Salazar 
et al., 2019), accurate detection of SV (De Coster et al., 2019), direct detection of base 
modification such as DNA methylation (Simpson et al., 2017), and direct RNA 
sequencing (Garalde et al., 2018).  
1.4 Pharmacogenetics of ADR 
Inter-individual difference in drug responses can lead to two broad undesired 
consequences, lack of efficacy or an adverse reaction. A good definition of an ADR 
was proposed by Edwards and Aronson as “an appreciably harmful or unpleasant 
reaction, resulting from an intervention related to the use of a medicinal product, 
which predicts hazard from future administration and warrants prevention or 
specific treatment, or alteration of the dosage regimen, or withdrawal of the product’’ 
(Edwards & Aronson, 2000). 
ADRs cause high morbidity and mortality burdens in healthcare. It is estimated that 
ADRs contribute to 6-7% of hospital admissions (Al Hamid et al., 2014; Giardina et 
al., 2018). ADRs are also associated with longer hospital stays (Stausberg, 2014) and 
are one of the leading causes of death in hospitalised patients (Landrigan et al., 2010). 
In the USA, a study over a nine-year period from 2006 to 2014 reported a doubling 
in the number of adverse drug events (Sonawane et al., 2018). However, research 
shows that approximately 70% of all ADRs are preventable (Giardina et al., 2018).  
Two types of ADRs have been recognised (Wang et al., 2017). The first can be 
described in general terms as an exaggerated drug response. This is called a type A 
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ADR (intrinsic) which represents ~80% of all ADRs (Wang et al., 2017). An example 
of this is the increased risk of bleeding in individuals with loss of function CYP2C9 
taking warfarin. Warfarin exists as racemic stereoisomers with the more active S-
enantiomer mainly metabolised by CYP2C9 to its inactive metabolites. The 
diminished enzyme activity leads to a higher warfarin plasma level and therefore 
increased time “in” anticoagulation (Ma et al., 2017). Another example is myopathy 
caused by high plasma levels of simvastatin (Vrablik et al., 2014). The second type of 
ADRs, Type B ADRs (idiosyncratic) occur independent of the intended drug effect, 
and are usually regarded as dose-independent. A well-studied example of a type B 
ADR is severe cutaneous reaction by the antivirus abacavir or anticonvulsant 
carbamazepine, mediated by genetic variants in the HLA locus (Alfirevic & 
Pirmohamed, 2011). Compared with type-A ADRs, type B ADRs are reported to be 
more serious, leading to hospitalisation or mortality (Wang et al., 2017). 
Various factors contribute to susceptibility to ADRs including disease state, age, 
gender, polypharmacy, and genetics. Genetic factors are estimated to contribute to 
one third of serious ADR cases (Roden et al., 2019). Many associations of variability 
in plasma drug/metabolite levels and genetic variations have been established. For 
example, HLA-B* 57:01 significantly increased the risk of hypersensitivity reaction to 
the antiviral drug abacavir (Hughes et al., 2004). Similarly carbamazepine-induced 
Steven Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) is strongly 
associated with the HLA-B*15:01 and 02  alleles specifically in patients of South-East 
Asian descent with odds ratio of more than 1000 (Ferrell & McLeod, 2008).  
The FDA table on Pharmacogenomic Biomarkers in Drug Labeling has listed more 
than 250 drugs with genetic information (FDA, 2019). However, there are several 
drug classes for which variability in response-associated with genetics and risk of 
ADRs are poorly characterised. For example, in about three per 1000 individuals 
taking angiotensin converting enzyme inhibitor (ACEi), a potentially fatal reaction of 
swelling in the deeper layer of skin, called angioedema (ACEi-A), can occur. As ACEi-
A was a significant focus of this thesis, the following section critically reviews the 




1.5 Angioedema induced by angiotensin converting enzyme 
inhibitors 
1.5.1 Angiotensin converting enzyme inhibitor and ADR. 
ACEi are widely used to treat hypertension, heart failure, as well as to prevent 
diabetic nephropathy. Since the introduction of the first agent, captopril in 1981, 
more than ten different ACEi have been marketed. They were amongst the top five 
most prescribed drugs globally with spending estimated at 34 billion US dollars in 
2015 (IMS Institute for Healthcare Informatics, 2011). Lisinopril was the second 
most prescribed drug in the USA, with 106 million prescriptions in 2015 (IMS 
Institute for Healthcare Informatics, 2016). In comparison, cilazapril, is reported as 
the most commonly prescribed ACEi in New Zealand and is among the top 10 drugs 
prescribed in this country, with approximately 760,000 prescription scripts in 2016 
(Pharmaceutical Management Agency, 2016). 
Although generally safe, a number of ADR have been reported with ACEi, including 
rash (Wilkin et al., 1980), cough (Rossetto, 1987), hypotensive transfusion reaction 
(Quillen, 2000), and angioedema (Wood & Mann, 1987). Dry persistent cough is the 
most common but relatively benign ADR which has been reported to cause cessation 
of ACEi therapy. The incidence of this ADR varies by ethnicity with the highest 
incidence (45%) reported in East Asian populations, and approximately 10% in 
Caucasians (Mosley et al., 2016; Woo & Nicholls, 1995). In complete contrast, ACEi-A 
is relatively rare with an estimated incidence of 0.1% - 0.7% (Banerji et al., 2017; 
Makani et al., 2012; Miller et al., 2008; Toh et al., 2012). However, ACEi-A is 
potentially life-threatening and often requires hospitalisation or emergency 
intervention (Makani et al., 2012).  
1.5.2 Angioedema 
Angioedema, a non-pitting swelling of the skin and/or mucous membranes, was 
recorded as a medical condition as early as the 19th century (Bruun, 1953). 
Aetiologically, it can be categorized as allergic or non-allergic. Allergic angioedema is 
IgE induced and histamine mediated, while non-allergic angioedema is usually 
induced by the accumulation of bradykinin. Bas et al. (2007) further subcategorised 
non-allergic angioedema into five types, hereditary angioedema (HAE), acquired 
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angioedema, drug-induced angioedema, pseudoallergic angioedema and idiopathic 
angioedema. The first three are bradykinin-mediated (Bas et al., 2007). 
HAE is characterised by genetic variation in the SERPING1 gene coding for C1 
esterase inhibitor (C1-INH) whose main function is the inhibition of the complement 
system to prevent spontaneous activation. More than 450 mutations have been found 
in this gene (Germenis & Speletas, 2016), which can result in either reduced levels of 
protein, or reduced function of protein (type 1 or type 2 HAE respectively). As C1-
INH is an important regulator of the contact-kinin system, deficiency can lead to 
uncontrolled bradykinin production and accumulation, which in-turn may induce 
angioedema (Zuraw & Herschbach, 2000). Type 3 HAE with normal C1 INH level and 
functionality was initially associated with genetic variations in coagulation factor XII 
(F12) gene, also a regulator of bradykinin formation (Bork et al., 2009). Recent 
reports revealed other subgroups of HAE with normal C1-INH, including those with 
mutations in angiopoietin-1 (ANGPT1) gene (Bafunno et al., 2018), plasminogen 
(PLG) gene (Bork et al., 2018; Dewald, 2018) and kininogen (KNG1) gene (Bork et al., 
2019). Another form of non-allergic angioedema, acquired angioedema, is an 
extremely rare condition with prevalence estimated as low as 1:500,000. It is brought 
about by the presence of autoantibodies against C1-INH or is associated with B-cell 
lymphoproliferative disorders (Cicardi & Zanichelli, 2010).  
Drug-induced bradykinin-mediated angioedema is predominantly caused by ACEi 
(Malde et al., 2007). Other drugs have been associated with angioedema, including 
angiotensin receptor blockers (Chiu et al., 2001; Lo, 2002; Nykamp & Winter, 2007), 
dipeptidyl peptidase IV (DPP4) inhibitors (gliptin drugs) (Hermanrud et al., 2017), 
neutral endopeptidase P/neprilysin (NEP) inhibitors (Zanchi et al., 2003), 
nonsteroidal anti-inflammatory drugs (NSAID), fibrinolytic agents, oestrogen, and 
some cardiovascular drugs (Agostoni & Cicardi, 2001). 
Pseudoallergic angioedema has similar features to allergic angioedema, but is not 
mediated by IgE. NSAID, contrast agents and opioids can lead to such angioedema 
through different mechanisms (Andreucci et al., 2014; Doña et al., 2011; Li et al., 
2017). Idiopathic angioedema, as reflected by its name, has no known underlying 
mechanism, and can be induced by several factors, including emotional and physical 
factors (Zingale et al., 2006).  
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1.5.3 ACE inhibitor-induced angioedema 
The first case of ACEi-A was reported two years post-marketing of captopril (Jett, 
1984). The first case series of ACEi-A report was published in 1987 reporting 13 
angioedema cases related to enalapril (over one year) and five cases with captopril 
(over five years). The majority of angioedema cases had a time-to-onset of five days 
and resolved after drug withdrawal (Wood & Mann, 1987). The Centre for Adverse 
Reactions Monitoring in New Zealand reported a total of 68 cases of ACEi-
angioedema (captopril, enalapril and lisinopril) between 1981-1994. They also 
reported that the time to onset for most (60-77%) ACEi-A was within five days to 
three weeks after initiation of treatment. Severe angioedema requiring emergency 
intervention was reported in a total of 15 patients (Pillans et al., 1996). The incidence 
of ACEi-A was reported to be 0.2% from this New Zealand report. This is comparable 
to a recently conducted meta-analysis of 26 clinical trials which reported the 
incidence of ACEi-A as three in every 1000 patients or 0.3% (Makani et al., 2012). 
Due to the wide use of ACEi, ACEi-A has an incidence exceeding HAE, which is one in 
50,000 (Lang et al., 2012). For example, with 760,000 prescriptions per year in New 
Zealand, the incidence of ACEi-A will reach over 2000 cases per year, or 
approximately one in 2000. Furthermore, an analysis of admissions data to 
emergency departments showed that about one third of all angioedema cases were 
induced by ACEi (Banerji et al., 2008a; Gandhi et al., 2015). 
1.5.4 Clinical features of ACE inhibitor-induced angioedema 
ACEi-A is most commonly reported to occur in the head and neck area, often with 
swelling of the lips and/or tongue. In rare cases, larynx, intestinal and genital 
angioedema have also been reported (Bas, 2017; Miller et al., 2012; Wagner et al., 
2015). The severity of ACEi-A varies; mild ACEi-A is more frequent, but symptoms 
can recur and potentially worsen over time (Brown et al.; Roberts et al., 2008). 
Although rare, serious cases of ACEi-A can require intensive care, including tracheal 
intubation, and may lead to death (Banerji et al., 2008a; Piller, 2006; Roberts et al., 
2012). A factor that often obscures or delays correct diagnosis is the variable time to 
onset. As described above, time to onset for ACEi-A varies from days to years (Cicardi 
et al., 2004; Howarth, 2013; Miller et al., 2008) and has also been reported to occur 
after discontinuation of the ACEi (Veronez et al., 2017).  
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1.5.5 Proposed mechanism of ACE inhibitor-induced angioedema 
The accumulation of bradykinin as a result of inhibiting ACE degradation is thought 
to be a major factor in ACEi-induced cough and angioedema, and was first speculated 
upon in a series of case reports (Wood & Mann, 1987). ACEi work primarily by 
inhibiting the conversion of angiotensin I to angiotensin II. ACE is also the main 
enzyme that breaks down bradykinin into its inactive metabolites (Figure 1.11). 
Importantly, ACE has a much greater affinity for bradykinin (Km = 0.18 M) 
compared with angiotensin I (Km = 16 M), which results in classification of ACE as 
a kininase (often referred to as kininase II) rather than as an angiotensinase (Jaspard 
et al., 1993). 
Bradykinin exhibits its action through binding with its specific receptor, bradykinin 
type 2 receptor (B2R), whereas its active metabolite, des-Arg9-bradykinin acts via 
the bradykinin type 1 receptor (B1R). Both stimulate a number of pathways resulting 
in vasodilation, increased membrane permeability, inflammatory processes, and 
various other physiological and pathological pathways (Regoli & Barabe, 1980). The 
B2R is ubiquitously expressed throughout the body, while B1R expression is induced 
by inflammation (Hoover et al., 2010). Increased levels of bradykinin, induced either 
by uncontrolled production or due to a defect in its metabolism pathway, will 




Figure 1.11 Accumulation of bradykinin as a result of inhibition of ACE 
ACE is involved both in renin-angiotensin and kinin pathways by breaking down 
angiotensin I and bradykinin, respectively. This action is blocked by ACEi, leading to 
lowering blood pressure and accumulation of bradykinin. AT = angiotensin, ACE = 
angiotensin converting enzyme, ACEi = Angiotensin converting enzyme inhibitor. 
 
It has been reported that plasma bradykinin levels increase 1.25-fold 24 hours after 
ACEi administration (Pellacani et al., 1994). With respect to ACEi-A, bradykinin levels 
have been shown to increase more than ten-fold compared to healthy controls, and 
to decrease to normal levels after angioedema has subsided (Cugno et al., 2016). 
Moreover, bradykinin concentration was shown to be higher in ACEi-A compared to 
controls taking the same drug (Hubers et al., 2018). The increased level of bradykinin 
in ACEi-A is not accompanied with higher levels of its precursor, kininogen, as seen 
in angioedema induced by C1-INH deficiency (Cugno et al., 2003) indicating an 
impaired catabolism and not an overproduction of bradykinin. Physiologically, 75 to 
95% of bradykinin (BK1-9) is rapidly metabolised by ACE to its inactive metabolites, 
mainly BK1-5 and also BK1-7 (Blais et al., 2000). The second most important enzyme 
involved in the breakdown of bradykinin is aminopeptidase P (APP), which cleaves 
BK1-9 to BK2-9 (Figure 1.12). A small portion of bradykinin (1 to 4%) is also 
converted by kininase I (carboxypeptidase N/M) to des-Arg9-bradykinin (BK1-8), an 
active metabolite, which is in turn metabolised by APP and ACE, with APP being the 
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main enzyme. During ACE inhibition, the activity of kininase I is reported to increase 
more than ten-fold (Blais et al., 2000). Other kininases with minor contributions 
include DPP4 (BK4-9), neutral endopeptidase (NEP) (BK1-7 and BK1-4), endothelin 
converting enzyme (ECE) (BK1-7), chymase, cathepsin G and A (Blaes & Girolami, 
2013) (Figure 1.12). In a study comparing 39 individuals with a history of ACEi-A and 
39 matched controls, the levels of APP activity were on average significantly 
(P=0.003) lower in angioedema cases (16 nmol/min/ml) when compared with 
controls (22 nmol/min/ml) (Adam et al., 2002). Levels of carboxypeptidase N were 
not affected by ACEi in this study, however, they were reported to be significantly 
decreased in ACEi-A cases in another study (Sigler et al., 1997). 
 
Figure 1.12 Bradykinin metabolising enzymes.   
The nonapeptide bradykinin (BK1-9) and sites cleaved by various enzymes. APP: 
Aminopeptidase P, DPP4: Dipeptidyl peptidase 4, NEP: Neutral Endopeptidase, ECE: 
endothelin converting enzyme-1, CPN: Carboxypeptidase N, CPM: Carboxypeptidase M.  
 
Another substrate of ACE, substance P, has also been postulated to mediate 
angioedema. Substance P is a neurokinin present in the nervous system which has 
vasodilatory and pro-inflammatory properties through the neurokinin-1 receptor 
(O'Connor et al., 2004). As a result of ACE inhibition, substance P is mainly degraded 
by NEP and DPP4. Studies in rodents have shown that substance P induced plasma 
extravasation, leading to tissue swelling, if ACE was inhibited (Emanueli et al., 1998). 
In comparison, human studies have been inconsistent. Byrd et al. reported lower 
DPP4 antigen levels and activity in patients with ACEI-A compared to controls 
exposed to ACEi (Byrd et al., 2008). This suggests the involvement of substance P, but 
was not supported by the finding that ACE and DPP4 inhibition had no impact on 
vasodilatation stimulated by substance P (Devin et al., 2014). 
Despite the proposed involvement of bradykinin and substance P, the exact 
mechanism of ACEi-A remains largely unknown. A number of environmental factors 
Insert Figure 2 here 
                 ACE ACE, NEP, ECE, chymase, capthesin G 
Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9 (Bradykinin) 
      APP        DPPIV                       CPN, CPM, cathepsin A 
                                  NEP 
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have also been postulated to increase the risk of ACEi-A, including smoking, a history 
of seasonal allergies and local trauma (Hoover et al., 2010). Several observational 
studies have shown that the risk of ACEi-A varies according to ethnicity and gender, 
suggesting that a genetic association exists. Africans, particularly women, were 
reported to have a higher risk of ACEi-A compared with Caucasians (Brown et al., 
1996; Gibbs et al., 1999; Hoover et al., 2010; Mahoney & Devaiah, 2008). The 
suggestion of a genetic predisposition has led to several studies trying to elucidate 
any underlying genetic mechanism.  
1.5.6 Pharmacogenetics of ACE inhibitor-induced angioedema 
Differences between individuals, particularly the observation that APP levels are 
lower in ACEi-A cases, led to the first pharmacogenetic study on ACEi-A. This first 
candidate gene study reported that a variant upstream of the XPNPEP2 gene coding 
for the APP enzyme was more common in cases of ACEi-A than controls (Duan et al., 
2005). Several case-control candidate gene studies and one genome-wide association 
study (GWAS) have been published since this initial report (Table 1.1). The 
hypothesised role of the genetic variants associated with ACEi-A can be grouped into: 
1) genes responsible for the degradation of bradykinin or substance P, (2) the ACE 
gene, (3) the bradykinin receptor 2 gene, (4) genes associated with immune 
regulation, and (5) genes associated with fibrinolytic and coagulation pathway 
(Figure 1.13). 
1.5.6.1 Genes responsible for the degradation of bradykinin or substance P  
A SNP in the upstream region of XPNPEP2 (2399C>A, rs3788853) was found 
through a linkage association study of plasma APP levels in seven of the eight families 
with members having angioedema (Duan et al., 2005). The association of the variant 
with the ADR was confirmed in a follow-up case-control study, although only nine 
out of their 20 cases had the particular variant. (Duan et al., 2005). About 30% of 
ACEi-A cases in this study had APP activity < 10 IU, compared to only 10% in general 
population. 
A larger case-control study with 169 cases and 397 controls reported that gender 
(P=0.02) and the SNP rs3788853 (2399C>A) in XPNPEP2 accounted for the 
variability in APP activity in men and women (P<0.001). Using multivariate analysis, 
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the authors showed that the XPNPEP2 2399C>A genotype was associated with a 
2.2-fold increased risk of ACEi-A in all males (P=0.03). However, when multivariate 
analysis was further stratified by race, the XPNPEP2 −2399C>A genotype was only 
significant in African-American males (P=0.01). In addition, lower APP activity was 
observed in men compared to women, and in Africans compared to Caucasian males, 
independent of 2399C>A genotype. Interestingly, this study reported no differences 
in APP activity between cases and controls (Woodard-grice et al., 2010).  
A further genetic study in a cohort of 537 healthy subjects reported two additional 
variants upstream of the XPNPEP2 gene, that were associated with APP activity. The 
2399C>A SNP (rs3788853) together with SNPs rs205011 and rs2235444 formed a 
haplotype that accounted for 10.8% of the variability in APP activity. The haplotype 
ATG across these three SNPs had a significantly lower APP activity compared to the 
common haplotype CGG (0.11 vs 0.21 nmol/min/ml). By further analysis in an 
angioedema population, this study found that haplotype ATG was more prevalent in 
ACEI-A cases compared to controls with an odds ratio of 4.87 compared to 







Table 1.1 Genetic reports of ACEi-A 
Ref Design Ethnicity Sex Population 
(Total subjects or 
case vs control) 
Genetic Variants Results 
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The ATG haplotype of the three SNPs 
was associated with lower APP 
activity and increased risk for ACEi-A. 
The risk associated with the haplotype 
is higher compared to the rs3788853 
alone (4.9-fold vs 3.0-fold) 
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Table 1.1 Genetic reports of ACEi-A – continued 
Ref Design Ethnicity Sex Population 
(Total subjects or 
case vs control) 
Genetic Variants Results 

























2 variants with moderate association 
by GWAS were successfully replicated 
(rs500766 and rs2724635). 
 
From 33 SNPS of 17 genes, one was 
found to be significant and 
successfully replicated (rs989692) 





161 subjects (3 
ACEi-A) 
F12 (c.1032C >A or 
c.1032C > G); 
SERPINE1/PAI1 (4G/ 5G 
polymorphism);  





From the three patients with ACEi-A, 
one had the SERPINE1 5G/5G 
polymorphism. Other variants not 
found 


















This study was not specifically on 
ACEi-A. However, this study found 
eight variants with genome wide 
statistical significance (< 10-8) 
associated with ACEi-intolerance. 
(Veronez et al., 2017) Single case Mixed 
Caucasian-
African 
Male 1 case F12 
c.971_1018þ24del72 
Found a 72-bp deletion in exon 9 of 
F12 gene, a variant previously 
associated with type III HAE 








Figure 1.13 Reported genetic variants for ACEi-A 
Genetic variants reported for this ADR can be grouped into several mechanisms: (1) genes responsible for the degradation of bradykinin 
or substance P, (2) the ACE gene, (3) the bradykinin receptor 2 gene, (4) genes associated with immune regulation, (5) genes associated 





Another study reported that a variant (rs989692) in MME, the gene coding for NEP, 
another bradykinin and substance P degrading enzyme, was associated with ACEi-A 
(Pare et al., 2013). Involvement of the NEP enzyme is plausible as omapatrilat, a dual 
NEP and ACEi, exhibited a three-fold greater risk of angioedema compared to ACEi 
alone, and was not approved by the FDA due to angioedema safety concerns (Kostis 
et al., 2016; Pickering, 2002). 
1.5.6.2 ACE gene 
Genetic variation in ACE, specifically insertion-deletion (indel) variations of an Alu 
element in intron 16, can result in increased or decreased enzyme activity (Payne et 
al., 2007; Rigat et al., 1990; Tsutaya et al., 1997). The ACE DD genotype, in which both 
copies of the ACE gene lack the 287 base pair indel region, is associated with higher 
ACE activity, but not with higher risk of ACEi-A. In contrast, the ACE II genotype with 
the insertion of 287 base pairs on both alleles, was shown to be associated with ACEi-
A in an African-American population (Ducroix et al., 2004). However, three further 
case-control studies did not support these initial findings (Bas et al., 2010b; Gulec et 
al., 2008; Moholisa et al., 2013). One of these studies reported a 50% lower ACE 
activity in ACEi-A cases compared to controls taking the same drug, and independent 
of the presence of the indel variation (Moholisa et al., 2013) and, the two other 
studies failed to replicate this finding (Bas et al., 2010b; Gulec et al., 2008). No other 
variants in ACE have been studied in association with ACE-A. The only GWAS of ACE-
I angioedema also did not find any significant associations with variants in this gene 
(Pare et al., 2013).  
1.5.6.3 Bradykinin receptor genes 
The presence or absence of a 9 base-pair tandem repeat sequence (GGTGGGGAC) in 
exon 1 of BDKRB2 coding for bradykinin receptor 2 can affect bradykinin-induced 
vasodilation during ACE inhibition (Van Guilder et al., 2008). This indel variation, 
involving one of the three 9bp tandem repeats, was identified as rs772945381 or 
rs71103505 and referred to by different names, 9+/9- or -21-29/+21-29 or 2G/3G 
(Table 1.1). The 9bp indel variant in exon 1 influences the transcription of BDKRB2 
(Braun et al., 1996), and therefore alters the physiological effects of bradykinin. 
Previous research has shown that the 9+/9- variant is related to the degree of 




investigating these BDKRB2 variants and their association with ACEi-A gave 
discordant results. Bas et al. (2010) found no association of the 9+/9- variant with 
ACEi-A (Bas et al., 2010b), whereas another study found a significant association 
(Moholisa et al., 2013). The latter study also assessed the correlation of the -58C>T 
SNP (rs1799722) in the promoter region of the gene, which has been previously 
associated with ACEi-induced cough (Mukae et al., 2002) but found no association 
with ACEi-A.  
1.5.6.4 Genes involved in immune function and regulation of inflammation. 
The first GWAS of 175 individuals with ACEi-associated angioedema and 489 ACEi-
exposed controls found no genome-wide significant SNPs (p<5x10-8) but the authors 
selected a number of genetic variants of interest with a P<10-4 to be included in a 
replication study. The variant rs500766 in PRKCQ was nominally associated with 
protection against ACEi-A in Caucasians (dominant model, odds ratio=0.28, p=0.03), 
whereas the rs2724635 variant in ETV6 was nominally associated with an increased 
risk of ACEi-A in African Americans (recessive model, odds ratio=3.27, p=0.04). 
PRKCQ has a functional role in T lymphocyte activation and ETV6 is involved in the 
regulation of T-helper cell homeostasis (Pare et al., 2013). Although no correction for 
multiple testing was performed, and the variants reported are yet to be replicated in 
a further study, the association of immune regulation in ACEi-A is plausible as recent 
literature has shown the many roles of ACE in immune regulation (Bernstein et al., 
2016; Zhao et al., 2017).  
1.5.6.5 Genes in fibrinolytic and coagulation pathways 
Fibrinolytic and coagulation factors contribute to the pathophysiology of HAE 
(Farkas, 2013). A descriptive study in 2014 attempted to elucidate the genetic 
variants in different types of bradykinin-mediated angioedema, and reported that 
one out of three ACEI-A patients had a 5G/5G polymorphism in the SERPINE1 gene 
coding for Plasminogen Activator Inhibitor-1 (PAI-1). This polymorphism was 
associated with a lower level of plasma PAI-1 (Levy et al., 2014), therefore may 
contribute to increased bradykinin concentration. A recent report on a single case of 
ACEi-A that persisted even after drug withdrawal, found a heterozygous deletion in 




In summary, pharmacogenetic efforts including candidate gene studies and GWAS to 
elucidate the genetic underpinnings of ACEi-A, have resulted in a number of plausible 
genetic variants that could influence risk of this ADR. However, these studies were 
biased towards common variants and none of them appears to be a strong 
contributor.  
1.6 Epigenetics and drug response 
Genetic variants have been extensively studied in relation to pharmacological 
treatment, but were estimated to explain only approximately one third of the total 
variability in drug response (Lauschke et al., 2018). In addition to a variety of non-
genetic factors including age, state of disease, and co-administrated drugs, there is 
growing evidence that epigenetic regulation also plays roles in drug responses. 
Epigenetics refers to genetic regulation beyond the variation in DNA sequences. This 
includes regulation of gene expression by DNA methylation and histone modification, 
and the role of many non-coding RNA molecules in altering translation of messenger 
RNA (mRNA) (Ivanov et al., 2014). The study of these mechanisms in association with 
medication is referred to as pharmacoepigenetics (or pharmacoepigenomics in a 
genome wide context).  
1.6.1 Overview of DNA methylation 
DNA-methylation and its effect on gene expression is an active area of research in 
epigenetics (Lauschke et al., 2018). DNA methylation is important in silencing 
retroviral elements, establishing gene imprinting, regulating tissue-specific gene 
expression and during embryonic development (Moore et al., 2013). In eukaryotes, 
methylation predominantly occurs on the fifth carbon of cytosines that are followed 
by a guanine along the 5’-3- direction (CpG dinucleotides). CpGs are often found in 
the promoter regions as regulators of gene expression. Approximately 70% of 
promoter regions have high CpG density, referred to as CpG islands (Saxonov et al., 
2006). Other regions rich in CpGs are the Alu retrotransposons, estimated to 
represent ~25% of all CpG sites. The majority of Alu elements are highly methylated 





The traditional consensus view on the association of DNA methylation and gene 
expression is that unmethylated CpG sites in the promoter regions are associated 
with increased gene expression through binding with transcription factors, while 
hypermethylated CpGs are associated with repressed gene expression (Figure 1.14). 
However,  a growing body of evidence has challenged this view, and the relationship 
of DNA methylation and gene expression is clearly more complex than originally 
thought. Studies have reported that DNA methylation in promoter regions could be 
associated with either lower or higher levels of gene expression (Rauluseviciute et 
al., 2020; Wan et al., 2015) (Spainhour et al., 2019). DNA methylation in other regions 
of the genes might also have different consequences. For example, DNA methylation 
in the gene body or 3’untranslated regions (UTR) could increase gene expression and 
modify exon splicing (Tirado-Magallanes et al., 2017). Moreover, changes in gene 
expression have been found to precede changes in DNA methylation during infection 
(Pacis et al., 2019), and some of the roles of CpGs in regulating transcription might 
be independent of DNA methylation (Hartl et al., 2019).  
The regulation of DNA methylation status is facilitated by the family of DNA 
methyltransferases (DNMTs). DNMT3a and 3b can create a new methylation pattern 
by adding methyl group to native cytosine, thus known as de novo DNMTs. DNMT3L 
is another member of the family which mainly exerts its function during early 
development to establish genomic imprinting and methylation in the 
retrotransposons. DNMT1 maintains DNA methylation patterns during DNA 
replication by adding methyl groups to newly synthesised DNA strands according to 
parental DNA. A reverse, or demethylation mechanism also exists, facilitated by ten-
eleven translocation (TET) enzymes. TET enzymes add a hydroxyl group to 
methylcytosine to form 5-hydroxymethylcytosine, which can be converted back to 






Figure 1.14 DNA methylation and gene expression 
Figure (A) shows the addition of methyl group to cytosine is regulated by the DNMT 
enzyme family, and the reverse reaction is enabled by TET enzyme family. In figure (B), 
unmethylated cytosines allow for active chromatin and transcription factor binding to 
start gene expression while methylated cytosines are generally associated with 
repressed expression. Figure is reproduced with modification from (Agrawal et al., 
2018). 
 
Although the majority of methylation patterns are considered stable (Lanata et al., 
2018), various genetic and non-genetic factors do impact on patterns of DNA 
methylation, including variations in DNA sequence (Kerkel et al., 2008), physiological 
factors such as aging (Field et al., 2018) and environmental exposures such as 
tobacco (Lee & Pausova, 2013) or alcohol consumption (Philibert et al., 2014). 
1.6.2 Scope of pharmacoepigenetics 
Epigenetic regulation is reported to affect the pharmacokinetics and 
pharmacodynamics of drug response (Majchrzak-Celińska & Baer-Dubowska, 2017).  
With respect to pharmacokinetics, one example is the regulation of CYP3A4 
expression. The hepatic levels of CYP3A4 are highly variable between individuals, 




Methylation status of CpG sites in the upstream promoter of the gene was shown to 
affect the expression of CYP3A4. (Kacevska et al., 2012).  Another study interrogating 
methylation status of more than 450,000 CpG sites in human liver tissues reported 
that 37 drug metaboliser genes showed significantly variable DNA methylation level. 
They also reported an inverse correlation between DNA methylation status and 
mRNA expression of seven of these genes, CYP1A2, CYP2C19, CYP2D6, GSTA4, GSTM5, 
GSTT1, and SULT1A1 (Habano et al., 2015). With respect to drug transporters, ABCB1 
was shown to be regulated by histone modification, and expression of this gene was 
decreased by histone deacetylase inhibitor (Ye et al., 2016). 
Epigenetic regulation also affects pharmacodynamics through its effect on drug 
targets. For example, decreasing methylation level in the adrenergic β1 receptor gene 
was reported to increase the expression of the gene and improve response to 
metoprolol, a commonly prescribed antihypertensive drug (Jiang et al., 2011). ACE, 
one of the targets in anti-hypertensive medication, is also strongly influenced by DNA 
methylation status in the gene promoter with cell-specific methylation patterns, 
possibly contributing to the differential tissue-specific expression of this enzyme 
(Rivière et al., 2011). 
Aberrant methylation status has been reported in diseases such as cancers (Koch et 
al., 2018) and also in drug resistance (Lund et al., 2017). Hence, epigenetic 
modification, for example altering DNA methylation level, has been developed as a 
target for medications, designated as epigenetic drugs. Two examples of epigenetic 
drugs are the DNMT inhibitors azacytidine and its deoxy-derivative aza-
deoxycytidine or decitabine (DAC) (Majchrzak-Celińska & Baer-Dubowska, 2017) 
that induce a decrease in global DNA methylation levels. These two drugs were 
approved for the treatment of myelodysplastic syndrome, a blood disorder marked 
by hypermethylation of multiple genes (Xie et al., 2015) and have also shown a 
therapeutic benefit in acute myeloid leukemia (Bohl et al., 2018). 
Epigenetic profiles can also serve as biomarkers with the potential to predict 
treatment and disease outcomes such as drug resistance.  For example, 
hypermethylation in MGMT promoter regions was associated with resistance to 
alkylating agents in glioma (Esteller et al., 2000). Other examples including the role 




colorectal cancer (Herbst et al., 2017) and the association of E-cadherin methylation 
with resistance to tamoxifen in breast cancer (Wang et al., 2019b). In addition to 
cancer therapy, epigenetic biomarkers have been explored in the response of other 
drugs. For example, methylation profiles in several genes were associated with 
inflammatory responses after treatment with fenofibrate, a drug commonly used to 
treat dyslipidemia (Yusuf et al., 2017).  
1.6.3 Epigenetic effects of common drugs 
In addition to drugs designed to target epigenetic regulation, many drugs initially 
used for other indications were found to have epigenetic effects. For example, 
valproic acid, which has been used for years to treat epilepsy and mood disorders, is 
known to inhibit histone deacetylase (Zhang et al., 2002). Epigenetic modulation can 
also induce side effects, such as an induction of a lupus-like autoimmune disease by 
the drug hydralazine, an antihypertensive drug, and procainamide, an antiarrythmic 
drug. Both drugs were later discovered to be DNMT inhibitors, causing global 
hypomethylation in T cells, leading to the adverse effect (Cornacchia et al., 1988; Sun 
et al., 2016). Another example is the association of long-term use of tamoxifen with 
the suppressed expression of oestrogen-responsive genes through DNA methylation, 
contributing to the resistance of the drug (Stone et al., 2012).  
Many other drugs from various classes  including opioids, NSAID and antidepressants 
such as selective serotonin reuptake inhibitors (SSRI) also demonstrated epigenetic 
effects, as reviewed in (Csoka & Szyf, 2009) and (Lötsch et al., 2013). Since the 
publication of these reviews, evidence of epigenetic effects of other common drugs 
has continued to accrue. Inhibition of the renin angiotensin system by angiotensin II 
receptor blockers decreased methylation levels in the promoter region of nephrin 
and increased expression of the gene (Hayashi et al., 2015). In another example, 
methadone was shown to induce global hypermethylation in a cell culture model 
(Knothe et al., 2016). Furthermore, an epigenome-wide association study comparing 
statin users and non-users found several significant associations in three genes 
potentially involved in statin-induced risk of type 2 diabetes (Ochoa-Rosales et al., 
2018). Finally, genome wide DNA methylation assessment in cells exposed to the 
antipsychotic drug perospirone showed methylation changes in the pharmacological 




association of other drugs with epigenetic modification as an area to consider when 
exploring mechanisms underlying ADR.  
1.7 Summary and thesis aims 
Massively parallel short read sequencing technologies have advanced 
pharmacogenetics in the past two decades, enabling interrogation of variants 
associated with drug response discovered through WES or WGS. Limitations of this 
technology in phasing variants, deciphering regions with high homology or detecting 
SV have been recognised and partly contribute to the slow clinical implementation of 
pharmacogenomics. These limitations can be overcome by novel third generation 
sequencing technologies such as nanopore sequencing. In addition, despite the low 
running cost of NGS technology, the initial capital-cost associated with buying the 
machine means these sequencing technologies are not accessible to all. In contrast, 
nanopore sequencing offers portability and low capital cost, increasing accessibility 
of genomic sequencing. The ability to genotype multiple variants in multiple samples 
using sample barcodes in one sequencing run also means that the sequencing cost 
per variant will be much lower compared to traditional methods such as Sanger 
sequencing or Taqman PCR assay. The error profile of the earlier versions of this 
technology made it unsuitable for application in human genetics. However, the read 
accuracy has improved greatly in recent years along with the advent of improved 
bioinformatics tools, making nanopore long-read sequencing a potentially valuable 
tool for pharmacogenetics.  
As discussed, up to 70% of all ADRs are reported to be preventable. Yet, there is an 
increasing trend of serious ADRs reported worldwide. Despite the advancement of 
genomic technologies, only one third of serious ADRs are currently associated with a 
strong causative genetic factor, with many ADRs requiring further investigation. 
Genetic investigation through GWAS lacks information of rare variants, which have 
been increasingly reported to be represented in populations with certain 
pathologies. Application of methods capable of detecting these rare variants, such as 
WES and WGS, may be valuable to elucidate genetic factors contributing to rare ADRs. 
Epigenetic regulation has also been reported to be a contributor towards ADRs and 




This thesis has applied various approaches and technologies to advance knowledge 
of pharmacogenetics. The thesis is divided into two parts (Figure 1.15). The first part 
of this thesis explored nanopore sequencing technology for pharmacogenetic 
implementation, with the following aims: 
1. Develop a cost-effective multiplex assay covering multiple pharmacogenetic 
variants using nanopore sequencing. 
2. Develop an assay and bioinformatic pipeline to genotype and detect structural 
variation in the complex CYP2D6 gene using nanopore sequencing.  
The second part of the thesis applied a wide range of genetic and epigenetic analyses 
to investigate a rare and serious ADR, ACEi-A, with the following aims: 
1. Explore the application of WES and WGS to elucidate candidate rare genetic 
variants associated with ACEi-A 
2. Explore the involvement of epigenetics in pharmacogenetics by investigating the 
effect of ACEi on DNA methylation.  
 





Chapter 2 : Materials and Methods 
2.1 General methods 
2.1.1 Nucleic acid extraction  
2.1.1.1 DNA extraction from blood  
DNA was extracted from peripheral blood samples using an in-house protocol 
modified from (Miller et al., 1988). Red blood cells were lysed by a hypotonic solution 
leaving DNA containing-white blood cells intact, and these were pelleted by gentle 
centrifugation. White blood cells were then lysed to release the DNA from the cells. 
RNA was eliminated by adding RNase solution. After addition of 
phenol:chloroform:isoamyl alcohol (25:24:1), DNA was separated in the aqueous 
phase, which could then be precipitated by isopropanol and eluted in 1x Tris-EDTA 
(TE) solution. DNA was quantified using ultraviolet spectrophotometry and stored at 
4°C for short term or –20°C for long term. 
2.1.1.2 DNA extraction from saliva 
Saliva samples were collected using the Oragene OG-250 kit (DNA Genotek, ON, 
Canada), and DNA was extracted according to the manufacturer’s recommendation.  
2.1.1.3 DNA extraction from cultured cells 
DNA was extracted from cultured cells using DNeasy Blood and Tissue Kit (Qiagen 
GmBH, Hilden, Germany), according to the manufacturers’ protocol with some 
modifications. Cell pellets were lysed with Proteinase K in the presence of 20 L 
RNase (20 mg/mL) (Purelink RNase I, ThermoFisher Scientific Inc, Waltham, USA), 
with 16 hour incubation at room temperature. In the final step, DNA was eluted in 
two successive rinses with 100 L pre-warmed AE buffer from the kit (56°C) with 10 
minutes incubation.  
2.1.2 DNA quantification 
2.1.2.1 Spectrophotometry (Nanodrop) 
DNA and purified PCR products were quantified by ultraviolet spectrophotometry 
using NanoDrop 8000 (ThermoFisher Scientific Inc, Waltham, USA), based on the fact 




absorbance was measured and converted to concentration. Water or elution buffer 
was used as blank, and for each sample, 1.5 l solution was loaded onto the cleaned 
NanoDrop pedestal. Purity of DNA and PCR products could also be assessed by 
A260/A280 (expected to be >1.8) and A260/230 (>1.5-2.0) ratios. 
2.1.2.2 Fluorometry (Qubit) 
For more accurate quantification (eg. for nanopore sequencing in Chapter 3 and 4, 
and bisulfite sequencing in Chapter 7), DNA was measured on the fluorescence-based 
Qubit 2.0 Fluorometer using QubitTM dsDNA HS Assay Kit (ThermoFisher Scientific 
Inc., Waltham, USA). Measurement was based on signal generated by a fluorescent 
dye bound to DNA. For each measurement, two-point calibration was performed. 
Standard 1 served as a blank, and standard 2 had the concentration of 500 ng/L. For 
each DNA sample to be measured, 1 L of sample was added to 199 L Qubit working 
solution in Qubit tubes. As for standard, 10 L of standard was added to 190 L of 
Qubit working solution. The value obtained was multiplied by 200 as the dilution 
factor to calculate the DNA concentration in ng/L. 
2.1.3 DNA purification 
For many steps of the library preparation for sequencing, DNA needed to be purified, 
quantified and normalised in concentration before proceeding to the next step. 
Purification was performed using paramagnetic beads technology, with the 
HighPrepTM PCR reagent (Magbio, Gaithersburg, USA). The concentration of the 
paramagnetic beads (hereafter referred to as “beads”) was determined based on the 
desired purified product size. As a general rule, an increased ratio of beads:DNA 
volume increases the efficiency of purifying smaller fragments. The ratios of beads 
used are described in respective sections throughout this thesis. 
In a 1.5 mL Eppendorf LoBind tube, PCR products and designated amount of beads 
were added, and mixed by pipetting. For long fragments (for example: ligation 
product), care must be taken to avoid over vigorous mixing. The mixture was 
incubated in a roller mixer or by inverting the tubes manually for 5 minutes. Beads 
were then pelleted on a magnetic stand until a clear supernatant was observed. The 
supernatant containing all impurities was discarded, and DNA-containing beads 




hydrochloric acid solution was added to beads, and tubes were removed from the 
magnetic field. The mixture was again gently mixed for 5 minutes. After a brief spin-
down, tubes were placed in a magnetic stand for 5 minutes. The clear eluant 
containing the DNA was removed to a new tube for use in downstream analysis or 
quantified as necessary. For purification of longer DNA fragments, the final elution 
was incubated at 55°C for longer than 5 minutes, to increase recovery.  
2.1.4 Primer design 
General primers for PCR and Sanger sequencing were designed using Primer 3 v2.3.4 
built into Geneious version 8.1.8 (Biomatters Ltd., Auckland, New Zealand). PCR 
products were designed to range between 300 and 1200 bp in length. Melting 
Temperature (Tm) calculation was based on monovalent and divalent salt 
concentration of 50 mM and 1.5 mM, respectively with oligo and dNTP concentration 
of 50 nM and 0.6 mM. Primer length was designed to range between 18 and 27 bp, 
with melting temperature between 57 and 63°C. Specificity of each primer was 
checked using Primer-BLAST (Ye et al., 2012). Primers were chosen with no 
mismatch with the target regions and containing at least one mismatch in the three 
most 3’-end bases with non-target regions. Primers were ordered from Integrated 
DNA Technologies or Sigma Aldrich, and reconstituted with 1x tris-EDTA solution to 
a stock concentration of 50 M. This stock solution was diluted to a working solution 
with concentration of 5 or 10 M with Millipore-purified water. The stock solution 
was stored at -20°C and working solution at 2- 8°C.  
For multiplex PCR assay on MinION (Chapter 3), primers were designed using MFE-
primer3.0 (https://design.igenetech.com/) (Wang et al., 2019a), with help from the 
author, Wubin Qu (iGeneTech Bioscience, Beijing, China). Criteria included melting 
temperature between 59-61 °C, GC content between 29-66%, amplicon size between 
163-240 bp and primer length of 18-28 bp. 
Primers for bisulfite-sequencing (Chapter 6) were designed using Methprimer v2.0 
(Li & Dahiya, 2002), Bisulfite Primer Seeker (Zymo Research Corp, Irvine, CA, USA), 
Bisearch primer design (http://bisearch.enzim.hu/?m=search) or Primersuite (Lu et 
al., 2017). Criteria included amplicon length of 100 – 400 bp, primer length of 20–36 




default in respective software. For bisulfite amplicon sequencing (BSAS), where 
uniform amplicon length was desirable, amplicon length was restricted to 250-275 
bp. Not all software would generate primers of interest due to the restriction in 
amplicon length. All primers generated that spanned the CpG of interest were then 
checked for specificity using Bisearch ePCR, which aligned the primers against a 
“bisulfite-converted” human genome reference.  
2.1.5 Visualisation of PCR product 
Separation and sizing of PCR products was carried out in 1-2% agarose Gels 
(Hydragene, Fujian, China). The agarose gel powder was dissolved by heating in 1x 
Tris-acetic acid-EDTA acid buffer. Typically, 1 g of agarose gel was dissolved in 50 mL 
Tris-acetic acid-EDTA acid buffer, and 1x SYBR® Safe DNA Gel Stain (ThermoFisher 
Scientific Inc, Waltham, USA) was added to the gel before casting in the Easy-CastTM 
Electrophoresis System (Owl Scientific, San Francisco, CA, USA) with comb 
embedded to create wells for loading. Once the gel solidified, it was entirely covered 
with 1x Tris-acetic acid-EDTA acid buffer to a depth of least 1 mm from the surface 
of the gel. PCR products were mixed with 4x DNA loading dye and loaded into the 
wells. After all samples were loaded, they were electrophoresed at 90 V for 25 
minutes, or until the dye had traversed ~75% the length of the gel. For each row of 
wells, a DNA marker (KAPA Universal Ladder from Kapa Biosystems, 
Wilmington, USA) was included in one of the wells to serve as a size marker for the 
PCR product. 
2.1.6 Sanger sequencing 
Sanger sequencing was performed using 1 L of 1:3 diluted PCR product, 1 L of 
primer, 1x sequencing buffer, and 0.5 l of Big Dye Terminator (ThermoFisher 
Scientific Inc, Waltham, USA) in 10 L reaction. Dye incorporation was performed in 
a thermal cycler with 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds, and 60°C 
for 4 minutes, and subsequently purified using Sephadex G-50 before sequencing 
using in-house AB3130xL Genetic Analyzer (ThermoFisher Scientific Inc, Waltham, 





2.2 Methods for the multiplex panel on MinION (Chapter 3)  
The development of this method is the subject of Chapter 3. In total, Four nanopore 
sequencing runs (Run 1 – Run 4) were performed. 
2.2.1 Single target PCR 
Target amplification in the proof-of-principle protocol (Run 1) was performed in five 
single target PCR using the TAQ-TI Heat-Activated DNA Polymerase (Fisher Biotec, 
Wembley, WA, Australia) with 1x PCR buffer concentration, 1.5 mM magnesium 
chloride (MgCl2), 0.2 mM of each dNTPs, 0.5 M of each primer and 1.25 unit of Taq 
Polymerase in 50 L reaction. The PCR conditions consisted of 94°C for 2 minutes, 45 
cycles of 94°C for 15 seconds, 61°C for 15 seconds, and final extension of 72°C for 1 
minute. 
The primer sequences for the five targets are shown in Table 2.1. As the initial 
protocol (described in Chapter 3) involved ligation of PCR products, two enzyme 
restriction sites were added to the 5’ end of each primer to enable sticky-end ligation 
of the PCR products. 
2.2.2 Restriction with KpnI 
Forty microliter PCR product of each amplicon was digested with 4 l of KpnI (10,000 
U/mL) from New England Biolabs (NEB, Ipswich, USA) in the presence of 1x Tango 
Buffer (Thermo Fisher Scientific, Waltham, USA) in 60 L reaction, and incubated at 
37°C for 1 hour. 
Table 2.1 Primer sequences for MinION proof-of-principle assay 
No. Primers name 5’-tail (enzyme 
restriction 
sites)* 













































2.2.3 Sticky-end ligation 
The restriction products were purified together with 1.8x beads as described in 
Section 2.1.3, eluted in 50 L water, and quantified using the Nanodrop device. Thirty 
microliter of the purified DNA was subjected to ligation with four microliters of T4 
DNA Ligase (5 Weiss U/L) (ThermoFisher Scientific Inc, Waltham, USA) in 40 L 
reaction at 22°C for 1 hour.   
2.2.4 Blunt ligation 
Some samples were ligated using Blunt/TA Ligase (NEB, Ipswich, USA), hereafter 
referred to as Blunt/TA ligase. Fifteen microliters of each PCR product were mixed 
with 10 l of Ultra II End Prep reaction buffer and 5 L Ultra II End Prep reaction mix 
from NEBNExt Ultra II End Repair/dA-tailing Module (NEB, Ipswich, USA), making a 
total of 90 L reaction, and incubated for 5 minutes at 20°C followed by 5 minutes at 
65°C. The mixture was purified with 1.8x beads and eluted in 50 L water and 
quantified. Thirty microliters of this eluted product was then incubated with 30 L 
Blunt/TA ligase at 25°C for 1 hour.  
Both Sticky-end ligation and blunt ligation products were purified using 1x beads, 
eluted in 50 l of water, and quantified using Qubit.  
2.2.5 Multiplex PCR 
For Run 2 to Run 4, an extended assay with 15 amplicons was designed to run in 
multiplex PCR in one tube (Table 2.2). ONT specific sequences were added to forward 
(TTTCTGTTGGTGCTGATATTGC) and reverse (ACTTGCCTGTCGCTCTATCTTC) primers to 
enable the incorporation of sample barcodes by second-round PCR. The 15 forward 
primers and 15 reverse primers were pooled separately in 10 M working solution 
each. The reaction consisted of 1x PCR buffer, 3 mM of MgCl2, 0.4 mM of dNTPs, 1 M 
of each pooled primer, 1 M betaine, and 2.5 unit of TAQ-TI Heat-Activated DNA 
polymerase in 50 L reaction. The PCR condition was 94°C for 2 minutes, followed by 
35 cycles of 94°C for 15 seconds, 59°C for 15 seconds, 72°C for 30 seconds, and final 





Table 2.2 Primer sequences and variants detected by the extended multiplex PCR 


















































































2.2.6 Confirmatory PCR 
To ensure that all targets were amplified in the multiplex PCR, a second PCR of each 
primer pair was performed using 1:10 dilution of the multiplex PCR product. The 
reaction consisted of 1x PCR buffer, 1.5 mM of MgCl2, 0.2 mM of dNTPs, 0.5 M of 
each primer forward and reverse, and 1 unit of TAQ-TI Heat-Activated DNA 
polymerase in 20 L reaction. The PCR was run at 94°C for 2 minutes, followed by 20 
cycles of 94°C for 15 seconds, 59°C for 15 seconds, 72°C for 30 seconds, and final 
extension of 72°C for 1 minute.  
2.2.7 Real time PCR 
A real time PCR was performed to assess the efficiency and uniformity of 




series of a reference DNA sample or the PCR products were prepared as templates. 
Each PCR consisted of 1x PCR buffer, 1.5 mM of MgCl2, 0.2 mM of dNTPs, 0.5 M of 
each primer forward and reverse, 1 M betaine, 1 M of SYTO 9 (ThermoFisher 
Scientific, Waltham, USA), and 0.5 unit of TAQ-TI Heat-Activated DNA polymerase in 
10 L reaction. Reactions were carried out in a 384 well-plate in the LightCycler 480 
instrument (Roche Molecular Systems, Basel, Switzerland) in duplicate for each 
sample concentration. The PCR conditions consisted of 94°C for 2 minutes, followed 
by 35 cycles of 94°C for 15 seconds, 59°C for 15 seconds, 72°C for 30 seconds, and 
final extension of 72°C for one minute. Fluorescent signal was acquired at the 
extension phase with excitation at 465 nm and detection at 510 nm.  
2.2.8 Barcoding PCR 
A maximum of 96 PCR barcodes were available from ONT in the PCR 96 Barcoding 
Kit (EXP-PBC096). These barcodes were included in Run 2 to Run 4 by way of a 
second-round PCR. The original protocol from ONT recommends the use of LongAmp 
Taq polymerase (NEB, Ipswich, USA). However, as the PCR products were of short 
fragments (~200 bp), an ordinary Taq polymerase was used instead. In brief, 0.5 nM 
of purified multiplex PCR product was mixed with 2 L of barcode, 1x PCR Buffer, 1.5 
mM of MgCl2, 0.2 mM of dNTPs and 5 unit of TAQ-TI Heat-Activated DNA polymerase 
in 100 L reaction. This second-round PCR consisted of an activation step of 94°C for 
2 minutes, 15 cycles of 94°C for 15 seconds, 62°C for 15 seconds, 72°C for 30 seconds, 
and completed by a final extension of 72°C for 1 minute. The successful addition of 
barcodes was confirmed by a shift in DNA band size in gel electrophoresis and 
increased concentration by Qubit.  
2.2.9 MinION library preparation 
In total, three different library preparation were used in the multiplex assay 
development and the details of each workflow are described in the following 
sections. 
2.2.9.1 Native barcoding genomic DNA (R9 Version) 
MinION library preparation for the proof-of-principle (Run 1) was prepared 
according to the Native barcoding genomic DNA protocol (ONT). After PCR, enzyme 




using NEBNext End repair/dA-tailing module (NEB, Ipswich, USA). Forty-five 
microliters of each DNA sample were mixed with 7 l of Ultra II End Prep reaction 
buffer and 3 L Ultra II End Prep enzyme mix in 60 L reaction and incubated for 5 
minutes at 20°C followed by 5 minutes at 65°C. Afterwards, purification using 1x 
beads was performed and DNA was eluted in 31 L water. Native Barcode Adapter 
from ONT (2.5 L of each) was added to 22.5 L of each DNA in the presence of 25 L 
Blunt/TA ligase and incubated at room temperature for 10 minutes. Another step of 
purification using 1x beads was performed and DNA was eluted in 26 L nuclease-
free water and quantified.  
All barcoded samples were then pooled together in approximately equimolar 
concentration, concentrated using 2.5x beads and eluted in 38 l nuclease-free water.  
MinION specific adapter was added to the library where the 38 L of DNA was mixed 
with 10 L of Native Barcoding Adapter Mix, 2 L of Native Barcoding Hairpin 
Adapter and 50 L of Blunt/TA ligase in a total of 100 L reaction. After incubation 
at room temperature for 10 minutes, 1 l of Hairpin (HP) Tether was added, and the 
mixture was incubated for another 10 minutes at room temperature.  
Dynabeads MyOne Streptavidin C1 (ThermoFisher Scientific Inc, Waltham, USA) was 
prepared to be used in the next step of cleaning up the DNA+adapter mixture reaction 
as per protocol. The beads were vortexed and 50 L was transferred into a 1.5 mL 
Eppendorf LoBind tube and pelleted on the magnet until the eluate was clear and 
colourless. After the supernatant was discarded, the beads were washed two times 
with 100 L Bead Binding Buffer. In each step, the mixture was homogenised by 
vortexing, and beads were pelleted with the magnet. Finally, beads were 
resuspended in 100 L Bead Binding Buffer and vortexed. 
The 100 l of washed MyOne C1 beads was added to the DNA+adapter mixture, 
mixed for 5 minutes at room temperature and pelleted on the magnet. After 
supernatant was discarded, beads were washed two-times by resuspending in 150 
L Bead Binding Buffer by pipetting and pelleted on magnet. Finally, the pellet was 




Final DNA libraries ready for loading on to the MinION flow cell were prepared by 
adding 75 L of RBF1 and 50 L nuclease-free water to 25 L eluted DNA. Before 
sample loading, the flow cell was primed according to the protocol.  
2.2.9.2 2D PCR barcoding (96) amplicons (SQK-LSK208) 
Library for Run 2 was prepared according to this 2D protocol. PCR products of each 
sample were first ligated to create a concatenated DNA library using Blunt/TA ligase. 
Thirty microliters of end-repaired/dA-tailed barcode PCR product of each sample 
was incubated with 30 L of Blunt/TA ligase at 25°C for 1 hour, followed by beads 
purification (1x beads). Two of the 12 samples were additionally prepared as 
unligated library. The total 14 DNA samples were pooled in equimolar concentration, 
concentrated using 2.5 x beads, and quantified using Qubit. Approximately two 
micrograms of the DNA were subjected to another step of end-repair/dA-tailing, 
purified with 1x beads and quantified using Qubit. Ten L of Minion Adapter Mix 
(ONT) and 2 L of HP Adapter (ONT) was added to the DNA by ligation with Blunt/TA 
ligase and after incubation at room temperature for 10 minutes, 1 mL of HP Tether 
was added and mixture was incubated for another 10 minutes. The 40 microliters 
eluted DNA was then washed with 40 L Dynabead MyOne Streptavidin C1 which 
was prepared as described in Section 2.2.9.1, and eluted in 25 L of Elution Buffer. 
Final library was prepared by mixing 12 L of the eluted DNA with 37.5 L of Running 
Buffer with Fuel Mix and 25.5 L of Library Loading Beads.  
2.2.9.3 1D PCR barcoding (96) amplicons (SQK-LSK108) 
For the Run 3 (84 barcodes), barcoded PCR products of sample were pooled in two 
separate pools, concentrated using 2.5x beads and quantified using Qubit. One 
microgram of DNA from each pool was subjected to end-repair/dA-tailing as above. 
After another step of beads purification, 120 ng (~0.6 picomoles) of total pool 1 and 
2 was brought to the next step of adapter ligation reaction, consisting of 20 L of 
Adapter Mix (ONT) and 50 L of Blunt/TA ligase, incubated for 10 minutes at room 
temperature, and purified using HighPrep Beads. DNA was eluted in 15 L Elution 





Run 4 with fewer barcoded products (24) was prepared in the same manner, except 
more DNA was used in the adapter ligation step (2 x ~500 ng), and DNA was loaded 
into the flow cell twice, 24 hours apart, each containing ~200 ng.   
2.2.10 Data analysis 
Nanopore sequencing resulted in a fast5 file for each DNA strand being sequenced. 
These raw data were processed into variant calls using various bioinformatics tools, 
reflecting the continual development and release of new software over the period of 
this thesis. In general, the process consisted of basecalling or converting raw data 
into DNA sequence, demultiplexing, or grouping the reads into each sample based on 
barcodes, alignment to reference sequences, and variant calling. The details of the 
data analysis processes and tools are described in Chapter 3. 
2.3 Methods for CYP2D6 sequencing on GridION (Chapter 4) 
2.3.1 CYP2D6 long PCR 
The 6.6-kb long PCR amplifying the whole CYP2D6 gene was performed according to 
(Gaedigk et al., 2007). Specific sequences from ONT (Section 2.2.5) were added to the 
5’ end of forward and reverse primers to enable sample barcoding in subsequent 
steps. Genomic DNA (~250 ng) was amplified in the presence of 1x Kapa LongRange 
Buffer, 0.3 mM dNTPs, 1.75 mM MgCl2, 0.7 M of each primer, 1 M of betaine, and 
1.25 unit of Kapa LongRange Hot Start DNA Polymerase in 50 L reaction. PCR was 
run as follow: 94°C for 3 minutes, 30 cycles of 94°C for 25 seconds, 68°C for 10 
seconds, 68°C for 7 minutes, and final extension at 68°C for 7 minutes. PCR products 
were purified using beads. 
2.3.2 Detection of CYP2D6 gene deletion/duplication 
The CYP2D6 gene is known to have duplication and deletion alleles. Deletion and 
multiplication of the CYP2D6 gene can be identified by amplifying a 3.5-kb fragment 
with  CYP-13 and CYP-24 primers (Steen et al., 1995) for deletion, and Frag B primers 
(Gaedigk et al., 2007) for duplication in a duplex PCR together with the 6.6-kb 
primers. This PCR was carried out as above using 0.4 M of the 6.6-kb primers and 




2.3.3 CYP2D6 long PCR for duplicated allele 
In samples with a known duplicated allele, amplification of the whole duplicated gene 
was done using the long PCR primers (Gaedigk et al., 2007), producing an 8.6-kb 
fragment, which has been shown to be specific for the duplicated gene (Figure 2.1). 
PCR conditions were similar to those for CYP2D6 gene above, except for the use of 0.4 
M primers and extension for 10 minutes instead of 7 minutes. PCR products were 
purified using beads. Primers for this amplification were also equipped with 
sequences to enable sample barcoding.  
 
 
Figure 2.1 Positions of the CYP2D6 long PCR amplicons 
The 6.6-kb primers amplified the whole CYP2D6 gene including upstream and 
downstream sequences. The 8.6-kb primers specifically recognised the REP-DUP 
sequence and amplified the duplicated gene only. The size of genes and distance 
between them in the figure is not to scale. 
 
2.3.4 Barcoding PCR 
Barcodes were assigned to the 6.6-kb PCR products of each sample and 8.6-kb PCR 
products from duplicated alleles (where applicable) using the PCR Barcoding 
Expansion 1-96 kit (EXP-PBC096) (ONT). Barcodes were added using a second-
round PCR which contained ~ 0.5 nM of CYP2D6 6.6-kb or 8.6-kb purified PCR 
product in the presence of 1x LongAMP PCR buffer, 2 mM of MgCl2, 0.3 mM of dNTPs, 
and 5 units of LongAmp Taq DNA polymerase in 50 L reaction. PCR was performed 
as follows: 95°C for 3 minutes, 15 cycles of 95°C for 15 secs, 62°C for 15 seconds, 65°C 
for 7 minutes (6.6-kb amplicons) or 10 minutes (8.6-kb amplicons), with a final 





2.3.5 Library preparation 
The DNA library was prepared according to the 1D PCR barcoding (96) 
amplicons/cDNA (SQK-LSK109). It was an update of and essentially similar to SQK-
LSK108, which was used for the multiplex panel described in Section 2.2.9.3. After 
pooling the barcoded samples, 47 L (containing ~200 femtomoles of the pool) were 
subjected to DNA repair using 2 L of NEBNext FFPE DNA Repair enzyme mix and 3 
mL of Ultra II End Prep enzyme mix (both products from NEB, Ipswich, USA) and 3.5 
L of their respective buffers. After incubation at 20°C for 5 minutes and 65°C for 5 
minutes, the products were purified using 1x beads, and eluted in 61 L of nuclease-
free water. 
Sixty microliters of the library were used in the adapter ligation step, with the 
addition of 10 L of NEBNext Quick T4 DNA Ligase, and 25 L of Ligation Buffer and 
5 L of Adapter Mix from the ONT Sequencing Kit followed by incubation for at least 
10 minutes at room temperature. 
Purification was done with 0.4x beads, with L Fragment Buffer (LFB) as the washing 
solution. According to the protocol, LFB enriches for DNA fragments longer or equal 
to 3 kb. If DNA shorter than 3 kb was desired, S Fragment Buffer (SFB) could be used 
instead. Both buffers were included in the sequencing kit. DNA was eluted in 15 L 
of elution buffer.  
The final library was prepared by combining 12 L of the DNA library, 37.5 l of 
Sequencing Buffer (SQB), and 25.5 l of loading buffer. The library was loaded into 
the SpotON sample port of the flow cell following priming.  
2.3.6 Special beads purification 
Commercial beads such as Magbio beads typically purify DNA in the range of 150 – 
800 bp. In order to remove larger DNA fragments of <3-4 kb, special beads were 
prepared according to a protocol published on protocols.io (Nagar & Schwessinger, 
2018) by decreasing NaCl and polyelthylene glycol concentration to enable selection 
of longer DNA fragments (Stortchevoi et al., 2020). In brief, the required amount of 
Magbio beads (e.g. 5 mL) was pelleted and re-suspended in special buffer containing 




glycol 8000, 0.25% (v/v) Tween-20, and Millipore water to make up to the original 
volume (e.g. 5 mL).  
2.3.7 Data analysis 
Two sequencing runs were performed on GridION (ONT, Oxford, UK), and raw fast5 
files generated were basecalled in real time during sequencing, using Guppy 
basecaller. After completion of sequencing, a newer version of Guppy with a new 
algorithm of basecalling was released and all sequencing data were re-basecalled 
using this newer version (Guppy v2.2.2). After basecalling, various tools were used 
to demultiplex, filter, and align the reads to reference sequence and subsequently call 
and phase the variants. Confirmation of the variants detected was either available 
from public database (for Coriell reference samples) or generated using Sanger 
Sequencing. Data analysis is described in more details in Chapter 4. 
2.3.8 Sanger sequencing 
Sanger sequencing was carried out on nested PCRs covering different regions (Table 
2.3) of the 6.6-kb CYP2D6 PCR product. Nested PCRs were carried out in 20 L 
reactions containing 1x PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, 0.2 M of each 
primer, 0.5 unit of TAQ-TI Heat-Activated DNA Polymerase (Fisher Biotec, Wembley, 
WA, Australia) and 2 L of 1:1000 diluted 6.6-kb PCR product. DNA was amplified in 
a touchdown PCR consisting of 15 cycles of 94°C for 15 seconds, 70°C for 15 seconds, 
and 72°C for 1 minute with annealing temperature decrease of 1°C /cycle followed by 
20 cycles of 94°C for 15 seconds, 55°C for 15 seconds, and 72°C for 1 minute and a 
final extension at 72°C for 5 minutes. Sanger sequencing was performed as described 










Table 2.3 Primer sequences for the CYP2D6 sequencing 
No. Primer name Sequence (5’-3’) Reference 
Primers for long PCR 
1. 6.6kbF* ATGGCAGCTGCCATACAATCCACCTG (Gaedigk et al., 2007) 
2. 6.6kbR* CGACTGAGCCCTGGGAGGTAGGTAG (Gaedigk et al., 2007) 
3. FragD_8.6kbF* CCAGAAGGCTTTGCAGGCTTCAG (Gaedigk et al., 2007) 
4. FragD_8.6kbR* CGGCAGTGGTCAGCTAATGAC (Gaedigk et al., 2007) 
5. CYP-13 ACCGGGCACCTGTACTCCTCA (Steen et al., 1995) 
6. CYP-24 GCATGAGCTAAGGCACCCAGAC (Steen et al., 1995) 
7. FragB_Dup_F CCATGGAAGCCCAGGACTGAGC (Gaedigk et al., 2007) 
8. FragB_Dup_R CGGCAGTGGTCAGCTAATGAC (Gaedigk et al., 2007) 
Primers for Sanger sequencing 
1. 2D6_5UTRF GCAGCTGCCATACAATCCAC  
2. 2D6_5UTRF TGCTTTCTGGCCTCCATGTT  
3. 2D6Prom_R TCCTCCATAACGTTCCCACCAGAT (Wright et al., 2010) 
4. 2D6Prom_F CCATACCTGCCTCACTACCAAATG (Wright et al., 2010) 
5. 2D6Ex1F TCTGGAGCAGCCCATACCCG (Wright et al., 2010) 
6. 2D6Ex1SR CCCCAGACTACAGGTCCTAGTCCTATTTG (Chua et al., 2016) 
7. 2D6Ex2F TCCTCCTTCCACCTGCTCAC (Wright et al., 2010) 
8. 2D6Ex2SR CTTTGCCCCACCTCGTCTCT (Wright et al., 2010) 
9. 2D6Ex34F AGCTGGAATCCGGTGTCGAA (Wright et al., 2010) 
10. 2D6Ex34SR AGCCATCTCCAGGTAGACCCAG (Wright et al., 2010) 
11. 2D6Ex56F ACAGGCAGGCCCTGGGTCTA (Chua et al., 2016) 
12. 2D6Ex56SR CCTGGTCACCCATCTCTGGTC (Wright et al., 2010) 
13. 2D6Ex7F CCAACATAGGAGGCAAGAAG (Wright et al., 2010) 
14. 2D6Ex7R ACTGGACTCTAGGATGCTGG (Wright et al., 2010) 
15. 2D6Ex8F CAGAATGTTGGAGGACCCAA (Wright et al., 2010) 
16. 2D6Ex8R AGGAAAGCAAAGACACCATG (Wright et al., 2010) 
17. 2D6Ex9F TGAAGGATGAGGCCGTCTGG (Wright et al., 2010) 
18. 2D6-R ACTGAGCCCTGGGAGGTAGGTAG (Wright et al., 2010) 
*Specific sequences were added to the 5’ end of forward primers (tttctgttggtgctgatattgc) and the 5’ 
end of reverse primers (acttgcctgtcgctctatcttc) to enable sample barcoding  
 
2.4 Methods for genetic analysis of angiotensin converting enzyme 
inhibitor – induced angioedema (Chapter 5) 
2.4.1 Clinical samples 
Blood samples from 20 individuals with ACEi-A were acquired via UDRUGS 
(Understanding Adverse Drug Reaction Using Genome Sequencing) (Maggo et al., 
2017) or Genomic Analysis of Adverse Reactions to Drugs (GAARD) biobanks. These 
studies received ethical approval respectively from Southern Health and Disability 
Ethics Committee (URA/11/11/065) and Central Health and Disability Ethics 





2.4.2 Whole exome sequencing  
Samples for WES were sent to the Liggins Institute, Auckland University, New 
Zealand, and this was performed on the Ion Torrent Sequencer (ThermoFisher 
Scientific Inc, Waltham, USA). The Ion Torrent exome sequencing approach uses PCR-
enrichment, with a large pool of primers designed to target and enrich exome regions 
of the genome. Lists of variants in the form of VCF files were generated by Ion Torrent 
proprietary data analysis.  
2.4.3 Whole genome sequencing  
Samples for WGS were sent to Macrogen, Korea. WGS was performed on the Illumina 
NovaSeq 6000 using NovaSeq Control Software v1.0.1 for system control with the 
sequencing library prepared using TruSeq DNA PCR Free (350) (Illumina, San Diego, 
CA, USA). Basecalling was performed by Real Time Analysis v3.1.2, and converted to 
Fastq files using Illumina package bcl2fastq v2.20.0. Alignments and VCF files were 
generated using Genome Analysis Toolkit pipeline, which was carried out by a 
collaborator, Dr Klaus Lehnert from School of Biological Sciences, The University of 
Auckland. 
2.4.4 Array-based comparative genomic hybridisation (aCGH) 
The lab work for aCGH was led by Dr Kit Doudney (formerly: Canterbury Health 
Laboratories, Canterbury District Health Board, Christchurch). Genome-wide CNVs 
were screened in six of the ACEi-angioedema samples using the CGX SNP v2 180k 
array (PerkinElmer, Waltham, MA, USA), as per manufacturer’s instructions. In brief, 
subject DNA samples and reference DNA samples were restriction digested and 
labelled with Cy3 and Cy5 dyes respectively. Reference DNA samples and dyes were 
from the SureTag DNA Labelling Kit (Agilent Technologies, Santa Clara, CA, USA). 
Reference DNA samples were concentration- and gender- matched to each subject 
DNA sample. Labelled DNA was purified, quantified, and equal amounts of subject 
and reference DNA were mixed and hybridised onto the microarray slides for 24 
hours. After hybridisation, slides were scanned using the SureScan Microarray 
Scanner (Agilent Technologies, Santa Clara, CA, USA). Data were analysed using 
Genoglyphix software (PerkinElmer, Inc., Waltham, MA, USA), with candidate CNV 




number difference. The threshold cut-off for deletion was set at -0.44 and for 
duplication at 0.33. Candidate CNVs were further analysed for pathogenicity and 
frequency in population using various databases including Genome Aggregation 
Database (gnomAD) SV, DECIPHER, Database of Genomic Variants (DGV), and in-
house Canterbury Health Laboratories’ database.  
2.5 Method for examining effect of ACE inhibitor (lisinopril) on DNA 
methylation (Chapter 6) 
2.5.1 Clinical samples 
Clinical samples consisted of 49 male samples from healthy patients taking ACE 
inhibitors compared to 233 male samples from heathy patients not taking the drug. 
A collaborator, Associate Professor Greg Jones (Department of Surgery, University of 
Otago), provided this subset of data from the control cohort of a study investigating 
abdominal aortic aneurysm. Methylation data for all samples were obtained using the 
Illumina Infinium HumanMethylation450 (450K) BeadChip (Illumina, San Diego, CA, 
USA), that interrogates ~450K CpG sites. These data were generated previously by 
Assoc. Prof Jones and were made available for this analysis.  
2.5.2 Cell culture (Jurkat cell line)  
Jurkat cells were obtained from American Type Culture Collection (Manassas, USA) 
and grown in Advanced RPMI (Roswell Park Memorial Institute) 1640 media 
(ThermoFisher Scientific Inc, Waltham, USA). Media were supplemented with 1% 
heat-inactivated Fetal Bovine Serum (FBS), 0.1% Pen Strep (10,000 units/mL 
Penicillin and 10,000 g/mL Streptomycin) (ThermoFisher Scientific Inc, Waltham, 
USA) and 4 mM GlutaMAXTM (ThermoFisher Scientific Inc, Waltham, USA). Advanced 
RPMI was used to enable reduction of FBS down to 1%. FBS, even after heat 
inactivation, contains very high ACE activity, up to >400-fold of those found in human 
sera (Lubel et al., 2008), which can interfere with the effects of ACE inhibitor. 
Cells were propagated in 75 cm2 (T75) cell culture flasks at 37°C in 5% CO2. Cells 
doubled approximately every 24 hours, and cell density was maintained at 105 – 106 
cells/mL density.  For storage of the cell lines, cells were grown to ~8x105 cells/mL 




minutes. Supernatant was carefully aspirated without disturbing the cell pellet and 
discarded, while cells were re-suspended in culture media, and centrifuged as above. 
After removal of supernatant, 1 mL freezing media (Advanced RPMI with 20% FBS 
and 10% DMSO) was added to the cells. Cells were re-suspended and transferred into 
NuncTM CryoTube vials (Thermo Scientific, Waltham, USA) and placed in Mr. FrostyTM 
freezing container (ThermoFisher Scientific, Waltham, USA) at -80°C. 
Each independent experiment to induce DNA methylation changes was conducted 
with a new aliquot of frozen cells. The frozen aliquot was thawed rapidly at 37°C and 
added to 9 mL of culture media in a 15-mL Falcon tube and centrifuged at 250 rcf for 
5 minutes. Supernatant was discarded and cells were re-suspended in culture media 
then seeded into T75 flask at ~5x105 cells/mL. Cells were cultured for 1 week, or 
until cells were doubling every 24 hours before starting any drug treatment. 
2.5.3 Cell viability 
Counting of living cells was done by trypan blue exclusion. Living cells have intact cell 
membranes that will exclude dyes such as trypan blue while dead cells do not. Living 
cells will therefore show clear cytoplasm and dead cells will have blue cytoplasm. An 
equal part of 0.4% trypan blue solution (ThermoFisher Scientific, Waltham, USA) was 
added to 50 L of cells to achieve two times dilution, and mixed by pipetting up and 
down. An aliquot of 10 L was loaded into a haemocytometer with the coverslip in 
place, and cells were counted under a light microscope. All live cells (clear) were 
counted in each large square in each corner of the haemocytometer. Number of live 
cells per mL can be calculated by dividing number of total cells counted by 4 and 
multiplied by dilution factor of 2, and multiplied by 10,000 to convert 10 L to 1 mL. 
2.5.4 ACE activity 
ACE activity was measured to confirm ACE inhibition by ACEi treatment of Jurkat 
cells. ACE activity in culture media was measured at Canterbury Health Laboratories 
using a commercial kinetic assay. Cells were cultured in Advanced RPMI media 
supplemented by 20% FBS. A higher proportion of FBS was used because when cells 
were grown in the presence of 1% FBS, ACE activity was found to be below the limit 
of detection of the ACE activity assay at 3.0 IU/mL. Cells were cultured without ACE 




(number of cells ~8x105 cells/mL). An aliquot of each conditioning media was used 
for ACE activity measurement. 
2.5.5 Drug treatment of cultured cells 
ACE inhibitor (lisinopril) and DAC were purchased from Sigma Aldrich (Saint Louis, 
MO, USA). Nicotine-derived nitrosamine ketone (NNK), also known as 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone, was purchased from Toronto 
Bioscience (Toronto, Canada). DAC and NNK served as hypomethylation and 
hypermethylation controls, respectively. Lisinopril is soluble in water, and for this 
experiment, was dissolved in sterile PBS to make stock solution at 25 mM. Solution 
was further sterilised by filtering through 0.2 m syringe filter (ReliaPrepTM, 
Ahlstrom, Helskinki, Finland) in a biosafety cabinet. DAC and NNK were dissolved in 
DMSO at 10 mM and 500 mM respectively. Stock solutions were aliquoted into small 
amounts and frozen at -80°C.  
Various concentrations of the drugs were then prepared by diluting stock solution 
into culture media. In every experiment, DMSO was added to all treatment and 
control flasks to achieve the same concentration of DMSO in each flask. DMSO in 
culture media of all treatments never exceeded 0.05%. 
For experiments to induce DNA methylation changes, cells were treated with 0.1 M 
DAC for 48 hours, 300 M NNK for 2 days, and 500 nm and 1 M lisinopril for 6 days. 
These concentrations were determined based on literature review and cytotoxicity 
assays using various concentration of respective drug (details in Chapter 6).  
2.5.6 Methods for DNA methylation assays 
2.5.6.1 Bisulfite conversion  
Bisulfite conversion was performed using the EZ DNA Methylation-GoldTM Kit from 
Zymo Research (California, USA), according to the manufacturer’s protocol. CT 
Conversion Reagent containing sodium metabisulfite was added to 500 ng of DNA, 
and incubated at 98°C for 10 minutes, 53°C for 30 minutes, followed by 8 cycles of 
53°C for 6 minutes and 37°C for 30 minutes. The mixture was then transferred to a 
Zymo-Spin IC column containing the M-Binding buffer. After spinning down and 




conversion of unmethylated cytosine to uracil (Figure 2.2). The two washes were 
performed, and finally, bisulfite-converted DNA was eluted in 10 L of M-Elution 
Buffer. Naked cytosines would be converted into uracils by this reaction, which are 
then converted into thymines during PCR, while methylated cytosines were 
protected from the reaction and remained as cytosine after PCR (Kristensen & 
Hansen, 2009). 
 
Figure 2.2 Bisulfite conversion of cytosine to uracil 
Unmethylated cytosine is converted into uracil through three steps of reaction: 
sulfonation of cytosine to cytosine-6-sulfonate, deamination to uracil-6-sulfonate, and 
desulfonation to uracil. Methylated cytosine is protected from this reaction and remains 
cytosine. Figure is reproduced with permission from (Kristensen & Hansen, 2009). 
 
2.5.6.2 Bisulfite PCR 
Bisulfite PCR was performed using TaKaRa EpiTaq™ HS (Takara, Shiga, Japan). Two 
microliters of bisulfite-converted DNA were amplified in the presence of 1.25 U 
TaKaRa EpiTaq HS, 1x EpiTaq PCR Buffer, 2.5 mM or 3 mM of MgCl2, 0.3 mM of dNTP 
mixture, and 0.4 M of each primer in 50 L reaction. Primer sequences used for 
bisulfite PCR for multiple target loci were presented in Table 2.4. The PCR was run 
using  a touch down approach as follow: 94°C for 3 min, 15 cycles of denaturation at 
92°C for 15 seconds and extension at 68°C for 1 minute with annealing temperature 
decreasing 1°C per second, from 60°C to 45°C, followed by 40 cycles of 92°C for 15 
seconds, 45°C for 15 seconds and 68°C for 1 minute, and finished with a final 
extension at 68°C for 5 minutes.  
2.5.6.3 Bisulfite amplicon sequencing (BSAS) 
BSAS is a method to sequence multiple bisulfite-converted DNA targets in multiple 
samples in one NGS run. This analysis was performed using Illumina sample indexing 




with bisulfite conversion and bisulfite PCR of each DNA target, as described above. 
Specific sequences according to the 96 NEXtera kit (Illumina, San Diego, CA, USA) 
were added to each sequence-specific primer, allowing the addition of NEXtera index 
to the PCR products in subsequent step.  
Individual PCR product for each amplicon from each sample was prepared as in 
Section 2.5.6.2.  Purification of each PCR product was performed using 0.9x beads 
and eluted in 1 mM Tris-hydrochloric acid and all PCR products of each sample were 
pooled in an equimolar manner to obtain a similar concentration in all samples, and 
then diluted to 0.4 ng/L. Two ng of pooled PCR product from each sample was 
subjected to a second round PCR, to introduce the index sequences. Indexing using 
the 96 NEXtera kit required two indexes per sample, combinations of which were 
chosen using the Illumina Experiment Manager. The indexed products were purified 
using 0.9x beads, quantified using Qubit, and diluted to 4 nM and pooled together 
resulting in a 4 nM final pool containing all amplicons of all samples.  
This final pool was used to prepare library for the BSAS run on MiSeq Instrument 
(Illumina). In brief, PhiX Control DNA was diluted to 4 nM using Resuspension Buffer 
containing 0.1% Tween 20 and both sample and PhiX Control DNA were denatured 
using 0.2N NaOH and further diluted to 12.5 pM. The final library was prepared by 














Table 2.4 Primer sequences for bisulfite sequencing 




c10orf108_F TTATGTATTTTATATAAAAGATAGGGTTTTTTTG 300 
c10orf108_R TCTCCTAAAACTAAATTACTAACAACTC 
cg10322879 YWHAQ_F  TGTTATAGTATAGTGGTGTTTTATAGGGAAAGGG 300 
YWHAQ_R ACATTAAATAAAATAAAAAAACAAACACTC 
cg24443446 JMJD1C_F TAGAGTATTTAAAGGTAGGGTG 283 
JMJD1C_R AACCTATTCCCAAAATCTAA 
cg09015232 SLC12A5_F  AGAAGGTTTTTGGTTGTGGG 251 
SLC12A5_R CCAAACCCTCTTTCATACCACTA 
cg12875534 CXCR3_F  GGAAAAAGAAAGGGAATTATTAG 251 
CXCR3_R CACTTAAAAAAAACTAAAAACAA 
cg10948471 MAP3K13_F TGTGTGTGTTTTATAAAGATGAAA 269 
MAP3K13_R TCTACAAAATCTCAAAACATAACT 
cg08004425 GRIK3_F  TTTGTTTTTATAGGGAGGAG 246 
GRIK3_R CTCCRAAATCTAATTTAAAAATA 
cg26947966 APBB2_F TGTGTTTTTGTGGAGAAATT 248 
APBB2_R AACTTTTACTTTACAAATACC 
cg14801158 ZNF506_F GAGATAATGGGTTYGTTAAAGT 275 
ZNF506_R TTACAATCCAACCTAAACAACAAAA 
cg02366400 CD44_F GTGTTGGGATTATAGGTTTG 258 
CD44_R ATAAAAATATTAAATTCTTTTACATAAATA 
cg19324996 BRD7_F GTTGATAGGTGAAGGTTATTAGA 248 
BRD7_R TATTAATTACCAACAATAAAATCCTAAAAT 
cg18106045 cg18106045_F TGGTATTTTGGTTGGTTGTTATT 267 
cg18106045_R CCTAAAATCTCTTTATTTCAC 
cg01507639 cg01507639_F ATTAATGAAGAAATTGAGGTTTTAAGAAG 267 
cg01507639_R AAAATTCTCAATACTAAACATAACATTT 
cg12424249 mir1268A_F TTGAAGTTGATTGAGATAGG 253 
mir1268A_R AATTCTTCATCTACCCAAAAATAC 
NNK 
cg02933100 grb10_F TTTTGAGTTGTTTTTTTTATATTTATG 267 
grb10_R AAAAAAACAAAAACTTAACTCTAATTC 
cg17064296 ZFR_F ATATAATTTAATATGAGGAATAAAAGG 252 
ZFR_R TCTTTATTATATTAACTCCATAATAAC 
cg20424974 NPNT_F TTGTAGGTATAAAAGAGTTTGTAGA 256 
NPNT_R TAAAATCCCCAAACTTAATACTCA 
cg20299690 ZNF521_F AGGATAGAATAAGTTTGTTA 248 
ZNF521_R ATCCTAAAAATCCATCTCCTAAA 
cg02790260 LRIT2_F TTATTAATTAGGGTATTTTTAGT 270 
LRIT2_R CTCTCTCTTTATTTTAAATTTTTACC 
cg09200221 FOXK1_F AAAGTTTTGTTTTTTGTGATTTGTA 268 
FOXK1_R CCAATCACCAAATAAAACCC 
Multiple LOX_F GATTTAATAGTATTTTTTTTYGTG 275 
LOX_R RCCCCTCAACTATTTATTCA 
Multiple DAPK_F GGTAGAGGAATTTAGTTTAA 305 
DAPK_R ATTACTAAACTACCCTCTAA 
DAC 
Multiple GNA14_F TAGTTAGGGAGGTAAGTGTGGGAG 275 
GNA14_R AAACCTAACTAACCTTTACCTAAAAA 
*Specific sequences were added to the 5’ of forward primers (tcgtcggcagcgtcagatgtgtataagagacag) and 




Two BSAS runs were performed in this thesis. The first one was performed at Massey 
University together with a library generated by another researcher using MiSeq 500 
cycle Kit v2 (Illumina, San Diego, CA, USA). The second run was performed at the 
Canterbury Health Laboratories with the lead of Dr Meik Dilcher, using MiSeq 
Reagent Nano Kit v2 (Illumina, San Diego, CA, USA).  
2.5.6.4 BSAS data analysis 
Two fastq files were generated for each sample, representing each of the paired-end 
sequencing datasets. These fastq files were aligned to reference sequence and 
analysed for methylation percentage at CpG sites using Bismark v0.20.0 (Krueger & 
Andrews, 2011). Reference sequences for each amplicon were prepared in a fasta file 
and put in one directory. Running Bismark_genome_preparation created two 
additional directories, each consisting of CT and GA converted reference 
sequences, respectively. 
The two fastq files of each sample were then aligned to these reference sequences, 
creating a binary alignment map (BAM) file for each sample. Running 
Bismark_methylation_extractor combined with bedgraph created a browser 
extensible data (BED) file consisting of contig names, position, methylation 
percentage, and coverage of C and T in the particular position. The BAM files were 
sorted and indexed using samtools to enable visualisation on Integrative Genome 
Browser (IGV, Broad Institute, Boston, MA)(Robinson et al., 2011). The methylation 
percentages were then compiled into one Microsoft Excel file, and imported into 
GraphPad (GraphPad Software, San Diego, CA, USA) to analyse the difference 
between controls and treatments. Analysis was done by t-test with correction for 
multiple testing at false discovery rate (FDR) of 1% using the two-stage step-up 
method of Benjamini, Krieger and Yekutieli (Figure 2.3). The script prepared for 






Figure 2.3 Bioinformatic workflow for BSAS 
Data analysis using Bismark consisted of preparing and indexing references, mapping 
of paired read to reference, and extraction of methylation data in Browser Extensible 
Data files.  
 
2.5.6.5 Methylation array (Infinium MethylationEPIC BeadChip Kit) 
Genome-wide differential methylation sites were interrogated using Infinium 
MethylationEPIC BeadCHIP (EPIC array) from Illumina. Samples for this assay were 
sent to Australian Genome Research Facility (AGRF) in Melbourne, Australia. This 
EPIC array assesses more than 850,000 methylation sites across the genome.  
The principle of the EPIC methylation array is similar to that of SNP arrays. After 
bisulfite conversion, unmethylated cytosines are converted into uracil while 
methylated cytosines remain unchanged. The proportion of these are measured 
using two site-specific probes, one for the methylated locus (M bead type) and 
another for the unmethylated locus (U bead type).  
If a CpG site is methylated, the M probe will bind and allow for one base extension 
with labelled dideoxynucleoside triphosphates and generate signal. The U probe will 
have one base mismatch, inhibiting the one base extension. If a CpG site is 
unmethylated, the contrary occurs. The signal ratio between the methylated and 
unmethylated probes provides a quantitative measurement of the methylation state 





Figure 2.4 Principle of methylation array detection  
At the methylated locus (left side), the M probe, but not the U probe, binds and enables 
one base extension with labelled dideoxynucleoside triphosphates to take place. On the 
contrary, at the unmethylated locus (right side), the U probe binds and allows for one 
base extension. Figure is reproduced from (Illumina, 2019a) 
 
2.5.6.6 Methylation array data analysis 
Methylation array data from clinical sample were analysed using Qlucore Omics 
Explore 3.3 (64-bit) (QOE, www.qlucore.com). Correction for age and cell types was 
done for these clinical samples within the Qlucore software. Correction for cell types 
was done based on Horvath method for blood cell composition. Methylation array 
data from cell culture work were processed, normalised and filtered using the R 
package minfi. Both treatment groups (lisinopril and NNK) were compared to the one 
control group, and significant CpG sites were called using the R package limma 
(Ritchie et al., 2015). The lisinopril dataset was also analysed using a modified 
Dunnett’s t-test-based from the R package MulCom (Isella et al., 2011). FDR was set 
at 5% for both packages. Manhattan plot was generated using the R package, qqman 




Chapter 3 : A multiplex pharmacogenetic assay using the 
MinION nanopore sequencing device 
 
The material in this chapter formed the basis of the following paper: Liau, Y., Cree, S. 
L., Maggo, S., Miller, A. L., Pearson, J. F., Gladding, P. A., & Kennedy, M. A. (2019). A 
multiplex pharmacogenetics assay using the MinION nanopore sequencing device. 
Pharmacogenetics and Genomics, 29(9), 207-215 (Liau et al., 2019b).  
3.1 Introduction 
This chapter describes the development of a pharmacogenetic multiplex assay using 
the nanopore sequencing technology. The assay consists of a panel of genetic variants 
relevant to response to clopidogrel and warfarin, chosen based on available 
guidelines and recent publications.  
3.1.1 Pharmacogenetics of clopidogrel and warfarin 
Clopidogrel is an anti-platelet agent, commonly used together with aspirin in patients 
with coronary artery disease undergoing percutaneous coronary intervention (Lewis 
& Shuldiner, 2017). Clopidogrel is a prodrug that requires activation in the liver, with 
CYP2C19 being an important enzyme in this process (Polasek et al., 2011). Inter-
individual variations in response to clopidogrel both in terms of antiplatelet response 
and clinical outcome have been associated with variation in the CYP2C19 gene 
(Holmes et al., 2010; Mega et al., 2010; Simon et al., 2009). This association has been 
labelled as actionable pharmacogenetics by CPIC with clinical annotation of 1A by 
PharmGKB which means that this information is implementable in clinics (Whirl-
Carrillo et al., 2012). More than 30 variants are known for this gene, with various 
effects on the enzyme activity (Gaedigk et al., 2018b; Relling & Klein, 2011). Despite 
this established association, the CYP2C19 genetic variation only explains about 12% 
of total drug response variability (Shuldiner et al., 2009).  
The partial understanding of pharmacogenetics of clopidogrel has led to studies 
trying to find other genetic contributors. A study based on exome sequencing 




This gene encodes the beta-1,4-galactosyltransferase 2 protein which is highly 
expressed in platelets and might affect platelet adhesion. The variant was 
significantly associated with low platelet response, independent of the CYP2C19 
variants (Scott et al., 2016). 
Another variant reported to modify clopidogrel response is rs1045642 in ABCB1. 
ABCB1 codes for the intestinal efflux transporter P-glycoprotein. It regulates the 
absorption of several xenobiotics from the intestinal lumen, including clopidogrel. 
Several studies have shown the association between ABCB1 rs1045642 C allele with 
lower platelet response and poorer clinical outcomes compared to T allele (Su et al., 
2017; Zhong et al., 2017).  
Association of CYP2C9 and VKORC1 variants with prediction of warfarin response and 
toxicity is another example of actionable pharmacogenetics (Relling & Klein, 2011). 
Warfarin is an oral anticoagulant commonly used to prevent and treat 
thromboembolic diseases such as vein thrombosis, pulmonary embolism, atrial 
fibrillation and cardiac valve replacement (Johnson & Cavallari, 2015). Warfarin 
therapeutic range is narrow, and the optimal dose is highly variable among 
individuals (Wadelius & Pirmohamed, 2006). The more active S-enantiomer of 
warfarin is mainly metabolised by CYP2C9 enzyme in the liver, and it is known that 
people with mutations in the gene coding for this enzyme will need lower dose to 
reach desired therapeutic range and are at higher risk of bleeding (Higashi et al., 
2002). VKORC1 is the pharmacological target of warfarin. VKORC1 converts vitamin 
K epoxide to its reduced form, which is an important cofactor to many clotting 
proteins. Inhibition of VKORC1 by warfarin decreases the generation of reduced 
vitamin K and provides inhibition of coagulation. VKORC1 rs9923231 A allele is 
associated with lower expression of the gene and people with this variant require a 
lower dose of warfarin (Owen, 2010). The variations in CYP2C9 and VKORC1 are 
responsible for ~ 40% of warfarin dose requirement (Sconce et al., 2005) and the 
initial dose based on these variations has been included in the drug label of warfarin.  
Variation in CYP4F2, especially the V433M (rs2108622) variant has been reported to 
be moderately associated with warfarin response (Liang et al., 2012). The alternative 
T allele was associated with a higher level of vitamin K oxidation in the liver and 




2009). Gamma-Glutamyl Carboxylase (GGCX) is another important enzyme in the 
vitamin K cycle, being a cofactor in the activation of coagulation factors. A meta-
analysis showed that the rs11676382 variant in the gene modulated the requirement 
of warfarin dose, and the effect was variable throughout different ethnicities (Sun et 
al., 2015). Together with CYP2C9, VKORC1, genotype information for CYP4F2 and 
GGCX could be used to optimise warfarin dose in the warfarindosing.org website. 
3.1.2 Development of a pharmacogenetics multiplex assay on MinION 
Being a portable and affordable device, MinION serves well the purpose of point-of-
care testing, a feature desired in pharmacogenetics where genotypes of interest are 
made available, preferably in short time, prior to prescription of a certain drug. 
Moreover, sample barcodes are available from ONT, enabling multiple samples (up 
to 96) to be sequenced simultaneously.  
To enable an efficient multiplex PCR in which regions containing all variants of 
interest are amplified together in one tube, short amplicons are preferred over long 
amplicons. However, MinION was designed both in the library preparation and 
bioinformatics tools, to sequence long DNA strands. For example, the concentration 
of adapter used in the library preparation is optimised to 1 ug of DNA, assuming the 
DNA was at least 3 kb long. When using short DNA fragments (500 bp), DNA 
concentration should be reduced to <100 ng to be compatible to the amount of 
adapter available in the sequencing kit. Moreover, the early bioinformatics tools 
could not handle short reads.  
Therefore, the first step in this assay development was to apply strategies to adapt 
the short amplicons containing variants of interest to work well in the nanopore 
sequencing workflow. This was done by ligating the amplicons of each sample to 
generate a long-concatenated DNA strand prior to adding sample barcode and 
MinION specific adapter.  
3.2 Specific methods 
A proof-of-principle assay, covering five SNPs related to response of clopidogrel and 
warfarin treatment was initially developed to validate the ligation approach. The 




5’ end of each primer to allow generation of sticky-ends for ligation of amplicons. 
Native Barcoding kit (ONT, Oxford, UK), enabling barcoding up to 12 samples, was 
used to multiplex the samples. In the next steps following the promising results of 
this preliminary assay (as described further in Section 3.3.1), an extended assay 
covering more SNPs was subsequently developed. 
It is important to note that at the time of this work, the MinION platform was still 
undergoing rapid evolution, and throughout the development of this 
pharmacogenetics panel, the sequencing chemistry, bioinformatics tools, and the 
device itself developed and changed as well. Some important changes included 
discontinuation of the 2D sequencing chemistry used in the early phase of this work 
and changes in flow cell from R9 to R9.4 and R9.5. In addition to those inevitable 
changes, some changes were also introduced by design. For example, the Native 
Barcoding Kit used in the proof-of-principle assay, was later replaced by PCR 
barcoding kit, which has a higher capability of multiplexing up to 96 samples. Short 
read direct sequencing was also proven to not be a limitation anymore, and the 
ligation step was omitted in later stages of assay development. The various 









Proof-of-principle run (Run 1) 
MinION Workflow: Native barcoding genomic DNA (R9 Version) 
Flow Cell: R9 






Extended assay with reference samples (Run 2) 
MinION workflow: 2D PCR barcoding (96) amplicons (SQK-LSK208) 
Flow Cell: R9.4 






Extended assay with clinical samples (Run 3 and 4) 
MinION workflow: 1D PCR barcoding (96) amplicons (SQK-LSK108) 
Flow cell: R9.5 





Figure 3.1 Workflows of multiplex assays using MinION 
Sequencing run 1 and 2 used 2D chemistry while the subsequent runs used 1D 
chemistry. Sample barcodes were employed through ligation (Run 1) or PCR (R77un 3-
4). Ligation of amplicons was applied in Run 1 and 2 only. *Some samples were run with 
and without ligation in Run 2. 
PCR (separately 
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3.2.1 Data analysis 
Following each sequencing run, several steps of data analysis were required to 
convert the raw FAST5 file to the final VCF files containing the genotypes of the 
variants of interest in each sample (Figure 3.2).  
 
Figure 3.2 Bioinformatic workflow for the MinION multiplex assay 
Bioinformatic workflow consisted of basecalling, demultiplexing, extraction to fastq 
files, mapping to reference, and variant calling.  
 
Newer bioinformatic tools for various steps of the data analysis were introduced 
throughout the assay development, with the main improvements being in the 
basecalling and variant calling tools. Basecalling was done with two different tools. 
The tool available at the time of the proof-of-principle assay was the cloud-based 
epi2me from Metrichor Ltd. Albacore was the next first-line basecaller from ONT 
(released in April 2017), available during the development of this chapter. Epi2me 
by Metrichor gave fast5 as the output file, while later versions of Albacore generated 




poretools. Epi2me and Albacore would simultaneously bin the resulting fast5/fastq 
files in respective barcodes. This demultiplexing process could also be done using 
tools like PoreChop (https://github.com/rrwick/Porechop).  
The fastq files were then mapped to an indexed reference using Burrows–Wheeler 
Aligner Maximal Exact Matches (BWA MEM), resulting in sequence alignment map 
(SAM) files. These were converted to sorted BAM files, and indexed using samtools 
(Li et al., 2009). Another mapping tool, Graphmap (Sovic et al., 2016) was also 
explored.  
Lastly, variants were called from either SAM/BAM files using various variant calling 
tools, resulting in a VCF file per sample. MarginCaller (Jain et al., 2015) was used in 
initial runs as it was the nanopore sequencing specific variant caller available at the 
time. In the later runs, different tools were tested including VarScan 2 (Koboldt et al., 
2012), nanoplish (Quick et al., 2016), and Clairvoyante (Luo et al., 2019). Various 
tools, NanoOK (Leggett et al., 2015), Qualimap 2 (Okonechnikov et al., 2015) and 
MinION QC (Lanfear et al., 2019) were used to generate quality control parameters 
including coverage per amplicon and error rates. The details on list of tools used to 
analyse the data from the MinION sequencing run are given in Table 3.1 and the 







Table 3.1 Bioinformatic tools for the MinION assay 
No. Steps Processes Tools Link References 
1.  Basecalling Conversion of raw 





Albacore (v0.8 – v2.3.0) 
Available through nanopore community 
 
Available through nanopore community 
 
 
2. Demultiplexing Sorting of basecalled 









Conversion of fast5 to 
fasta/fastq files 
 
Poretools https://github.com/arq5x/poretools (Loman & Quinlan, 
2014) 








(Sovic et al., 2016) 
5. Conversion to 
BAM files 
Conversion of SAM to 
BAM files 
 
Samtools https://github.com/samtools/ (Li et al., 2009) 













(Jain et al., 2015) 
 
(Quick et al., 2016) 
(Koboldt et al., 2012) 
(Luo et al., 2019) 
7. Quality control 
and statistics 












(Leggett et al., 2015) 
(Lanfear et al., 2019) 






The assay development was completed in four nanopore sequencing runs. It started 
with a proof-of-principle assay (Run 1), followed by development of an extended 
assay. The extended assay was first validated with reference samples (Run 2), and 
then with clinical samples (Run 3). A final run, with increased read depth (Run 4) was 
performed to further validate the accuracy of the assay. Key information about the 
four sequencing runs is summarised in Table 3.2.  
Table 3.2 Summary of the four nanopore sequencing runs 






































Barcode Native Barcode 
(by ligation), max. 
12 
PCR Barcode (by 
PCR), max. 96 
PCR Barcode (by 
PCR), max. 96 
PCR Barcode (by 
PCR), max. 96 
PCR Individual Multiplex Multiplex Multiplex 






Metrichor – BWA 
MEM – 
marginCaller 
Albacore v0.8.4 – 
BWA MEM – 
marginCaller 
Albacore v1 – v2.3 





Albacore v2.3 – 




3.3.1 Proof-of-principle assay (Run 1) 
This assay was designed to test the adaptability of ligation-based long-read library 
preparation and the overall accuracy of the MinION technology for genotyping. Two 
in-house DNA samples were included, and the native barcoding kit, enabling 
multiplexing up to 12 samples, was used. Eight barcodes were used to test different 
parameters. Library preparation  was detailed in Chapter 2, Section 2.2.9.  
Two ligation methods were tested i.e. sticky-end and blunt-end. Additionally, 




concentration on sequencing results. There was no observed correlation between 
DNA amount and read depth (pearson test, p-value=0.95) (Table 3.3), as seen in 
NB02 and NB04, which had approximately the same starting material, but different 
read depth. Moreover, NB11, which had the lowest DNA amount and was ligated 
through blunt-end ligation appeared to have higher read depth compared to some 
other samples. ANOVA test for read length distribution among samples showed 
significant difference (p-value <0.05). Contrast among samples using Tukey Honest 
Significant Difference test showed significant difference between all pairs of samples, 
except for NB02 (sticky-end ligation) vs NB03 (blunt-end ligation) (p-value=0.16). 
This demonstrated no difference in read length between sticky-end and blunt-end 
ligation. However, blunt-end ligation seemed to result in fewer reads compared to 
sticky-end.  
Table 3.3 Metrics of the proof-of-principle run (Run 1) 
General metrics   
Parameters Results 
Total yield 60 Mb 
Read length 160 – 16,936 (mean: 1391) 












Reads mapped to reference 42,653 (99.92%) 
Metrics per barcode 
Sample Barcode Ligation 
type 





length (bp) sample 1 NB01 sticky- nd 448 151,170 1,636  
NB03 blunt-end 278 19,290 1,363 
sample 2 NB02 sticky-end 380 354,960 1,435  
NB04 blunt-end 380 142,050 1,238  
NB11 blunt-end 128 250,140 1,104 
 
Reads were basecalled and demultiplexed into each barcode directly by the 
basecalling tool, cloud-based epi2me from Methricor. Fastq or fasta files of each 
barcode were extracted using poretools, and then aligned to reference using BWA 
MEM, generating SAM files. Samtools was used to convert SAM to BAM files, which 
were then used to visually detect the SNPs of interest. Sanger sequencing was used 
to generate the reference genotype of each sample. The genotyping result generated 







Table 3.4 Genotyping results of the proof-of-principle run (Run 1) 
Sample Barcode CYP2C19*2 CYP2C19*3 CYP2C9*2 CYP2C9*3 VKORC1 
rs9923231 




























NB04 G/A G/G C/C A/A A/A 





3.3.2 Extended assay with reference samples (Run 2) 
Following the accurate genotyping by the proof-of-principle assay (Run 1), a more 
comprehensive panel was developed (Run 2), including 15 amplicons covering 27 
SNPs in 7 genes, related to pharmacogenetics of clopidogrel and warfarin (Table 3.5 
and Figure 3.3) 
To simplify the workflow, a multiplex PCR, with product sizes ranging from 167 bp 
to 240 bp was designed. The details of the PCR primers can be found in Chapter 2. 
PCR Barcoding Expansion 1-96 kit (EXP-PBC096, ONT) was used to replace native 
barcodes used in the previous run, to enable multiplexing more than 12 samples.  
Specific sequences from ONT were added to each forward and reverse primer to 
accommodate subsequent addition of the barcodes through PCR. No enzyme 
restriction site was added to the primer, as previous runs showed that blunt ligation 
resulted in comparable read length to sticky-end ligation. Moreover, more tails in the 
primers would likely complicate the multiplex PCR optimisation.  
Table 3.5 List of amplicons and SNPs for the extended assay 
Amplicons Length SNPs detected 
CYP2C192 212 CYP2C19*2, CYP2C19*10, CYP2C19*7 
CYP2C193 214 CYP219*3 
CYP2C194 238 CYP2C19*4, CYP2C19*15 
CYP2C195 170 CYP2C19*5, CYP2C19*16 
 
CYP2C19*16 




CYP2C19 218 * 7 
B4GALT2  222 B4GALT2 rs1061781 
ABCB1 195 ABCB1 rs1045642 
CYP2C92 237 CYP2C9*2, CYP2C9*8, CYP2C9*14 
CYP2C19*14 CYP2C93 202 9*3, CYP2C9*5 
CYP2C96 179 CYP2C9*6, CYP2C9*9, CYP2C9*10 
GGCX  163 GGCX rs11676382 
CYP4F2 237 CYP4F2 rs2108622 
VKORC1 rs7294 216 VKORC1 rs7294 
VKORC1 rs9923231 240 VKORC1 rs9923231 
Before applying the primer pairs in a multiplex PCR, each primer pair was run 
individually using a real time PCR and serial dilution of test DNA samples to ensure 
comparable efficiency among the primer pairs. All PCR gave comparable efficiency 
and the critical threshold (Ct) values of sample with highest concentration (50 ng/ul) 
were maintained in the range of 20-25, reflecting a comparable yield among 








Figure 3.3 Position of amplicons and variants throughout the genes of the extended assay 
Figure shows approximate position of the 27 variants in the respective genes detected by the extended assay. Several variants are present 




Table 3.6 PCR efficiency and Ct value of individual PCR 
Amplicons PCR efficiency 
Ct of undiluted samples 
Replicate 1 Replicate 2 
CYP2C192 2.26 23.89 24.55 
CYP2C193 2.134 21.67 21.77 
CYP2C194 2.244 21.79 21.91 
CYP2C195 2.14 22.38 24.78 
CYP2C196 2.439 23.57 24 
CYP2C19 2.098 20.78 20.86 
B4GALT2  2.492 22.71 22.89 
ABCB1 2.243 20.85 20.82 
CYP2C92 2.052 20.74 20.92 
CYP2C93 2.231 23.09 23.37 
CYP2C96 1.988 21.02 21.09 
GGCX  36.58* 21.96 21.99 
CYP4F2 2.114 21.82 22 
VKORC1 rs7294 2.056 21.5 21.68 
VKORC1 rs9923231 2.496 22.88 23.17 
*The PCR efficiency for GGCX is anomalous, however the Ct values of the undiluted sample were not 
different from other amplicons. 
 
To ensure that all amplicons were amplified in the multiplex PCR, a second PCR with 
individual primer pairs of each amplicon was performed using a tenth dilution of the 
multiplex PCR products. All amplicons were successfully amplified (Figure 3.4). 
 
Figure 3.4 Gel electrophoresis of the confirmatory second PCR with individual primer 
pairs 
Electrophoresis was run on 1.5% agarose gel stained with SYBR-Safe in 1x TBA buffer 
and run at 90V for 30 minutes. Lanes: 1. CYP2C192 (212 bp); 2. CYP2C193 (214 bp); 3. 
CYP2C194 (238 bp); 4. CYP2C195 (170 bp); 5. CYP2C196 (226 bp); 6. CYP2C1917 (218 
bp); 7. B4GALT2 (222 bp); 8. ABCB1 (195 bp); 9. CYP2C92 (237 bp); 10. CYP2C93 (202 
bp); 11. CYP2C96 (179 bp); 12. GGCX (237 bp); 13. CYP4F2 (163 bp); 14. VKORC1 rs7294 
(216 bp); 15. VKORC1 rs9923231 (240 bp); M. Universal Ladder (Kapa Biosystem, 
Boston, MA, USA) 




To validate this extended assay, nanopore sequencing was performed using 
reference samples (Coriell institute, Camden, NJ, USA) or lab DNA samples. A total of 
12 samples were used, two of which were also run without ligation to test the 
accuracy of direct short read sequencing, resulting in a total of 14 barcodes used. 
Reads were basecalled using the basecalling tool from ONT, Albacore v1.0.1, and then 
mapped to reference using BWA MEM. VCF files containing the variants were 
generated using marginCaller from marginAlign with allelic fraction threshold of 0.2.  
3.3.2.1 Run 2 read characteristics 
This MinION run resulted in more than 1 million reads, with over a half passing the 
criteria of 2D reads. Most of the 2D reads could be mapped to reference, indicating a 
low percentage of unspecific reads (Table 3.7). 
Table 3.7 Metrics of Run 2 
No. Parameters Results 
1. Total yield 239 Mb 
2. Read length 5 – 14,239 (mean: 327.19) 






1,127,972 (from Albacore 
1.0.1) 
 
732,215 (from NanoOK) 
4. Reads mapped to reference  
(from total pass reads) 
650,218 (88.88%) 
5. Mean qscore 11.2 (minION QC) 
 
Most of the target reads (more than ~300 bp) had good quality, with qscore >10, 
which referred to approximately 90% accuracy. Most of the low-quality reads were 
less than 300 bp (Figure 3.5).  
Twelve samples with ligation and two samples without ligation were included in this 
run. Poretools and Qualimap were used to generate the read lengths and read quality 
of each sample. Interestingly, there was no difference in read length and read quality 
(represented by the error rates) between ligated and non-ligated libraries (Table 
3.8). The high proportion of short reads in the ligated libraries might indicate an 
inefficiency in ligation reaction. However, these data also showed that short read 





Figure 3.5 Reads quality for Run 2 
Figure shows plotting of qscore against read length. Majority of reads within target 
length (>300 bp) had qscore >10 indicating good quality of target reads. Colours 
represent events per base, with lower events per base associating with good reads. 
 
Table 3.8 Read length and quality of the 14 barcoded samples of Run 2 












1 U53 Barcode50 No 333 (118-1865) 7.75% 109043 514 
2 Barcode69 Yes 327 (113-2071) 7.89% 46379 267.5 
3 NA12878 Barcode59 No 335 (89-2101) 9.23% 125479 688 
4 Barcode66 Yes 320 (93-3129) 8.66% 85144 700 
5 NA17214 Barcode10 Yes 334 (115 – 2490) 8.64% 53841 585 
6 ES9 Barcode11 Yes 342 (123-4029) 7.97% 18898 166.5 
7 ES5 Barcode61 Yes 323 (118-1928) 7.28% 21157 292.5 
8 NA07439 Barcode62 Yes 324 (92-1865) 8.55% 14251 226.5 
9 NA17019 Barcode63 Yes 325 (78-2650) 7.16% 47534 134 
10 NA17240 Barcode64 Yes 339 (114-1860) 8.65% 17675 232 
11 NA19311 Barcode65 Yes 334 (119-2195) 7.99% 44447 185 
12 NA19834 Barcode67 Yes 332 (114-2036) 7.91% 20939 246.5 
13 NA20588 Barcode68 Yes 332 (108-1912) 7.8% 15322 208.5 




3.3.2.2 Genotyping results 
BWA MEM was used to align the reads of each sample, and marginCaller from 
marginAlign was used to generate VCF files containing the genotypes. The cut-offs 
for heterozygote and homozygote genotype calls were made at 0.2 and 0.65 
respectively. These genotypes were then compared to the reference genotypes. The 
comparative results were displayed in Table 3.9, which showed that MinION could 
accurately genotype all samples, except for one SNP in two samples (VKORC1 rs7294 
in sample BC62 and BC63). This SNP was called correctly in other samples. 
When the BAM files of these two samples were visualised on IGV, the minor allele of 
this SNP (A) was present, but in reduced percentage. In a perfect case, heterozygote 
samples would give a 50%:50% allele percentage, while in these two samples, the A 
allele was present in approximately 20–25% (Figure 3.6). The possibility of CNV 
causing this unbalanced allele ratio could be excluded as both BC62 and BC63 were 
reference samples with known genotypes, and sample BC62 (NA07439) was 
included in the next run where it gave 50%:50% ratio of G/A (Table 3.14, sample 
BC25).  
 
Figure 3.6 Alignment of sample BC62 and BC63 for VKORC1 rs7294 
Figure shows the position of the rs7294 variant between the two vertical lines. Different 
colours marked the two alleles in the position: G allele (brown) and A allele (Green). 







Table 3.9 Genotyping results of Run 2 
 
*Ref refers to variants found in 1000Genomes database or Sanger Sequencing 
#BC50 and BC69 are the same samples, and ##BC59 and BC66 are the same sample.  
Coloured cells indicate discordant genotypes between Ref and MinION sequencing.  




























































































The biased allelic fraction could result from errors in many stages of the data 
analysis, or in the sequencing/basecalling itself. A number of bioinformatics tools 
were tested to further analyse the errors for this SNP in these two samples. 
1. Alignment tool 
There is a possibility that the genotyping error was generated during the 
alignment. Graphmap has been reported to be a better alignment tool for 
complicated sequences (Sovic et al., 2016). The fastq files of these two samples 
was re-aligned to reference using Graphmap v 0.5.2 and the BAM file was viewed 
on IGV. Graphmap resulted in even lower A allele percentage (16%) compared to 
BWA MEM (Figure 3.7). 
 
Figure 3.7 Alignment of samples BC62 and BC63 for VKORC1 rs7294 with GraphMap 
Figure shows the position of the rs7294 variant between the two vertical lines. 
Different colours marked the two alleles in the position: G allele (brown) and A allele 
(Green). The A allele was present in 16% of the total reads.  
 
2. Demultiplexing 
Demultiplexing or dividing the total reads into each sample barcode used in the 
sequencing run was automatically done while basecalling using Albacore. 
However, Albacore applied relatively loose criteria while demultiplexing, 
requiring only that a barcode be present at one end of each read. This might result 
in a proportion of misclassified reads, resulting in less accurate genotyping. 





Porechop was used to demultiplex all fastq files generated by Albacore, using the 
arguments: -- require_two_barcodes and -- barcode_threshold 
85. Porechop would retain only barcodes that were called in agreement between 
Albacore and Porechop. More than half of the pass reads by Albacore did not agree 
to barcoding criteria by Porechop and were removed to the bin directory (337,813 
of total 639,972 reads). The consensus barcoded reads were re-aligned using BWA 
MEM. Again, stringent demultiplexing failed to resolve the genotyping error in 
BC62 and BC63 samples. The percentages of A allele in the two samples were 12% 
and 17% respectively after demultiplexing using Porechop (Figure 3.8). 
 
Figure 3.8 Alignment of samples BC62 and BC63 for VKORC1 rs7294 after 
demultiplexing with PoreChop 
Figure shows the position of the rs7294 variant between the two vertical lines. The A 
allele was present in 12 and 17%, but not shown in different colours. 
 
3. Variant calling tool 
Nanopolish has been reported to increase the accuracy of nanopore reads (Wick 
et al., 2019). Unfortunately, the nanopolish variant calling tool was not 
compatible with 2D reads called using Albacore v1. Thus, the raw reads were re-
basecalled using Albacore v0.8.4 and re-aligned using BWA MEM. Nanopolish 
v0.9 was used to call the variant for rs7924 in the two samples. Nanopolish also 





Modification in different steps of data analysis failed to improve the allele proportion 
of this SNP in the two samples. It is therefore plausible that the reduced Allelic 
fraction specific in this SNP was attributed to the sequencing data or imperfect 
basecalling itself. Albacore v1 was used to basecall the reads in this run. The 
subsequent updated versions of Albacore (particularly v2) which used recurrent 
neural network instead of HMM have been claimed to result in higher accuracy but 
are unfortunately not compatible for use with 2D chemistry. More detailed 
explanation on the differences of Albacore version can be found later in this chapter. 
Overall, despite the problematic SNP calling in the two samples, this extended assay 
resulted in reasonable accuracy. In fact, although the variant calling tool failed to call 
the SNP rs7294 variant in two samples, the SNP could still be detected by visual 
inspection of the BAM files on IGV and could be confidently differentiated from 
reference G/G genotype (Table 3.10). All samples with G/G genotypes have a very 
low proportion of A Allele (<5%), while sample BC62 and BC63 have a proportion of 
more than 20%.  
Table 3.10 Reference and alternate allele frequencies of the rs7294 SNP* 
No. Samples Allele G (%) Allele A (%) Genotype 
1. BC50 94 3 G/G 
2. BC69 100 0 G/G 
3. BC59 98 1 G/G 
4. BC66 99 0 G/G 
5. BC10 8 86 A/A 
6. BC11 72 24 G/A 
7. BC61 4 92 A/A 
8. BC62 77 22 G/A 
9. BC63 75 25 G/A 
10. BC64 99 1 G/G 
11. BC65 10 86 A/A 
12. BC67 56 40 G/A 
13. BC68 97 3 G/G 
14. BC70 100 0 G/G 
*Reads percentage were calculated manually on IGV 
 
Following this initial validation using reference samples, clinical samples were 




3.3.3 Extended assay with clinical samples (Run 3) 
Seventy-eight clinical samples with CYP2C19*2, CYP2C9*3, and CYP2C19*17 
genotype status available by other platforms (Nanosphere Verigene® or Sequenom 
MassARRAY platform) were generously provided by a collaborator (Dr Patrick 
Gladding, Theranostics Laboratory, North Shore Hospital, Auckland, NZ). These 
samples, together with six reference samples used in Run 2 as controls, were 
examined in a multiplex format, using the PCR Barcoding Expansion 1-96 kit.  
Based on previous results, two changes were applied. The first one was re-
optimisation of the multiplex PCR. In the previous run (Run 2), a variation in read 
depth was observed among amplicons, with some amplicons being preferentially 
amplified while the others had low read depth. The mean read depth varied by 500-
fold difference, ranging from 50 (CYP2C93 amplicon) to 25,000 (ABCB1). While read 
depth of 50 was enough to provide accurate genotypes, increasing sample 
multiplexing to 84 barcodes might result in very low read depth or even 
unrepresentative amplicons in some samples. Therefore, the multiplex PCR was 
optimised prior to continuing to the next nanopore sequencing run, with the aim to 
achieve more comparable yield among amplicons. Second, the similar read depth and 
read length between ligated and non-ligated reads in the previous run allowed for a 
simplified workflow by omitting the step of amplicon ligation. 
Another substantial modification was inevitable as the more accurate 2D chemistry 
was discontinued by ONT by the time the clinical samples were available. 
Consequently, the clinical samples were sequenced using the 1D chemistry. 
3.3.3.1 Optimisation and validation of the multiplex PCR assay 
A real time second-round PCR was performed to observe the yield of each amplicon 
resulting from the multiplex PCR. In brief, a 10x dilution of multiplex PCR product 
was used in a real time PCR using each individual primer pair and amplified by 20 
cycles of PCR. To achieve a more comparable PCR yield between amplicons, primer 
concentrations were adjusted by decreasing those with higher yield and increasing 
those with lower yield in the previous run. Agarose gel electrophoresis of products 




The most optimised result was achieved by increasing the concentration to 1.25-fold 
for CYP2C19*6, CYP2C19*17, CYP2C9*3, GGCX, VKORC1 rs9923231 and VKORC1 
rs7294 and decreasing the concentration to 0.8-fold for ABCB1 and B4GALT2. This 
final condition resulted in more comparable Ct values and band intensity among 
amplicons (Figure 3.9 and Table 3.11). 
 
Figure 3.9 Gel electrophoresis of the modified multiplex PCR product 
Electrophoresis was run on 1.5% agarose gel stained with SYBR-Safe in 1x TBA buffer 
and run at 90V for 30 minutes. Lanes: 1. CYP2C192 (212 bp); 2. CYP2C193 (214 bp); 3. 
CYP2C194 (238 bp); 4. CYP2C195 (170 bp); 5. CYP2C196 (226 bp); 6. CYP2C1917 (218 
bp); 7. B4GALT2 (222 bp); 8. ABCB1 (195 bp); 9. CYP2C92 (237 bp); 10. CYP2C93 (202 
bp); 11. CYP2C96 (179 bp); 12. GGCX (237 bp); 13. CYP4F2 (163 bp); 14. VKORC1 rs7294 
(216 bp); 15. VKORC1 rs9923231 (240 bp); M. Universal Ladder (Kapa Biosystem, 
Boston, MA, USA). 
Table 3.11 Ct values of confirmatory real time PCR before and after re-optimisation 
 Amplicons Original Ct value Ct value after optimisation 
Replicate 1 Replicate 2 Replicate 1 Replicate 2 
CYP2C192 8.62 8.22 8.29 7.22 
CYP2C193 7.8 7.65 7.16 7.14 
CYP2C194 8.91 7.57 7.64 7.64 
CYP2C195 13.45 12.82 7.64 7.26 
CYP2C196 10.69 10.19 8.65 8.27 
CYP2C1917 8.07 7.7 7.33 7.1 
B4GALT2  7.7 7.48 7.2 7.33 
ABCB1  7.71 7.3 7.52 7.33 
CYP2C92 8.77 8.64 7.23 7.11 
CYP2C93 11.95 12.18 7.13 7.32 
CYP2C96 8.75 8.16 7.57 7.67 
GGCX 9.25 8.72 7.17 7.13 
CYP4F2 9.4 8.97 8.37 8.29 
VKORC1 rs7294 9.63 9.53 7.36 7.24 
VKORC1 rs9923231 10.29 10.5 7.19 7.25 




3.3.3.2 Run 3 read characteristics 
There were approximately 0.9 million reads generated from the 84 barcodes in Run 
3. The resulting raw reads were initially basecalled using Albacore v1, the version 
available at the time of sequencing completion. At the end of 2017, the second version 
of Albacore was released with significant improvement in basecalling accuracy, and 
the raw reads were re-basecalled using this new version of the tool. 
The read metrics after basecalling using Albacore v1 and v2 are listed in Table 3.12. 
Compared to the 2D chemistry where most reads had quality score of more than 10 
(Figure 3.5), the reads from 1D chemistry showed lower quality with most of the 
reads having quality score less than 10, corresponding to <90% accuracy (Figure 
3.10).  
Table 3.12 Metrics of Run 3 
No. Parameters Albacore v1 Albacore v2.3.0 
1. Total yield ~ 288 Mb 
2. Read length 55 - 9160 bp (N50 = 365) (Albacore v2.3.0) 













4. Reads mapped to 
reference (from total pass 
reads) 
70.81% 94.96% 








Figure 3.10 Reads quality of Run 3 




The number of pass reads was decreased in the second version of Albacore, but the 
resulting reads were of better quality as only reads with quality >7 were classified as 
“pass” in this newer version. This was partly shown by the increased proportion of 
reads being mapped to reference. The q-score seemed to be lower in Albacore v2.3.0 
compared to v1, however this was caused by the different way of q-score calculation 
in Albacore v2.1 and later. Previously, Albacore calculated q-score based on matches, 
mismatches, insertions, but not deletion, which was covered by the newer version of 
Albacore. This resulted in a reduced q-score by ~2. Taking this into account, the q-
score from Albacore v2.30 was generally comparable to Albacore v1.  
The average read depth per amplicon varied significantly between 42 and 956x 
(F(14,1245)=146.6, p<0.001) (Figure 3.11) and also per sample, between 8 and 753x 
(F(83-1176)=1.609, p<0.001) (Figure 3.12). Levene’s test showed that the variances 
for read depth were equal among samples (P =0.318), but not among amplicons (P < 
0.001). Three amplicons (ABCB1, CYP2C96, and VKORC1 rs7294) showed relatively 
high read depth relative to the others, as analysed using reads from Albacore v2.3.0 
(Figure 3.11). On the other hand, four amplicons (CYP2C192, CYP2C1917, CYP2C194, 
and CYP2C93) showed relatively low read depth of <100 across all samples. Three 




amplicons. Some samples had very low coverage (<10) for B4GALT2 (12), CYP2C194 
(2), CYP2C93 (1), and CYP4F2 (4) amplicons, and were also excluded from analysis. 
 
 
Figure 3.11 Read depth per amplicon of Run 3 
Figure shows variability in average read depth among amplicons ranging from 42x to 








Figure 3.12 Read depth per sample of Run 3 
Figure shows the read depth of all amplicons per sample. It shows a generally uniform read depth among samples except for three samples, 




3.3.3.3 Bioinformatics workflows 
In addition to different basecalling tools, several variant calling tools were also 
tested: marginCaller, nanopolish, Varscan2 and Clairvoyante. The threshold for 
calling heterozygote variants was set at 0.2 for all variant calling tools, except for 
Clairvoyante, where 0.25 is the recommended threshold (Luo et al., 2019).  For 
homozygote variants, the threshold was set at 0.65, except for nanopolish and 
Clairvoyante, where there was no threshold for homozygote. Instead, they used their 
own algorithms to call a variant as homozygote or heterozygote. Albacore v1 was 
compared to the second version using marginCaller as the variant calling tool, and 
the four variant calling tools were compared using data from Albacore v2, resulting 
in five different bioinformatic workflows (Table 3.13). All analyses used BWA MEM 
as the aligner.  
Table 3.13 Bioinformatic workflows of Run 3 











Variant calling tool marginCaller marginCaller nanopolish Varscan2 Clairvoyante 
 
3.3.3.4 Genotyping results 
1. Control samples 
The accuracy of the assay was first examined on the control samples. The reference 
genotypes of the control samples were obtained from data from the 1000Genomes 
(http://grch37.ensembl.org/Homo_sapiens/Info/Index) or by Sanger sequencing. 
Workflow 3 using nanopolish resulted in 100% accuracy while workflow 1 and 2 
missed the CYP2C9*6 variant. Varscan2 missed some genotypes in most of the 
samples. Clairvoyante missed the 2 variants in two samples, including the one-base 
deletion, CYP2C9*6. The single-base deletion of CYP2C9*6 variant in sample BC02 










Table 3.14 Genotyping accuracy of the control samples by the five different bioinformatic workflows 
Control  
Samples 
Reference Genotype  Accuracy  
Workflow 1 









(Albacore v2.3.0 & 
Varscan2) 
Workflow 5 
(Albacore v2.3.0 & 
Clairvoyante) 
BC01 CYP2C9*2 rs1799853 C/T 
CYP2C19*2 rs4244285 G/A 
ABCB1 rs1045642 T/C 
VKORC1 rs9923231 G/A 
100% 100% 100% CYP2C19*2 
rs4244285 G/A not 
detected 
100% 
BC02 CYP2C9*6 rs9332131 A/- 
VKORC1 rs7294 A/A 
ABCB1 rs1045642 C/C 
CYP2C19*15 rs17882687 A>C 
CYP2C9*6 
rs9332131 A/- not 
detected 
CYP2C9*6 
rs9332131 A/- not 
detected 
100% 100% CYP2C9*6 
rs9332131 A/- not 
detected 
BC25 CYP2C9*9 rs2256871 A/G  
VKORC1 rs7294 G/A 
CYP2C19*2 rs4244285 G/A 
CYP2C19*10 rs6413438 C/T 
ABCB1 rs1045642 C/C 
100% 100% 100% Only CYP2C9*9 






BC64 VKORC1 rs7294 G/A 
CYP2C19*17 rs12248560 C/T 
ABCB1 rs1045642 C/C 




BC70 CYP4F2 rs2108622 A/A 
VKORC1 rs7294 G/A 
CYP2C19*17 rs12248560 C/T 
B4GALT2 rs1061781 C/T 




BC71 CYP2C9*3 rs1057910 A/C 
CYP4F2 rs2108622 G/A 
VKORC1 rs9923231 G/A 
VKORC1 rs7294 G/A 
100% 100% 100% CYP2C9*3 







2. Clinical samples 
A shown in Figure 3.12, three samples (BC34, BC44, and BC67) were excluded from 
analysis due to low read depth in all amplicons. All three samples showed low yield 
after the first multiplex PCR as well as the barcoding PCR, compared to other samples. 
Moreover, all three samples showed less than 50% of reads being mapped to 
reference. This might be due to poor quality of the DNA samples or failed PCR 
reactions; however we did not have enough DNA to test for these possibilities. The 
remaining 75 samples, together with control samples were examined for accuracy.  
The first analysis was focused on three variants (CYP2C19*2, CYP2C19*3 and 
CYP219*17), for which genotypes were available from other platforms. The accuracy 
for CYP2C19*3 was consistently high among the three analysis workflows, with all 
workflows resulted in 100% genotyping accuracy. However, accuracy for CYP2C19*2 
and CYP2C19*17 varied among the different workflows (Figure 3.13).  
Using Albacore v1, 21 of the 81 samples showed CYP2C19*2 genotypes that were 
discordant with with the reference genotypes. Most of the discordant results were 
false positive where samples with G/G genotypes were called as G/A. Other 
discordant genotypes resulted from the inability to call homozygote variants 
correctly. For the four samples with A/A genotypes (BC49, BC52, BC66, BC68), 
marginCaller failed to generate allelic ratio >0.65, the threshold used to differentiate 
homozygote from heterozygote. However, the allelic ratio of the four samples (0.46, 
0.38, 0.34, 0.43) were different from the heterozygote samples, which were typically 
<0.3.  
Applying Albacore v2 increased the accuracy of CYP2C19*2 and reduced the 
discordant results to only eight of the 81 samples, using marginCaller. Using 
nanopolish as the variant calling tool further increased the accuracy to 96% with only 
four discordant samples where G/G genotypes were mis-called as G/A. All four 
samples were of low read depth, which may have contributed to the inaccuracy. 
Varscan2 has been used as the variant calling tool in several reports of MinION panel 
sequencing (Euskirchen et al., 2017; Orsini et al., 2018). However, it failed to call any 
of the CYP2C19*2 variants, resulting in 0% sensitivity. Clairvoyante also performed 
less accurately than nanopolish, with eight mis-genotyped samples for CYP2C19*2. 









Figure 3.13 Genotyping sensitivity, specificity and accuracy for three common SNPs of CYP2C19 by different bioinformatic workflows 
Sensitivity, specificity, and accuracy of (A) CYP2C19*2, (B) CYP2C19*3, and (C) CYP2C19*17 genotyping by nanopore sequencing using 
different bioinformatics tools compared to  reference genotypes  obtained from the Nanosphere Verigene® or Sequenom MassARRAY 








Table 3.15 Discordant results for CYP2C19*2 genotypes by different bioinformatic workflows* 
Workflow 1  
(Albacore v1 & marginCaller) 
Workflow 3 
(Albacore v2.3.0 & marginCaller) 
Workflow 4 
(Albacore v2.3.0 & nanopolish) 
Workflow 5 


















BC09 40 G/A G/G BC18 68 G/A G/G BC49 70 G/A A/A BC18 68 G/A G/G 
BC15 64 G/A G/G BC37 8 G/G G/A BC52 72 G/A A/A BC19 65 G/A G/G 
BC16 95 G/A G/G BC49 70 G/A A/A BC68 111 G/A  A/A BC23 66 G/G G/A 
BC18 68 G/A G/G BC52 72 G/A A/A BC87 85 G/G G/A BC49 70 G/A A/A 
BC29 116 G/A G/G BC53 73 G/A G/G     BC53 73 G/A G/G 
BC35 104 G/A G/G BC62 82 G/A G/G     BC62 82 G/A G/G 
BC40 105 G/A G/G BC66 109 G/A A/A     BC68 111 G/A A/A 
BC46 61 G/A G/G BC68 111 G/A A/A     BC80 86 A/A G/G 
BC49 70 G/A A/A BC85 90 G/A G/G         
BC52 72 G/A A/A               
BC53 73 G/A G/G               
BC55 75 G/A G/G               
BC57 77 G/A G/G               
BC62 82 G/A G/G               
BC65 94 G/A G/G               
BC66 109 G/A A/A               
BC68 111 G/A A/A               
BC69 112 G/A G/G             
BC73 92 G/A G/G             
BC83 88 G/A G/G               
BC85 90 G/A G/G               




For CYP2C19*17, two samples were excluded from analysis due to very low read 
depth (<10).  There were three discordant results with Albacore v1; this resulted 
from a low allelic fraction of the alternate allele (<0.65) in these samples with 
homozygote variants and were mis-called as heterozygotes. Albacore v2 with 
marginCaller correctly genotyped one of the three samples, while Albacore v2 with 
nanopolish left only one mis-genotyped sample. Clairvoyante performed the best for 
this variant with 100% accuracy. Varscan2 failed to call genotype correctly in 13 out 
of 17 samples with heterozygote variants and two out of three homozygote variants, 
resulting in the lowest sensitivity and accuracy.  
Combining data from control and clinical samples, the combination of Albacore v2 
and nanopolish resulted in the higher accuracy compared to the other three 
workflows, followed by the combination of Albacore v2 and Clairvoyante. These two 
combinations were then used to examine the accuracy of the other variants in this 
assay. Many of the variants included in this assay are rare, and there were only eight 
variants detected in at least three of the 81 samples. Reference genotypes for the 
eight variants for random subsets of the samples were generated using Sanger 
sequencing (Table 3.16).  



















B4GALT2 rs1061781 176 21 1 95.2% 0 100.00% 
ABCB1 rs1045642 1020 29 0 100% 0 100.00% 
CYP2C9*2 204 26 0 100% 0 100.00% 
CYP2C9*3 45 25 2 92% 1 96.00% 
GGCX rs11676382 123 29 0 100% 0 100.00% 
CYP4F2 rs2108622 126 27 0 100% 2 92.59% 
VKORC1 rs9923221 168 30 7 76.7% 1 96.67% 
VKORC1 rs7294 814 32 1 96.9% 0 100% 
 
In general, nanopolish and Clairvoyante resulted in comparable accurate genotyping, 
except for VKORC1 rs9923231 where Clairvoyante showed superior accuracy over 
nanopolish with only one discordant result, while nanopolish resulted in seven. All 
false genotypes by nanopolish in this amplicon and in VKORC1 rs7294 and B4GALT2 
were homozygote variants mis-genotyped as heterozygotes. While nanopolish failed 




easily resolve these errors. Mis-genotyped homozygote samples had distinct 
alternate allelic fraction compared to genuine heterozygote samples and could be 
easily differentiated (Figure 3.14).  
 
Figure 3.14 IGV screenshot of VKORC1 rs9923231 
BAM files of samples with homozygote variants mis-genotyped as heterozygote by 
nanopolish (row 1 and 2), heterozygote variants (row 3 and 4) and no variant (row 5 
and 6) of VKORC1 rs9923231.  
 
The inaccuracy in some variants could be attributed to low read depth, as was shown 
for the CYP2C19*2 variant. The two discordant samples for CYP2C19*3 by nanopolish 
were also of relatively low read depth (<30x). However, the VKORC1 rs9923231 
samples misgenotyped by nanopolish and one of the two false genotype in CYP4F2 
by Clairvoyante had reasonably good read depth (~100x).  
3.3.3.5 In silico validation of the specificity of the generated reads 
The short nature of the amplicons and the high sequence identity between some of 
the genes in the panel raised the question of whether some of the inaccuracy resulted 


























specificity of the reads to their target amplicons, all pass reads were re-aligned 
(quality score >7 and barcoded) to the human genome (hg38), and measured the 
number of reads using Qualimap 2. Alignment to human genome showed that 88% 
of all reads were mapped. The majority of reads were mapped to the appropriate 
chromosomes of the target amplicons (Figure 3.15).  
 
Figure 3.15 Alignment of pass reads to human genome hg38 
Figure shows specificity of the reads that predominantly aligned to six chromosomes 
where the target genes are located. 
 
The read depth of each target amplicon was manually counted on IGV. The number 
of reads in target chromosomes in Figure 3.15 were comparable to the number of 
reads present in the respective amplicons showing that the reads mapped to each 
chromosome actually came from the target amplicons (Table 3.17). There were ~200 
reads on chrX that did not contain any target amplicon. These reads came from the 
VKORC1 pseudogene, VKORC1P2. Reads on the other VKORC1 pseudogene on chr1 
(~100 reads) were also found. However, the very low number of reads (~1-3 









Table 3.17 Read coverage of target amplicons 





Read depth of target amplicons (manually 
counted on IGV)2 












chr7 76,677 ABCB1 ~76,000 
chr16 66,838 VKORC1 ~11,000 (rs9923231) and ~58,000 (rs7294) 
chr1 12,470 B4GALT2 ~13,000 (VKORC1P2: ~100 reads) 
chr2 9,680 GGCX ~9600 
chr19 7,611 CYP4F2 ~7500 
chrX 246 - VKORC1P1:~220 reads 
Other 
chromosomes 
28 (chr.3), 6 (chr.4), 9 (chr.5), 14 (chr.6), 8 (chr.8), 33 (chr.9), 27 (chr.11), 11 
(chr.12), 36 (chr.13), 19 (chr.14), 9 (chr.15), 9 (chr.17), 34 (chr.18), 5 (chr.20), 1 
(chr.21), 2 (chr.Y).  
 
3.3.4 Increasing read depth (Run 4) 
MinION errors include both random and systematic errors (Krishnakumar et al., 
2018; Wick et al., 2019). Unlike systematic errors, random errors could be 
compensated for by increasing read depth. Moreover, there were some samples in 
the previous MinION run having very low read depth. To examine whether increasing 
read depth could improve the genotyping accuracy of this assay, another run with a 
smaller subset of samples (n=24) was performed. Decreasing sample number should 
allow for a higher input DNA per sample, and thus increase the read depth.  
Twenty-four barcoded PCR products from the previous run were selected to prepare 
a new MinION library, including four control samples. Sequencing results were 
analysed as before, using Albacore v2 as the basecalling tool, and nanopolish as the 
variant calling tool.  
3.3.4.1 Run 4 reads characteristics 
This run resulted in ~1.5 million reads, with only approximately 10% of them 
passing the default criteria of Albacore v2.3.0 (q-score >7). However, most of the pass 





Table 3.18 Metrics of Run 4 
No. Parameters Albacore v2.3.0 
1. Total yield ~ 324 Mb 
2. Read length 20 – 3988 bp (N50 = 355) 







4. Reads mapped to 
reference (from total pass 
reads) 
88.36% 
5. Mean qscore 4.5 
 
Comparison of the read depth between samples from the previous run to the latest 
run confirmed increased coverage in the later run across all amplicons (Figure 3.16).  
However, the increase was more pronounced in samples with already high coverage 










Figure 3.16 Comparison of read depth per amplicon between Run 3 and Run 4 




3.3.4.2 Genotyping results 
The three previous failed samples (BC34, BC44, BC67) were included in this run 
using the PCR products from previous run, but the alignment rates for these three 
samples were still very low, and those samples were again excluded from analysis. 
For the remaining 21 samples, analysis was initially done on the four control samples 
resulting in 100% agreement (Table 3.19). 
Table 3.19 Genotyping accuracy for control samples of Run 4 
Control  
Samples 
Reference Genotype Accuracy 
Workflow 1 (Albacore v2 & nanopolish) 
BC01 CYP2C9*2 rs1799853 C/T 
CYP2C19*2 rs4244285 G/A 
ABCB1 rs1045642 T/C 
100% 
BC02 CYP2C9*6 rs9332131 A/- 
VKORC1 rs7294 A/A 
ABCB1 rs1045642 C/C 
100% 
BC25 CYP2C9*9 rs2256871 A/G  
VKORC1 rs7294 G/A 
CYP2C19*2 rs4244285 G/A 
CYP2C19*10 rs6413438 C/T 
ABCB1 rs1045642 C/C 
100% 
BC71 CYP2C9*3 rs1057910 A/C 
CYP4F2 rs2108622 G/A 
VKORC1 rs9923231 G/A 
VKORC1 rs7294 G/A 
100% 
 
Accuracy for other samples was then examined as previously described. There were 
three, two, and two discordant samples for CYP2C19*2, CYP2C19*17, and VKORC1 
rs9923231 respectively. All of them were homozygote variants mis-genotyped as 
heterozygote, except for one sample in CYP2C19*2 which was a failure to correctly 
call a heterozygote variant. There were no discordant samples in other amplicons, 
resulting in 100% accuracy for eight amplicons (Table 3.20).  
The full genotype information of the reference and clinical samples from all platforms 
are available in the supplementary material of the paper published based on this 






Table 3.20 Genotyping accuracy of clinical samples for Run 4 





CYP2C19*2 21 3 86% 
CYP2C19*3 21 0 100% 
CYP2C19*17 21 2 90% 
B4GALT2 (C>T) 12 0 100% 
ABCB1 (T>C) 12 0 100% 
CYP2C9*2 (C>T) 10 0 100% 
CYP2C9*3 (A>C) 10 0 100% 
GGCX (G>C) 10 0 100% 
CYP4F2 (G>A) 12 0 100% 
VKORC1rs7294 (G>A) 10 0 100% 
VKORC1 rs9923231  
(G>A) 
10 2 80% 
3.4 Discussion 
MinION nanopore sequencing is generally used to sequence long DNA strands, 
however its portability and relative simplicity makes it interesting to consider and 
explore applications that do not require long-read sequencing. This chapter 
describes development of an assay that examines multiple amplicons targeting 
important pharmacogenetic variants of relevance to treatment with clopidogrel or 
warfarin. The pharmacogenetics approach serves as a proof-of-principle and this 
method is adaptable to any other variant panels in other regions within human 
genomes.    
The assay was based on PCR to enrich regions containing variants of interest that 
were subsequently sequenced on MinION. PCR-based assays work best with short 
amplicons, which are amenable to multiplexing during the PCR, simplifying the 
laboratory workflow of the assay. In preliminary phase, ligation of such short 
amplicons into longer products was considered and tested, to see whether this would 
better suit the long-read capabilities of the MinION. However, experiments trialling 
ligated versus non-ligated PCR products surprisingly showed no overall difference in 
sequencing yield and read length, confirming the ability of the MinION to sequence 
short amplicons of DNA.  
Development of this multiplex nanopore sequencing assay was performed with two 
different sequencing chemistries, due to ongoing refinement and changes in products 
supplied by ONT during the period of this experimental work. In particular, the 




project, and 2D products became unavailable. The earlier trials on reference samples 
using 2D chemistries showed accurate results (Section 3.2.2.2, Table 3.9). However, 
the same bioinformatics tools on 1D sequencing chemistries resulted in much lower 
accuracy, with 21 out of 81 samples having mis-labelled genotypes for CYP2C19*2 
(Section 3.2.3.6). Therefore, the changing chemistries presented some significant 
technical challenges to this work. Fortunately, rapid evolution of bioinformatic tools 
appropriate for nanopore sequencing data, generated by both ONT and research 
groups in the wider academic community, offered opportunity to increase accuracy. 
3.4.1 Bioinformatics development 
Early bioinformatic tools resulted in poor accuracy for 1D sequencing, however the 
introduction of Albacore v2 in late 2017 resulted in significantly increased accuracy 
compared to its first version. Albacore v2 uses a quality threshold for pass reads 
(qscore >7) and resulted in a lower number of pass reads. Although this threshold 
can be set to a lower value, this was not done during this assay development in order 
to achieve higher quality reads and genotyping. At the time of analysis, Albacore 
version 2 was one of the most accurate basecalling tools available, however the error 
rates were still more than 20% in human DNA (Teng et al., 2018). Testing on three 
variants (CYP2C19*2, CYP2C19*3, and CYP2C19*17) in this data confirmed improved 
accuracy of Albacore v2 compared to Albacore v1, using marginCaller as the variant 
calling tool. 
In addition to basecallers, tools to call variants were also evolving rapidly. 
MarginCaller from MarginAlign was one of the first variant calling tools specifically 
designed for nanopore sequencing at the time this assay was first developed (2016). 
However this tool still resulted in many discordant genotypes in this assay, especially 
for the CYP2C19*2 variant. Trialling three additional variant calling tools (VarScan 2, 
nanopolish, Clairvoyante) showed that using different variant calling tools further 
altered the genotyping accuracy. Overall, nanopolish and Clairvoyante resulted in 
better accuracy compared to other tools.   
Nanopolish was first developed as an error correction and genome assembly tool 
(Quick et al., 2016). It has a function called nanopolish variants that could call 




and the reference. Rather than looking at single bases, nanopolish examines a block 
of 10 bases, and then generates all possible haplotypes, which could be calculated as 
2n where n is the number of variants in a particular stretch of sequence. A hidden 
Markov model was then applied to calculate the likelihood of each haplotype. 
Haplotypes with the greatest likelihood would be chosen as the sequence and the 
variants were output in a VCF file. Rather than looking at single bases at a time, this 
approach would better reflect the nature of nanopore sequencing (Quick et al., 2016). 
Clairvoyante is another recently introduced variant calling tool, designed specifically 
to work on error-prone long sequencing reads from PacBio and ONT. It had 
advantage in higher speed and was claimed to outperform nanopolish with regards 
to accuracy on nanopore sequencing (Luo et al., 2019). Results from this thesis 
showed that the performance of nanopolish and Clairvoyante was comparable and 
varied among amplicons. However, the accuracy of Clairvoyante for indel variant is 
much lower than for substitution variant (Luo et al., 2019), and this was reflected in 
this study where this tool failed to call the CYP2C9*6 delA variant.  
3.4.2 Genotyping errors 
Most of the inaccurate genotype calling by nanopolish found in this assay was due to 
mislabelling of homozygote variants as heterozygote. Another study has reported the 
mislabelling of homozygote as heterozygote variants as the dominant genotyping 
error for nanopore sequencing data (Jain, 2018). Using nanopolish to genotype a 
fraction of variants on chromosome 20, they reported that 3,217 out of 4,781 
mislabelled variants were due to this kind of error (Jain et al., 2018). However, 
another variant calling tool trialled in this chapter, Clairvoyante, did not generate this 
type of error, suggesting that this is a nanopolish specific issue.  
The accuracy of this assay varied between variants, and between variant calling tools. 
For example, ABCB1 rs1045642 showed 100% accuracy, both using nanopolish and 
Clairvoyante, while VKORC1 rs9923231 showed eight out of 30 samples being mis-
genotyped by nanopolish. This observation suggested that occurrence of the error 
might be dependent on the sequences adjacent to the variants. Two variants with the 
higher error rates by nanopolish (CYP2C19*2 and VKORC1 rs9923231) sit between 




Clairvoyante generated higher accuracy for VKORC1 rs9923231. but lower accuracy 
for CYP2C19*2 compared with nanopolish. 
Variants Flanking sequence 
CYP2C19*2 CCC[G/A]GG 
VKORC1 rs9923231 CC[G/A]GGCC 
Figure 3.17 Sequences flanking CYP2C19*2 and VKORC1 rs9923231 
The sequences flanking these two variants consisted of homodimers or trimers that 
might be challenging for nanopore sequencing. 
 
 
The observation that nanopore basecalling accuracy was sequence-dependent has 
been reported before (Krishnakumar et al., 2018). By studying bacterial genomes 
with nanopore sequencing, these investigators observed that A or G has lower quality 
compared to T or C. Sequencing in two directions of DNA strands compensated for 
this bias, explaining the consistently higher accuracy for 2D sequencing. This report 
also observed that the accuracy of a base would depend on the position of the base 
within a read, with bases in the beginning and end of a read having lower quality 
(Krishnakumar et al., 2018). Although some of the MinION errors are random, these 
observations suggest that systematic errors do exist, which explains the failure to 
increase accuracy by increasing read depth in this assay (Section 3.3.4). 
While variant calling by nanopolish resulted in high specificity with no false positive 
genotypes in the targeted variants, there were 17 false positive calls across all 
amplicons and samples. Fifteen out of the 17 false variants were transition 
substitutions (CT or AG), which have been reported to be the dominant 
substitution errors in nanopore sequencing (Jain et al., 2018). For these positions, 
the alternate alleles were present in the aligned reads for all samples in the 
proportion of 15-20%, and being called as variants in subsets of samples, and these 
were easily ruled out as false variants by visual inspection on the BAM files on IGV. 
3.4.3 Technical challenges 
The application of short fragments to nanopore sequencing was reported to be 
challenging (Wei & Williams, 2016). Library preparation for nanopore sequencing 
involved ligating adapters to the DNA molecules. Using an older version of the 




bp DNA fragments resulted in very low adapter ligation when using the ONT 
recommended protocol. Optimisation of the protocol by decreasing reaction volume 
and altering incubation temperature and duration was shown to improve this (Wei 
& Williams, 2016).  However, the library preparation of short fragments (~200 bp) 
using the ONT recommended protocol resulted in very good number of reads (~1 
million) when multiplexing 84 samples. The 15 amplicons were represented in all 
but three samples, with reasonable read depth, confirming the successful adapter 
ligation.  
The read depth, however, varied significantly between amplicons despite the 
optimisation of the multiplex PCR. This variation resulted in very low depth in some 
amplicons in some samples. One of the most affected amplicon was that for B4GALT2. 
In run 2, B4GALT2 was the second highest represented amplicons after ABCB1 and 
real time PCR also showed that this amplicon had low Ct values compared to other 
amplicons (Table 3.11), indicating a high yield from PCR. During the multiplex PCR 
optimisation, concentration of primers for B4GALT2 was reduced together with those 
for ABCB1, in an attempt to increase the representation of other amplicons. This 
primer reduction did not resulted in alteration in Ct value; however, during nanopore 
sequencing in run 3, some samples suffered from very low read depth for B4GALT2.  
In fact, the read depth for B4GALT2 showed the highest variability, ranging from 2-
1314 (Figure 3.11). A threshold of minimum 10x coverage was applied when calling 
the variants using nanopolish, resulting in failure to call the B4GALT2 rs1061781 
genotypes in some samples.  
Lastly, although each sequencing run reported in this chapter was performed with 
changes in the sequencing chemistry or analysis tool, inclusion of several control 
samples from Run 2 to 4 demonstrated good reproducibility in genotyping accuracy 
with 100% accuracy in the control samples in Run 3 and 4 using nanopolish as the 
variant calling tool.  
3.5 Conclusion 
This chapter describes the development of a multiplex assay using nanopore 
sequencing. Multiplex PCR required only one PCR per sample simplifying the 




up to 96 samples in one sequencing run. The assay development in early stages using 
the 2D sequencing chemistries from ONT resulted in accurate genotyping. 
Discontinuation of the 2D chemistries and adoption of the less accurate 1D chemistry 
required appropriate bioinformatic tools to enable accurate genotyping.  
The accuracy of 1D chemistry was improved with the development and introduction 
of new bioinformatics tools, particularly the second version of Albacore that uses a 
new basecalling algorithm that resulted in significant improvements in accuracy. The 
choice of variant calling tool was the other significant determinant of accuracy, with 
nanopolish and Clairvoyante showing the comparable accuracy which was better 
compared to marginCaller and VarScan2. Nanopolish resulted in at least 90% 
accuracy except for one variant, VKORC1 rs9923231 and Clairvoyante resulted in at 
least 90% accuracy except CYP2C19*2. Increasing read depth did not significantly 
increase the accuracy.  
With current accuracy, this assay might be useful in a research setting; however its 
application in a clinical setting would require greater accuracy. Improved 
chemistries, flow cell and bioinformatics tools in the future are expected to improve 
the accuracy and will enable such genotyping assays to be applied in clinical 
laboratories or in point of care settings. In addition to the accuracy issue, the current 
cost of the flow cell would mean that a high number of samples is required to achieve 
a cost-effective assay. This might be impractical in point of care settings where 
results are expected to be delivered as soon as possible with each individual sample. 
The recent introduction of a smaller scale flow cell (Flongle, ONT) with the cost of 
one tenth of ordinary flow cell would make it possible to genotype a fewer numbers 




Chapter 4 : CYP2D6 long amplicon sequencing on GridION 
nanopore sequencer 
 
The material in this chapter formed the basis of the following paper: Liau Y, Maggo S, 
Miller AL, Pearson JF, Kennedy MA, and Cree SL (2019). Nanopore sequencing of the 
pharmacogene CYP2D6 allows simultaneous haplotyping and detection of 
duplications. Pharmacogenomics. 20(14), 1033-1047 (Liau et al., 2019c). 
4.1 Introduction 
4.1.1 CYP2D6 
CYP2D6 is one of the most important and widely studied genes in pharmacogenetics. 
It codes for the cytochrome P450 (CYP) 2D6 enzyme, which is responsible for the 
metabolism and bioactivation of ~25% of all available drugs, including 
antidepressants such as SSRIs, analgesics such as codeine, and anti-cancer drugs such 
as tamoxifen (Ingelman-Sundberg et al., 2007). CYP2D6 is one of the most 
polymorphic human genes, leading to variability in enzyme activity between 
individuals and the need for accurate genotype information for clinical purposes 
(Gaedigk et al., 2018a). 
CYP2D6 is a relatively small gene (4.4 kb from start to stop codon) compared to other 
CYP genes (for example, CYP2C19 spans ~90 kb). However, the complexities of this 
gene make accurate genotyping challenging. CYP2D6 is located on the long arm of 
chromosome 22 clustered together with two more distal pseudogenes, CYP2D8P and 
CYP2D7. Both pseudogenes, but especially CYP2D7, share high sequence identity with 
CYP2D6 (Kimura et al., 1989). The sequence homology between CYP2D6 and CYP2D7 
spans large regions except for some specific differences (Gaedigk, 2013): 
1. A T-insertion in exon 1 of CYP2D7, which creates a frame-shift and results in a 
dysfunctional protein. 
2. A cluster of seven nucleotide differences in intron 1 at position 214-245 after the 
ATG initiation codon. 




4. A cluster of nucleotides in exon 9 that lead to a seven amino acid difference.  
These surrounding pseudogenes have been thought to contribute to the high number 
of variations in CYP2D6 gene (Kimura et al., 1989). Currently, more than 130 different 
star (*) alleles have been recorded for CYP2D6, and compiled in the PharmVar 
database (Gaedigk et al., 2018b). In addition, the gnomAD database from exomes or 
whole genomes of more than 140K individuals revealed more than 1000 variants in 
the gene, including more than 400 missense and 30 loss-of-function variants (Lek et 
al., 2016) (accessed March 2019). A comprehensive review of CYP2D6 gene was 
recently published (Nofziger et al., 2019). 
The number of variants present in the gene has raised the question of which variants 
to be detected or screened when applying strategies other than whole gene 
sequencing. While many haplotypes are assigned based on key variants, in many 
cases these key variants are also shared by other haplotypes. For example, while the 
normal function allele *2 is marked by rs16947, a SNP in exon 6, this SNP is also 
present in loss-of-function alleles such as *12 or *14, and unless other variants 
specific to these two haplotypes are screened, they will be overlooked and lead to 
inaccurate genotyping.  Another example is *4 and *10 which both have the 
rs10655852 SNP; *4 is marked by another key SNP, rs3892097 while *10 lacks this 
variant.  
4.1.2 CYP2D6 structural variations 
In addition to its polymorphic sequence and complexity due to the wider locus, 
CYP2D6 is also affected by copy number variations, and the gene can be duplicated 
or deleted. The gene copy number can range from zero up to 13 copies (Gaedigk et 
al., 1991; Johansson et al., 1993).  Deletion of CYP2D6 is referred to as CYP2D6*5, 
while duplication and multiplication are marked as the allelic variant followed by x2 
or xN (Gaedigk et al., 2018b). When duplication occurs on a functional allele, CYP2D6 
enzyme activity is assumed to increase (Bertilsson et al., 2002; Jarvis et al., 2019).  
Hybrids of CYP2D6 and CYP2D7 genes where the two genes merge at various 
breakpoints also exist. Two forms occur:  CYP2D6/CYP2D7 hybrids where the 5’-
region originates from CYP2D6 and the 3’-region is from CYP2D7; and 




grouped together as *13 in the PharmVar database, and all share the T-insertion of 
CYP2D7 exon 1, which renders them dysfunctional. CYP2D6/CYP2D7 has CYP2D7 
sequence in the downstream part, including spacer and REP7, hallmarks of CYP2D7. 
Examples of CYP2D6/CYP2D7 hybrids include *4N, *10D, *31, *63, *66 and *68. While 
these hybrids are usually dysfunctional, their presence can interfere with genotyping 
and phenotype prediction (Gaedigk et al., 2018b). 
Other than hybrid genes, small CYP2D7 fragments embedded within the CYP2D6 gene 
also exist, referred to as the intron 1 and exon 9 gene conversions.  These conversions 
are part of many allelic variants, for example *2A, *35, *41 (intron 1 conversion) and 
*36, *57 (exon 9 conversion) (Gaedigk et al., 2018b). CYP2D6 can also contain one or 
several SNPs corresponding to the CYP2D7 gene (Gaedigk, 2013). 
Last, tandem rearrangement where the duplicated gene is not identical to its 
downstream CYP2D6 gene in the locus, is also occasionally observed. One study found 
that tandem arrangement occurred at around 12% of all duplication-positive CYP2D6 
samples in Caucasians, but only less than 2% in Africans (Gaedigk et al., 2010). All 





Figure 4.1 Structural variations of CYP2D6 gene (modified from PharmVar) 
REP7 and REP6 indicate 2.8-kb long repetitive sequences specific to CYP2D7 and 
CYP2D6, respectively. REP7 is interrupted by a 1.6-kb region, denoted as spacer in the 
figure. REP-DUP refers to repetitive sequences found in duplicated genes. REP6, REP7 
and REP-DUP share high sequence identity. The size of genes and distance between 
them in the figure is not to scale. 
 
 
Various methods have been developed to genotype CYP2D6, from the basic 
restriction fragment length polymorphism to the more sophisticated real time PCR, 
microarray, mass spectrometry, or NGS (Chua et al., 2016; Rebsamen et al., 2009; 
Sachse et al., 1997). Most methods are limited by the ability to detect only a subset of 
pre-selected variants. While short read based NGS methods have the ability to screen 
all CYP2D6 variants, these methods are hampered by the risk of misalignment of 
CYP2D6 and CYP2D7 due to the short-reads generated, and are not the method of 
choice of CYP2D6 genotyping (Yang et al., 2017). 
Another challenge in accurate CYP2D6 genotyping is phasing or assigning variants to 
their particular haplotype. Most currently available methods do not provide 




information can usually be obtained using various software and exploiting 
information from haplotype reference databases (eg. 1000genome or HapMap 
database), the accuracy is usually poor for rare variants (Sariya et al., 2019). 
Moreover, this population-based variant phasing will be not feasible for novel 
variants not present in the current databases (Lee et al., 2019). Accurate phasing of 
variants is particularly important when more than one loss-of-function variant exists 
in an individual sample, in order to confirm whether the variants exist on different 
haplotypes, which can result in a poor metaboliser phenotype.  
The traditional method to confidently obtain haplotypes is by using allele-specific 
primers to isolate one or both alleles, followed by Sanger sequencing of the 
amplification products (Gaedigk et al., 2015). This is labour intensive, requires a 
greater investment of time, and can be technically demanding. 
Long read sequencing offers the opportunity to resolve challenges faced by previous 
methods. For CYP2D6 genotyping, long amplicon sequencing not only permits 
unequivocal variant detection without interference from the homologous 
pseudogene, it also means that variant phasing can be carried out in a reliable and 
straightforward fashion. With long read sequencing, phasing can be done using 
information from the reads alone (read-based variant phasing), and will be able to 
handle rare or novel variants. A preliminary report described CYP2D6 sequencing of 
a single sample using the ONT MinION with an earlier, more error-prone version of 
the technology (Ammar et al., 2015). In this chapter, I explored and validated the 
application of current ONT long read sequencing chemistry to analyse CYP2D6 from 
multiple reference and clinical samples. Sequencing was performed on the GridION 
platform, a compact nanopore-based instrument from ONT (Oxford, UK) which 
enabled sequencing and data computation in the same module in a real time manner.  
4.2 Specific methods 
Thirty-two samples were genotyped over two sequencing runs with 12 samples in 
the first and 24 samples in the second run. Four samples from the first run were 
repeated in the second run as control samples. Seven CYP2D6 genotyped samples 
(Pratt et al., 2016; Pratt et al., 2010) were obtained from Coriell Institute (Camden, 




laboratory. These studies received ethical approval respectively from Southern 
Health and Disability Ethics Committee (URA/11/11/065) and Northern B Health 
and Disability Ethics Committee (18/NT/21), Ministry of Health, New Zealand.  The 
clinical samples consisted of 14 blood samples and 11 saliva samples.  
CYP2D6 and duplicated versions of CYP2D6 (when present) were amplified on a long 
6.6-kb DNA product for CYP2D6 and 8.6-kb for the duplicated gene. A barcode was 
assigned to each sample through another round of PCR. Both initial and barcoded 
PCR products were purified using magnetic beads. In the first sequencing run, short 
(~1 kb), off-target DNA fragments were sequenced. Therefore, for the second run, to 
remove any DNA fragments shorter than 3-4 kb, modified beads were made based on 
an online protocol (Nagar & Schwessinger, 2018). Details of the bead preparation are 
described in Chapter 2. For each sample, 0.8x volume of beads was used. 
Genotype information for reference samples was available through the published 
Genetic Testing Reference Materials (GeT-RM) dataset (Pratt et al., 2016; Pratt et al., 
2010). Genotype information for the clinical samples were determined using Sanger 
Sequencing based on key variants (Table 4.1).  
Table 4.1 Sequence variants to detect star (*) alleles in Sanger sequencing 
Star (*) Alleles Variants 
RSID Position based on NG_008376.3  
(1=sequence start) 
*2 rs16947 7051C>T 
*3 rs35742686 6750delA 
*4 rs1065852, rs3892097 4300C>T, 6047G>A 
*6 rs5030655 5098delT 
*7 rs5030867 7136A>C 
*9 rs5030656 6816delAAG 
*10 rs1065852 4300C>T 
*15 rs774671100, rs1081004 4337insT, 5369G>A 
*17 rs28371706 5222C>A/T 
*28 rs72549358, rs78482768 4219G>A, 5905C>G 
*29 rs61736512, rs59421388 5860G>A, 7384G>A 
*33 rs28371717 6684G>T 
*35 rs769258 4231G>A 
*41 rs28371725 7189G>A 
*71 rs118203758 4325G>A 
 
4.2.1 Data analysis 
DNA sequences were extracted from fast5 files using Guppy v2.2.2 with flip-flop 




analysis. Guppy basecaller did not accommodate demultiplexing or length filtering 
when I performed this analysis, and these were done subsequently using Porechop 
(https://github.com/rrwick/Porechop) and NanoFilt (De Coster et al., 2018). 
Filtered fastq files obtained from NanoFilt were then mapped to reference 
sequence(NG_008376.3, 8593 bp) using minimap2 (Li, 2018)  or NGMLR (Sedlazeck 
et al., 2018), and variants were called from the mapped BAM files using nanopolish 
(Quick et al., 2016) or Clairvoyante (Luo et al., 2019), and written in VCF files. The 
threshold for calling variants was set at 0.2 for nanopolish and 0.25 for Clairvoyante 
as recommended. A trained model for ONT was also used when calling variants using 
Clairvoyante. Variant phasing in samples containing more than one heterozygote 
variant was carried out using WhatsHap (Martin et al., 2016) with maximum 
coverage of 25x, resulting in phased VCF and phased BAM files. Quality control 
metrics were obtained using NanoOK (Leggett et al., 2015) and MinIONQC (Lanfear 
et al., 2019). The process was illustrated in Figure 4.2 and the scripts used are 
available in Appendix A. 
Variant nomenclature follows the numbering used in PharmVar based on 
NG_008376.3 counting from the sequence start. Haplotype information was 
determined by comparing the variants in each haplotype to the PharmVar haplotype 
table. Duplicated alleles were identified by examining the allelic ratio between 
variants from the two alleles of each sample. The presence of duplicated alleles was 






Figure 4.2 Bioinformatics workflow for CYP2D6 genotyping on GridION 
Figures shows different tools and processes to convert sequencing raw data to phased 






4.3 Results  
4.3.1 Reads characteristics 
Both sequencing runs resulted in similar yield (~3.6 Gb), but different numbers of 
reads. The first sequencing run resulted in more than 90% reads having length less 
than 6 kb, possibly due to unspecific amplification during barcode PCR. In the second 
run, short reads were significantly reduced and target sequences of 6 kb were 
enriched (~55% of total reads) with the use of modified beads during PCR product 
purification (Figure 4.3). Although the first run resulted in more reads in total, there 
were more barcoded reads with >6 kb length in the second run (35% compared to 
4%). Despite the differences in number of reads between runs and among samples, 
all samples had adequate coverage for subsequent analysis and genotyping, with the 
lowest sample coverage at 235x (Table 4.2).  
 
Figure 4.3 Read length distribution for CYP2D6 sequencing runs 
Read length distribution of (A) the first run showed a high peak near 1-kb while (B) the 





Table 4.2 Metrics of CYP2D6 nanopore sequencing runs 
No. Parameters 1st run 2nd run 
1. Total yield 3.24M reads (3.63 Gb) 748K reads (3.62 Gb) 
2. Read length N50: 2955 bp 
Median: 307 bp 
N50: 6741 bp 
Median: 6437 bp 
3. Number of barcodes 14 26 
4. Number of barcoded 
reads 
 
690K reads (47.6% of 
total pass reads) 
242K reads (46% of 
total pass reads) 
6. Number of barcoded 
reads with length >6 kb 
57K reads (3.96% of 
total pass reads) 
186K reads (35.4% of 
total pass reads) 
 
7. Number of reads per 
barcode (length >6 kb 
and qscore >7) 
235-11,832 555-21,853 
8. Mean qscorea 6.1 8.1 
9. Error rates (subs – del – 
ins)b 
6.53% - 4.56% - 5.13% 4.99% - 3.97% - 3.78% 
10. Alignment to CYP2D7c 0.02% 0.01% 
a Mean qscores were obtained from MinION QC  
b Error rates were obtained from NanoOK 
c Using only reads >6 kb 
 
4.3.2 Comparison of mapping and variant calling tools 
The first data analysis performed was comparing the two mapping  tools, minimap2 
(Li, 2018) and NGMLR (Sedlazeck et al., 2018) and the two variant calling tools, 
nanopolish (Quick et al., 2016) and Clairvoyante (Luo et al., 2019), resulting in a total 
of four different analyses. These comparisons were carried out with seven reference 
samples from the first sequencing run and seven randomly selected samples from 
the second sequencing run. False positive and negative variants were confirmed by 
visually inspecting the BAM files on IGV.  
A misalignment event in the intron 1 CYP2D7 conversion region (seven SNPSs, 4414-
4445) was observed when mapping using NGMLR (Figure 4.4). Due to this 
misalignment, the combination of NGMLR and nanopolish inaccurately called 
4423C>G and 4427T>C as 4423insG and 4427delT, while the combination of 
minimap2 and nanopolish called the seven SNPs accurately. Moreover, NGMLR 





Figure 4.4 Misalignment by NGMLR mapper 
Misdetection of two out of the seven variants of intron 1 CYP2D7 conversion due to 
misalignment by NGMLR. The two variants were called incorrectly as indel (4423insG 
and 4427delT) instead of the two variants of 4423C>G and 4427T>C.  
 
All tool combinations resulted in negative predictive value and accuracy of more than 
99%. The relatively high number of true negative variants (6514 – 6561 variants) 
dominated the calculation for these two measurements. Clairvoyante resulted in 
more false positive variants than nanopolish, resulting in higher FDR values (Table 








Table 4.3 Accuracy comparison between different mapping and variant calling tools 














Data from the first sequencing run (7 out of 12 samples) 
minimap2 nanopolish 27 [1-32] 1 [0-4] 6 [5-7] 79.12 20.87 96.43 
minimap2  Clairvoyante 23 [1-32] 2 [0-5] 17 [10-19] 57.50 42.50 92.0 
NGMLR nanopolish 25 [1-30] 3 [0-6] 11 [6-13] 66.52 33.48 89.29 
NGMLR Clairvoyante 26 [1-30] 2 [0-4] 19 [12-21] 54.55 45.45 92.86 
Data from the second sequencing run (7 out of 24 samples) 
minimap2 nanopolish 20 [1-31] 1 [0-2] 13 [12-15] 57.08 42.92 95.24 
minimap2  Clairvoyante 19 [1-28] 1 [0-5] 15 [13-17] 55.88 44.12 95.00 
NGMLR nanopolish 20 [1-29] 1 [0-4] 16 [15-19] 50.64 49.36 95.24 
NGMLR Clairvoyante 20 [1-28] 2 [0-5] 18 [14-21] 52.63 47.37 90.91 
Abbreviation: TP: True Positive, FN: False Negative, FP: False Positive, PPV: Positive Predictive Value, FDR: False Discovery Rate. PPV, FDR, 




Generally, nanopolish resulted in better sensitivity compared to Clairvoyante. 
Moreover, the quality scores in nanopolish-generated VCF files were more indicative 
of the trueness of the variants, and false positive variants were more easily filtered. 
The filtering of false positives is further described in Section 4.3.3. 
Based on these analyses, the combination of minimap2 and nanopolish was used to 
analyse the entire sample cohort.  
4.3.3 Filtering of false positive variants 
As described in Section 4.3.2, the systematic errors currently present in ONT 
sequencing reads led to several false positive variants in each sample. The first type 
of false positive variants arose from the limitation of ONT sequencing to accurately 
basecall homopolymer strings. Due to the structure of the currently used nanopore 
protein, each signal is dominated by the three central nucleotides. In sequences 
where a string of consecutive identical bases is present, current ONT sequencing 
cannot determine the accurate number of nucleotides in the string. When aligned to 
reference, this usually leads to a drop in coverage, and variant calling tools report 
this as a deletion. Two to 13 false positive indel events were found in each sample in 
this cohort. 
The second type of false positive variants were transition variants that occurred in 
two or three variants per sample. These variants are non-random, always transitions 
(AG or CT) and called only in specific position of 2381A>G, 2446T>C, 5207C>T, 
6440T>C, 8046C>T, 8047C>T, or 8723G>A. These false alternate alleles were present 
in ~20% of total reads in all samples. In some samples, they were present above the 
cut-off applied by nanopolish to call a variant, and were called in the VCF files.  
Run 2 produced more false positive variants compared to run 1 when using 
nanopolish as the variant calling tool. This was not read depth related; samples with 
read depth ~500 had a similar rate of false positive variants (S023, read depth: 555, 
false positive variants: 16) with samples with very high read depth (S012, read 
depth: 21853, false positive variants: 15). The mean quality score of the second run 
was actually higher compared to the first run (8.1 vs 6.1) but this could have simply 




Both types of false positive variants had lower quality in the nanopolish produced 
VCF files compared to the true variants. A previously reported strategy (Leija-Salazar 
et al., 2019) was applied by using quality/coverage ratio to differentiate true and 
false variants. Most of the true variants have quality/coverage ratio of >1, while most 
of the false variants have ratio <0.5. For variants with ratio value between 0.5-1, the 
trueness of the variant was determined visually on IGV. For Clairvoyante, the 
differences between true and false variants are less distinctive. Some of the false 
variants generated by Clairvoyante had quality values identical to the true variants, 
restraining the opportunity of straightforward false variants filtering (Table 4.4). 
Table 4.4 Quality value of false positive variants (nanopolish vs Clairvoyante) 








5862 G C 9461.4 0.405 2.445 TRUE 
6047 G A 12164.2 0.425 3.146 TRUE 
6298 A G 9509.7 0.442 2.459 TRUE 
6893 CA C 362.3 0.463 0.094 FALSE 
6962 TG T 136.8 0.413 0.035 FALSE 
7585 A C 14169.8 0.429 3.664 TRUE 
7783 A G 8166.2 0.440 2.112 TRUE 
8190 AG A 182.9 0.396 0.047 FALSE 
8273 G A 295.3 0.322 0.076 FALSE 
8381 G C 11920.2 0.443 3.083 TRUE 
8602 C T 8169.8 0.429 2.113 TRUE 
Clairvoyante 
5862 G C 999 0.318 0.258 TRUE 
5907 GT G 999 0.452 0.258 FALSE 
6047 G A 999 0.342 0.258 TRUE 
6298 A G 999 0.341 0.258 TRUE 
6773 GCCC G 999 0.739 0.258 FALSE 
6838 TG T 154 0.481 0.040 FALSE 
6892 CA C 120 0.468 0.031 FALSE 
7585 A C 999 0.290 0.258 TRUE 
7686 TG T 999 0.682 0.258 FALSE 
7783 A G 999 0.384 0.258 TRUE 
8273 G A 999 0.313 0.258 FALSE 
8381 G C 999 0.351 0.258 TRUE 
8602 C T 999 0.393 0.258 TRUE 
* Alternate allele proportion was designated as “support fraction” by nanopolish and “allele 




4.3.4 Variant phasing and determination of star (*) alleles. 
Together, the reference and clinical samples cover a total of 16 different star (*) 
alleles (*1, *2, *3, *4, *6, *7, *9, *10, *15, *17, *28, *29, *33, *35A, *41, and *71), as 
well as one sample with gene deletion (*5) and four samples with gene duplication.  
After filtering out of false positive variants, a total of 70 true variants was present in 
the 32 samples. Most of the variants were SNPs, but small indels were also found.  
To determine the star (*) alleles of each sample, the VCF files containing all variants 
of any samples were phased using WhatsHap. The resulting phased variants 
representing each haplotype were separated and each haplotype was matched to the 
PharmVar haplotype table. Despite the high number of variants in some samples, all 
of them could be phased accurately, and confident star (*) alleles could be assigned. 
One example of variant phasing is illustrated in Figure 4.5. The sample (NA18518, 
reference genotype: *17/*29) had a total of 17 heterozygote and nine homozygote 
variants. After variant phasing, haplotype 1 had six of the 17 heterozygote variants, 
while haplotype 2 had 11 of them. The variants in haplotype 1 matched to *17.001 
except the presence of a novel variant 4853C>T; this was later assigned as *17.003 
by the PharmVar CYP2D6 committee. The other haplotype in this sample matched 
completely to *29.001. 4853C>T was confidently shown to be in a different haplotype 









Figure 4.5 Variant phasing and determination of star (*) alleles 
Nanopore sequencing results for sample NA18518, assigned as *17/*29 by Pratt, et al (2016). Top: all variants present in the sample.  
Variants in blue are homozygous variants that were present in both haplotypes. Bottom:  Variants phased with Whatshap, showing that 






Figure 4.6 Phasing of two variants in sample NA18518 
 
The IGV screenshot showed that the 4853C>T was confidently phased in a different 
haplotype to *29. 
 
Genotypes for all reference samples matched completely to reference genotypes 
based on the GeT-RM dataset (Pratt et al., 2016). However, recently published 
characterisation of Coriell samples for CYP2D6 alleles reported that two of the 
reference samples (NA12878 and NA21781) used in this study also had an additional 
hybrid gene (*68) in the *4 allele (Gaedigk et al., 2019). This hybrid gene was not 
amplified by the 6.6-kb primer set I used, and thus was not detected or sequenced in 
this assay (Figure 4.7). 





Figure 4.7 Hybrid gene (*68) in one of the reference samples (NA12878) 
Figure shows the haplotypes of NA12878 (*3/*68+*4). this assay amplified the *3 and 
*4 and determined their haplotypes accurately, however it missed the presence of the 
hybrid *68. 
 
From the 64 haplotypes represented by the 32 samples (excluding the *68), 52 of 
them were assigned to known subvariant catalogue entries on PharmVar. For the 
remaining 12 haplotypes in 11 samples, they either had key variants matched to 
certain star (*) alleles but not to the existing subvariants, or contained variants that 
did not match any known allele pattern on PharmVar. These, upon submission to 
PharmVar, were assigned as novel star (*) allele or novel subvariants of known 
alleles. The details of these 12 haplotypes are elaborated in the next paragraphs and 
summarised in Table 4.5. 
One sample (S016) contained one variant (6504C>T, rs79738337) which is only 
associated with *60, but lacked the key variant of *60 (6088insTA). As 6504C>T is an 
intronic variant, this sample was proposed to be a new subvariant of *1 and it was 
assigned by PharmVar committee as *1.026. The other haplotype of S016 matched 
*10.002 except for the presence of 4945C>G in this sample. This haplotype was 
assigned as *10.003.  
Sample S007 had two variants (4325G>A and 5695T>C), associated with *71 but 
lacked the 2617C>G variant, and therefore could not be matched to either *71.001 or 
*71.002 as per the PharmVar catalogue. This was assigned as *71.003.  
One sample (S003) had a 6750delA variant in one haplotype which was called as *3. 
In the other haplotype, there were 9 SNPs and one insertion variant, which taken 




7436A>G, 7455T>C, 7466G>A, 7585A>C, 7679A>G, 7685G>A, 7746insA, 7753C>T, 
7783A>G). From the 10 variants found in this haplotype, three of them are in the 
exonic regions, one of which, 7436A>G, is a missense variant, classified as moderate 
by Ensembl variant effect predictor (VEP) tool (McLaren et al., 2016) and is one of 
the key variants associated with *108. However, the *108 allele has another key 
variant also in exon 7, 7427A>G (rs61736517), which was not present in this sample. 
7466G>A, also a missense variant and predicted to be deleterious by VEP, has been 
associated with *4.021, but this sample lacked other key variants of *4. This was 
assigned by PharmVar as a new star (*) allele, *127. 
Five variants not yet catalogued in PharmVar were found. Two of the Coriell samples 
(NA18518 and NA23297) with *17 allele had an additional intronic variant 
(4853C>T, rs376217512). This is a rare variant with MAF ~1%. This was assigned as 
*17.003.  
One sample with variants matching to *41 allele (S013) contained two non-
catalogued variants, 5578C>G (rs143170489) in intron 2 and 5814C>T 
(rs61736504) in exon 3. Both are rare with MAF ~1%. The exonic variant is predicted 
to be benign when annotated using VEP. This was assigned as new subvariant of *41, 
*41.004. Another sample with *4 allele (S023) also had a rare (MAF ~0. 1%) intron 
2 variant, 5604C>T, rs557722765, and was assigned as a new subvariant, *4.026. 
The fifth variant not catalogued in PharmVar was an upstream variant (3836G>A, 
rs1080992) which was found in four samples, and was the only variant in the 
particular haplotype of each sample. This rare variant with an MAF <1% has been 
reported in another population (He et al., 2016). No functional information is 
available for this variant. This haplotype was assigned as *1.025.  
Table 4.5 Novel star (*) allele and subvariants submitted and accepted by PharmVar 
Samples Star (*) allele Description 
S003 *127.001 Novel star (*) allele 
S001, S009, S020, S021 *1.025 Novel subvariant of *1 
S013 *41.004 Novel subvariant of *41 
S023 *4.026 Novel subvariant of *4 
S016 *1.026 Novel subvariant of *1 
S007 *71.003 Novel subvariant of *71 
NA18518, NA23297 *17.003 Novel subvariant of *17 




There was only one sample with a heterozygous gene deletion (*5 heterozygote) 
(S022), with one haplotype available to be sequenced. This haplotype contains a 
hemizygous variant (6684G>T), which corresponds to *33. This variant was 
confirmed on Sanger sequencing and the sample was assigned as *5/*33. The 
haplotypes of all samples are detailed in Table 4.6. 
Table 4.6 Genotyping results for all samples 








No. of variants 
subs del ins 
Reference samples 
1 NA07439 run 1 *4XN/*41 hap1 *4.004XN 15 0 0 
hap2 *41.003 23a 1 0 
run 2 *4XN/*41 
  
hap1 *4.004XN 14b 0 0 
hap2 *41.003 22a,b 1 0 
2 NA23348 run 1 *7/*35 
  
hap1 *35.001 23b 1 0 
hap2 *7.001 1 0 0 
run 2 *7/*35 
  
hap1 *7.001 1 0 0 
hap2 *35.001 23b 1 0 
3 NA18518 run 1 *17/*29 
  
hap1 *17.003# 20b 0 0 
hap2 *29.001 17c 1 0 
4 NA21781 run 1 *2x2/*68+*4§ 
  
hap1 *2.001XN 22b 1 0 
hap2 *4.001 14b,d 0 0 
5 NA12878 run 1 *3/*68+*4§ hap1 *3.001 0 1 0 
hap2 *4.001 17b 0 0 
6 NA23405 run 1 *1/*7 
  
hap1 *7.001 1 0 0 
hap2 *1.001 0 0 0 
  7 NA23297 run 1 *10(XN) / *17  hap1 *17.003# 20b 0 0 
    hap2 *10.002XN 13b 0 0 
Clinical samples 
8 S001 run 1 *1/*1 
  
hap1 *1.001 0 0 0 
hap2 *1.025# 1 0 0 
run 2 *1/*1 
  
hap 1 *1.025# 1 0 0 
hap 2 *1.001 0 0 0 
9 S002 run 1 *6/*4 
  
hap1 *6.005 2 1 0 
hap2 *4.001 17b 0 0 
run 2 *6/*4 
  
hap 1 *6.005 2 1 0 
hap 2 *4.001 17b 0 0 
10 S003 run 1 *1/*3 
  
hap1 *127.001# 9 0 1 
hap2 *3.001 0 1 0 
11 S004 run 1 *4/*9 
  
hap1 *4.001 17b 0 0 
hap2 *9.001 0 1 0 
12 S005 run 1 *2/*10 
  
hap1 *2.001 22b 1 0 
hap2 *10.002 13b 0 0 
13 S006 run 2 *2/*9 
  
hap 1 *2.001 22b 1 0 
hap 2 *9.001 0 1 0 
14 S007 run 2 *71/*41 
  
hap 1 *71.003# 2 0 0 
hap 2 *41.001 22b 1 0 
15 S008 run 2 *15/*2 
  
hap 1 *15.001 1 0 1 
hap 2 *2.001 22b 1 0 
16 S009 run 2 *1/*6 
  
hap 1 *6.005 2 1 0 




Subs = substitution, del = deletion, ins = insertion 
§     Based on new GeT-RM data for CYP2D6 (Gaedigk et al., 2019) 
#     New star (*) allele/subvariant 
a. Variant 7189G>A was not called in the VCF file but visually confirmed on BAM file. 
b. Variant 5042T>G was incorrectly called as delT  
c. Variant 6416A>G was not called in the VCF file but visually confirmed on BAM file. 
d. Variants 2775C>T, 3201G>A and 4300C>T were not called in the VCF file but visually 
confirmed on BAM file. 
e. Variant 2775C>T was not called in the VCF file but visually confirmed on BAM file. 
 
4.3.5 Detection of duplicated alleles 
The duplicated alleles in samples were detected by interrogating the allelic ratio 
between alleles. Samples without a duplication were expected to have a 1:1 ratio 
between alleles, while samples with a duplication were expected have a skewed ratio 

















No. of variants 
subs del ins 
Cllinical samples – continued 
17 S010 run 2 *4/*10 
  
hap 1 *10.002 13b 0 0 
hap 2 *4.015 18b 0 0 
18 S011 run 2 *2/*2 
  
hap 1 *2.001 22b 1 0 
hap 2 *2.001 22b 1 0 
19 S012 run 2 *4/*4 
  
hap 1 *4.001 17b 0 0 
hap 2 *4.001 17b 0 0 
20 S013 run 2 *2/*41 
  
hap 1 *41.004# 23 1 0 
hap 2 *2.001 23 1 0 
21 S014 run 2 *4/*28 
  
hap 1 *28.001 25 1 0 
hap 2 *4.015 19 0 0 
22 S015 run 2 *4/*35 
  
hap 1 *4.001 18 0 0 
hap 2 *35.001 24 1 0 
23 S016 run 2 *10/*1 
  
hap1 *1.026# 1 0 0 
hap2 *10.003# 14 0 0 
24 S017 run 2 *35/*41 
  
hap1 *41.001 22b 1 0 
hap2 *35.001 23b 1 0 
25 S018 run 2 *1/*1 
  
hap1 *1.016XN 1b 0 0 
hap2 *1.012 2 0 0 
26 S019 run 2 *1/*1 
  
hap1 *1.012 1 0 0 
hap2 *1.001 0 0 0 
27 S020 run 2 *1/*1 
  
hap1 *1.025# 1 0 0 
hap2 *1.001 0 0 0 
28 S021 run 2 *1/*1 
  
hap1 *1.025# 1 0 0 
hap2 *1.001 0 0 0 
29 S022 run 2 *5/*33 
  
hap1 *5.001 Gene deletion 
hap2 *33.001 1 0 0 
30 S023 run 2 *4/*4  hap1 *4.001 17b 0 0 
    hap2 *4.026# 18b 0 0 
31 S024 run 2 *3/*4 
  
hap1 *3.001 0 1 0 
hap2 *4.001 17b 0 0 
32 S025 run 2 *4/*41 hap1 *41.001 22b 1 0 




of ~2:1 (Figure 4.8). All four samples that indicated gene duplication during the 
initial PCR screening showed an uneven allelic ratio in the nanopore sequencing data, 
and the duplicated alleles could be determined from the over-represented allele. 
Allele duplication was called if the proportion of variant calls was greater than a ratio 
of 2:1, with p-value <0.05. All duplicates were called on samples with greater than 
1000x coverage, which requires a minimum of 637x coverage for an allele to be called 
a duplication and is well above the minimum 141x coverage for which the 95% 
binomial confidence interval for a ratio of 1:1 overlaps that for a ratio of 2:1.     
4.3.6 Validation of duplicated allele and variant phasing using the 8.6-kb 
fragment.  
In addition to the 6.6-kb amplicons, the 8.6-kb amplicons from three out of the four 
samples with duplication were sequenced. The 8.6-kb products are derived from the 
duplicated allele (illustrated in Figure 2.1 in Chapter 2), and aligned to the 
NG_008376.3 reference sequence from position 3860 to 8593. Interrogating the 
variants in the 8.6-kb amplicons served two purposes. First, this directly validated 
the duplicated allele and confirmed calls made using the allele ratio of the 6.6-kb 
amplicons. In all three samples, the 8.6-kb fragments revealed the same variants as 
the duplicated alleles identified from the 6.6-kb fragments, thus confirming the 
duplicated alleles of these samples (NA07439, NA23297, S018) (Table 4.7).  Second, 
comparison of the variants found in the 8.6-kb amplicon to those found in the 6.6-kb 
amplicon allowed validation of variant phasing performed in the 6.6-kb amplicon. All 
variants found in the 8.6-kb amplicons of the three samples matched completely 
those found in the over-represented (duplicated) allele on the 6.6-kb fragments, thus 
validating the accuracy of variant phasing of the 6.6-kb amplicons. In addition, all 
phased variants in all samples could be matched to a particular allele or subvariant, 























Figure 4.8 Phased BAM file for duplicated and non-duplicated samples 
Phased variants for (A) sample with no duplicated allele (NA23348, *7/*35A) and (B) 
sample with duplicated allele (NA07439, *4XN/*41). Colours represented each of the 
phased haplotypes of the samples. Figure 4.8(B) showed the overrepresented reads of 












Table 4.7 Variants in duplicated allele in 6.6-kb and 8.6-kb fragments 
No. Sample Variants found in duplicated  
allele in 6.6-kb amplicon  
(from position 3860 – 8593) 
Variants found in 8.6-kb 
amplicon  




4300C>T, 4510G>T, 5042T>G, 
5238C>T, 5862G>C, 6047G>A, 
6298A>G, 7585A>C, 7783A>G, 
8381G>C, 8602C>T, 8923T>G 
4300C>T, 4510G>T, 5238C>T, 
5862G>C, 6047G>A, 6298A>G, 
7585A>C, 7783A>G, 8381G>C, 
8602C>T, 8923T>G * 
2.  NA23297 
(*10XN) 
4300C>T, 4510G>T, 5238C>T, 
5862G>C, 6298A>G, 7585A>C, 
7783A>G, 8381G>C, 8602C>T, 
8923T>G* 
4300C>T, 4510G>T, 5238C>T, 
5862G>C, 6298A>G, 7585A>C, 





4300C>T, 4510G>T, 5238C>T, 
5862G>C, 6047G>A, 6298A>G, 
7585A>C, 7783A>G, 8381G>C, 
8602C>T, 8923T>G * 
4300C>T, 4510G>T, 5238C>T, 
5862G>C, 6047G>A, 6298A>G, 





*5042T>G not shown in this amplicon as it was missed by the variant calling tool (see Section 4.3.7) 
 
4.3.7 False negative variants 
Although all samples could be genotyped unequivocally, several variants failed to be 
detected in the VCF file. One variant that was present but not reported in many 
samples was 5042T>G. This SNP sits between four Gs in the upstream and another G 
downstream, and when the alternate G exists, it created a string of 6 G’s and the read 
depth dropped significantly at the variant site, due to the inability of nanopore 
sequencing to detect homopolymers correctly (Figure 4.9). As a result, this SNP was 
often called incorrectly as a T-deletion instead of a SNP. However, this variant is quite 
common and is shared by many star (*) alleles including the normal and reduced 
function *1, *2, *4, *10, *41 and many others, and the absence did not interfere with 





Figure 4.9 IGV screenshot of the 5042T>G variant 
Top sample: homozygote variant (allele ratio of T: 10%, G: 77%), middle sample: 
heterozygote variant (allele ratio of T: 80%, G: 15%), bottom sample: no variant (allele 
ratio of T: 95%, G: 1%). Sample with homozygote or heterozygote 5042T>G variants 
showed drop of coverage.  
 
Another variant that was missed due to homopolymers is the 6416A>G variant. The 
A sits between two Gs in the upstream and one G downstream. When the G allele is 
present, it again creates a string of four G’s and a drop in coverage. This variant was 
present in one sample in this cohort (NA18518), where the G allele ratio was ~20% 








Figure 4.10 IGV screenshot of the 6416A>G variant 
Top sample: heterozygote variant (allele ratio of A: 74%, G: 25%), bottom sample: no 
variant (allele ratio of A: 98%, G: 2%). Sample with heterozygote 6416A>G variant 
showed drop of coverage.  
 
Several false negative variants were also found in samples with duplications, in the 
non-duplicated alleles. Variants in the non-duplicated allele had lower allele ratio 
and some variants were missed by the variant calling tool (Table 4.6). These variants 
could be confirmed by inspecting the BAM file on IGV. 
4.4 Discussion 
This chapter described the application of long amplicon nanopore sequencing of the 
whole CYP2D6 gene (including upstream and downstream regions) on the GridION 
nanopore sequencing platform. This was the first extensive analysis of CYP2D6 on a 
nanopore sequencing platform across multiple star (*) alleles, including assessment 
of SV. An earlier report of CYP2D6 nanopore sequencing only used one reference 




error rates were associated with that version, and unresolved ambiguity was 
reported in the sample diplotype, although variant phasing was performed 
accurately (Ammar et al., 2015). The initial relatively high error rate associated with 
nanopore sequencing has improved as the technology continues to evolve. This is 
mainly attributed to improvements in the pore, sequencing chemistries and 
bioinformatic algorithms available for analysis. The accuracy of ONT nanopore 
sequencing has improved from less than 80% with the R7.3 flow cell (Jain et al., 2015) 
used by Ammar et. al, to more than 90% with the current R9.4 version (Tyler et al., 
2018).  
I used the R9.4 flowcell with 1D sequencing chemistry, and generated DNA sequences 
using the Guppy basecaller v2.2.2 from ONT. At the time of analysis, this version of 
Guppy was not embedded in the “live” basecalling (basecalling during sequencing) 
and required  re-basecalling all reads after completion of sequencing. High accuracy 
“live” basecalling using the later version of Guppy (since v3.1.5) has since been made 
available, which allows high accuracy basecalling during sequencing, substantially 
shortening the analysis time. Basecalled reads can be used at any time point for initial 
analysis if necessary. 
Sample barcoding permits efficient use of the flow cell and reduction in per sample 
assay costs. For high throughput laboratories or for research studies on larger 
cohorts, sample number could potentially be multiplexed up to 96 using the ONT 
barcode kit. This 26-plex sequencing run resulted in a minimum read depth of ~500x 
in one sample, while the lowest read depth was found in one sample in the first 14-
plex run (~200x). These minimum coverages were more than adequate for accurate 
variant calling and phasing, while some samples had tens of thousands of reads. No 
difference in accuracy was observed in these low coverage samples compared to 
samples with higher read depth. When using nanopore sequencing for a long 
amplicon from the GBA gene, Leija-Salazar et al reported that coverage >100x is 
sufficient for accurate variant calling (Leija-Salazar et al., 2019).  
Two papers using another long sequencing platform, the PacBio SMRT system, have 
recently reported the advantages of long amplicon sequencing of CYP2D6 (Buermans 
et al., 2017; Qiao et al., 2016). Both papers describe the advantages of long read 




capital costs, and a unique opportunity to deliver results in real-time settings such as 
in the field (Quick et al., 2017; Quick et al., 2016) or at point of care.  
The main advantage of long read sequencing is enabling straightforward variant 
phasing. The method described in this chapter, however, relied on amplification to 
enrich the target regions, and issues such as PCR chimera can potentially 
compromise the accuracy of phasing (Laver et al., 2016) or result in ambiguous 
biallelic variants (Gao et al., 2012). Data from CYP2D6 nanopore sequencing on a 
single sample (Ammar et al., 2015) resulted in four haplotypes instead of two, 
indicating that potential PCR chimera had occurred (Laver et al., 2016). Reducing 
PCR cycle number and increasing PCR extension time can minimise the formation of 
PCR chimera (Gao et al., 2012; Judo et al., 1998; Laver et al., 2016). In this thesis, all 
samples resulted in two haplotypes, and validation on the reference samples showed 
that each haplotype of these samples matched completely to their reference 
haplotypes, demonstrating there was no interference from PCR chimera for these 
samples. For all remaining samples, the variants of all but 12 haplotypes matched 
completely to known star (*) allele subvariants. For the 12 haplotypes not assignable 
to a definite star (*) allele/subvariant due to the presence of additional variants, the 
BAM files were tagged with phase information using WhatsHap, and interrogated 
each variant manually on IGV. All additional variants were confirmed to be present 
in the haplotype as indicated by WhatsHap, again showing that there was minimal 
interference of PCR chimera.  
All variants found in this study were also confirmed by Sanger sequencing. However, 
due to the inability to phase the variants, results from Sanger sequencing could not 
be used to provide haplotype information. 
In addition to variant phasing, duplicated alleles when present, were also identified. 
Using the 8.6-kb PCR amplicon derived from duplicated alleles as a confirmation 
sequence, the duplicated alleles could be detected from the 6.6-kb CYP2D6 amplicon 
by the skewed allelic balance of reads. The allele ratio could be observed from the 
VCF file or by visualising the phased BAM file on IGV. I demonstrate that the biological 
ratio of alleles is accurately retained throughout the long PCR process. This result is 
relatively unsurprising as there is no expectation that (even in later cycles of the PCR) 




alleles were quite different in sequence, they may display different amplification 
kinetics. All  duplication samples in this thesis have an allele ratio of ~2:1, indicating 
two copies of the duplicated gene. Statistical analysis revealed that the minimum 
read depth of 141x was required to call a duplicated allele confidently when present. 
Due to the limited range of available duplication samples in this cohort, it remains 
inconclusive whether this method could determine the exact number of gene copies 
accurately in cases with more than two copies.  
4.4.1 False positive and negative variants 
CYP2D6 variant detection and phasing could be performed accurately with this 
method; however, data analysis was complicated by the presence of false positive 
and negative variants. These false variants were attributed to error rates of ONT 
sequencing, arising from various sources. First, errors could arise from the 
sequencing raw signal itself, due to inherent properties of the sequencing chemistry 
or flow cell (Rang et al., 2018). For example, the change of pore materials of R7 to 
CsgG in R9 significantly increased the sequencing accuracy (Jain et al., 2017). Another 
source of errors could originate from translating the raw signal to DNA sequences. In 
this hypothesis, the correct information was contained in the raw signal, however the 
algorithms and bioinformatics tools used to interpret this data failed to accurately 
convert the signal to the correct DNA sequences (Rang et al., 2018). For example, 
updating of the basecalling tool from Guppy v1.8.5 to v2.2.2 with flip-flop basecalling 
reduced the number of false positive variants by half, confirming the higher accuracy 
of the newer tool. 
Most of the false positive variants had very low quality scores as calculated by 
nanopolish, compared to other variants in the same sample. These quality scores 
correlated linearly to the read depth of the sample. Therefore, using a ratio of 
quality/read depth is more useful than the quality score itself to differentiate false 
from true variants (Leija-Salazar et al., 2019). Although this strategy proved to be 
effective in most cases, a small number of false variants had high quality scores 
similar to the true variants. For example, in one sample, the false positive 2627delA 
variant sat between two true variants, and the quality score of this variant was 
identical to the true variant 2617C>G (Table 4.8). If filtering was done solely based 




however visual checking of the BAM file on IGV, as well as Sanger sequencing, 
revealed that this was a false variant. I suspect that this anomaly was caused by error 
in writing the VCF file by nanopolish. 
Table 4.8 False positive variants with high quality scores 







2381 A G 28.2 0.268 0.002 FALSE 
2431 G A 52827.4 0.893 4.431 TRUE 
2617 C G 64959.1 0.928 5.449 TRUE 
2627 CA C 64959.1 0.472 5.449 FALSE 
2966 A G 108059.8 0.933 9.064 TRUE 
3461 C T 59191.6 0.885 4.965 TRUE 
3523 G A 60694.4 0.858 5.091 TRUE 
3901 AG G 862.9 0.490 0.072 FALSE 
 
False variant filtering followed by variant phasing using WhatsHap and matching to 
the PharmVar CYP2D6 haplotype table resulted in 52 out of the 64 haplotypes in this 
study being accurately assigned to known subvariants of star (*) alleles. The 
remaining 12 haplotypes were assigned as new star (*) alleles or subvariants due to 
the presence of novel variants or pattern of variants.  
4.4.2 Other challenges 
One of the issues reported with nanopore sequencing is the limitation in reliable 
detection of small indel events (Leija-Salazar et al., 2019; Magi et al., 2017), and 
several false positive indel were encountered in homopolymer regions. However, 
true indel outside the homopolymer regions could be detected accurately, including 
key indel variants associated with CYP2D6 star (*) alleles such as 6750delA (*3), 
5098delT (*6), 6816delAAG (*9), and 4337insT (*15). All samples with these 
haplotypes were identified accurately. In addition, other indel variants were also 
detected including 4943delC, 7746insA, and 8857delACA which is associated with 
several star (*) alleles including *2, *41, and *35. The 4943delC sits in a string of four 
Cs.  
The different ways to annotate indel variants especially in repeat sequences required 
manual modification of the variant call in the VCF file. PharmVar annotates indel 




in contrast, nanopolish calls indel based on the 5’-most position, resulting in different 
labelling of variant position in the NG_008376 reference sequence between VCF files 
and PharmVar haplotype table. Also, in nanopolish generated VCF file, the positon of 
the indel variant is written as one position before the actual indel. For these indel 
variants, positions in the VCF files were manually modified to match the position in 
the PharmVar haplotype table. 
The challenge that homopolymer regions present to nanopore sequencing also 
means that this technology remains limited for investigating the two long 
homopolymer strings of A’s in the upstream region of the CYP2D6 gene (2943-2964 
and 3098-3107). The regions in between these two strings are notoriously difficult 
to sequence, resulting in a gap in most PharmVar catalogued star (*) alleles or 
subvariants. Variation in the number of A’s within 2943-2964 has been reported 
previously (Buermans et al., 2017), however this region has not  been included as 
part of the haplotype definition (Gaedigk et al., 2018a). Although nanopore 
sequencing was not able to reliably detect variation in the poly A string, the regions 
adjacent to the strings were sequenced accurately in this study, including the 
detection of variants such as 2966A>G, which is still ambiguous in many star (*) 
alleles. The status of this variant was clarified in several known star (*) alleles and 
subvariants (*3.001, *17, *29.001, *4.004). 
Another technical challenge was the PCR failure rate of the saliva samples. Twenty 
percent of saliva samples failed to be amplified or gave very low yield, possibly due 
to degraded and low purity DNA in saliva. Increasing the number of PCR cycles or 
altering the concentration of starting DNA template did not help to increase the PCR 
yield of these samples. All DNA from blood samples was successfully amplified, and 
together with successfully-amplified DNA from saliva samples, were barcoded via 
second round PCR and quantified.  
Barcoded samples were then pooled in an equimolar manner. Despite this attempt to 
achieve uniform coverage among samples, the number of reads still varied. One 
possible explanation is the variable barcoding PCR efficiency. After the barcoding 
PCR, barcoded DNA could not be purified from non-barcoded DNA because of the 
very small size difference between the two products. Different PCR efficiency would 




to the total DNA amount, leading to different barcoded read numbers per sample. 
This variability, however, did not affect the genotyping accuracy, as demonstrated by 
the accurate calling of almost all variants, both in control and clinical samples.  
This method required amplification of the gene before sequencing, which has several 
limitations. First, as discussed in Section 4.3.4, hybrid genes in two of the reference 
samples were undetected in this study. The *68 allele is not amplified by the 6.6-kb 
primer sets, and the detection of this allele will require another set of primers or 
modification of PCR cycles using the 8.6-kb primer set. The *68 was recently reported 
to exist solely in tandem with *4 and up to a quarter of *4 alleles were predicted to 
have this additional allele (Gaedigk et al., 2019). Both *68 and *4 are non-functional 
alleles, and thus the mis-detection of *68 did not change the prediction of enzyme 
activity. However, future work could include screening of all samples with *4 for the 
presence of *68 to provide a more accurate genotype.  
Second, the whole gene deletion allele (*5) still requires detection by a separate 
duplex PCR, as the 6.6-kb primer sets resulted in no amplification from this allele. In 
samples with homozygote *5, the 6.6-kb long PCR will result in no amplification and 
no sequencing is required. In samples with heterozygote *5, one copy of the gene is 
available to be amplified and sequenced, and unless information regarding the 
presence of gene deletion is made available through initial duplex PCR, sequencing 
of the amplification product can lead to mis-genotyping. 
Additionally, the methods described here also have not been extended to the 
detection of other complex CYP2D6 structural variation such as other CYP2D6-
CYP2D7 or CYP2D7-CYP2D6 hybrids or tandem rearrangements. Other sets of 
primers would be required to amplify and sequence these hybrid or non-identical 
duplicated genes. 
An alternative approach such as using CRISPR-cas9 methods to target and enrich 
regions of interest could be applied (Hafford-Tear et al., 2019; Slesarev et al., 2019). 
Without the need for amplification, all SV present in the gene locus could be enriched 
and sequenced under a single protocol. Theoretically, the *5 whole gene deletion 
could also be detected using this approach. However, since sample barcoding is not 




samples in this manner will require use of one flow cell per sample making it very 
costly. 
4.5 Conclusion 
In summary, nanopore sequencing of the CYP2D6 gene allows accurate detection and 
phasing of variants and determination of sample haplotypes to the subvariant level. 
The presence of false positive variants required an additional filtering step, and false 
negative variants in specific sequence context and samples with gene duplication 
required visual checking of the BAM files. Sample multiplexing through ONT specific 
barcodes permitted sequencing and analysis of multiple samples simultaneously, 
improving cost and time efficiency. 
In this study, I discovered five novel rare variants not yet catalogued in PharmVar 
CYP2D6 database, and key indel variants could be reliably detected. All new star (*) 
alleles and subvariants were submitted to PharmVar. In total, this study contributed 
to one novel allele (*127) and seven novel subvariants of known alleles (*1.025, 
*1.026, *4.026, *10.004, *17.003, *41.004, *71.003). variants adjacent to the poly A 
strings (2966A>G, 3201G>A) which were previously ambiguous in several star (*) 
alleles were also clarified. For samples with gene duplication, nanopore sequencing 
enabled detection of the duplicated alleles providing better prediction of CYP2D6 
phenotype. However, this method in its current format was unable to detect complex 
SV such as hybrid genes. 
This method will be valuable in research settings to provide a more accurate 
genotyping and detection of duplicated gene of CYP2D6 without the need of 
expensive instruments. The high accuracy genotyping also mean it could potentially 
be used in clinical the setting, however the need for manual steps of false positive 
filtering and false negative confirmation on IGV might make this approach 
impractical at present. Future improvement in nanopore flow cells, kit chemistry, 
and bioinformatics might lead to more accurate variant detection and allow direct 




Chapter 5 : Genome wide genetic analysis of angiotensin 
converting enzyme inhibitor induced angioedema cases 
5.1 Introduction 
ACEi-A is a relatively rare ADR with incidence varying across ethnicities, suggesting 
genetic variation to be a risk factor. The accumulation of bradykinin and/or 
substance P is thought to contribute to this ADR; however, the exact mechanism and 
the underlying genetic factors remain elusive. Several genetic studies including 
GWAS have been conducted (detailed in Chapter 1 Section 1.5) but no strong genetic 
candidate has been identified to date. 
The existing genetic studies have a bias towards common variants. Considering ACEi-
A itself is rare in prevalence (~0.3%), I hypothesised that this ADR is caused by rare 
variants in one or more genes and applied methods capable of investigating these 
variants including WES and WGS. Additionally, limited CNV analysis was also 
performed. 
5.2 Specific methods 
5.2.1 Samples 
Twenty ACEi-A samples were acquired as described in Section 2.4.1. Five initial 
samples of ACEi-angioedema were analysed by WES, and 15 subsequent samples 
were analysed by WGS. WES data from three samples, and WGS data from 22 samples 
with other ADR unrelated to ACEi-A were available as control sets. Six of these 25 
control patients had a history of ACEi use without any documented history of 
angioedema. Both WES and WGS data for control samples were acquired through the 
same sequencing platform and processed through the same bioinformatics pipelines 
as the ACEi-A samples. For samples with only WES data, Sanger sequencing was 
performed to detect several previously reported variants, all of which are outside of 
coding regions. Additionally, CNV analysis was done using aCGH for six samples, and 




Macrogen (Seoul, South Korea) using Control-FREEC (Boeva et al., 2012). An outline 
of the analyses done in this chapter is illustrated in Figure 5.1. 
 
Figure 5.1 Outline of genetic analysis on ACEi-A in this chapter 
Genetic analysis was first done on previously reported variants. Investigation was 
performed through WES or WGS with candidate and non-candidate gene approaches. 
Variants were filtered based on various criteria, and the resulting filtered variants were 
analysed using biological network analysis. A limited CNV analysis was performed on 
subsets of samples. MAF is minor allele frequency, AFR is African ethnicity, and NFE is 
Non-Finnish European ethnicity. 
5.2.2 Filtering criteria for prioritising variants from WES and WGS data 
Both WES and WGS generated a vast number of variants, most of which would be 
neutral or unrelated to the phenotype being analysed. Therefore, stepwise filtering 




and WGS datasets was done separately, using commercial software, VarSeq 2.1.0 
(Golden Helix, Bozeman, MT, USA). 
In principle, two approaches were used. The first approach used a set of a priori 
generated candidate genes that were thought to be associated with ACEi-A. A small 
subset containing 23 genes associated with bradykinin and substance P metabolism 
and their relevant receptors was first used. A more comprehensive list (n=421 genes) 
was later established to include genes with reported variants associated with ACEi-
A, genes associated with HAE, genes in the signalling pathway of activated bradykinin 
receptors, genes related to vasodilation, and genes related to angioedema as 
generated on gene.iobio.io (Ward et al., 2017) (Appendix D).  
The second approach was applied to all variants without initially restricting to 
candidate genes. In both approaches, the initial filtering step was to remove common 
variants based on population MAF using data from gnomAD, being the largest dataset 
available at the time of analysis (Karczewski et al., 2019). As all the ACEi-A patients 
in this thesis were of European ancestry, MAF from the non-Finnish European (NFE) 
population in gnomAD was used. MAF cut-off to define a variant as rare/low 
frequency differed among studies, but was usually between 1% (Bomba et al., 2017; 
Jalali Sefid Dashti & Gamieldien, 2017) and 5% (Balicza et al., 2019; Gorlov et al., 
2011). A conservative MAF cut-off of ≤5% was applied to find variants enriched in 
the ACEi-A samples in this chapter. Analysis for multiple variants in a single gene that 
when combined, were enriched in the ACEi-A cases used the MAF cut-off of ≤1%. 
For WES, the next filtering step was to retain variants enriched in ACEi-A samples 
but not in control samples. As only five samples were analysed through WES, variants 
enriched in five down to two samples were included.  
For WGS, variant classes were first prioritised for analysis in the following order, 
reflecting the expected hierarchy of functional impacts: (1) coding regions and 5-UTR 
variants, (2) intronic and 3’-UTR variants, and (3) intergenic variants. Retained 
variants in each class were filtered based on enrichment in the ACEi-A samples. 
Variants with a MAF ≤5% and present in at least four out of 15 ACEi-A samples were 
calculated as being significantly enriched compared to the general population using 




samples. Variants with MAF≤5% enriched in both ACEi-A and control groups were 
judged likely to be false positives and therefore removed during this filtering step. 
For coding variants, another filtering criterion is functionality of the variants based 
on in silico prediction. This was mainly done using the Functional Analysis through 
Hidden Markov Models Multiple Kernel Learning (FATHMM MKL) prediction tool 
(Shihab et al., 2015), which is embedded in VarSeq. The FATHMM MKL prediction 
tool is reported to have better performance than Combined Annotation Dependent 
Depletion (CADD) score (Rentzsch et al., 2019) for noncoding variants and similar 
performance for coding variants (Shihab et al., 2015). For variants where prediction 
by FATHMM MKL was not available, CADD scores were obtained through VEP on 
Ensembl (McLaren et al., 2016). No single cut-off of CADD score was available for 
deleterious variants, and I used a cut-off of ≥15 as was proposed previously (Itan et 
al., 2016). Other pathogenicity or deleterious prediction tools such as Rare Exome 
Variant Exemble Learner (REVEL) score (Ioannidis et al., 2016) and MutationTaster 
(Schwarz et al., 2014) were also considered, and are presented in the tables of filtered 
variants as additional information.  
Using current sequencing methodology, variant calling can be done confidently in 
approximately 70% of the genome, with 20% regarded as less reliable and 
approximately 10% to be almost unattainable (Laurie et al., 2016). Using the Genome 
in a Bottle DNA sample from the National Institute of Standards and Technology 
(GIAB/NIST), certain regions in the genome have been marked as being reliably 
callable, spanning ~2.2 Gb. (Zook et al., 2014). The information on these NIST callable 
regions was available at ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/release and was 
used to filter out potentially non-reliable variants. However, more than half of the so-
called non-reliably callable genome is actually mappable (Laurie et al., 2016), so 
filtering based on this criterion was done with caution.  
Variants with multiple alleles were also removed in most filtering steps. These multi-
allelic variants were rare, predicted to be ~0.15% in the NIST dataset (Laurie et al., 
2016). Multi-allelic variants might be retained after filtering with low MAF due to the 
low population frequency of one of the alternate alleles, however in most cases, the 





Individuals of African ancestry have been consistently shown to have higher risk of 
ACEi-A compared to European (Brown et al., 1996; Gibbs et al., 1999; Hoover et al., 
2010; Mahoney & Devaiah, 2008) and I hypothesised that any causative variants of 
this ADR would have higher MAF in Africans compared to the European population. 
Filtering for variants with higher African compared to European MAF was applied in 
certain situations. 
Different filter criteria were applied in multiple steps, and were adjusted in an 
empirical fashion according to the number of variants generated. For coding variants 
and variants enriched in a high number of samples, less stringent criteria were 
applied, based on two reasons. First, the variants falling in these groups are more 
likely to be potentially relevant to the ADR, and second the number of variants 
generated by this approach was usually manageable and did not need stringent 
filtering. On the contrary, filtering for non-coding variants, and variants enriched in 
only two out of five WES samples or less than five out of 15 WGS samples resulted in 
a high number of variants. To manage this, criteria that are more stringent were 
applied, including removing variants not in the NIST callable regions and reducing 
the MAF cut-off to 1%. Details of filtering criteria for each step are described in the 
respective sections in this chapter. 
For all prioritised variants, the last step of filtering involved manual inspection of the 
BAM files to remove false positive variants. One example of such a false variant is one 
showing very low allele frequency across all samples (Figure 5.2A), but with different 
genotypes being called.  Another false variant recognised was due to mis-genotyping 
with the VCF file reporting a low frequency variant while it was actually a common 





Figure 5.2 Examples of false positive variants recognised from visual inspection of BAM 
files 
Figure shows (A) false positive variant with low allelic fraction in a sample with 
heterozygote genotype (top row), and a similar allelic fraction in a sample without the 
variant (bottom row), and (B) false positive variants caused by mis-genotyping. The 
variant was reported as delTG in VCF files, which has not been reported before in 
gnomAD NFE population, however, the BAM file showed presence of a delTTG variant 






5.3.1 Characteristics of clinical samples 
All 20 study participants were of European ancestry. The number of male and female 
was similarly distributed (11 male vs 9 female). Study participant age ranged from 
48-87, with an average age of 69. None of the participants reported a family history 
of angioedema. Interestingly, more than half of the participants (11) had been taking 
ACE inhibitors for years before the ADR occurred (Table 5.1).  
Table 5.1 Clinical characteristics of ACEi-A subjects 





gender Ethnicity Drug ACEi-A onset 
(after first 
dose of ACEi) 
UDRUGS053 Probable 84 female European cilazapril  7 years 
UDRUGS059 Probable 48 male European cilazapril, change 
to quinapril  
immediate 
UDRUGS068 Definite 81 male European cilazapril  + HCT# immediate 
UDRUGS069 Probable 76 female European quinapril + HCT# years 
UDRUGS070 NA 87 male European enalapril  one day  
GAARD025 Probable 68 male European enalapril 8-10 years 
GAARD026 Probable 52 male European enalapril 4-5 years 
GAARD027 Probable 71 female European cilazapril immediate 
GAARD035 Probable 61 female European enalapril NA 
GAARD036 Possible 73 male European enalapril NA 
GAARD037 Probable 81 male European cilazapril + HCT# immediate 
GAARD038 Probable 86 female European quinapril + HCT# years 
GAARD039 Probable 56 male European cilazapril 5-6 years 
GAARD040 Probable 71 female European cilazapril years 
GAARD041 Probable 54 female European cilazapril at least 5 years 
GAARD042 Probable 70 male European cilazapril 5-10 years 
GAARD043 Probable 62 male European cilazapril days 
GAARD044 Probable 74 female European cilazapril 
+bendrofluazide 
years 
GAARD045 Probable 71 male European cilazapril at least 5 years 
UDRUGS105  Probable 48 female European cilazapril immediate 
*Samples UDRUGS053, UDRUGS059, UDRUGS068, UDRUGS069 and UDRUGS070 were 
analysed using WES and the other samples by WGS 
#HCT: hydrochlorothiazide.  
NA: not available 
5.3.2 Analysis of previously reported variants 
Initially, genetic analysis was carried out to identify variants previously reported as 




al., 2011; Duan et al., 2005), PRCKQ, MME, ETV6 (Pare et al., 2013), RBFOX3, GABRG2, 
MBOAT1 (Mahmoudpour et al., 2016b), and BDKRB2 (Moholisa et al., 2013). Sample 
genotypes were obtained using Sanger sequencing (five samples) or WGS (15 
samples).  
The MAF found in the ACEi-A samples was compared to the population MAF in the 
gnomAD database (Karczewski et al., 2019) and MAF in a control group of 22 samples 
with ADR unrelated to ACEi-A from our laboratory. This analysis of previously 
reported variants did not identify any significant signals, possibly partly due to the 
lack of power of the small sample size. The rs1799722 variant in BDKRB2, which 
encodes bradykinin receptor 2, is the most promising of the candidate variants 
examined, with MAF of 60% in ACEi-A cohort when compared with that reported in 
gnomAD (43%, p=0.07) and the control group (36%, p=0.07) (Table 5.2). 
The rs2235444 variant in XPNPEP2 also showed an increased MAF in the ACEi-A 
group (18%) compared to gnomAD (11%) but not to the control group (16%). 
Interestingly, four common variants in RBFOX3 had lower MAF in the ACEi-A cohort 
compared to controls and gnomAD.  
Table 5.2 Allele frequency of reported variants 

















XPNPEP2 rs3788853 C>A 0.23 0.22 1.00 0.18 0.83 
XPNPEP2 rs2050011 G>T 0.40 0.37 0.85 0.32 0.58 
XPNPEP2 rs2235444 G>A 0.18 0.11 0.33 0.16 1.00 
PRCKQ rs500766  C>T 0.20 0.29 0.31 0.20 1.00 
MME rs989692  T>C 0.63 0.54 0.36 0.57 0.76 
ETV6 rs2724635  G>A 0.60 0.61 1.00 0.64 0.91 
RBFOX3 rs56044629  G>T 0.05 0.15 0.13 0.20 0.08 
RBFOX3 rs2061538  G>A 0.08 0.17 0.17 0.25 0.06 
RBFOX3 rs56209714  G>A 0.05 0.15 0.13 0.23 0.04 
RBFOX3 rs62063838  C>T 0.08 0.18 0.14 0.25 0.06 
GABRG2 rs77370934  G>T 0.05 0.04 1.00 0.05 1.00 
MBOAT1 rs10946364  T>A 0.43 0.43 1.00 0.25 0.14 
BDKRB2 rs71103505 GGTGGGGAC/- 0.40 0.47 0.84 0.55 0.32 
BDKRB2 rs1046248 C>T 0.10 0.09 1.00 0.11 1.00 
BDKRB2 rs1799722 C>T 0.60 0.43 0.07 0.36 0.07 




It has been reported that the combination of three XPNPEP2 variants as a haplotype 
has a stronger association with APP levels, and that the ATG haplotype was enriched 
in the ACEi-A group (29%) compared to controls (13%, p=0.004) (Cilia La Corte et 
al., 2011). The haplotypes of these three variants in 15 of the ACEi-A samples in this 
thesis were determined from the WGS dataset using BEAGLE 5.0 (Browning & 
Browning, 2007). The haplotypes of 22 control samples were also determined as 
comparison. The prevalence of the ATG haplotype in the ACEi-A samples was 13.3% 
and not different from the prevalence of ATG in the control group (15.9%, p=0.93).  
Other variants, rs500766 in PRCKQ and rs989692 in ETV6 were reported in a GWAS 
of 175 ACEi-A cases and 489 controls, and replicated in another cohort (Pare et al., 
2013), as described in Section 1.5.6.4. In addition, the study showed that the alternate 
alleles of both SNPs had a protective effect towards ACEi-A. A similar trend was 
observed in the ACEi-A cohort for rs500766, which had a lower allele frequency 
compared to gnomAD, but not for rs989692. Both variants had allele frequencies 
comparable to control group. 
All these previously reported variants are common in the population (MAF >10%), 
while ACEi-A itself is very rare (~0.3%). Moreover, the sample size in this cohort is 
small, thus it remains unclear whether any of the differences detected here are 
biologically relevant.  
5.3.3 Whole exome sequencing 
Genome-wide genetic analysis was initially done on five ACEi-A cases by WES (WES 
ACEi-A) on the Ion Torrent platform, together with three other ADR cases. This was 
to enable screening of variants in the coding region of genes that may be associated 
with ACEi-A. 
5.3.3.1 Analysis of genes for bradykinin, substance P metabolism and their 
receptors. 
The WES data were initially examined for variants in 23 genes involved in the 
bradykinin and substance P metabolism pathway and their relevant receptors 
(Appendix D). I identified 29 variants in 14 of these genes with gnomAD NFE MAF 
less than or equal to 5%. Four out of the five ACEi-A samples had at least one variant 




had at least one variant in any of the 23 genes initially assessed, even when only 
variants with a CADD score ≥15 were considered. All variants were in NIST callable 
regions except for rs61735573 in ENPEP and rs117647476 in ACE. There appears to 
be a higher burden of variants in these genes in the ACEi-A group compared with the 
control group, with only two of the 29 variants present in the three control samples 








Table 5.3 Variants in the bradykinin and substance P metabolism and receptor genes in WES data  






















No. of ACEi-A 
samples w/ 
variant in the 
gene 
No of Controls 
w/ variant in 
the gene 
1:21546356 G/T rs3026907  5.152 - - - - ECE1 3_prime_UTR 0.0302 0.0057 4 0 
1:21551718 C/T rs71636966  0.335 - - - - ECE1 intron 0.0330 0.0107 
1:21553723 G/T rs3026903  6.911 - - - - ECE1 splice_region 0.0332 0.0110 
1:21560080 A/G rs2228321 13.1 - - - - ECE1 synonymous 0.0357 0.3909 
1:21564631 C/T rs141146885  12.42  0.082 tolerated tolerated 0.51 ECE1 missense 0.0036 0.0008 
1:21571475 G/A rs28368004  10.39 - - - - ECE1 splice_region 0.0408 0.0057 
2:162865133 C/T rs41268649  4.7 - - - - DPP4 synonymous 0.0425 0.0105 2 0 
2:162904013 T/C rs116302758  18.28  - tolerated tolerated 0.285 DPP4 splice_acceptor 0.0423 0.0061 
3:154801978 A/G rs61762319  19.62 0.332  damaging damaging 5.27 MME missense 0.0253 0.0047 1 0 
4:111397585 G/A rs61735573 12.31 - - - - ENPEP synonymous 0.0332 0.0086 1 1 
5:96322360 G/A rs41276279  0.155 0.065  tolerated tolerated -8.65 LNPEP missense 0.0484 0.0113 2 1 
5:96358060 G/A - 0.691 - - - - LNPEP synonymous 0.0066 0.1360 
6:105729600 T/C rs28362537  - - - - - PREP intron 0.0031 0.0014 1 0 
10:101823460 -/G rs769250215 - - - - - CPN1 frameshift 0.0001 0.0000 1 0 
10:111640651 G/A rs138300438  8.866 - - - - XPNPEP1 synonymous 0.0078 0.0016 1 0 
11:82550387 A/G rs4843 17.6 - - - - PRCP synonymous 0.0435 0.2306 1 0 
11:82625814 G/A rs61902276  23.1 - damaging damaging 4.37 PRCP intron 0.0227 0.0045 2 0 
11:82644764 C/G rs11826199 19.76 - damaging tolerated 4.93 PRCP intron 0.0165 0.1621 
17:61566095 A/G rs117647476  15.49 0.046  damaging damaging 1.37 ACE missense 0.0053 0.0008 3 0 
17:61574712 G/A rs4365  16.89 - - - - ACE synonymous 0.0392 0.0058 
19:2796197 G/A rs2302495  7.545 - - - - THOP1 intron 0.0103 0.0039 1 
 
0 
19:2808457 GGGCAG/- rs369163630 - - - - - THOP1 intron 0.0124 0.0128 
19:2810497 G/T rs1228602361 0.1 - 0.142 - - THOP1 intron 
  
20:44519742 G/A rs117529875  5.961 -  - - - CTSA 5_prime_UTR 0.0105 0.0129 1 0 
10:71164595 T/C rs58692969 15.41 0.024 tolerated tolerated 1.42 TACR2 missense 0.0021 0.1812 1 0 
 10:71164692 T/C rs57900755 5.481 0.04 tolerated tolerated -0.844 TACR2 missense 0.0021 0.1814 
10:71167047 A/G rs7097827 18.38 -    TACR2 intron 0.0021 0.1815   
10:71168766 C/G rs79030584 16.37 0.144 damaging tolerated 3.96 TACR2 missense 0.0019 0.0657 
14:96707675 A/G rs144659195 23.3 0.205 damaging damaging 4.77 BDKRB2 missense 0.0034 0.0005 1 0 
CADD:  combined annotation dependent depletion, REVEL: rare exome variant ensemble learner, FATHMM MKL: functional analysis through hidden Markov models multiple 




5.3.3.2 Analysis of candidate genes by WES 
The next analysis was conducted on the broader candidate gene set (n=421 genes) 
(Appendix D). Filtering this candidate gene list using a MAF ≤5% generated 583 
variants across the five samples. There was one variant in the ACE gene (rs4365) that 
was shared in at least three out of the five samples, and there were 34 variants in 
other genes that were shared in two out of the five samples. Visual inspection of WES 
BAM files of these 34 variants showed that six of the variants were likely false 
variants, leaving 28 true variants (Table 5.4).  
From these 28 variants, three out of the five ACEi-A samples had variants in the F5, 
and four had variants in ECE1, while none of the variants was present in the control 
samples. A further filtering step to include variants present in at least three samples 
was then applied. At least four samples had variants in COL6A3, ARAP3, ITPR3, and 
COL6A2 genes. However, the control samples also had variants in these genes at a 
similar frequency to the ACEi-A cases. At least three of the ACEi-A samples also had 
variants in CELA3B, COL5A, MAP2, COL4A4, COl4A3, KDR, EGFR, MGAM, SLC1A1, 
CDK20, COL5A1, CTSH, and COL9A3. Only variants in COL9A3 were unique to the ACEi-


















































1:21546356 G/T rs3026907 5.152 - - - - ECE1 3_prime_UTR 0.0302 0.0057 2 0 4 0 
1:21551718 C/T rs71636966 0.335 - - - - ECE1 intron 0.0330 0.0107 2 0 
1:21553723 G/T rs3026903 6.911 - - - - ECE1 splice_region 0.0332 0.0110 2 0 
1:21560080 A/G rs2228321 13.1 - - - - ECE1 synonymous 0.0357 0.3909 2 0 
1:21564631 C/T rs141146885 12.42 0.082 tolerated tolerated 0.51 ECE1 missense 0.0036 0.0008 2 0 
1:169498835 G/A rs6008 16.59 - - - - F5 intron 0.0167 0.1341 2 0 3 0 
1:169500210 T/C rs6010 8.224 - - - - F5 synonymous 0.0322 0.0385 2 0 
1:169510118 G/A rs9332608 1.296 0.021 tolerated tolerated 1.38 F5 missense 0.0317 0.0303 2 0 
1:169519112 C/T rs6020 21.3 0.442 damaging damaging 5.71 F5 missense 0.0133 0.2937 2 0 
2:1497831 G/A rs10189329 0.073 - - - - TPO intron 0.0340 0.1876 2 0 2 0 
3:186459475 C/G rs5030084 1.995 - damaging tolerated 2.98 KNG1 missense 0.0295 0.0614 2 1 2 1 
3:186459646 G/A rs5030085 3.089 - - - - KNG1 synonymous 0.0296 0.0617 2 1 
3:186459775 C/T rs5030086 0.782 - - - - KNG1 synonymous 0.0297 0.0618 2 1 
3:186460110 G/C rs5030087 0.949 - damaging tolerated 4.4 KNG1 missense 0.0333 0.0631 2 1 
4:110890274 G/A rs115396821 23.6 0.769 damaging damaging 3.13 EGF missense 0.0026 0.0005 2 0 2 0 
5:96129802 G/A rs76553822 0.903 - - - - ERAP1 intron 0.0405 0.0289 2 1 2 1 
5:96139464 C/T rs3734016 9.343 0.043 tolerated tolerated 2.44 ERAP1 missense 0.0403 0.0701 2 1 
5:96239258 T/A rs17408150 24 0.157 damaging damaging 2.42 ERAP2 missense 0.0480 0.0110 2 0 2 0 
5:96244719 T/C rs17486915 7.143 - - - - ERAP2 synonymous 0.0481 0.0110 2 0 
5:96322360 G/A rs41276279 0.155 0.065 tolerated tolerated -8.65 LNPEP missense 0.0484 0.0113 2 0 2 0 
5:150867719 C/T rs78441677 3.635 - - - - SLC36A1 synonymous 0.0488 0.0431 2 0 2 0 
6:10404932 G/A rs143363077 18.92 - - - - TFAP2A synonymous 0.0014 0.0003 2 0 2 0 
6:33658780 C/T rs35506178 14.04 - - - - ITPR3 synonymous 0.0487 0.0094 2 0 2 0 
9:90588970 C/A rs28364935 4.793 - tolerated tolerated 1.56 CDK20 missense 0.0444 0.1909 2 1 2 1 
15:79214429 G/A rs12549 4.047 - - - - CTSH 3_prime_UTR 0.0290 0.0048 2 0 2 0 
15:79224727 T/C rs78155742 23.9 0.273 damaging damaging 3.57 CTSH missense 0.0301 0.0046 2 0 
19:50393269 A/G rs56359967 18.76 - - - - IL4I1 synonymous 0.0213 0.1424 2 0 2 0 
19:50399354 G/C rs3810269 1.622 - - - - IL4I1 intron 0.0115 0.0064 2 0 
CADD:  combined annotation dependent depletion, REVEL: rare exome variant ensemble learner, FATHMM MKL: functional analysis through hidden markov models multiple 




5.3.3.3 Analysis of all variants 
The strength of whole exome (or genome) sequencing is to enable analysis of variants 
throughout the exome (or genome) without prior information of predisposing 
variants/candidate genes. WES of the five ACEi-A samples generated 73,906 variants. 
A stepwise filtering approach was used to remove potentially neutral variants 
(Figure 5.3). 
 
Figure 5.3 Stepwise filtering for WES generated variants 
There was one variant present in five samples, 14 variants in four samples. For variants 




As described in Section 5.2.2, the first step of filtering involved removing common 
variants based on MAF, resulting in 21,429 variants (Figure 5.3). These were then 
filtered based on the enrichment of the variants in the ACEi-A samples. There was 
only one variant present in all five ACEi-A samples and 14 variants present in four 
ACEi-A samples, after filtering out false positive variants (Table 5.5 and Figure 5.3).   
As seen in the flow diagram, there were more variants shared by two or three ACEi-
A samples, and harder filtering criteria were applied to create manageable, 
prioritised shortlists for these variants. After removing non-coding variants, variants 
in the NIST non-callable regions (Zook et al., 2014), and false variants based on BAM 
files, 25 variants remained, and were present in three out of the five ACEi-A cases 
(Table 5.6). However, none of these had MAF <1%.  
For variants shared by only two ACEi-A samples, the MAF cut-off was lowered to 1% 
and non-coding variants and variants in the non-callable regions by NIST were 
removed, resulting in 91 variants. Visual inspection of BAM files further reduced the 
list to 27 true variants shared by two ACEi-A samples (Table 5.7). Three variants 
were predicted to be deleterious/damaging by all prediction tools being used: 
rs17010210 in CAPN13, rs115396821 in EGF and rs1034168031 in CTBP2. The cut-
off for CADD was set at 15 and for REVEL at 0.5. Each variant was present in at least 
two of the ACEi-A samples, and four of the ACEi-A samples had at least one of these 
variants. 
As ACEi-A has been reported to have 4-5x higher incidence in an African population; 
the causative variants would be expected to have higher MAF in an African compared 
to a European population. From the total list of 119 variants filtered from WES (using 
either the candidate gene or agnostic approach), there were 27 variants identified as 
having a higher MAF in an African population compared to that reported in a 
European population. These included four variants in KNG1, three variants in F5, one 
variant each in ECE1, LNPEP, PRCP, THOP1, ERAP1, IL4I1 from the candidate genes, 
and variants in CTSA, TPO, CDK20, GTF2IRD1, GMNN, ANKRD6, LYRM2, IPO4,RP11-
468E2.2, ARG2,VTI1B, BPI, MAPK8IP1, NOTCH2, LOXL3, ATP6V0D2,PSKH2, LILRA4 









Table 5.5 Variants with MAF ≤5% and present in at least four ACEi-A samples by WES 





































1:24294362 A/T rs9424411 16.10 - - - - false SRSF10 3_prime_UTR - - 5 1 
1:55555285 G/- rs768724557 - - - - - true USP24 intron  -  - 4 1 
2:74687550 T/- rs773064295 - - - - - true INO80B 
WBP1 
frameshift 0 0.0002 4 1 
6:167789473 C/T rs76263155 0.685 - - - - false TCP10 synonymous 0.0263 0.0044 4 0 
7:73949411 T/C rs59656369 0.026 - - - - true GTF2IRD1 intron 0.0374 0.067 4 1 
9:136433542 C/T rs534165083 0.152 - - - - false ADAMTSL2 synonymous  -  - 4 0 
9:136435696 C/T rs2301607 0.093 - - - - false ADAMTSL2 intron  -  - 4 1 
9:136438985 G/A rs62637566 8.525 - - - - false ADAMTSL2 synonymous  -  - 4 0 
12:133625276 A/T rs7314140 1.766 - - - - false ZNF84 intron  -  - 4 1 
17:21202123 A/G rs68151103 6.153 - - - - false MAP2K3 intron  -  - 4 1 
20:1895950 C/G rs138283486 4.102 0.299 tolerated tolerated -2.65 false SIRPA missense  -  - 4 1 
20:1895951 C/T rs149634649 0.002 0.03 tolerated tolerated -8.38 false SIRPA missense  -  - 4 1 
20:1895952 T/C rs146163282 0.098 0.072 tolerated tolerated -7.65 false SIRPA missense  -  - 4 1 
20:33169493 GAAA/-  - - - - - - true PIGU intron  -  - 4 1 
20:33169499 G/A rs759080941 2.467 - - - - true PIGU intron 0 0.0003 4 1 
CADD:  combined annotation dependent depletion, REVEL: rare exome variant ensemble learner, FATHMM MKL: functional analysis through hidden markov models multiple 








 Table 5.6 Variants with MAF ≤5% and present in three ACEi-A samples by WES  































1:114226143 G/A rs61742849 13.29 0.091 tolerated tolerated 2.21 MAGI3 missense 0.0418 0.0093 3 0 
1:145560918 G/A rs41296196 0.713 - - - - ANKRD35 missense 0.0438 0.0086 3 0 
2:88474166 G/A rs34841493 16.37 0.074 tolerated damaging 3.99 THNSL2 missense 0.0132 0.0029 3 0 
3:56650012 G/A rs4681904 18.7 0.12 tolerated damaging 3.71 CCDC66 missense  -  - 3 1 
6:24780892 A/C rs1923185 14.53 0.062 damaging tolerated -0.698 GMNN missense 0.0353 0.0899 3 0 
6:90326360 C/T rs2273238 14.68 0.139 tolerated tolerated 1.64 ANKRD6, 
LYRM2 
missense 0.0391 0.2955 3 0 
7:63981559 T/C rs17852813 13.44 0.055 tolerated tolerated 1.31 ZNF680 missense 0.0458 0.0217 3 0 
8:17396415 G/A rs13259978 0.525 0.073 tolerated tolerated -1.78 SLC7A2 missense - - 3 1 
9:71820148 G/A rs4493966 9.405 - damaging tolerated -2.56 TJP2 missense 0.0363 0.0114 3 0 
10:81702210 G/C rs17878336 3.033 0.023 tolerated tolerated -6.72 SFTPD missense 0.0349 0.0074 3 0 
14:24653965 C/T rs45484197 0.044 - - - - IPO4,RP11-
468E2.2 
synonymous 0.0489 0.1082 3 0 
14:68118132 C/T rs15493 19.21 - - - - ARG2,VTI1B missense 0.0414 0.1587 3 0 
14:74060512 A/- -  - -  - - - ACOT4 frameshift - - 3 1 
14:74060513 G/T -  -  - damaging damaging 4.32 ACOT4 missense - - 3 1 
14:74060515 T/A rs74553611 9.396 - - - - ACOT4 synonymous - - 3 1 
14:74060516 T/A rs77408762 25.7 0.398 damaging damaging 5.25 ACOT4 missense - - 3 1 
14:74060518 -/G rs562751690 - - - - - ACOT4 stop_gained - - 3 1 
16:1268979 C/T rs72552054 10.3 - tolerated tolerated 3.48 CACNA1H missense 0.0227 0.0039 3 0 
17:61574712 G/A rs4365 16.89 - - - - ACE synonymous 0.0392 0.0058 3 0 
19:42132273 C/T rs1041992 0.267 - - - - CEACAM4 synonymous 0.0315 0.0235 3 1 
20:36952342 C/T rs5741804 5.56 0.015 tolerated tolerated -0.992 BPI missense 0.0443 0.2116 3 0 
20:44351095 C/A rs16990631 0.183 0.067 tolerated tolerated -3.46 SPINT4 missense 0.0436 0.0273 3 0 
22:18609642 C/T rs362203 17.42 - - - - PEX26, 
TUBA8 
synonymous 0.0373 0.0365 3 0 
22:39222598 G/A rs56034166 10.75 - - - - NPTXR synonymous 0.0394 0.0059 3 0 
22:51048721 G/A rs14136 0.531 - - - - MAPK8IP2 synonymous 0.0468 0.1117 3 0 
CADD:  combined annotation dependent depletion, REVEL: rare exome variant ensemble learner, FATHMM MKL: functional analysis through hidden markov models multiple 










































1:21564631 C/T rs141146885 12.42 0.082 tolerated tolerated 0.51 ECE1 missense 0.0036 0.0008 2 0 
1:44134887 T/C rs143990622 18.98 0.11 damaging damaging 5.23 KDM4A missense 0.0073 0.0014 2 0 
1:55119790 C/T rs143941239 0.712 - - - - MROH7,MROH7-
TTC4 
synonymous 0.0037 0.0017 2 0 
1:120468425 G/A rs17024525 0.84 - - - - NOTCH2 synonymous 0.0023 0.0097 2 0 
2:30985977 G/A rs17010210 25.6 0.62 damaging damaging 4.78 CAPN13 missense 0.0052 0.0010 2 0 
2:74763258 C/G rs17010022 17.43 - - - - LOXL3 synonymous 0.0009 0.0044 2 0 
2:88423990 C/T rs79448072 0.021 - tolerated tolerated -9.94 FABP1 missense 0.0099 0.0023 2 0 
3:33038747 C/G rs77226678 2.572 - - - - GLB1 synonymous 0.0062 0.0030 2 0 
3:146251266 C/T rs41267859 13.62 0.075 damaging tolerated 2.67 PLSCR1 missense 0.0019 0.0007 
 
2 0 
4:110890274 G/A rs115396821 23.6 0.769 damaging damaging 3.13 EGF missense 0.0026 0.0005 2 0 
5:16681974 A/T rs190734011 0.85 - - - - MYO10 splice_region 0 0 2 0 
6:10404932 G/A rs143363077 18.92 - - - - TFAP2A synonymous 0.0014 0.0003 2 0 
6:44250215 C/T rs146833594 9.676 - tolerated tolerated 2.46 RP11-444E17.6, 
TCTE1,TMEM151B 
missense 0.0023 0.0008 2 0 
7:48016442 G/- - - - - - - HUS1 splice_region - - 2 0 
8:87060843 T/C rs16876805 15.96 0.098 tolerated damaging 3.82 ATP6V0D2,PSKH2 missense 0.0076 0.17 2 0 
8:142367350 C/T rs201039593 16.64 0.113 tolerated tolerated 3.67 GPR20 missense 0.0078 0.0016 2 0 
10:126686557 C/T rs1034168031 23.5 0.579 damaging damaging 4.73 CTBP2 missense - - 2 0 
12:64521724 A/G rs61754221 22.1 0.152 damaging damaging 5.65 SRGAP1 missense 0.0080 0.0014 2 0 
13:37600337 T/A - - - - - - SUPT20H splice_region - - 2 0 
13:102231711 C/T rs34438356 16.52 - - - - ITGBL1 synonymous 0.0045 0.0011 2 0 
14:21555481 G/A rs55901089 27.6 0.132 damaging damaging 5.05 ARHGEF40 missense 0.0054 0.0013 2 0 
15:66644502 T/G rs137903222 17.8 - - - - TIPIN synonymous 0.0030 0.0005 2 0 
17:4451453 C/T rs56716962 23.6 0.281 damaging damaging 0.857 MYBBP1A missense 0.0091 0.0024 2 0 








Table 5.7 Variants with MAF ≤5% and present in two ACEi-A samples by WES - continued 































19:54848157 A/G rs76665615 17.5 0.016 tolerated tolerated 1.37 LILRA4 missense 0.0074 0.0499 2 0 
21:40569102 G/A rs61742658 1.97 0.08 tolerated tolerated 0.852 BRWD1 missense 0.0019 0.0003 2 0 
X:134994054 G/- - - - - - - SAGE1 frameshift - - 2 0 
CADD:  combined annotation dependent depletion, REVEL: rare exome variant ensemble learner, FATHMM MKL: functional analysis through hidden markov models multiple 




5.3.4 Whole genome sequencing 
WGS of 15 ACEi-A samples (WGS ACEi-A) and 22 control samples with other ADRs 
resulted in approximately 17 million variants across the 37 samples. Approximately 
10 million variants were in the intergenic regions, and almost seven million variants 
were in the non-coding region of genes, leaving just over 100,000 variants in the 
coding regions, as annotated using Ensembl transcripts in the VarSeq software.  
5.3.4.1 Attempted validation of the WES filtered variants/genes 
Given the vast number of variants and the small number of samples in the WES 
dataset, the shortlisted variants, although rare and enriched in the ACEi-A cohort, 
could be present in the samples by chance. If the variants shortlisted by WES are also 
enriched in the WGS ACEi-A cohort, it could provide validation of an association 
between the variants identified and ACEi-A. Therefore, the first analysis of the WGS 
dataset was done by using variants shortlisted in the WES dataset (67 variants in 58 
genes) as a candidate variant list. Five of the variants were present in three of the 
WGS ACEi-A samples and the rs4365 variant in ACE was found in five WGS ACEi-A 










Table 5.8 WES-shortlisted variants tested for enrichment in WGS dataset  




























NFE  MAF 
gnomAD 
AFR MAF 
1:145560918 G/A rs41296196 0.713 -  -  -   - ANKRD35 missense 3/15 2/22 0.0438 0.0086 
3:56650012 G/A rs4681904 18.7 0.12 tolerated damaging 3.71 CCDC66 missense 3/15 1/22 0.0346 0.0194 
7:63981559 T/C rs17852813 13.44 0.055 tolerated tolerated 1.31 ZNF680 missense 3/15 3/22 0.0458 0.0217 
8:17396415 G/A rs13259978 0.525 0.073 tolerated tolerated -1.78 SLC7A2 missense 3/15 1/22 0.0376 0.0070 
17:61574712 G/A rs4365 16.89 -  -  -   - ACE synonymous 5/15 1/22 0.0392 0.0058 
20:44351095 C/A rs16990631 0.183 0.067 tolerated tolerated -3.46 SPINT4 missense 3/15 3/22 0.0436 0.0273 
CADD:  combined annotation dependent depletion, REVEL: rare exome variant ensemble learner, FATHMM MKL: functional analysis through hidden markov models multiple 




To further expand the WGS analysis, all  genes containing variants found through 
WES with a MAF ≤5%, and those that were present in at least two of the five WES 
ACEi-A samples (n=854 genes) were assessed in the WGS dataset. Variants with MAF 
>5%, and variants with multi-allelic sites were removed, resulting in 189,759 
variants. To assess these variants, two approaches were applied, as outlined in Figure 
5.4.  
 
Figure 5.4 Stepwise filtering for variants in genes found in the WES analysis, applied 
to the WGS dataset 
Variants were initially grouped into coding/5’-UTR variants or intronic/3’-UTR 
variants. Coding/5’-UTR variants were initially filtered based on enrichment in the 
ACEi-A samples followed by filtering based on in silico prediction tools. Additional filters 
for intronic variants included higher AFR MAF and being in NIST callable regions. 







The first approach excluded variants in intronic and 3-UTR regions. This resulted in 
2086 variants, which were further filtered based on enrichment of the variants in the 
ACEi-A samples. There were eight variants present in five or more WGS ACEi-A 
samples, and 215 variants present in three to four ACEi-A samples. Removing 5-UTR 
and synonymous variants from the 215 variant set retained 75 variants, but only 25 
of them were predicted to be damaging by FATHMM MKL predictor. Potentially 
functional variants from the WES filtered gene set that were present in five or more 
ACEi-A samples, and variants predicted to be damaging in three or more ACEi-A 
samples are shown in Table 5.9.  
Looking at Table 5.9, ACEi-A samples contained an average of eight variants per 
sample, compared with two variants per control sample. Seven of these 36 variants 
had higher AFR MAF compared to NFE MAF.  
In the second approach, with the vast number of intronic and 3’-UTR variants, only 
variants with higher MAF in African compared to European population, and variants 
in the NIST callable regions were retained, resulting in 32,824 variants. After filtering 
for variants that were present in at least six ACEi-A samples, not more than three 
controls, and removing false variants based on BAM files, 35 variants remained. 
Three genes (PRKCB, RP1L1, and CLPTM1) had multiple variants, which were present 
in the same samples for each gene, except for one variant in PRKCB (rs72779937) 
which was present in different samples. All these multiple variants are correlated to 
the other variants in the same gene, except for rs72779937 which is weakly 
correlated, as analysed in European population database using LDlink 
(https://ldlink.nci.nih.gov/) (Machiela & Chanock, 2015). The 35 filtered variants 
were in intronic regions and only two had a CADD score of >10, therefore their 
contribution or association with the ACEi-A is likely to be negligible/weak/unknown 















































1:145039744 C/A rs367568901 5.992 - - - - PDE4DIP 5_prime_UTR true 5 3 0.0077 0.0373 
1:158261015 C/T rs3138099 0.396 - - - - CD1C synonymous true 5 1 0.0498 0.1479 
7:27211548 C/T rs34957925 15.76 - - - - HOXA10 synonymous true 5 1 0.0403 0.0073 
10:93978 G/A rs189892388 0.426 - - - - TUBB8 synonymous false 5 2 0.0335 0.0534 
19:12936644 A/C  - - 0.141 Tolerated tolerated 0.715 HOOK2, 
RTBDN 
missense true 5 2  -  - 
19:45458212 G/A rs117316645 4.808 - - - - CLPTM1 5_prime_UTR true 6 3 0.0437 0.0337 
19:45458235 A/G rs41334244 7.836 - - - - CLPTM1 5_prime_UTR true 6 3 0.0442 0.1088 
19:47217746 C/G  - - - - - - PRKD2 5_prime_UTR false 5 2 0.0492 0.0241 
1:115417175 A/G rs61730057 18.23 0.041 Tolerated damaging 2.73 SYCP1 missense true 3 0 0.0180 0.0029 
1:155175089 C/T rs72704117 26.3 - Damaging damaging 4.85 THBS3 missense true 4 1 0.0172 0.0042 
1:155290231 T/C rs41314549 23.4 - Damaging damaging 3.39 FDPS missense true 4 1 0.0239 0.0047 
1:169484767 A/G rs9332701 24.1 0.751 Damaging damaging 5.61 F5 missense true 3 1 0.0492 0.0078 
1:182873431 C/T rs12138972 25.4 0.427 Damaging damaging 5.55 SHCBP1L missense true 3 1 0.0291 0.0044 
1:205030522 C/T rs139732336 15.21 0.105 Damaging damaging 2.15 CNTN2 missense true 3 1 0.0073 0.0015 
2:179396162 C/G rs56308529 19.98 0.056 Damaging damaging 3.67 TTN missense true 3 3 0.0478 0.0091 
2:179637861 C/G rs56142888 18.76 0.111 Tolerated damaging 4.71 TTN missense true 3 0 0.0440 0.0124 
2:179641975 C/T rs12476289 18.07 0.215 Tolerated damaging 5 TTN missense true 3 0 0.0438 0.0125 
3:56650012 G/A rs4681904 18.7 0.12 Tolerated damaging 3.71 CCDC66 missense true 3 1 0.0346 0.0194 
4:141320021 C/T rs2175563 16.21 0.095 Damaging damaging 3.12 CLGN missense true 4 2 0.0430 0.0921 
4:141323162 C/A rs2567241 9.234 0.097 Damaging damaging 4.59 CLGN missense true 4 2 0.0427 0.0929 
5:140222450 G/T rs146195620 29.3 - Damaging damaging 3.72 PCDHA1 missense false 3 1 0.0131 0.0023 
8:110505963 A/G rs118053060 23.1 0.37 Damaging damaging 4.88 PKHD1L1 missense true 3 1 0.0228 0.0039 
9:26984277 A/G rs12004404 16.89 0.034 Tolerated damaging 3.52 IFT74 missense true 3 2 0.0429 0.0263 
9:113192279 A/T rs142508835 23.7 0.207 Damaging damaging 4.96 SVEP1 missense true 4 1 0.0373 0.0062 
10:73490310 G/A rs41281316 22.9 0.182 Damaging damaging 3.41 C10orf105, 
CDH23 
missense true 3 0 0.0240 0.0056 
11:5632018 C/A rs61756355 22.3 0.549 Damaging damaging 3.26 HBG2,TRIM6, 
TRIM6-TRIM34 














































11:47611940 C/G rs142453721 22.7 0.183 Damaging damaging 3.57 C1QTNF4 missense true 3 1 0.0491 0.0073 
12:39735348 C/A rs79089655 16.6 0.069 Damaging damaging 3.65 KIF21A missense true 4 2 0.0494 0.0086 
14:24909629 C/A rs11538256 26.8 - Damaging damaging 4.9 KHNYN, 
SDR39U1 
missense true 3 1 0.0252 0.0054 
16:70894087 T/C rs149857179 26.2 - Damaging damaging 5.51 HYDIN missense false 4 0 0.0015 0.0031 
17:39211189 C/G 
 
- - Damaging damaging 5.45 KRTAP2-2 missense false 4 3 0.0212 0.0044 
19:35718891 C/T rs35001809 38 - Damaging damaging 3.85 FAM187B stop_gained true 3 1 0.0313 0.0052 
21:38494273 C/G rs61999340 24 0.054 Tolerated damaging 2.21 TTC3 missense true 3 2 0.0485 0.0086 
CADD:  combined annotation dependent depletion, REVEL: rare exome variant ensemble learner, FATHMM MKL: functional analysis through hidden markov models multiple 








Table 5.10 Non-coding variants filtered by WES generated genes and higher AFR MAF in WGS dataset 
Chr:Pos Ref/Alt Identifier CADD 
PHRED 
score 




















- CYP4B1 intron 7/15 2/22 0.0433 0.1787 
3:184217288 A/G rs9858719 1.987 EIF2B5 intron 6/15 0/22 0.0463 0.2885 
7:105004853 -/T rs71152964 - SRPK2 intron 6/15 0/22 - - 
16:23861297* C/G rs57235540 4.364 PRKCB intron 6/15 2/22 0.0358 0.3028 
16:23867712 T/C rs2188354 4.337 PRKCB intron 6/15 2/22 0.0364 0.3847 
16:23869418 GAT/- rs146528658 - PRKCB intron 6/15 2/22 0.0366 0.3748 
16:23877549 G/C rs8060341  1.294 PRKCB intron 6/15 2/22 0.0333 0.2376 
16:24026560 A/G rs72779937  1.543 PRKCB intron 6/15 1/22 0.0480 0.0871 
20:44467883 G/A rs111858067  0.309 SNX21 intron 6/15 2/22 0.0474 0.2086 
8:10498237 T/C rs75002088 2.095 RP1L1 intron 6/15 3/22 0.0424 0.0443 
8:10499543 T/C rs118070064 0.42 RP1L1 intron 6/15 3/22 0.0429 0.0437 
8:10499730 G/A rs60448233 2.305 RP1L1 intron 6/15 3/22 0.0431 0.1053 
19:45463256 C/G rs61062133 2.205 CLPTM1 intron 6/15 3/22 0.0443 0.1097 
19:45471742 A/G rs16979586 12.2 CLPTM1 intron 6/15 3/22 0.0442 0.1070 
19:45472261 T/A rs59136988 8.313 CLPTM1 intron 6/15 3/22 0.0446 0.2113 
19:45472649 C/T rs56834222 0.069 CLPTM1 intron 6/15 3/22 0.0445 0.2116 
19:45474592 A/- - - CLPTM1 intron 6/15 3/22 0.0412 0.1792 
19:45474598 TAT/- rs72115840 - CLPTM1 intron 6/15 3/22 0.0414 0.1795 
19:45475938 T/C rs16979588 2.021 CLPTM1 intron 6/15 3/22 0.0442 0.2373 
19:45476504 T/G rs73558179 1.022 CLPTM1 intron 6/15 3/22 0.0454 0.2222 
19:45476657 C/G rs2293755 1.009 CLPTM1 intron 6/15 3/22 0.0452 0.2218 
19:45480174 G/A rs73558188 0.023 CLPTM1 intron 6/15 3/22 0.0446 0.2270 








Table 5.10 Non-coding variants filtered by WES generated genes and higher AFR MAF in WGS dataset – continued 
Chr:Pos Ref/Alt Identifier CADD 
PHRED 
score 


















19:45482239 -/T rs75083707 - CLPTM1 intron 6/15 3/22 0.0435 0.2298 
19:45483844 G/A rs73558194 1.22 CLPTM1 intron 6/15 3/22 0.0445 0.2411 
19:45485371 -/TGAG rs112449454 - CLPTM1 intron 6/15 3/22 0.0444 0.2205 
19:45485491 G/A rs73558195 2.309 CLPTM1 intron 6/15 3/22 0.0447 0.2211 
19:45486148 G/A rs57270598 0.671 CLPTM1 intron 6/15 3/22 0.0447 0.2206 
19:45486687 G/C rs143668237 0.835 CLPTM1 intron 6/15 3/22 0.0461 0.0737 
19:45486730 C/T rs112417029 1.105 CLPTM1 intron 6/15 3/22 0.0450 0.2228 
19:45487420 A/C rs16979600 4.216 CLPTM1 intron 6/15 3/22 0.0455 0.2216 
19:45487670 A/T rs73558200 0.201 CLPTM1 intron 6/15 3/22 0.0454 0.2218 
19:45488093 C/T rs112329279 0.227 CLPTM1 intron 6/15 3/22 0.0455 0.0749 
19:45489950 C/T rs34112623 1.672 CLPTM1 intron 6/15 3/22 0.0450 0.2212 
19:45490428 G/A rs7257610 0.488 CLPTM1 intron 6/15 3/22 0.0451 0.1085 
1:54723658 T/C rs72664201 15.65 SSBP3 intron 3/15 3/22 0.0462 0.0888 
2:160471434 A/G rs73010640 19.91 BAZ2B intron 5/15 2/22 0.0437 0.1304 
5:66489858 A/G rs1428467 16.88 CD180 intron 3/15 0/22 0.0183 0.1500 
11:5452298 G/A rs60189221 15.44 HBE1,HBG2 intron 3/15 1/22 0.0393 0.0927 
14:24906094 T/C rs73593291 17.32 KHNYN intron 5/15 1/22 0.0422 0.3522 
14:67763456 A/C rs17093616 15.16 ATP6V1D,MPP5 intron 3/15 0/22 0.0257 0.3327 
14:67805253 A/C rs1045060 16 ATP6V1D 3_prime_UTR 3/15 0/22 0.0258 0.3341 
14:71270996 A/G rs77672193 17.99 MAP3K9 intron 3/15 2/22 0.03778 0.0942 
17:63589516 C/T rs149866023 16.91 CTD-2535L24.2 intron 3/15 1/22 0.0150 0.0311 
20:17519388 G/C rs76524029 15.89 BFSP1 intron 3/15 3/22 0.0417 0.0646 
*Shaded rows indicates haplotypes of genes with strong linkage disequilibrium. All variants are in NIST callable regions. There are not REVEL score,  




5.3.4.2 Analysis of bradykinin and substance P metabolism and receptor genes 
Filtering for variants present in the bradykinin, substance P metabolism and relevant 
receptor genes in the WES dataset resulted in several potential variants that were 
enriched in the ACEi-A samples (Section 5.3.3.1). The same list of 23 genes was 
applied to the WGS dataset, resulting in a total of 1086 variants with a MAF ≤1%, 
which were also in NIST callable regions and not multi-allelic. The total number of 
samples having any variant in each gene was compared between ACEi-A and the 
control group. A p-value threshold after adjustment for multiple testing was 
calculated to be 0.05/23 = 0.002. None of the variants in any gene reached statistical 
significance using a chi-square test. Furthermore, when variants in the intronic and 
3’-UTR regions were filtered out, only 45 variants remained. Comparison using these 
45 variants between the two groups also resulted in no significant differences. When 
considering only the 45 variants outside the intronic and 3’UTR regions, the 
proportion of ACEi-A samples with variants in DPP4, ACE, and THOP1 genes were 
generally elevated compared to the control group (Table 5.11). Eleven out of the 15 
ACEi-A samples had at least one of these variants, a proportion that was not different 
when compared with the control group (15 out of 22 samples). Only three out of the 
45 variants were predicted to be damaging according to FATHMM MKL, and two 












All types of variants Chi-
square p-
value 
Exclude intronic and 3’UTR variants Chi-
square p-
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with variant  
in this gene  
 
ECE1 12 0.80 19 0.86 0.64 1 0.07 0 0.00 0.87 
DPP4 10 0.67 11 0.50 0.5 3 0.20 2 0.09 0.64 
MME 15 1 22 0.100 NA 1 0.07 0 0.00 0.87 
ENPEP 15 1 20 0.91 1 0 0.00 0 0.00 NA 
LNPEP 12 0.80 19 0.86 0.64 0 0 0 0 NA 
PREP 12 0.80 19 0.86 0.64 0 0.00 1 0.05 1 
CPN1 12 0.80 8 0.36 0.1 0 0.00 1 0.05 1 
XPNPEP1 9 0.60 11 0.50 0.79 1 0.07 1 0.05 1 
PRCP 13 0.87 19 0.86 1 1 0.07 2 0.09 1 
CPM 15 1 22 1 NA 1 0.07 1 0.05 1 
CMA1 1 0.07 1 0.05  0 0.00 1 0.05 1 
ANPEP 10 0.67 17 0.77 0.18 4 0.27 4 0.18 0.83 
ACE 10 0.67 10 0.45 0.35 4 0.27 2 0.09 0.33 
THOP1 11 0.73 10 0.45 0.27 2 0.13 2 0.09 1 
CTSA 1 0.07 2 0.9 1 0 0.00 2 0.09 0.65 
XPNPEP3 9 0.60 17 0.77 0.45 0 0.00 2 0.09 0.65 
ACE2 3 0.20 11 0.50 0.13 0 0.00 1 0.05 1 
XPNPEP2 4 0.27 8 0.36 0.79 0 0.00 1 0.05 1 
TACR1 10 0.67 19 0.86 0.19 0 0 0 0 NA 
TACR2 1 0.07 2 0.09 1 1 0.07 0 0.00 0.87 
BDKRB2 9 0.60 15 0.68 0.68 3 0.20 4 0.18 1 





5.3.4.3 Analysis of all candidate genes by WGS 
The filtering approach described in Section 5.3.4.1 was applied using the same 
candidate gene list (n=421 gene) as outlined in Figure 5.5. Only one variant (rs4365) 
in the coding region of ACE was present in five or more ACEi-A samples. Sixty variants 
were present in three to four ACEi-A samples, of which three variants in F5, ADCY6, 
TPP2 were predicted as damaging by FATHMM MKL. For intronic and 3’-UTR 
variants, the rs73449681 variant in the COL22A1 gene was the only  variant with a 
higher MAF in African population, and present in at least six ACEi-A samples. All 
variants filtered in this candidate gene approach are shown in Table 5.12. 
 
Figure 5.5 Stepwise filtering of variants in the candidate gene list in WGS data 
Candidate variants in coding/5’-UTR regions were filtered based on enrichment in the 
ACEi-A samples followed by filtering based on in silico prediction tools. Additional filters 
for intronic variants included higher AFR MAF, being in NIST callable regions and CADD 
score ≥15. Filtering resulted in four variants in the coding/5’-UTR regions and six 







Table 5.12 Variants in candidate gene list in WGS dataset 
































17:61574712 G/A rs4365 16.89 - - - - ACE synonymous 5 1 0.0392 0.0058 
1:169484767 A/G rs9332701 24.1 0.751 damaging damaging 5.61 F5 missense 3 1 0.0492 0.0078 
12:49176860 G/A rs55770045 18.65 0.241 damaging damaging 4.93 ADCY6 missense 3 0 0.0228 0.0028 
13:103249509 G/A rs200366836 26.7 0.471 damaging damaging 4.13 TPP2 missense 3 0 0.0041 0.0003 
8:139676558 G/A rs73449681 0.697 - - - - COL22A1 intron 6 2 0.0497 0.1578 
6:39196392 C/T rs9471016 19.94 - - - - KCNK5 intron 3 0 0.0274 0.1765 
7:22768249 G/T rs2066992 19.13 - - - - IL6 intron 3 3 0.0478 0.0805 
10:45894006 T/G rs60146827 15.11 - - - - ALOX5 intron 3 3 0.0484 0.0852 
19:33899778 C/T rs8100424 17.89 - - - - PEPD intron 3 1 0.0283 0.3055 
19:33903589 G/A rs6510380 16.79 - - - - PEPD intron 3 1 0.0283 0.3103 
CADD:  combined annotation dependent depletion, REVEL: rare exome variant ensemble learner, FATHMM MKL: functional analysis through hidden markov models multiple 




WES analysis of candidate genes (Section 5.3.3.2) identified three genes, ECE1, F5, 
and COL9A3, that had multiple variants enriched in ACEi-A, but not in the control 
group. Prior analysis of ECE1 (Table 5.11) showed no enrichment of variants in the 
WGS dataset. Further analyses was done on F5 and COL9A3. Looking only at variants 
with MAF ≤1%, there was no enrichment of variants in these two genes in the ACEI-
A group, whether considering all variants or only coding variants (Table 5.13). 
Table 5.13 Variants in the F5 and COL9A3 genes from the WGS dataset 
Gene 
names 
ACEi-A group (n=15) Control group (n=22) Chi-
square 
p-value 
  All types of variants (MAF≤1%)  
No. of sample 
with variant 




in this gene  
No. of sample 





in this gene  
 
F5 8 0.53 16 0.73 0.3884 
COL9A3 10 0.67 14 0.64 1 
Gene 
names 
Exclude intronic and 3’-UTR variants (MAF≤1%) 
 
 
No. of sample 
with variant 
in this gene 
No. of sample 
with variant in 
this gene 
No. of sample 
with variant in 
this gene 
No. of sample 
with variant in 
this gene 
 
F5 1 0.06 0 0 0.8451 
COL9A3 0 0 3 0.14 0.3796 
 
5.3.4.4 Analysis of all variants  
For variants not in candidate or WES filtered genes, analysis was first done on coding 
and 5’-UTR variants, described in Figure 5.6. Approximately 67,000 coding and 5’-
UTR had MAF ≤5%, and ~10,000 variants predicted to be damaging by FATHMM 
MKL. There were no variants in more than five ACEi-A samples in this category, and 
there were 12 variants present in five ACEi-A samples. For variants present in at least 
three or four samples, they were further filtered to retain variants with a higher MAF 
in the African population, resulting in 3 variants. More than 50,000 variants were 
predicted to be tolerant or had no prediction by FATHMM MKL. Eleven of these 
variants were present in at least six ACEi-A samples. For the approximately 2000 
variants present in three to five ACEi-A samples, further filtering was done using 









Figure 5.6 Filtering of all coding and 5'-UTR variants in the WGS dataset 
Variants were initially grouped based on prediction by FATHMM MKL. Damaging variants were filtered based on enrichment in the ACEi-
A samples followed by filtering based on higher AFR MAF. Additional filters for non-damaging variants included CADD score ≥15 and 
















































1:94512565 C/T rs1801581 19.93 0.539 tolerated damaging 3.54 true ABCA4 missense 5 0 0.0425 0.0110 
2:37543544 T/C rs11896614 22.1 0.141 damaging damaging 5.67 true PRKD3 missense 5 2 0.0463 0.0521 
2:85570849 C/T rs4832168 25.9 0.584 damaging damaging 4.13 false RETSAT missense 5 3 0.0179 0.0121 
2:85570857 G/A rs4832169 23.9 0.07 damaging damaging 4 false RETSAT missense 5 3 0.0259 0.0180 
7:88965609 A/G rs6963781 13.6 0.017 tolerated damaging 2.16 true ZNF804B missense 5 1 0.0458 0.0710 
14:67759282 C/A rs61744208 22.1 0.114 damaging damaging 5.6 true MPP5 missense 5 2 0.0443 0.0059 
15:67457698 A/G rs35874463 21.1 0.302 damaging damaging 4.95 true SMAD3 missense 5 4 0.0441 0.0091 
16:11540761 G/A rs72775600 21 - damaging damaging 3.17 true CTD-
3088G3.8 
missense 5 1 0.0394 0.0085 
16:75646423 A/G rs62619985 16.8 0.147 tolerated damaging 5.71 true ADAT1 missense 5 1 0.0436 0.1276 
16:75661803 G/C rs6834 22.2 0.314 damaging damaging 5.82 true KARS missense 5 1 0.0439 0.3317 
20:29628261 T/C rs111331725 20.5 - damaging damaging 2.08 false FRG1B missense 5 3 0.0218 0.0134 
20:29633902 C/A rs145072022 20.5 - tolerated damaging 1.62 false FRG1B missense 5 1 0.0016 0.0000 
2:169985338 C/T rs34564141 22.4 - damaging damaging 5.75 true LRP2 missense 3 0 0.0082 0.0088 
7:12675713 T/C rs17166250 22 0.173 damaging damaging 5.55 true SCIN missense 4 2 0.0403 0.0457 
20:61598731 C/T rs7271712 23.8 0.294 damaging damaging 2.6 true SLC17A9 missense 4 3 0.0232 0.0919 
1:21806624 A/G rs3820292 0.836 - tolerated tolerated -1.02 false NBPF3 missense 6 5 0.0429 0.0190 
2:179315903 G/C   - -  -  -  - true PRKRA 5_prime_UTR 6 6 0.0410 0.0257 
7:100642576 C/A rs199717981 13.86 0.028 tolerated tolerated 0.481 false MUC12 missense 6 3 0.0419 0.0520 
7:100646235 G/A   - - tolerated tolerated 0.53 false MUC12 missense 7 2 0.0078 0.0154 
7:143955954 G/T rs201430433 12.15 -  -  -  - false ARHGEF35, 
OR2A7 
synonymous 6 6 0.0371 0.0044 
7:144060877 G/T rs200205335 5.416 0.061 tolerated tolerated -1.89 false ARHGEF5 missense 7 5 0.0140 0.0186 
14:73961982 C/T rs76429074 1.082 - tolerated tolerated 1.12 true HEATR4 missense 6 4 0.0278 0.0060 
















































17:34797975 C/T   - -  -  -  - false TBC1D3G, 
BC1D3H 
synonymous 7 5 0.0320 0.0006 
17:74000784 A/G rs17883492 4.516 -  -  -  - true CDK3,EVPL splice_region 6 3 0.0399 0.1068 
22:18655999 A/G rs138527339 13.42 0.068 tolerated tolerated 3.8 false USP18 missense 6 1 0.0173 0.0019 
9:97349591 G/T rs2280301 22.9 0.479 - - - true FBP2 synonymous 4 0 0.0359 0.2403 
12:56233518 G/A rs2291267 17.81 - - - - true MMP19 missense 5 1 0.0483 0.0869 
17:73826120 C/T rs35628234 19.65 - - - - true UNC13D synonymous 5 2 0.0455 0.1408 
22:24628908 G/A rs117249571 21.9 0.22 damaging tolerated 3.28 true GGT5 missense 5 2 0.0247 0.0052 
6:56505063 A/G rs2144407 21.2 0.339 - - - true DST synonymous 4 1 0.0374 0.3847 
CADD:  combined annotation dependent depletion, REVEL: rare exome variant ensemble learner, FATHMM MKL: functional analysis through hidden markov models multiple 




For intronic and 3’-UTR variants, variants with gnomAD NFE MAF ≤5% were filtered 
by enrichment in the ACEi-A samples. Two variants were present in at least eight 
samples. These were rs759252512 in KLHL31 and rs117051263 in CALN1. There is 
no CADD score for the variant in KLHL31 and the CADD score for rs117051263 is 
0.382. Both variants also had a lower MAF in African compared to European 
population. 
Almost 2000 variants were present in six or seven samples. Filtering based on a 
higher MAF in African population and a CADD score of ≥15 removed all but one 
variant, rs4970290 in ZNF595. This intronic variant was present in seven ACEi-A 
samples and only two of the control samples. 
Over 27,000 rare variants (MAF ≤1%) were present in three to five ACEi-A samples, 
and no further filtering was done on this subset given the large number of variants 
and the relatively small number of samples.  
For intergenic variants, filtering was done to identify highly enriched variants in the 
ACEi-A samples (≥10 samples). No variants fell into this category. Again, due to the 
high number of variants, no further filtering was done on variants present in less than 
10 ACEi-A samples. Stepwise filtering for intronic, 3’-UTR and intergenic variants is 





Figure 5.7 Stepwise filtering of intronic, 3'-UTR and intergenic variants in the WGS 
dataset 
Filtering on intronic, 3’-UTR and intergenic variants were done based on enrichment in 
ACEi-A samples. Intronic and 3’-UTR variants present in less than six samples and 
intergenic variants present in less than 10 samples were not further filtered.  
5.3.4.5 Analysis of multiple variants present in the same gene 
Most of the variants shortlisted through enrichment analysis in the ACEi-A samples 
(Table 5.8, Table 5.9, Table 5.10, Table 5.12 and Table 5.14) are not very rare (MAF 
>1%). Rare variants are important as they tend to be deleterious (Gibson, 2012) and 




98 genes in those tables, only seven variants had MAF ≤1%, one each in CNTN2, 
FRG1B, HYDIN, LRP2, MUC12, PDE4DIP, TPP2 genes.  
To identify other rare variants, I shortlisted all variants with MAF ≤1% in the coding 
or 5’-UTR regions present in one to four ACEi-A samples. Rare variants in the coding 
or 5’-UTR regions present in five or more ACEi-A samples have been interrogated 
intensively, as described in previous sections, and are not included in this analysis. 
After removing false positive variants based on alternate allelic fraction (<0.2) and 
including only variants with rsID, there were 8379 variants in 5864 genes, among 
which 218 genes had multiple variants, when combined were present in at least three 
ACEi-A samples (Appendix E, available online at: 
https://github.com/yusmiatiliau/Thesis_Appendix_E).  
From the seven genes with multiple variants, five of them (CNTN2, HYDIN, LRP2, 
MUC12, PDE4DIP) had additional rare variants present in one or two ACEi-A samples 
(Table 5.15). CNTN2 and LRP2 had a higher proportion of samples with rare variants 
in ACEi-A compared to control group, but this was not statistically significant. Two 
other genes, FRG1B and TTP2, did not have additional rare variants. In total, 221 

























































1 1 0.0030 0.0002 
1:205028229 C/T rs142502980 14.11 damaging CNTN2 missense True 1 0 0.0073 0.0009 
1:205030522 C/T rs139732336 15.21 damaging CNTN2 missense True 3 1 0.0099 0.0015 
1:205033518 C/G rs79431021 0.002 tolerated CNTN2 missense True 1 0 0.0062 0.0899 





1 1 0.0015 0.0016 
16:70894087 T/C rs149857179 26.2 damaging HYDIN missense False 4 0 0.0015 0.0031 
16:71009054 C/T rs201855097 7.981 tolerated HYDIN missense False 1 0 0.0041 0.0105 
16:71054116 T/C rs183427172 9.144 tolerated HYDIN missense False 1 0 0.0007 0.0008 
16:71061604 A/G rs201092966 2.195   HYDIN synonymous False 1 0 0.0082 0.0015 





3 0 0.0051 0.0088 
2:170063263 G/A rs149367019 8.276   LRP2 synonymous True 1 1 0.0027 0.0011 
2:170082936 T/C rs138070797 21.3 damaging LRP2 missense True 1 0 0.0005 0.0003 
2:170092467 G/A rs141068435 5.954   LRP2 synonymous True 1 0 0.0003 0.0005 
2:170097478 A/G rs202173572 10.62   LRP2 synonymous True 1 0 0.0073 0.0001 








6 3 0.0419 0.052 
7:100646235 G/A - - tolerated MUC12 missense FALSE 7 2 0.0078 0.0154 
7:100636327 G/A rs199830571 3.466 tolerated MUC12 missense False 1 0 0.0097 0.0017 
7:100637073 C/T rs199836803 9.859 tolerated MUC12 missense False 1 1 0.0000 0.0024 
7:100644504 T/C rs141500497 5.259 tolerated MUC12 missense False 1 0 0.0031 0.0002 
7:100645807 G/A rs371001202 18.45 tolerated MUC12 missense False 1 0 0.0001 0.0008 
7:100646140 T/C rs139823939 0.199 tolerated MUC12 missense False 1 0 0.0004 0.0002 
7:100646404 A/T rs202045957 14.4 tolerated MUC12 missense False 1 0 0.0007 0.0003 
1:145039744 C/A rs367568901 5.992 - PDE4DI
P 
5_prime_UTR TRUE 6/15 11/22* 0.79 
 
 
5 3 0.0077 0.0373 
1:144855771 C/T rs368043502 5.49 - PDE4DI
P 
missense FALSE 1 0 0.0090 0.0000 
1:144994654 G/A rs147804991 19.61 - PDE4DI
P 
synonymous FALSE 1 0 0.0089 0.0002 




5.3.5 Biological network analysis on the filtered genes 
5.3.5.1 Protein-protein interaction and enrichment analysis of filtered genes 
using STRING 
Filtering based on enrichment of WGS variants resulted in a total of 98 genes (Table 
5.8, Table 5.9, Table 5.10, Table 5.12 and Table 5.14). These genes together with 
BDKRB2 and XPNPEP2 – two previously reported genes with variants enriched in the 
cohort in this thesis - were analysed for protein-protein interaction (PPI) using 
STRING (https://string-db.org/). This aimed to test for any association between the 
genes filtered agnostically with the filtered candidate genes. STRING curates 
information on associations between proteins based on experimental and curated 
databases, and currently contains information of 5090 organisms and 24.6 million 
proteins. The associations among proteins in STRING database are categorized into 
seven groups: genomic neighbourhood, gene fusion, gene-occurrence, gene co-
expression, text-mining, experimental data from IMEx and BioGRID dataset, and 
lastly curated databases, including KEGG, Reactome, BioCyc, Gene Ontology, PID and 
BioCarta databases (Szklarczyk et al., 2019). STRING, together with 
ConsensusPathDB and GIANT (now humanBase), was reported to outperform other 
similar molecular network tools (Huang et al., 2018). 
Twenty two associations with confidence score cut-off at 0.4 (medium confidence) 
were found among 29 genes, including eight candidate genes (PEPD, XPNPEP2, ACE, 
BDKRB2, ADCY6, IL6, F5, ALOX5). The eight candidate genes were found in association 
with four other genes filtered agnostically from the WES/WGS dataset (PRKCB, 
PRKD2, PRKD3, and CD1C). Nine other associations were also found among the non-
candidate genes (Figure 5.8). However, the PPI analysis did not show significantly 






Figure 5.8 PPI analysis of the 92 filtered genes by STRING 
Analysis by strings shows association among 13 genes, and nine other associations 
between two or three genes. Coloured nodes: query proteins. Coloured lines: predicted 
associations, red line: presence of fusion evidence, green line: neighbourhood evidence, 
blue line: co-occurrence evidence, purple line: experimental evidence, light blue line: 
database evidence, black line: co-expression evidence, yellow line: text-mining evidence. 
The thickness of the line indicate the degree of confidence prediction of the interaction.  
 
Further protein association analysis was done on these associated genes (n=29) by 
adding 10 genes from the STRING network (by using “More” button in the STRING 
interface). This resulted in an additional association of four genes, KARS, ADAT1, 
CLGN and SYCP1, to the previous set of 13 genes (Figure 5.9). The variants in these 





Figure 5.9 PPI analysis of the 29 genes by STRING 
Further analysis of the 29 genes showed additional interaction with four more genes. Symbols 
and links are as described in Figure 5.8. 
 
STRING also performs enrichment analysis for various databases including gene 
ontology, pathways, and domains. These 98 genes were enriched in several 
databases with statistical significance, including gene ontology (GO) molecular 
function terms of exopeptidase activity and tripeptidyl-peptidase activity, Reactome 
pathways of synthesis of leukotrienes and eoxins, and UniProt keywords including 








Table 5.16 Functional enrichment analysis of the 98 filtered genes 





FDR Matching proteins in your network (labels) 
GO Molecular Function Terms 
GO:0008238 exopeptidase activity 5 106 0.0117 ACE,GGT5,PEPD,TPP2,XPNPEP2 
GO:0008240 tripeptidyl-peptidase activity 2 3 0.0181 ACE,TPP2 
Reactome Pathways 
HSA-2142691 synthesis of Leukotrienes (LT) & 
Eoxins (EX) 
3 21 0.0182 ALOX5,CYP4B1,GGT5 
UniProt Keywords 




KW-0106 Calcium 13 866 0.00055 ALOX5,CALN1,CLGN,DST,F5,FBP2,LRP2,MMP19,PCDHA1,PRKCB,SCIN,
SVEP1,TTN 






KW-0434 leukotriene biosynthesis 2 6 0.014 ALOX5,GGT5 
Interpro protein domains and feature 
IPR001131 peptidase M24B, X-Pro 
dipeptidase/aminopeptidase P, 
conserved site 
2 3 0.0283 PEPD,XPNPEP2 
IPR006626 parallel beta-helix repeat 2 6 0.0296 PKHD1L1,SHCBP1L 
IPR011050 pectin lyase fold/virulence factor 2 8 0.0296 PKHD1L1,SHCBP1L 
IPR012334 pectin lyase fold 2 6 0.0296 PKHD1L1,SHCBP1L 
IPR029149 creatinase/aminopeptidase 
P/Spt16, N-terminal 
2 5 0.0296 PEPD,XPNPEP2 
IPR000994 peptidase M24 2 10 0.0307 PEPD,XPNPEP2 
IPR036005 creatinase/aminopeptidase-like 2 10 0.0307 PEPD,XPNPEP2 
Smart Protein domains 




A separate PPI analysis was done on the 221 genes containing rare variants in three 
or more ACEi-A samples (Section 5.3.4.5), which were shortlisted by the agnostic 
approach. There were 254 associations with medium confidence (score>0.4) found 
among the genes, which was significantly higher than expected (PPI enrichment p-
value: <1e-16) (Figure 5.10). The PPI enrichment stayed statistically significant (p-
value: 4.49e-06) with the highest confident score (>0.9). 
 
Figure 5.10 PPI analysis of the 221 genes containing multiple rare variants in the ACEi-
A samples 





Furthermore, pathway analysis on the 221 genes containing rare variants resulted 
in enrichment in various databases. The top 10 terms generated by each annotation 
tool are described in Table 5.17 and the complete functional enrichment results are 
in Appendix F (available online at: 
https://github.com/yusmiatiliau/Thesis_Appendix_F).  
Table 5.17 Functional enrichment analysis of the 221 genes containing rare variants* 





FDR No.  
terms 
Biological Process 
GO:0007010 cytoskeleton organisation 32 953 7.01E-05 45 
GO:0007155 cell adhesion 29 843 0.0001 
GO:0006928 movement of cell or subcellular 
component 
37 1355 0.00017 
GO:0048856 anatomical structure development 90 5085 0.00017 
GO:0007018 microtubule-based movement 15 276 0.00034 
GO:0048731 system development 76 4144 0.00042 
GO:0007017 microtubule-based process 22 605 0.00047 
GO:0032502 developmental process 91 5401 0.00061 
GO:0007156 homophilic cell adhesion via plasma 
membrane adhesion molecules 
11 158 0.00066 
GO:0032501 multicellular organismal process 104 6507 0.00066 
Molecular Function 
GO:0003777 microtubule motor activity 12 110 3.05E-06 30 
GO:0005509 calcium ion binding 28 700 3.05E-06 
GO:0003779 actin binding 19 413 3.41E-05 
GO:0051015 actin filament binding 12 158 3.71E-05 
GO:0008569 ATP-dependent microtubule motor 
activity, minus-end-directed 
5 15 0.00018 
GO:0005198 structural molecule activity 22 679 0.0006 
GO:0008307 structural constituent of muscle 6 45 0.001 
GO:0016462 pyrophosphatase activity 24 819 0.001 
GO:0017111 nucleoside-triphosphatase activity 23 778 0.001 
GO:0045503 dynein light chain binding 5 25 0.001 
Cellular Component 
GO:0043292 contractile fiber 17 228 6.65E-07 47 
GO:0030016 Myofibril 16 216 1.12E-06 
GO:0099512 supramolecular fiber 31 873 1.77E-06 
GO:0044449 contractile fiber part 15 212 2.04E-06 
GO:0030017 Sarcomere 13 195 2.89E-05 
GO:0032982 myosin filament 6 22 2.89E-05 
GO:0071944 cell periphery 90 5254 5.31E-05 
GO:0005859 muscle myosin complex 6 27 5.95E-05 
GO:0016459 myosin complex 8 69 7.55E-05 
GO:0005856 Cytoskeleton 44 2068 0.00047 
KEGG Pathway 
hsa04512 ECM-receptor interaction 6 81 0.0419 2 
 hsa04530 Tight junction 8 167 0.0419 
      




Table 5.17 Functional enrichment analysis of the 221 genes containing rare variants* - 
continued 








HSA-977068 termination of O-glycan 
biosynthesis 
6 22 0.00021 10 
 
 HSA-5083625 defective GALNT3 causes familial 
hyperphosphatemic tumoral 
calcinosis (HFTC) 
5 16 0.00056 
HSA-5083632 defective C1GALT1C1 causes Tn 
polyagglutination syndrome (TNPS) 
5 16 0.00056 
HSA-5083636 defective GALNT12 causes 
colorectal cancer 1 (CRCS1) 
5 16 0.00056 
HSA-5621480 dectin-2 family 5 26 0.0017 
HSA-3000171 non-integrin membrane-ECM 
interactions 
5 58 0.0384 
HSA-399955 SEMA3A-Plexin repulsion signaling 
by inhibiting Integrin adhesion 
3 14 0.043 
HSA-3781865 diseases of glycosylation 7 136 0.0471 
HSA-399954 sema3A PAK dependent Axon 
repulsion 
3 16 0.0471 
HSA-399956 CRMPs in Sema3A signaling 3 16 0.0471 
UniProt Keywords 
KW-0677 Repeat 108 4751 3.54E-14 31 
KW-0106 Calcium 33 866 8.61E-08 
KW-0621 Polymorphism 168 11707 2.89E-07 
KW-0245 EGF-like domain 16 229 6.88E-07 
KW-0175 coiled coil 52 2158 1.90E-06 
KW-0130 cell adhesion 21 476 4.71E-06 
KW-0787 thick filament 6 17 4.77E-06 
KW-0505 motor protein 11 131 1.34E-05 
KW-0009 actin-binding 14 266 6.57E-05 
KW-0518 Myosin 6 50 0.0008 
SMART Protein Domains 
SM00001 EGF domain, unclassified subfamily 11 76 3.44E-07 33 
SM00181 epidermal growth factor-like 
domain. 
14 208 9.86E-06 
SM00112 cadherin repeats. 10 115 4.92E-05 
SM00179 calcium-binding EGF-like domain 9 98 8.53E-05 
SM00015 short calmodulin-binding motif 
containing conserved Ile and Gln 
residues. 
8 83 0.00018 
SM00242 myosin. Large ATPases. 6 38 0.00018 
SM00282 laminin G domain 6 44 0.00032 
SM00200 domain found in sea urchin sperm 
protein, enterokinase, agrin 
4 14 0.00064 
SM00216 von Willebrand factor (vWF) type D 
domain 
4 15 0.00071 







Table 5.17 Functional enrichment analysis of the 221 genes containing rare variants* - 
continued 







INTERPRO Protein Domains and Features – continued 
IPR000742 EGF-like domain 18 225 8.64E-08 86 
IPR000152 EGF-type aspartate/asparagine 
hydroxylation site 
11 100 8.86E-06 
IPR013032 EGF-like, conserved site 14 193 1.05E-05 
IPR001881 EGF-like calcium-binding domain 11 121 2.66E-05 
IPR013783 immunoglobulin-like fold 25 708 4.11E-05 
IPR031904 cadherin, C-terminal catenin-
binding domain 
7 37 4.11E-05 
IPR020894 cadherin conserved site 10 108 4.73E-05 
IPR002126 cadherin-like 10 113 6.08E-05 
IPR015919 cadherin-like superfamily 10 115 6.27E-05 
IPR018097 EGF-like calcium-binding, 
conserved site 
9 96 0.00011 
PFAM Protein Domains 
  
    
PF00028 cadherin domain 10 113 0.00013 54 
PF02210 laminin G domain 7 39 0.00013 
PF02736 myosin N-terminal SH3-like domain 5 14 0.00013 
PF15974 cadherin C-terminal cytoplasmic 
tail, catenin-binding region 
7 37 0.00013 
PF00054 laminin G domain 6 34 0.00026 
PF00063 myosin head (motor domain) 6 38 0.00026 
PF01576 myosin tail 5 18 0.00026 
PF07645 calcium-binding EGF domain 8 78 0.00026 
PF13895 immunoglobulin domain 12 212 0.00026 
PF08266 cadherin-like 7 63 0.00033 
*Each category was ranked by FDR 
5.3.5.2 Functional module detection analysis of filtered genes using 
humanBase 
Functional module detection on humanBase (https://hb.flatironinstitute.org/) 
(Greene et al., 2015) enables functional analysis in tissue-specific networks. For a 
large number of genes, these will be clustered into functional modules. Functional 
analysis of the 221 genes containing rare variants was done on two different 
networks, for blood vessel and vascular endothelium, because these are the target 
tissues of bradykinin-related vasodilatation leading to angioedema. The genes were 
enriched in five functional modules in blood vessel and six functional modules in 
vascular endothelium (Figure 5.11). The top five terms in each module and the genes 
involved are described in Table 5.18, and the complete data are available in Appendix 





Figure 5.11 Enrichment in functional modules identified from the 221 genes containing 
rare variants 
HumanBase identified enrichment in five functional modules in blood vessel (A) and six 




































Table 5.18 Enriched terms in functional modules identified from the 221 genes by 
humanBase 
Cluster Term Name Q value TERM_GENES 
Blood vessel 
  
M1 centrosome localisation 1.235E-05 SYNE2,AKAP9,RANBP2 
M1 microtubule organising center localisation 1.235E-05 SYNE2,AKAP9,RANBP2 
M1 maintenance of location in cell 0.008 SYNE2,AKAP9 
M1 organelle localisation 0.008 SYNE2,AKAP9,RANBP2 
M1 DNA conformation change 0.0181 RECQL4,RSF1 
M2 cell-substrate adhesion 0.0004 VWF,MACF1,TRIOBP,LAMA5 
M2 cell morphogenesis involved in differentiation 0.004 MACF1,TRIOBP,LAMA5 
M2 positive regulation of cell morphogenesis 
involved in differentiation 
0.006 MACF1,TRIOBP 
M2 cell morphogenesis 0.008 MACF1,TRIOBP,LAMA5 
M2 substrate adhesion-dependent cell spreading 0.008 TRIOBP,LAMA5 
M3 tissue homeostasis 0.006 MUC4,ADGRV1 
M3 multicellular organismal homeostasis 0.008 MUC4,ADGRV1 
M3 response to mechanical stimulus 0.008 NRXN1,RYR2 
M3 anatomical structure homeostasis 0.015 MUC4,ADGRV1 
M3 nervous system process 0.021 NRXN1,ADGRV1 
M4 regulation of intracellular protein transport 0.008 SREBF1,TM9SF4 
M4 regulation of intracellular transport 0.014 SREBF1,TM9SF4 
M4 Autophagy 0.016 SREBF1,PACS2 
M4 process utilising autophagic mechanism 0.016 SREBF1,PACS2 
M4 regulation of cellular protein localisation 0.020 SREBF1,TM9SF4 
M5 heart development 0.014 TTN,MEGF8 
M5 tissue morphogenesis 0.014 TTN,MEGF8 
M5 circulatory system process 0.015 TTN,ACE 
M5 blood circulation 0.015 TTN,ACE 
M5 animal organ morphogenesis 0.018 TTN,MEGF8 
Vascular Endothelium 
  
M1 maintenance of location in cell 3.036E-05 ANK3,SYNE1,SYNE2 
M1 maintenance of protein location in cell 3.036E-05 ANK3,SYNE1,SYNE2 
M1 maintenance of protein location 3.036E-05 ANK3,SYNE1,SYNE2 
M1 cytoskeletal anchoring at nuclear membrane 3.036E-05 SYNE2,SYNE1 
M1 maintenance of location 0.0003 ANK3,SYNE1,SYNE2 
M2 regulation of membrane potential 0.0003 CACNA1H,RYR2 
M2 calcium ion transmembrane transport 0.0003 CACNA1H,RYR2 
M2 response to metal ion 0.0003 CACNA1H,RYR2 
M2 response to inorganic substance 0.0003 CACNA1H,RYR2 
M2 calcium ion transport 0.0003 CACNA1H,RYR2 
M3 regulation of microtubule-based process 0.0004 MACF1,AKAP9 
M4 multicellular organismal homeostasis 0.003 CFTR,ADGRV1 
M5 muscle contraction 0.005 TTN,MYH2 
M5 muscle system process 0.006 TTN,MYH2 
M6 nucleic acid phosphodiester bond hydrolysis 0.005 DCLRE1C,DROSHA 





5.3.6 Copy Number Variation 
Many pharmacogenetic studies have focused on SNPs, however SV such as CNV have 
been reported to be a contributor to variability in drug response (He et al., 2011; 
Santos et al., 2018). SV, defined as alteration of copy number or location of DNA 
regions ≥50 bp, are increasingly associated with human diseases (Escaramís et al., 
2015; Sudmant et al., 2015). CNV via deletion or duplication of regions in the genome 
has also been associated with variability in drug response (He et al., 2011; Santos et 
al., 2018). The DECIPHER database (https://decipher.sanger.ac.uk/) (Firth et al., 
2009) has curated more than 50, 000 CNVs in the human genome.  Data from more 
than 14,000 individuals in gnomAD has been used to call ~500,000 SV. Large SV with 
regions affecting ≥1 Mb are reported in gnomAD in approximately 3% of the genomes 
(Collins et al., 2019). 
To explore the attribution of CNV to ACEi-A, CNV information for 16 samples was 
analysed. CNV reports for six ACEi-A samples were obtained using aCGH and for the 
other twelve samples were generated from WGS data. 
aCGH on six samples detected at least one different deletion/duplication event in four 
samples, each of which was rare in the population as reported in various CNV 
databases (Table 5.19). All of these CNVs have been reported in databases such as 
DGV (MacDonald et al., 2014), DECIPHER (Firth et al., 2009), or gnomAD (Collins et 
al., 2019), although none of the CNVs from the aCGH analysis precisely matched those 
reported in the databases. For example, sample U59 has a duplication of 
approximately 20 kb on chromosome X, and although gnomAD has curated several 
duplications in this region, the sizes reported are either longer or shorter. Moreover, 
none of these CNVs were shared by two or more samples, as detected by the aCGH 
method. These samples, however, shared some common CNVs that are thought be 








Table 5.19 CNV result from aCGH of six samples 
Sample CNV type No. of 
probes 
(size) 
Position Previous report in database Gene affected 












DECIPHER: several,  longer deletion 
One example of phenotype: abnormality of head and neck, abnormality of immune 




proximal flanking gene: 
PSMA6 
distal flanking gene: INSM2 DGV: 1/17421 samples 
  
 
gnomAD SV: 14:35,883,510-35,883,620(110bp), European AF: 0 
                         14:35,896,134-35,898,478 (2.3kb), European AF: 0.002369 
Never seen in patients in Canterbury Health Lab. 
 





DECIPHER: several cases, EEG abnormality, intellectual disability; abnormality of lower 
limb, ataxia, delayed speech, intellectual disability, etc. 
ADGRE1, ADGRE4P, 
FLJ25758, MBD3L5, 
MBD3L4, MBD3L2, ZNF557, 




  DGV: Pinto, 2007: 10 / 771 samples, Itsara 2009: 4/1557 samples,  Cooper 2011: 




















DECIPHER: several cases noncoding region in chr.X 




DGV: nothing in DGV 
    gnomAD SV:X:859,915-1,433,961 (574kb), European AF: 0 

























            









1 unknown in database, marked as benign CLCNKB 
  
 
DECIPHER: 5 cases, might not be the exact same duplication   
  
 
DGV: 4 cases, might not be the exact same duplication, Cooper 2001: 1/17421 samples; 










Possibly common CNV, been seen in control samples   




DECIPHER: several longer duplication,  
Phenotype associated: abnormality of head and neck, limbs, behavioral abnormality, 
delayed speech, intellectual disability 
CCSER1 (probably non 
coding region) 
        DGV: 2 short duplication: Coe 2014: 2/29084 samples; Shaikh: 1/2026 samples   
        gnomAD SV:4:92,185,962-92,259,006 (73kb), European AF:0 





Each of the 12 WGS samples had 756-827 duplication/deletion events throughout 
the genome. Combined, there were 2947 CNV calls across the 12 samples. 
First, analysis was done to see whether any of the CNVs found in the five samples 
through aCGH were present in the CNV reports of the 12 WGS samples. Searching 
based on gene names revealed that CNVs near the regions of two CNVs reported by 
aCGH (19p13.2 and Xp22.33) were present in three and 12 of the 12 ACEi-A samples 
respectively. The duplication events found on chromosome 19 by WGS were similar 
to that found by aCGH with respect to position and impact on genes. In contrast, those 
called on chromosome X in the 12 WGS samples seemed to be more distal compared 
to those found using aCGH. Both regions contained several curated CNVs as reported 
in DGV, DECIPHER and the gnomAD databases, and had low population frequencies 
in DECIPHER and gnomAD. However, as the breakpoints recorded in the samples in 
this thesis are not the same as those reported in the online databases, it remains 
unclear whether they can be considered the same CNVs (Table 5.20). The alignment 
of these CNVs is illustrated in Figure 5.12. 
A second analysis was done to find any CNVs affecting known candidate genes. For 
this purpose, a list of 29 genes consisting of genes in the bradykinin/substance P 
metabolism/pathway, genes reported in GWAS of ACEi-A, and genes associated with 
HAE was used (Appendix D). This analysis only found CNVs in two regions on 
chromosome X affecting ACE2 and XPNPEP2. Both CNVs were duplications over large 
regions affecting numerous genes, and were detected in five of the 12 WGS ACEi-A 
samples. DGV, DECIPHER, and gnomAD report CNVs in the ACE2 gene region, 
however, all of the entries are of smaller size than those reported in this thesis. The 
CNV affecting XPNPEP2 has been reported in four samples in the DECIPHER database, 
and three of these were predicted to be likely pathogenic (Table 5.21). The 
























































































































































































































































































Figure 5.12 Alignment of CNVs found in both aCGH and WGS dataset. 
Figure shows (A) CNVs in chromosome 19, affecting ADGRE1 and other genes, and (B) 
CNVs in chromosome X affecting GTPBP6 and other genes. CNV1_1 and CNV2_1 were 








Figure 5.13 Alignment of CNVs affecting candidate genes 
Figure shows CNVs in chromosome X affecting (A) ACE2 and other genes, and (B) 






Published genetic analysis of ACEi-A to date were biased towards common variants, 
although the ADR itself is rare (~0.3%). Therefore, this study on 20 ACEi-A samples 
applied WES and WGS, methods capable of detecting rare variants to test the 
hypothesis that the ADR is caused by one or several rare variants.  
5.4.1 Previously reported variants 
First, analysis was done on previously reported variants associated with ACEi-A. All 
these variants found through GWAS or small case control studies were common and 
none of these variants were regarded as strongly causative. Variants in the regulatory 
region of XPNPEP2 associated with lower activity of the enzyme APP (Duan et al., 
2005) were reported in several studies. The variant rs3788853 was enriched in 
ACEi-A compared to control samples in one study (Duan et al., 2005) however, this 
was not replicated in this thesis. Interestingly, the allele frequency of this variant in 
the ACEi-A group (n=20) was 23%, which was similar to the study by Duan et al. 
(27.3%) and the gnomAD NFE MAF (22%). As in this thesis, the participants in the 
study by Duan et al. were also of European ancestry.  Another study confirmed the 
association of this XPNPEP2 variant with ACEi-A, but only in males of African ancestry 
(Woodard-grice et al., 2010). The allele frequency of this variant was reported to be 
higher in individuals of African ancestry (31.3%) compared to European (23.1%) in 
this study. The gnomAD MAF of this variant in African population is 23%. Another 
finding not replicated in this thesis is the enrichment of the ATG haplotype of three 
variants in XPNPEP2 (rs3788853C>A, rs2050011G>T, and rs2235444G>A) in ACEi-
A samples, which was also reported in participants of European ancestry (Cilia La 
Corte et al., 2011). Therefore, although variants in XPNPEP2 are plausibly involved in 
the pathogenesis of ACEi-A, at least in certain populations, they are not expected to 
be the main variants responsible. 
The only previously reported variant found to be enriched in the ACEi-A cohort in 
this thesis is rs1799722 in the BDKRB2 gene. However, the variant is very common 




5.4.2 Potential association of filtered variants enriched in ACEi-A cohort 
The only variant in the candidate gene list enriched in both the WES and WGS 
datasets was the rs4365 variant in the ACE. This is a synonymous variant with a 
CADD score of 16. This variant was predicted to be “likely benign” with regards to 
disease such as congenital renal dysplasia (www.varsome.com) (Kopanos et al., 
2018). However, the possible effect on ADR such as ACEi-A is unclear. Data from GTex 
suggest that rs4365 is an expression quantitative trait locus (eQTL) for FTSJ3 in 
oesophagus tissue (https://www.gtexportal.org/home/snp/rs4365). FTSJ3 encodes 
for an RNA methyltransferase which is involved in innate immune response as well 
as cancer progression (Manning et al., 2020).  In addition to rs4365, ACE contains six 
other variants in coding or 5-UTR regions  with MAF ≤5%. Combined, nine of 15 WGS 
ACEi-A cases had variants with MAF ≤5% in ACE.  
The most studied polymorphism of ACE, where an Alu element in an intronic region 
of the gene is present or absent, has been associated with altered bradykinin level 
and ACE activity (Bas et al., 2010b), but studies examining this variant have not found 
any association with ACE-A (Bas et al., 2010b; Gulec et al., 2008; Moholisa et al., 
2013). However, ACE contains some variants that are globally rare, except in African 
populations (Wright et al., 2018), which might be of interest, as Africans are shown 
to be less responsive to the effect of ACE inhibitor medication (Helmer et al., 2018), 
and also have a higher risk of ACEi-A (Brown et al., 1996). Individuals with lower 
levels of ACE activity were thought to have higher risk of developing ACEi-A. All 
samples in this thesis were collected retrospectively, and no measurement of ACE 
activity or bradykinin level was done. A previous study reported that variants in 
regions from intron 20 to 3’-UTR of the ACE gene were associated with higher ACE 
activity (Chung et al., 2013). This region will include the rs4365 variant which is 
located in exon 25. However, the study by Chung et al. was done only on Chinese 
population and future experiments to investigate the effect of the rs4365 variant and 
other variants in ACE on the enzyme activity and bradykinin level in other 
populations might be useful to elucidate their association with ACEi-A.  
While no other candidate genes had variants with MAF≤5% highly enriched in the 
ACEi-A samples, three genes (ECE1, F5, COL9A3) had multiple variants which, when 




and substance P metabolism/pathway and receptors also had combined variants 
enriched in the WES ACEi-A compared to control. However, the WES analyses were 
only done on five individuals with ACEi-A and these findings could not be replicated 
in the WGS dataset, which was of a larger sample size, suggesting these were random 
findings and may not be biologically relevant.  
From various filtering steps on the WES and WGS dataset, over 100 moderately 
enriched variants were shortlisted. PPI analysis of the genes of these variants found 
that eight of the genes (PRKCB, PRKD2, PRKD3, CLGN, SYCP2, ADAT1, KARS and CD1C) 
found through the agnostic approach, had interactions with some of the candidate 
genes. Five of the eight variants were predicted to be damaging by FATHMM MKL. 
The variants were present in four to six ACEi-A samples and combining the eight 
variants together and rs4365 in ACEi-A gene, 14 of 15 ACEi-A samples had at least 
one of the variants. In the five samples with WES data, five of the nine variants were 
present, with one each in PRKD3, CLGN, ADAT1, KARS, and ACE. Combined, three out 
of the five samples had at least one variant in these genes.  
PRKCB, PRKD2, PRKD3 encode for members of protein kinase C and D family, that are 
involved in downstream pathways upon activation of bradykinin receptors. 
Bradykinin receptors are part of the superfamily of G protein-coupled receptors, 
which upon binding to their ligands, activate adenylate cyclase and stimulate 
phospholipase A (PLA2) and C (PLC). These proteins hydrolyse phosphatidylinositol 
bisphosphate (PIP2) into two metabolites: inositol triphosphate (IP3) and 
diacylglycerol (DAG). DAC in turn activates several protein kinase C (PKC) processes 
(Blaes & Girolami, 2013). Protein kinase D (PKD) is activated by bradykinin and 
angiotensin II (Tan et al., 2004; Zugaza et al., 1997).  
PKC and PKD are protein kinases with various cellular functions, including cell 
proliferation, gene expression and immune regulation (Callender & Newton, 2017; 
Lim et al., 2015; Rozengurt, 2011). PKD regulates nitric oxide synthesis (Aicart-
Ramos et al., 2014). Activation of bradykinin receptors is known to increase nitric 
oxide (NO) release through activation of nitric oxide synthase (eNOS), resulting in 
vasodilatation and other beneficial cardiovascular effects (Blaes & Girolami, 2013).   
CD1C encodes T-cell surface glycoprotein CD1c that presents lipid and glycolipid 




with multiple autoimmune and malignant conditions (Guo et al., 2018).  KARS 
encodes lysyl-tRNA synthetase and ADAT1 encodes adenosine deaminase tRNA 
specific 1. Both genes are involved in tRNA function. KARS is also a regulator of 
immune response. Homozygote or biallelic heterozygote variants in this gene cause 
leukodystrophies with many neurodevelopmental defects including immune 
impairment (Itoh et al., 2019). Two moderately significant genes for ACEi-A found 
through GWAS were immune related (ETV6, PRKCQ), therefore the involvement of 
immune-related genes such as CD1C, KARS, and ADAT1 in ACEi-A is plausible.  
CLGN encodes calmedin and SYCP1 encodes synaptonemal complex protein 1, both 
of which play a role in male fertility. SYCP1 and CLGN are expressed predominantly 
in male tissues (www.gtexprotal.org), however CLGN mRNA is also expressed in the 
brain, endocrine and muscle tissues (www.proteinatlas.org) (Uhlén et al., 2015). An 
isoform of ACE is highly expressed in the testes, designated as testicular ACE (tACE). 
ACEi do not alter tACE, presumably due to the blood-testes barrier (Sakaguchi et al., 
1988). However cases of ACEi-induced penile angioedema have been reported 
(Miller et al., 2012; Wagner et al., 2015), suggesting a possible role of these proteins 
in ACEi-a related ADR. 
5.4.3 Potential association of genes containing multiple rare variants with 
ACEi-A 
The possibility that ACEi-A is a complex trait with multiple genetic contributors has 
been suggested before (Pare et al., 2013) as GWAS did not find any significant major 
locus for this ADR. the analysis using WES and WGS in this thesis targeting rare 
variants also could not confidently point to one particular gene. If multiple rare 
causative variants/genes exist, they are not necessarily highly enriched in the ACEi-
A samples, instead, different rare variants (whether in the same or different genes) 
can be present in different samples. Moreover, HAE, an inherited condition with 
episodes of angioedema with similar features such as increased bradykinin, has been 
associated with at least five different genes, SERPING1, F12, ANGPT1, PLG, and KNG1 
(Bafunno et al., 2018; Bork et al., 2009; Bork et al., 2019; Bork et al., 2018; Germenis 
& Speletas, 2016). Although the majority of HAE was caused by one of over 450 
mutations in SERPING1 coding for C1 inhibitor, it is now considered a heterogeneous 




Over 200 genes contained multiple rare variants in the coding regions, which when 
combined were enriched in three or more ACEi-A samples per gene (Appendix E). 
Functional analysis of these variants showed significantly enriched PPI interactions 
and enrichment in functional annotations in various databases, suggesting a 
potential biological relevance of these genes. However, most of the top genes with a 
high number of variants also had many variants in control samples. For example, TTN 
had multiple rare variants in 11 ACEi-A samples and 13 control samples. TTN is also 
a gene with very large coding regions (>300 exons), with gnomAD database reported 
more than 20,000 variants in coding regions (Karczewski et al., 2019). Therefore, the 
high number of samples with rare variants in this gene might simply reflect the high 
total number of variants contained in this gene. 
Two genes, LRP2 and CNTN2, had a single rare variant enriched in three or more 
ACEi-A samples as well as multiple rare variants present in one or two samples. 
Combinations of rare variants in this gene were found in five out of the 15 WGS ACEi-
A samples, and were in lower proportion in control samples. LRP2 encodes for low 
density lipoprotein receptor related protein 2, also called megalin. This receptor is 
expressed in multiple organs, including kidney, lung, intestine and nervous system 
(Cabezas et al., 2019) and is involved in the endocytosis of a wide range of ligands, 
including angiotensin II, angiotensin 1-7, calcium ions, and several coagulation 
related proteins such as plasminogen, plasminogen activator inhibitors and factor VII 
(Marzolo & Farfán, 2011). LRP2 was reported to regulate renin angiotensin 
homeostasis in the kidney (Ye et al., 2019), therefore plausibly associating it to ADR 
due to ACEi. One rare variant in LRP2 (rs34564141) was present in three out of the 
15 ACEi-A samples, and four other rare variants present in only one or two samples. 
In total, five out of 15 ACEi-A samples have at least one rare variant in this gene.  
CNTN2 encodes for contactin 2, a membrane protein involved in a volgate-gated 
potassium channel. A prior report on GWAS of ACEi-A has reported two significant 
variants in another potassium channel gene, KCNMA1 (Wadelius et al., 2017), 




5.4.4 Protein interactions and pathway analysis 
PPI and functional enrichment analyses were done on two groups of genes. First the 
genes containing variants with MAF ≤5% enriched in ACEi-A samples were 
considered. Second, the genes containing variants with MAF ≤1% which, though not 
necessarily enriched in ACEi-A as individual variants, when combined, were found in 
three or more ACEi-A samples.  
Both groups showed enrichment for the keyword “calcium” in UniProt. The genes 
involved are as follow: ALOX5, CALN1, CLGN, DST, F5, FBP2, LRP2, MMP19, PCDHA1, 
PRKCB, SCIN, SVEP1, TTN, ATP2C2, BEST2, CACNA1H, CACNA2D4, CELSR1, CUBN, 
DCHS2, FAT1, FBN3, FLG, FLG2, GPR98, HMCN1, HMCN2, HRNR, HSPG2, LRP2, MACF1, 
MEGF8, NRXN1, PCDHA1, PCDHA2, PCDHA3, PCDHA4, PCDHA5, PCDHA6, PCDHA7, 
PCLO, PKD1L1, RYR2, SNED1. Moreover, enrichment analysis of the 98 enriched genes 
by STRING showed enrichment in Synthesis of Leukotrienes (LT) & Eoxins (EX) 
pathway in Reactome database (Table 5.16). Enrichment analysis in Gene Ontology 
molecular function terms using STRING (Table 5.17) and functional module 
detection using network in vascular endothelium using humanBase (Table 5.18) also 
showed significant enrichment in calcium ion binding and transport. A GWAS on 
angioedema induced by another group of medications, NSAID, has reported genes 
related to calcium ion (Cornejo-García et al., 2013) and NSAID-induced angioedema 
is thought to be associated with reduced prostaglandin E2 and increased leukotriene 
(Nosbaum et al., 2013). Although angioedema induced by ACEi and NSAIDs was 
thought to arise from a different mode of pathogenesis, cases of angioedema caused 
by a combination of the two drugs have been reported, especially in delayed onset 
ACEi-A (Banerji et al., 2008b; Davin et al., 2019). Individuals with history of allergy 
to NSAID also had higher risk to develop ACEi-A (Banerji et al., 2017). Nine out of the 
20 ACEi-A samples in this thesis took NSAID (aspirin), however, only three of these 
were reported as late-onset ACEi-A.  
5.4.5 Potential association of CNVs with ACEi-A 
Contribution of CNVs in pharmacogenetics is less extensively studied compared to 
SNPs. Studies on pharmacogenetic-related CNV were still restricted to known 




et al., 2018). One study reported more than 5000 novel duplications/deletions in 201 
ADME genes with different frequencies among populations (Santos et al., 2018). This 
study also found that the highest number of CNVs in aggregate were found in the 
African population. GnomAD SV currently curates approximately 500,000 CNVs from 
14,891 individuals across different populations, completed with the information of 
the size, coordinate and frequency of the CNVs in different populations (Collins et al., 
2019).  Despite the availability of such a database, analysis of CNV is still challenging. 
Unlike SNP where the annotations and positions in the genome are much clearer, 
breakpoints of a certain CNV event can vary depending on the methods being used. 
For example, methods like aCGH have a limited number of probes throughout the 
genome and the size of the CNV recorded is restricted to the position of the probes. 
For CNV from the short reads based WGS dataset, standardisation in calling and 
annotating these variants was still an issue (Collins et al., 2019).  When comparing 
CNVs found in the samples to those in the databases, it is challenging to confirm that 
two CNVs are identical. Due to this limitation, it is also hard to assign a CNV as a 
common or rare event. Applying CNV analysis to pharmacogenetics/ADR application 
faces another challenge of determining whether a CNV is pathogenic or benign. 
Curation in database such as DECIPHER assigns a CNV as pathogenic or benign in 
relation to disease state, while a person with an ADR does not necessarily have a 
disease/pathological condition unless the associated drug is consumed. 
Hence, the analysis of CNV from the WGS in this thesis was limited to candidate genes. 
Two duplication events were found to affect two of the genes from the candidate gene 
list, ACE2, and XPNPEP2. However, contribution of these two genes to ACEi-A, if 
present, would seem more likely from loss of function or deletion. Therefore, the 
duplication events in these two genes might not be relevant to the ADR.  
Two CNVs were found in both aCGH samples and WGS samples. The first one is 
duplication on the short arm of chromosome 19 affecting several genes. CNVs in 
similar regions have been observed in several patients with developmental disorders 
in the DECIPHER database, although the CNVs are much smaller in some samples, as 
shown in Figure 5.12. Genes that are affected by all CNVs are MBD3L2 and MBD3L3. 
The second CNV is a duplication in chromosome X, which was found to span ~300kb 




WGS samples, however the size of the duplications varied between ~200 kb to >1 
Mb, and the overlapped regions among all the CNVs are in the non-genic regions 
(Figure 5.13).  
5.4.6 Limitations of the study 
This study was not successful in identifying a single rare variant/gene strongly 
associated with ACEi-A, as hypothesised. Another hypothesis yet to test is that ACEi-
A is a multi-genic phenotype and combinations of variants in more than one gene are 
required to induce the ADR. This study has shortlisted several moderately enriched 
variants. Genes with multiple rare variants which when combined were enriched in 
ACEi-A samples were also reported, with significant protein interactions and 
enrichment in functional pathways. Further research through experimental studies, 
studies in family members taking the same drug, or in cohorts with bigger sample 
size will be needed to validate the association of these variants to ACEi-A.  
Angioedema can vary in site, severity, and onset. The onset of the ADR can range from 
the first dose up to more than 20 years after taking the drug (Cicardi et al., 2004; 
Howarth, 2013; Miller et al., 2008), and even after the continuation of the drug 
(Veronez et al., 2017). In addition, although generally affecting lips and tongue, ACEi-
A in other organs such as gastrointestinal tract (Benson et al., 2013) and genital 
organs (Miller et al., 2012; Wagner et al., 2015) have been reported. Therefore, ACEi-
A may present as heterogeneous phenotypes. For example, eight ACEI-A cases in this 
thesis had the ADR soon after starting the drug while eleven cases took the drug for 
years before the ADR occurred. In addition, the resolution of oedema after drug 
withdrawal can also vary from hours to days, even months (Jackeviciute et al., 2018; 
Veronez et al., 2017). Due to the limitation in the sample number, all ACEi-A samples 
in this thesis were treated as a single group. In further studies of bigger sample size, 
analysing different phenotypes of ADR as separate groups might be beneficial.  
With respect to a control group, ideally for an ADR, this would comprise individuals 
taking the same medication but not suffering from the ADR. However, this is often 
not achievable. In this study samples from patients not experiencing ACEi-A and 
being analysed for different ADR projects were used as control. Only a subset of these 




possibility of ACEi-A in the other patients when given the drug cannot be fully 
excluded.  
Lastly, genetic analysis in this study was focused on finding genetic variants, and a 
limited analysis of CNVs. More in-depth analysis of CNVs as well as analysis on other 
aspects of genome regulation such as transcriptomic or epigenetic regulation that 
have been shown to contribute to drug response variability (Chhibber et al., 2017; 
Yusuf et al., 2017) should be considered for future studies. To address part of this 
question, a study of the effect of ACE inhibitors on DNA methylation is described in 
the next chapter.  
5.5 Conclusion 
WES and WGS analysis were conducted on ACEi-A which is reported to occur in 
approximately 3:1000 patients. This ADR is thought to have a genetic predisposition, 
and previous studies on common genetic variants were not successful in finding the 
genetic association. I hypothesised that one or a few rare variants were associated 
with the ADR. However, the results did not support this hypothesis with no single 
rare variant being highly enriched in the ACEi-A samples.  
Previously reported variants could not be consistently replicated, however there was 
some evidence that the rs1799722 variant in BDKRB2 was enriched in the ACEi-A 
cohort.  
Several variants were found to be moderately enriched, including rs4365 in ACE 
(present in 8/20 samples), rs11896614 in PRKD3 (5/20 samples), rs2175563 in 
CLGN (4/20 samples), rs62619985 in ADAT1 (5/20 samples) and rs6834 in KARS 
(5/20 samples). From analysis of multiple rare variants enriched in ACEi-A samples 
as combination, CNTN2 and LRP2 had variants in five ACEi-A samples, but less 
common in control samples, suggesting a potential association with ACEi-A. 
ACEi-A is likely a complex phenotype and further research using other approaches to 




Chapter 6 : Effect of angiotensin converting enzyme 
inhibitor on DNA methylation 
6.1 Introduction 
Genetic variants are currently estimated to explain approximately 20-30% of known 
variability in drug response (Lauschke et al., 2017), with the remaining variability 
arising from other contributing factors including drug-drug interactions, patho-
physiological conditions, and environmental factors (Ivanov et al., 2014). However, 
complexities of the human genome span beyond variations in the DNA sequence, and 
features such as epigenetic regulation are often overlooked. Many studies have 
demonstrated that epigenetic factors are a key aspect that could also contribute 
towards unexplained variation in drug responses.  
6.1.1 ACE inhibitors and DNA methylation 
ACE inhibitors are mainly known for their effect on the renin-angiotensin-
aldosterone system, where ACE converts angiotensin I to angiotensin II, a potent 
vasoconstrictor with various inflammatory effects (Davin et al., 2019). ACE inhibitors 
act by competitively inhibiting ACE and preventing it from binding with angiotensin 
I (illustrated in Figure 1.11). This reduces the level of angiotensin II, and results in a 
lowered blood pressure and attenuation in cardiac remodelling (Ferrario, 2016).  
However, ACE is a multi-functional enzyme and is also the main enzyme required to 
break down bradykinin, a vasodilator (Jaspard et al., 1993). ACE inhibitor treatment 
has been reported to increase bradykinin level and this is postulated to be 
responsible for some of the ACE inhibitor side effects, such as cough and angioedema 
(Bas et al., 2007; Dicpinigaitis, 2006). ACE is also involved in degrading amyloid beta 
peptide, a substance related to Alzheimer disease (Hu et al., 2001). People lacking 
apolipoprotein E4 alleles taking ACE inhibitors were reported to have lower risk of 
Alzheimer’s disease (Qiu et al., 2013) and improved cognitive function in people with 
Alzheimer disease (Gao et al., 2013). ACE also plays an important role in immune 
responses. Treatment with ACE inhibitor resulted in decreased CD4+ T cells 




ACE expression in various tissues is regulated by DNA methylation (Mudersbach et 
al., 2019; Rivière et al., 2011; Zill et al., 2012), and ACE inhibitors have been reported 
to affect gene expression (Reddy et al., 2013; Yakubova et al., 2018). Using in vitro 
models, Reddy et al. showed that captopril altered the expression of several growth-
related genes (Reddy et al., 2013). In vivo studies have shown that captopril induces 
gene expression changes associated with immune and inflammation responses, 
especially in the hearts of mice with metabolic syndrome (Yakubova et al., 2018). 
Combination of ACE with other drugs has also been reported to alter gene expression 
or induce cytotoxicity. The combination of silymarin and lisinopril was reported to 
decrease mRNA expression of nuclear transcription factor kappa B (Saber et al., 
2018), and combination of  ACEi with sunitinib resulted in decreased renal cell 
viability in vitro (McKay et al., 2015). 
DNA methylation is known to be a key regulator of gene expression, however, there 
have not been any studies investigating the potential effect that ACE inhibitors could 
have on DNA methylation. Moreover, endeavours to find the genetic variants 
responsible for some of the ADR of ACE inhibitors have not found any strong genetic 
candidate, and other potential contributing factors such as epigenetics seem 
important to consider. This chapter describes the investigation of potential DNA 
methylation changes associated with ACE inhibitors, using both a clinical cohort and 





6.2.1 Genome wide DNA methylation analysis of ACE inhibitor effects in a 
clinical cohort 
A preliminary investigation into the potential effects of ACEi on DNA methylation was 
performed using DNA extracted from peripheral blood samples. DNA methylation 
profiles were compared between subjects who had consumed any ACEi (Treatment, 
n=49) and those who had not (Control, n=233). The dataset showed no difference in 
age and smoking status between Treatment and Control. However, the treatment 
group showed higher prevalence for history of hypertension, diabetes, and 
dyslipidaemia, and consumption of statin (Table 6.1). No data on the type and length 
of ACEi consumption were available.  
 





















History of hypertension  89.8% 17.6% <0.001 
History of diabetes  16.3% 5.2% 0.02 
Statin medication use  44.9% 21.0% <0.001 
History of  dyslipidaemia  40.8% 12.4% 0.04 
*Data were obtained using the R package compareGroups (Subirana et al., 2014) 
 
Investigation of differentially methylated sites was done using Qlucore Omics 
Explore 3.3 (64-bit). This analysis was performed using an arbitrary p-value 
threshold at 5e-05, and generated a list of 27 potential CpG sites (Table 6.2). Only one 
CpG site on chromosome 10, cg05585149, had an adjusted p-value of <0.05 after 
adjustment for multiple testing (Figure 6.1).  For methylation array data, the 
methylation level of each CpG site is usually reported as a beta value, which is 




particular site. The beta values of ACEi and Control groups at cg05585149 are 
presented in Figure 6.2. 
Table 6.2 CpG sites from clinical data with p-value <5e-05 
CpG sites Chromosome Gene name t-statistic p-value Adjusted  
p-value 
cg05585149 10 C10orf108 -5.63857 4.29E-08 0.019574 
cg07469445 10 C10orf108 -4.95006 1.30E-06 0.297266 
cg06492112 X IDS -4.76844 3.03E-06 0.42392 
cg10322879 2 YWHAQ -4.68765 4.38E-06 0.42392 
cg01459030 7 EIF4H -4.67438 4.65E-06 0.42392 
cg12875534 X CXCR3 -4.6193 5.95E-06 0.452325 
cg26344867 4 GLRB -4.56226 7.67E-06 0.499627 
cg15363973 7 SUN1 -4.48154 1.09E-05 0.544924 
cg12824952 11 PGM2L1 -4.4652 1.17E-05 0.544924 
cg05523653 17 TIMM22 4.461154 1.19E-05 0.544924 
cg16981259 6 ATP6V1G2-
DDX39B 
4.416855 1.45E-05 0.60015 
cg03021100 3 STT3B -4.3821 1.68E-05 0.638813 
cg16543090 7 CYP2W1 -4.32547 2.14E-05 0.672514 
cg26434653 13 ENOX1 -4.32461 2.15E-05 0.672514 
cg16516888 11 C11orf67 4.317692 2.21E-05 0.672514 
cg23954066 14 DLK1 -4.27176 2.68E-05 0.706745 
cg02681173 12 FZD10 4.265236 2.76E-05 0.706745 
cg24443446 10 JMJD1C -4.24986 2.94E-05 0.706745 
cg09015232 20 SLC12A5 4.249772 2.94E-05 0.706745 
cg24816114 5 PSD2 -4.23092 3.18E-05 0.726424 
cg02711608 19 SLC1A5 -4.20363 3.57E-05 0.774994 
cg00433159 16 CEMP1 4.177249 3.98E-05 0.801116 
cg04487855 15 GOLGA8J 4.161611 4.24E-05 0.801116 
cg01273287 14 SNAPC1 4.151957 4.42E-05 0.801116 
cg03741155 16 MAP1LC3B -4.14601 4.52E-05 0.801116 
cg07439241 3 THUMPD3 -4.14192 4.60E-05 0.801116 






Figure 6.1 Manhattan plot of DNA methylation in clinical data: ACE-inhibitor treated 
vs control 
The Manhattan plot shows two outstanding CpG sites on Chromosome 10, one of 
which meets epigenome wide significance. Blue line: suggestive cut-off, arbitrarily set 
at p<5e-05, red line: epigenome wide significant cut-off at p<5e-08 
 
 
Figure 6.2 Beta values of cg05585149 in ACEi and control groups 
Figure shows significantly different beta value of cg05585149 in the C10orf108 locus 





Qlucore software was used for Principal Component Analysis (PCA) and heatmap 
analysis, generated using the beta values of the 27 most significant CpG sites. The 
first component of PCA contained 14% of the variance and demonstrated some 
segregation between subjects taking ACEi and those who did not (Figure 6.3). 
However, in contrast to this, the heatmap did not show a highly distinctive separation 
between the two groups (Figure 6.4).  
 
 
Figure 6.3 PCA plot of the top 27 CpG sites 
PCA analysis using the top 27 CpG sites showed a separation between control and ACEi 










Figure 6.4 Heatmap of the top 27 CpG sites 
On the top row, red colour indicates subjects taking ACE inhibitor (Treated) and blue 
indicates subjects not taking ACE inhibitor (Control). The next rows show the level of 
methylation for each CpG site represented by the gene names on the right, with red 
colour indicating high methylation level, green indicating low methylation level, and 
black indicating moderate methylation level.  
 
The significant signal on chromosome 10 and the PCA analysis suggested a potential 
effect of ACE inhibitor on DNA methylation, however, this analysis did not account 
for other potential contributing factors, such as hypertension, diabetes, 
dyslipidaemia and statin. In fact, one of the top 27 CpG sites, cg02711608 in SLC1A5, 
has been recently reported to influence blood pressure in a genome-wide 
methylation analysis across different populations (Richard et al., 2017). 
Re-analysis of the dataset with adjustment for statin use resulted in similar results 
as in no adjustment, with the three top differentially methylated CpG sites retained. 
The cg05585149 in c10orf108 remained significant (adjusted p-value = 0.03). 
However, adjustment for history of hypertension removed all these top differentially 
methylated CpG sites (Figure 6.5).  
ACEi use is a surrogate marker for history of hypertension and the top CpG sites 
might associate with either ACEi or hypertension, or both. In the next section, a cell 
culture model was used to study the effect of ACEi on DNA methylation without 






Figure 6.5 Manhattan plot of DNA methylation in clinical data: ACE-inhibitor treated 
vs control after adjustment for (A) statin use and (B) history of hypertension 
The Manhattan plot for analysis with adjustment for statin use (A) shows the three 
top CpG sites as found in analysis without adjustment, while the plot for analysis after 
adjustment for history of hypertension (B) does not replicate this finding. Blue line: 
suggestive cut-off, arbitrarily set at p<5e-05, red line: epigenome wide significant cut-
off at p<5e-08 
 
6.2.2 Developing a cell culture model to study drug-induced DNA methylation 
A cell culture model was developed to study the potential effect of ACE inhibitors on 
DNA methylation. Jurkat cell line (derived from an immortalised T lymphocyte cell) 
(Weiss et al., 1984) was chosen for this purpose as ACE inhibitors have shown effects 




(angioedema, Chapter 5) is thought to be immune-related (Mahmoudpour et al., 
2016a; Pare et al., 2013). 
Jurkat cells were treated with lisinopril, a commonly used ACE inhibitor. Unlike many 
of the other ACE inhibitors, lisinopril is an active compound that does not need 
bioactivation by liver enzymes, making it an ideal compound for in vitro studies. DAC 
and NNK were used as hypomethylation-inducing and hypermethylation-inducing 
control agents, respectively. DAC has been shown in various studies to induce global 
hypomethylation (Lu et al., 2016a; Ruiz-Magaña et al., 2012). NNK has been reported 
to induce hypermethylation in specific CpG sites (Beleford et al., 2010; Cheng et al., 
2015; Pulling et al., 2004) and induce the expression of DNMT1 (Taylor et al., 2018). 
6.2.2.1 Cytotoxicity assay 
The cytotoxicity assay was performed for DAC, NNK, and lisinopril to obtain the half 
maximal inhibitory concentration (IC50) for each treatment. For DAC, cells were 
seeded at ~2x105 cells/mL in 24-well culture plate and treated with concentrations 
of DAC, ranging from 0.001 M up to 5 M for 48 hours. For NNK, cells were seeded 
at ~2x105 cells/mL in 24-well culture plate, treated with concentrations of NNK, 
ranging from 1 M up to 1000 M for 48 hours. For lisinopril, cells were seeded at 
~105 cells/mL and treated with lisinopril ranging from 10 to 500 M for 72 hours. It 
is recommended to maintain Jurkat cells between 105 to 106 cells/mL and Jurkat cells 
typically double every 24 hours; therefore, cells were seeded at lower concentration 
for lisinopril to allow culturing up to 72 hours without the need to subculture. Live 
cells were manually counted after treatment, using Trypan blue exclusion.  
Cells treated with DAC showed a significant decrease in live cells after 48 hours 
compared to untreated cells, in a dose-dependent manner (Figure 6.6). IC50 was 
calculated at 0.017 M. The IC50 was different from previous reports, which 
indicated that treating Jurkat cells with DAC for 4 days resulted in an IC50 at 1.2 M 
(Qin et al., 2007). Both this and my study used Jurkat cells from American Type 
Culture Collection, and it is not clear why such a magnitude of difference between the 
IC50 exists between these studies. The study by Qin, et al. showed that the reduction 
in long interspersed nuclear elements methylation was most prominent at 0.1-1 M. 




controls (data not shown), which was similar to previous observations (Chen et al., 
2010; Cheng et al., 2015; Constantinescu et al., 1998). 
 
 
 Figure 6.6 Cytotoxicity graph for DAC 
The graph with fitted line plot showed significant decrease in live cells in higher 
concentration of DAC. Data for each concentration were obtained from three replicates 
of cells. IC50 for DAC treatment for 48 hours was calculated at 0.017M. Error bars 
represents SD from three technical replicates. 
 
6.2.2.2 ACE activity inhibition by lisinopril  
ACE activity was directly measured in the cell culture media with and without the 
addition of lisinopril to ensure that ACE inhibition by lisinopril was effective. Baseline 
ACE activity of untreated Jurkat cells is relatively low and was below the detection 
limit (3 U/L) when measured in culture media supplemented with 1% FBS. FBS itself 
showed high ACE activity (~80 U/L based on one measurement).  
To measure the effect of lisinopril on ACE inhibition, the culture media was 
supplemented with 20% FBS, and three different concentrations of lisinopril, 100 
nm, 10 m, and 500 M.  ACE activity in media with 20% FBS alone was ~11.8 U/L, 
and when supplemented with the three concentrations of lisinopril, the ACE activities 
reduced to <3 IU/L, confirming ACE inhibition by lisinopril in the cell culture.  
6.2.2.3 Treatment of Jurkat cells with DAC, NNK and lisinopril 
To investigate the effect of ACE inhibitor on DNA methylation, Jurkat cells were 
treated with 500 m and 1 m lisinopril for 6 days. In addition to a flask of vehicle 




DAC and 300 m NNK for 48 hours as methylation controls. It has been reported that 
DAC is unstable in culture media at 37°C and has a half-life of 21 hours (Stresemann 
& Lyko, 2008), therefore for 48 hour treatment of DAC, the drug was replaced at 24 
hours. A previous report showed that the reaction rate (K) of lisinopril solution at 
40°C was 0.00011 K-min-1 (Adam, 2014). Using the calculation of half-life equal to ln 
2/K, it is estimated the half-life of lisinopril solution at 40°C is 96 hours. For the 6-
day lisinopril treatment, media was washed out at day 3 and replaced with media 
containing fresh lisinopril.  
DAC concentration used was determined based on the cytotoxicity assay, where 0.1 
M was the concentration near the IC50 (0.017 M) and also the concentration in 
which viable cells were dropped by 50% after 48 hours (Figure 6.6). For NNK, as no 
toxicity to the cells was observed, concentration was chosen based on previous 
studies (Beleford et al., 2010; Cheng et al., 2015). Using rat fetal lung fibroblasts, 
Cheng et al. (2015) showed that NNK  induced hypermethylation in the promoter 
region of a tumor suppressor gene, lyxyl oxidase  at 30 M, 100 M, and 300 M for 
48 hours (Cheng et al., 2015).  In another study, a human bronchial cell line (BEAS-
2B) exposed to 500 M NNK for 24 hours showed increased methylation in the first 
exon of HtrA3 gene (Beleford et al., 2010).  
There are no previous studies of ACE inhibitor on DNA methylation. In this study, 
Jurkat cell were treated with the two concentrations of lisinopril, which were 
selected to reflect the plasma level of lisinopril observed in treated patients and 
concentrations usually used in cell culture experiments. The lower concentration 
was chosen based on the plasma level of lisinopril for a therapeutic dose. 
Administration of 20 mg of lisinopril has been shown to have maximal concentration 
of 195±109 nM if given in fasting state or 156±43 nM after standard meal (Raia et al., 
1990). The higher concentration was chosen based on several in vitro studies using 
ACE inhibitors. Constantinescu et al. (1998) showed that either 10 mM or 1 mM 
lisinopril reduced interleukin-2 production in human peripheral blood mononuclear 
cells, but 0.1 M did not show any effect (Constantinescu et al., 1998). The higher 
concentration used in this thesis was 1 M, which was in the lower range compared 
to those used by Constantinescu, et al. (1998). However, it is important to note that 




endogenous ACE activity. FBS, even after heat inactivation, can have ACE activity up 
to more than 400-fold of that found in serum from healthy humans (Lubel et al., 
2008). For the experiments in this thesis, a modified RPMI cell culture media was 
used. This “advanced” RPMI required only 1% FBS instead of the normal 
concentration of 10% in ordinary RPMI, ensured minimal interference of the ACE 
activity in FBS, and lowered the requirement of ACEi concentration to achieve ACE 
inhibition in the cells. 
DNA methylation changes were measured by two different methods. Effect of DAC on 
methylation status at specific genes was investigated by BSAS. BSAS enables bisulfite 
sequencing in multiple pre-designed amplicons across multiple samples using NGS. 
Genome wide methylation profiling was done for NNK and lisinopril using 
methylome array and validated using BSAS. Methylation array profiling was not done 
for DAC treatment as it has been reported before using 27K and 450K array (Giri & 
Aittokallio, 2019; Hagemann et al., 2011). CpG sites were designated by the cg 
number when present or by their positions in the genome using hg19 reference 
genome. 
6.2.3 Processing of methylation array dataset 
Genome-wide methylation changes by lisinopril and NNK were assessed using the 
EPIC array (Illumina). The study design consisted of four cell culture replicates per 
treatment/control. Treatment 1 consisted of 500 nM lisinopril for six days, 
Treatment 2 consisted of 1 M lisinopril for six days, and Treatment 3 consisted of 
300 M NNK for two days, with four replicates of vehicle control resulting in a total 






Figure 6.7 Experimental design for EPIC array 
EPIC array was performed on a total of 16 samples that consisted of four replicates of 
vehicle control, four replicates of cells treated with 500 nM lisinopril for 6 days, four 
replicates of cells treated with 1 M lisinopril for 6 days, and cells treated with 300 M 
NNK for two days 
 
 
Analysis of the EPIC array data was carried out based on a published method 
(Maksimovic et al., 2017). In outline, the raw data were first processed to generate 
methylation values of each CpG site using the R package, Minfi (Aryee et al., 2014). 
Comparison of the methylation level of each CpG site between groups were then 
analysed using R package, limma (Ritchie et al., 2015). A multiple comparison test 
was also done comparing the effect of the two different concentrations of lisinopril 
to control , using the R package, Mulcom (Isella et al., 2011). 
The first quality control step in minfi was to examine the quality of signal across all 
probes (detection p-value) in each sample, to identify any poorly performing 
samples. All samples gave detection p-value >0.01, indicating all samples were 
performing well. Following sample quality control, data were normalised to 






Figure 6.8 Normalisation of methylation array data 
Figure shows the distribution of beta values before and after normalisation 
 
After pre-processing and normalisation, the next step was to remove less reliable 
probes. An investigation of the probes used in the EPIC array has identified a number 
of potentially problematic probes (Pidsley et al., 2016). These include cross-reactive 
probes which bind to off-target sites (43,254 probes), or probes encompassing 
genetic variants with relatively common allele frequency in the target CpG sites 
(12,378 probes), or at the single base extension sites (772 probes) (Pidsley et al., 
2016). The report by Pidsley et al. also listed probes, which can potentially bind 
genetic variants at other positions within the probe body (97,345 probes); however, 
as these probes will have little effect on the methylation status, they were not 
removed from analysis.  
This multiple-step filtering resulted in 809,767 probes available for subsequent 





Figure 6.9 Multi-step filtering to remove less reliable probes 
Multi-step process filtered out ~50,000 probes based on published data on less reliable 
probes 
6.2.4 Effect of DAC on DNA methylation at specific genes by BSAS 
DAC was used in the cell culture model as a hypomethylation control to confirm the 
suitability of the model to detect drug-induced methylation changes. Previous studies 
reported that DAC treatment resulted in global increase in DNA methylation with 
some genetic loci more susceptible than the others (Hagemann et al., 2011; Qin et al., 
2009). The hypomethylation effect of DAC in Jurkat cells compared to vehicle control 




exposure, as found in the methylation array data from clinical samples (Section 6.2). 
These include c10orf108, CXCR3, SLC12A5, JMJD1C, and YWHAQ. In addition to these, 
one gene previously reported to be demethylated by DAC in Jurkat cells (GNA14) 
(Kuang et al., 2008) was included.  
There were a total of nine CpG sites in the C10orf108 locus, seven in CXCR3, three in 
SLC12A5, 10 in GNA14, and one each in JMJD1C and YWHAQ loci. DAC exposure 
induced a decreased methylation level for all sites compared to untreated cells. The 
difference between control and DAC treated cells for all CpG sites was statistically 
significant (p<0.05) after adjustment for multiple testing, except for three sites in 
CXCR3, one sites in c10orf108, one site in JMJD1C and two sites in SLC12A5 (Figure 
6.10 to Figure 6.13).  These seven sites had either borderline adjusted p-values or 
very low methylation levels that limited the methylation changes.  
 
Figure 6.10 Effect of DAC on CpG sites in the JMJD1C, SLC12A5 and YWHAQ loci. 
DAC induced lower methylation across all CpG sites in these three loci. Differences are 
statistically significant for cg09015232 in SLC12A5 and cg10322879 in YWHAQ. P = 






















Figure 6.11 Effect of DAC on CpG sites in the C10orf108 locus. 
DAC induced significantly lower methylation across all CpG sites in the c10orf108 locus, 
except for cg18404281 where the difference was not statistically significant. P = 





















Figure 6.12 Effect of DAC on CpG sites in the CXCR3 locus. 
DAC induced significantly lower methylation across all CpG sites in the CXCR3 locus, 
except for cg12875534, chrX:70839302 and chrX:70839319 where the differences were 



























Figure 6.13 Effect of DAC on CpG sites in the GNA14 locus. 
DAC induced significantly lower methylation across all CpG sites in the GNA14 locus. P 





















6.2.5 Effect of NNK on genome-wide DNA methylation 
6.2.5.1 Analysis of DNA methylation effect of NNK by EPIC array 
The effect of NNK on genome-wide DNA methylation of the human genome has not 
been reported before, therefore a comparison between the methylation profiles of 
NNK-treated cells with control cells using the EPIC array was performed. Data were 
processed as described in Section 6.4, and differentially methylated sites were 
interrogated using the R package limma (Ritchie et al., 2015). The top 100 most 
differentially methylated sites were called using the topTable function and the beta 
values of those sites were plotted using the plotCpG function (Table 6.3 and Figure 
6.14). The p-values of all sites were also presented using a Manhattan plot (Figure 
6.15). The data showed no significant differentially methylated sites upon treatment 
with NNK, and the top 10 CpG sites showed very small changes (<5%) of methylation 
level.  
Table 6.3 Top 10 most differentially methylated CpG sites after treatment with NNK 
No. CpG Sites Chr:Pos Gene 
name 
Beta P-value Adjusted  
P-value 
1 cg06771672 7:114718104 LINC01393 -3.25257 1.05E-05 0.804945 
2 cg03693069 8:53301179 ST18 -3.25741 1.18E-05 0.804945 
3 cg22457769 8:144822917 - -3.27268 1.67E-05 0.804945 
4 cg14026459 9:23820979 ELAVL2 -3.27857 1.89E-05 0.804945 
5 cg06719271 X:30591421 CXorf21 -3.27864 1.89E-05 0.804945 
6 cg01543544 2:8818972 ID2-AS1 -3.28365 2.10E-05 0.804945 
7 cg03232056 7:157461310 PTPRN2 -3.28384 2.11E-05 0.804945 
8 cg22651271 8:141477422 - -3.28894 2.34E-05 0.804945 
9 cg16573755 2:172958337 - -3.29708 2.75E-05 0.804945 











Figure 6.14 Top 10 most differentially methylated CpG sites after treatment with NNK 





Figure 6.15 Manhattan plot of NNK treated cells vs control 
The Manhattan plot shows no CpG sites with epigenome wide significance. Blue line: 
suggestive cut-off, arbitrarily set at p<5e-05, red line: epigenome wide significant cut-
off at p<5e-08 
 
6.2.5.2 Analysis of DNA methylation effect of NNK by BSAS 
The methylation levels of selected CpG sites between NNK treated and untreated cells 
were measured using BSAS. These included the CpG sites in c10orf108, CXCR3, 
SLC12A5, JMJD1C, and YWHAQ genes and two genes previously reported to be 
hypermethylated by NNK, LOX (Cheng et al., 2015) and DAPK (Pulling et al., 2004). In 
addition, seven CpG sites selected from the EPIC array result that showed mean 
difference of more than or equal to 10% between NNK treated and untreated cells 





Figure 6.16 Seven candidate NNK modified CpG sites from EPIC array result selected 
for BSAS 
The seven CpG sites show mean difference of beta value of ≥10%; however none of them 
was statistically significant. 
 
As some amplicons contained more than one CpG sites, a total of 71 CpG sites in the 
14 genes were interrogated. However, only one CpG site, cg24443446 in JMJD1C, 
showed significantly different methylation levels between Control and NNK treated 
cells (Figure 6.17). CpG sites in other loci had p-values of >0.05 after adjustment for 
multiple testing (Figure 6.18 to Figure 6.24). 
The seven CpG sites selected based on the difference of more than 10% between 
control and NNK treated cells in the EPIC array analysis (Figure 6.16) were not 
validated by BSAS. BSAS showed different methylation change direction compared to 
EPIC array, except for cg20424974 in NPNT (Figure 6.25). 
All these data suggest that treatment of Jurkat cells with 300 M NNK for 48 hours 





Figure 6.17 Methylation level of NNK treated cells vs control in the JMJD1C, SLC12A5, 
and YWHAQ loci 
NNK resulted in one significant methylation change in cg24443446 in the JMJD1C locus. 





















Figure 6.18 Methylation level of NNK treated cells vs control in the C10orf108 locus 
NNK did not result in significant methylation change in any CpG site in the C10orf108 




























Figure 6.19 Methylation level of NNK treated cells vs control in the CXCR3 locus 
NNK did not result in significant methylation change in any CpG site in the CXCR3 






















Figure 6.20 Methylation level of NNK treated cells vs control in the LOX locus 
NNK did not result in significant methylation change in any CpG site in the LOX locus. 































Figure 6.21 Methylation level of NNK treated cells vs control in the DAPK locus 
NNK did not result in significant methylation change in any CpG site in the DAPK 






























Figure 6.22 Methylation level of NNK treated cells vs control in the GRB10 locus 
NNK did not result in significant methylation change in any CpG site in the GRB10 






















Figure 6.23 Methylation level of NNK treated cells vs control in the FOXK1, LRIT2, and 
ZNF521 loci 
NNK did not result in significant methylation change in any CpG site in the FOXK1, 






















Figure 6.24 Methylation level of NNK treated cells vs control in the MAP3K13, NPNT, 
ZFR loci 
NNK did not result in significant methylation change in any CpG site in the MAP3K13, 

























Figure 6.25 Comparison of methylation level between EPIC array and BSAS for the seven NNK modified CpG sites 




6.2.5.3 Analysis of global methylation effect of NNK from the EPIC array data 
As EPIC arrays provide measurement for methylation levels in ~800,000 CpG sites, a 
combination of these values can be used to estimate the global methylation changes 
between treated and untreated cells.  Using the whole ~800,000 filtered CpG sites 
(Figure 6.9), a t-test showed no significant difference between NNK treated and 
control cells. Testing was also done on only the 1000 most differentially methylation 
CpG sites, generated using topTable in the R package, limma. These top 1000 CpG 
sites showed significantly higher methylation values in the NNK treated cells 
compared to untreated cells (Figure 6.26). 
 
Figure 6.26 Global methylation change between NNK treated and control cells using 
data from EPIC arrays. 
Figure shows (A) methylation change using the total ~800,000 probes and (B) 
methylation change using the top 1000 most significantly different CpG sites. 
6.2.6 Effect of lisinopril on genome-wide DNA methylation 
6.2.6.1 Analysis of DNA methylation effect of lisinopril by EPIC array 
The methylation profile of cells treated with two different concentrations of lisinopril 
(500 nM and 1 M) was compared with untreated cells using the EPIC array. Data 
were processed as described before in Section 6.4, and differentially methylated sites 
were interrogated using the R package limma (Ritchie et al., 2015) and MulCom 
(Isella et al., 2011).  Analysis using limma was done on data from each concentration 
of lisinopril as well on both concentrations combined. MulCom is a package designed 




6.2.6.2 Analysis using R package limma 
The top 10 most differentially methylated sites are presented in Table 6.4 and in 
Figure 6.27 to Figure 6.29. The p-value of all sites are also presented in a Manhattan 
plot (Figure 6.30). These data showed no significant differentially methylated sites 
upon treatment with 500 nm or 1 M lisinopril or both concentrations combined, 
after adjustment for multiple testing. There was also no overlap between top sites for 
the two concentrations of lisinopril.  
Table 6.4 Top 10 most differentially methylated CpG sites after treatment with 
lisinopril 
10 most significant sites for lisinopril (combination of the two concentrations) 
No. CpG Sites Chr:Pos Gene name B p-value Adj. p-value 
1 cg14022645 X:48901405 TFE3 -2.16492 8.93E-07 0.324107 
2 cg19537719 8:41583498 ANK1 -2.19112 1.28E-06 0.324107 
3 cg12939390 2:45795647 SRBD1 -2.1936 1.33E-06 0.324107 
4 cg26947618 X:3908767 - -2.25557 2.89E-06 0.467394 
5 cg11969670 20:10340229 - -2.3315 6.65E-06 0.775992 
6 cg05894734 4:40859249 APBB2 -2.34716 7.79E-06 0.775992 
7 cg24020826 8:140630180 KCNK9 -2.35197 8.18E-06 0.775992 
8 cg14532111 3:197721245 LMLN -2.35735 8.62E-06 0.775992 
9 cg17114501 10:59066158 - -2.41114 1.44E-05 0.999994 
10 cg11566977 4:4860617 MSX1 -2.49091 2.86E-05 0.999994 
10 most significant sites for lisinopril 1 M 
No. CpG Sites Chr:Pos Gene name B p-value Adj. p-value 
1 cg26947966 4:40939389 APBB2 -2.50249 5.18E-06 0.999944 
2 cg26947618 X:3908767 - -2.50428 5.35E-06 0.999944 
3 cg14022645 X:48901405 TFE3 -2.51784 6.82E-06 0.999944 
4 cg22841810 8:25902284 EBF2 -2.54024 9.88E-06 0.999944 
5 cg25910443 9:97488953 C9orf3 -2.54095 9.99E-06 0.999944 
6 cg05894734 4:40859249 APBB2 -2.54771 1.11E-05 0.999944 
7 cg14785303 1:4119624 - -2.56691 1.48E-05 0.999944 
8 cg22413420 6:33360204 KIFC1 -2.57401 1.64E-05 0.999944 
9 cg07109453 1:234669825 - -2.57486 1.66E-05 0.999944 
10 cg19537719 8:41583498 ANK1 -2.58162 1.82E-05 0.999944 
10 most significant sites for lisinopril 500 nM 
No. CpG Sites Chr:Pos Gene name B p-value Adj. p-value 
1 cg19324996 16:50403566 BRD7 -2.74574 4.26E-07 0.241311 
2 cg18480726 9:6502746 UHRF2 -2.83196 5.37E-06 0.869976 
3 cg13027571 2:219081765 ARPC2 -2.84527 7.14E-06 0.926909 
4 cg00078861 5:154429562 - -2.85091 8.01E-06 0.926909 
5 cg22261880 15:42840643 HAUS2 -2.88674 1.56E-05 0.999652 
6 cg18709998 14:68283647 ZFYVE26 -2.89249 1.72E-05 0.999652 
7 cg17740179 2:40377776 SLC8A1 -2.89648 1.84E-05 0.999652 
8 cg06166187 9:13190292 MPDZ -2.9049 2.11E-05 0.999652 
9 cg15179725 18:35147079 BRUNOL4 -2.92141 2.74E-05 0.999652 









Figure 6.27 Top 10 most differentially methylated CpG sites after treatment with 500 nM lisinopril 










Figure 6.28 Top 10 most differentially methylated CpG sites after treatment with 1 M lisinopril 









Figure 6.29 Top 10 most differentially methylated CpG sites after treatment with both concentrations of lisinopril 





Figure 6.30 Manhattan plot of lisinopril treated cells vs control 
The Manhattan plot shows no CpG site with epigenome wide significance for cells 
treated with (A) lisinopril 500 nM, (B) lisinopril 1 M, (C) lisinopril, both 
concentrations combined. Blue line: suggestive cut-off, arbitrarily set at p<5e-05, red 




6.2.6.3 Analysis using R package, MulCom 
Comparison between the two group of lisinopril treated cells with untreated cells 
was done by a modified Dunnett’s t-test from the R package MulCom, which was 
specifically designed to handle multiple comparisons against one control group. This 
package enables fine-tuning of fold-change and optimisation of test parameters to 
maximise the number of significant hits (Isella et al., 2011). This analysis compared 
the methylation profile of cells treated with the two concentrations of lisinopril and 
generated a list of significant CpG sites for each group. It resulted in 37 significant 
CpG sites for lisinopril 500 nM and 32 CpG sites for lisinopril 1 M (Table 6.5), with 
four overlapping CpG sites between them (Figure 6.31).  
Table 6.5 Significant differentially methylated CpG sites by lisinopril as analysed by R 
package, MulCom 
lisinopril 500 nM* 
No. CpG Gene name Chromosome 
1 cg13910822 COL5A1 9 
2 cg07810469 - 4 
3 cg23164183 C5orf38 5 
4 cg18158385 CNN 1 
5 cg18026227 LOC100192378;ZFHX4 8 
6 cg14109822 RAPGEF1; 9 
7 cg18106045 - 6 
8 cg03212480 TMCC2 1 
9 cg27090306 LINC01214 3 
10 cg09146629 PHC3 3 
11 cg08265451 - 8 
12 cg18480726 UHRF2 9 
13 cg00403186 - 1 
14 cg21895314 - 21 
15 cg18979423 ATF6B 6 
16 cg02366400 CD44 11 
17 cg16734734 POPDC3 6 
18 cg26570716 CFAP221 2 
19 cg09561367 LINC00457 13 
20 ch.15.415873F INO80 15 
21 cg12424249 MIR1268A 8 
22 cg01507639 - 4 
23 cg20827329 - 14 
24 cg20815371 PPP3CC 8 
25 cg15888274 - 7 
26 cg05168368 - 6 
27 cg24526587 PBX1 1 




Table 6.5 Significant differentially methylated CpG sites by lisinopril as 
analysed by R package, MulCom – continued 
lisinopril 500 nM* - continued 
No. CpG Gene name Chromosome 
29 cg03583084 SMAD5-AS1 5 
30 cg09584060 LINC01435 10 
31 cg15006455 SMARCC1 3 
32 cg13216946 FOXI1 5 
33 cg04544267 - 7 
34 cg19324996 BRD7 16 
35 cg04853129 TSPAN15 10 
36 cg01849603 - 4 
37 cg01840665 GALNT8 12 
lisinopril 1 M 
No. CpG Gene name Chromosome 
1 cg11566977 MSX1 4 
2 cg27196695 INPP5A 10 
3 cg21641817 ZAK 2 
4 cg18106045 - 6 
5 cg05039382 DOCK5 8 
6 cg10877247 OCA2 15 
7 cg09146629 PHC3 3 
8 cg01692968 - 9 
9 cg21926451 ADAMTS16 5 
10 cg27021765 - 1 
11 cg04908669 - 2 
12 cg23921367 - 1 
13 cg17853132 - 13 
14 cg14801158 ZNF506 19 
15 cg09561367 LINC00457 13 
16 cg01507639 - 4 
17 cg17740850 USP40 2 
18 cg04103291 ZNF680 7 
19 cg06254044 C11orf65 11 
20 cg26947966 APBB2 4 
21 cg11937920 UACA 15 
22 cg22012079 IFI44L 1 
23 cg17446583 BCAT1 12 
24 cg10948471 MAP3K13 3 
25 cg20107184 GPR110 6 
26 cg12939390 SRBD1 2 
27 cg19786285 - 13 
28 cg02095324 - 11 
29 cg02947456 - 11 
30 cg16576302 TOP2B 3 
31 cg24771684 - 4 
32 cg25432392 DNAJC19 3 





Figure 6.31 Four significant CpG sites after treatment with both concentrations of 
lisinopril, as analysed by R package, Mulcom 
Figure shows four CpG sites that showed significant differentially methylation change 
by both concentrations of lisinopril 
 
6.2.6.4 Analysis of DNA methylation effect of lisinopril by BSAS 
Validation of 76 CpG sites from five loci (C10orf108, CXCR3, YWHAQ, SLC12A5, 
JMJD1C) selected from the clinical sample results (Section 6.2) and nine loci 
(MAP3K13, cg18106045, cg01507639, BRD7, ZNF506, APBB2, CD44, GRIK3, and 
mir1268A) selected from the results of the effect of lisinopril on DNA methylation in 




Comparing the six CpG sites from five loci for the clinical sample results, the 
methylation profile of cells treated with 1 M lisinopril generally reflected the 
direction of methylation changes in the clinical samples. One exception was apparent 
in cg12875534 in CXCR3 locus, where data from clinical samples showed decreased 
methylation level with ACEi treatment while Jurkat cells treated with lisinopril 
showed increased methylation level, shown by both EPIC array and BSAS results. The 
results with 500 nM lisinopril did not show a linear change with the higher dose in 
most of the CpG sites. The direction of methylation change was similar between EPIC 
array and BSAS for all CpG sites, however, none of these sites showed significant 
methylation differences between lisinopril treated and untreated cells, when 
analysed using either EPIC array or BSAS (Figure 6.32). 
Comparison between methylation level obtained from the EPIC array and BSAS 
analysis for the nine CpG sites from cell culture work showed inconsistent results. 
CpG sites in BRD7, GRIK3, and mir1268A showed a similar direction of change 
between EPIC array and BSAS, while in other CpG sites the changes were in the 
opposite direction. None of these CpG sites showed significant differences between 










Figure 6.32 Comparison of EPIC array (clinical samples), EPIC array (cell culture), and BSAS (cell culture) for six CpG sites 
No CpG site showed significant methylation change with p-value <0.05 between lisinopril treated cells and untreated cells in the cell 





Figure 6.33 Comparison of methylation level change by lisinopril by EPIC array and 





Figure 6.32 (cont.) Comparison of methylation level change by lisinopril by EPIC array 
and BSAS analysis in nine CpG sites 
None of the CpG sites showed adjusted p-value <0.05  
 
As BSAS can interrogate the methylation level in all CpG sites contained in the 
amplicons, observation was extended to all the other CpG sites present in the 
amplicons of the 14 loci included in BSAS. Only three CpG sites showed significant 
methylation difference between lisinopril treated and untreated cells after 
adjustment for multiple testing (Figure 6.34 to Figure 6.41). One of them was 
cg01507639, and the other two were in the MAP3K13 locus. However the 
methylation change in cg01507639 apparent in BSAS was in the opposite direction 
from those found through EPIC array analysis.  
As for MAP3K13 locus, the designed amplicon contained three CpG sites, one of them 
was cg10948471 which was the CpG site identified through EPIC array to be 
differentially methylated upon treatment with lisinopril. However, BSAS showed 
significantly different methylation levels not in this particular CpG site but in the two 
other CpG sites in this locus, after treatment with 500 nM lisinopril, but not with 1 
M lisinopril (Figure 6.41). These two CpG sites were located ~130 bp and ~50 bp 






Figure 6.34 Methylation profile of lisinopril treated cells vs control in the JMJD1C, 
SLC12A5, and YWHAQ loci as analysed by BSAS 
Lisinopril did not result in significant methylation change in any CpG site in the JMJD1C, 






















Figure 6.35 Methylation profile of lisinopril treated cells vs control in the CXCR3 locus 
as analysed by BSAS 
Lisinopril did not result in significant methylation change in any CpG site in the CXCR3 





























Figure 6.36 Methylation profile of lisinopril treated cells vs control in the C10orf108 
locus as analysed by BSAS 
Lisinopril did not result in significant methylation change in any CpG site in the 






























Figure 6.37 Methylation profile of lisinopril treated cells vs control in the CD44 locus 
as analysed by BSAS 
Lisinopril did not result in significant methylation change in any CpG site in the CD44 






























Figure 6.38 Methylation profile of lisinopril treated cells vs control in the GRIK3 locus 
as analysed by BSAS 
Lisinopril did not result in significant methylation change in any CpG site in the GRIK3 






































Figure 6.39 Methylation profile of lisinopril treated cells vs control in the ZNF506 
locus as analysed by BSAS 
Lisinopril did not result in significant methylation change in any CpG site in the 
































Figure 6.40 Methylation profile of lisinopril treated cells vs control in the APBB2, 
BRD7, cg01507639, cg18106045, and mir1268A loci as analysed by BSAS 
Lisinopril did not result in significant differentially methylation change in any of these 
CpG sites except for cg01507639 between control and cells treated with lisinopril 500 























Figure 6.41 Methylation profile of lisinopril treated cells vs control in the MAP3K13 
locus as analysed by BSAS 
Lisinopril resulted in significant methylation change at position Chr3:185002038 and 
Chr3:185002858 after treatment with lisinopril 500 nM. P = adjusted p-value 
 
6.2.6.5 Analysis of global methylation effect of lisinopril from the EPIC array 
data 
As done with analysis of NNK treated cells (Section 6.2.5.3), combination of beta 
values was used to estimate the global methylation changes between lisinopril 
treated and untreated cells.  Using the whole ~800,000 filtered CpG sites, t-test 
showed no significant difference between cells treated with either concentration of 
lisinopril and control cells. However, if testing was performed on only the 1000 most 
differentially methylation CpG sites as generated using topTable, the data showed 
significantly higher methylation value in the lisinopril treated cells compared to 
untreated cells. The changes induced by both concentrations of lisinopril were in the 





Figure 6.42 Global methylation difference between lisinopril treated and control cells 
Figures show (A) global Methylation change using beta values from the whole 
~800,000 CpG sites and (B) methylation change using beta values from the top 1000 
most differentially methylated CpG sites.  
6.3 Discussion 
In this chapter, experiments to study the effect of therapeutic substance on DNA 
methylation, focusing on the ACE inhibitor lisinopril, were described. Two 
approaches to this question were attempted. In the first approach, the methylation 
profile of subjects taking ACE inhibitor was compared to subjects not taking the drug. 
These subjects were part of the control group of another cohort that studied DNA 
methylation markers in individuals with abdominal aortic aneurysm. This control 
group consisted of healthy individuals in regards to cardiovascular disease, although 
they were affected by other morbidities such as hypertension or diabetes, and half of 




Methylation profile from these individuals was obtained from DNA extracted from 
blood. ACEi inhibits the ACE enzyme in various tissues and is also present in 
circulation. The blood DNA methylation profile has also been shown to act as a good 
surrogate marker to predict methylation profile in other tissues such as 
atheroschlerosis plaque, brain, or adipose tissue (Declerck & Vanden Berghe, 2019; 
Huang et al., 2016; Liu et al., 2019). Moreover, the potential DNA methylation effect 
of ACEi might be not related to its function in inhibiting ACE, and blood serves as a 
suitable sample for this explorative work.  
Although average age did not vary between the two groups, correction was made to 
avoid confounding effects of age in addition to correction to different composition of 
cell types to methylation levels in individuals. Several putative CpG sites on 
chromosome 10 that appeared to demonstrate differential methylation in response 
to lisinopril treatment were identified, with one of them remaining significant after 
adjustment for multiple testing. However, as this group was confounded by other 
factors (hypertension, diabetes, statin consumption) as well as variability in the type 
and length of ACE inhibitor consumption, a second approach was developed to 
directly test the hypothesis that ACEi exposure leads to altered methylation patterns. 
For this approach, a cell culture model using Jurkat cell line was established.  
Two different methods to assess DNA methylation levels were applied in this 
experiment, which were genome-wide methylation array (EPIC array) analysis, and 
the more selective approach of BSAS. EPIC array assessed a total of 863,904 probes, 
almost double the number of probes covered by the previous version of array (450K 
array). It provides 400K new probes targeting enhancers and other regulatory 
regions. In relation to genes, the probes in the EPIC array are located in promoters 
(54%), gene bodies (30%), and intergenic regions (16%) (Zhou et al., 2017).  
Approximately 30K probes from the 450K array reported to be less reliable (Naeem 
et al., 2014) were removed in the EPIC array. The methylation data from methylation 
array has been reported to be highly reproducible and also correlates well with the 
method of whole genome bisulfite sequencing (Pidsley et al., 2016).  
Several reports have identified poorly performing probes due to cross-reactivity or 
overlapping with common genetic polymorphisms (Chen et al., 2013; Pidsley et al., 




updated list in the recent report focusing on EPIC array (Pidsley et al., 2016). One of 
the top CpG sites identified in the clinical sample dataset (which was based on data 
from the 450K array), cg10322879 in YWHAQ, was one of the probes filtered out in 
the EPIC array dataset of the cell culture experiment. This CpG site overlaps a genetic 
polymorphism that can affect the binding of methylated/unmethylated probes in the 
methylation array. 
BSAS is a short read bisulfite-amplification-based method to interrogate multiple loci 
simultaneously through massively parallel sequencing. For each locus, BSAS is able 
to interrogate all CpG sites contained in the particular amplicon. By using sample 
barcodes, BSAS also enables analysis of up to 96 samples simultaneously, making it a 
cost-effective approach to study multiple targets in multiple samples.  Primer design 
is an important part in BSAS analysis to minimise PCR bias. A uniform amplicon size 
for all targets is also essential to simplify the pooling process and to ensure all 
amplicons are present in equimolar amount to achieve desirable read depth, usually 
more than 1000x (Masser et al., 2015).  
The accuracy of bisulfite sequencing in detecting DNA methylation changes will be 
influenced by the convertion rate of non-methylated cytosine to thymine. Sanger 
sequencing of several PCR products after bisulfite conversion prior to BSAS showed 
that all non-CpG cytosines have been converted to thymine, confirming the complete 
bisulfite conversion (Figure 6.43).  
 
Figure 6.43 Complete conversion of all non-CpG cytosines to thymines 
Figure shows Sanger sequencing results of two bisulfite PCR in two genes,  c10orf108 in 
top figure, and JMJD1C in bottom figure. All non-CG cytosines were converted to 





For the cell culture model, two methylation controls were used. First, DAC -a cytosine 
analog- was used as a positive control for hypomethylation effects. During DNA 
replication, DNMT1 adds a methyl group to cytosine of the newly synthesised DNA to 
maintain the methylation mark of the parent DNA. However, when DAC is present, it 
can be used as a substrate in place of cytosine during DNA replication. DNMT1 cannot 
add a methyl group to this azacytosine, and methylation prints will be lost in the 
newly synthesised DNA. Data in this study demonstrated that exposure of Jurkat cells 
to 0.1 M DAC for 48 hours induces approximately 50% reduction in methylation 
level across all CpG sites being investigated, which was as expected and suggested 
that this in vitro exposure model was able to detect hypomethylation.  
Second, NNK was used as a hypermethylation control, as it has been reported to 
increase the expression of DNMT1. However, treatment of Jurkat cells with 300 M 
NNK for 48 hours did not result in significantly increased methylation levels at any 
of the sites contained in the EPIC array. The previously reported studies were mainly 
focused on lung cells and the effect of NNK on immune cells (such as Jurkat) might be 
less prominent. When comparison was done on the top1000 most differentially 
methylated CpG sites in combination, NNK treated cells showed significantly higher 
methylation value compared to untreated cells (Figure 6.26). This suggests that while 
no specific CpG site showed significant change upon treatment with NNK, there was 
potentially a cumulative effect, and the site-specific methylation value might become 
significant when a higher dose and longer exposure of NNK were used in this cell 
type. For future experiments, it would be worth evaluating these effects with higher 
doses or longer exposure to NNK. 
For ACEi, cells were treated with two concentrations of lisinopril. Both lisinopril 
concentrations used in this study reduced endogenous ACE activity in media 
supplemented with 20% FBS to below the detection level of the ACE activity 
measurement (≤3 U/L) (Section 6.2.2.2). Jurkat cells were reported to have ACE 
activity of approximately 20 units/mg of protein and expressed relatively high ACE 
mRNA (Costerousse et al., 1993). However, the levels of ACE activity measured for 
Jurkat cells during the experiment in this thesis were below the limit of detection of 




Treatment of Jurkat cells with lisinopril at 500 nm and 1 M concentrations 
demonstrated no significant effect on differential methylation, as assessed using the 
DNA methylation EPIC array by R package limma. MulCom analysis of the EPIC array 
data showed some potential differentially methylated CpG sites, however most of 
these findings were not confirmed by BSAS. BSAS showed that 500 nM lisinopril 
increased methylation level in cg01507639 and in two of the three CpG sites in the 
MAP3K13 locus. MAP3K13 codes for the Mitogen-Activated Protein Kinase 13, which 
is involved in the JAK signalling pathway, and activates the transcription factor, 
nuclear factor kappa B. However, exposure to 500 nM lisinopril only increased the 
methylation level by approximately 5% and the biological relevance of this small 
change, if any, is unclear.  
Global methylation change assessed by using the whole ~800,000 probes did not 
show significant methylation differences upon treatment with lisinopril. However, 
data from the top 1000 most differentially methylated CpG sites showed higher levels 
of methylation both with 500 nM or 1 M lisinopril. The same direction of change 
with both doses suggested a potentially cumulative and widespread effect, as for 
NNK. However, the magnitude of change was very small (<2%), and the biological 
consequences of this modest difference are unclear.  
There are some limitations of this tissue culture assay. Firstly, Jurkat cells were 
exposed with both concentrations of lisinopril for only 6 days, while ACE inhibitors 
are usually taken by patients for a life-long period, unless occurrence of side effects 
or lack of efficacy warrants a drug substitution. However, the particular interest of 
this thesis is in the potential contribution any effect ACEi might have on DNA 
methylation, on the occurrence of an ADR of this drug, angioedema. Many cases of 
this ADR occur within a week after starting the drug (Sabroe & Black, 1997), giving a 
rationale for exploration of changes in vitro with only a short window of drug 
exposure. This study showed little evidence of DNA methylation changes upon 
treatment with lisinopril, but it remains unknown whether exposing the cells either 
to a higher concentration or for a longer period would more clearly impact on DNA 
methylation patterns. This would be worth examining in future experiments.  A 
second limitation of this work is that this experiment was carried out solely in Jurkat 




other cell types, so future work could also include examination of effects in an array 
of cell lines.  
6.4  Conclusions 
The preliminary investigation on clinical samples showed a potential association 
between consumption of ACEi and differential methylation at several CpG sites. 
However, this cohort of clinical samples was confounded by other factors, and this 
result requires further validation. A cell culture model was established to directly 
study DNA methylation effects of therapeutic substances, with a focus on lisinopril, a 
commonly used ACEi. The experimental design included exposure to two control 
substances with prior reports of methylation impacts. Exposure of Jurkat cells to 
DAC, a known hypomethylation agent, resulted in 50% reduction in methylation level 
across all loci investigated. However, NNK, as a hypermethylation control, did not 
result in any significant differential methylation in any CpG sites in this cell culture 
model. 
The differentially methylated CpG sites found in clinical samples upon ACEi 
consumption were not replicated in the in vitro study using Jurkat cells exposed with 
low and high dose of lisinopril. Analysis using R package limma of the genome wide 
CpG methylation after treatment with lisinopril did not generate evidence of any 
significant differential methylation. However, analysis with the R package MulCom 
resulted in several significant CpG sites. Among these was cg10948471 in the 
MAP3K13 that showed ~10% increase in methylation level after treatment with 1 M 
lisinopril. BSAS did not validate this finding, although it did demonstrate an 
approximately 5% increase in methylation in two other CpG sites in the MAP3K13 
amplicon in samples treated with 500 nM lisinopril. These were two of the only three 
significant findings among the 76 CpG sites measured by BSAS in this study. Other 
than this finding, treatment with lisinopril showed little evidence of significant 
change in DNA methylation.  
The overall conclusion from this body of work is that if lisinopril does have effects on 
DNA methylation, they are subtle and difficult to detect. It therefore seems unlikely 
that DNA methylation changes by lisinopril would play a role in initiation of rapid-




Chapter 7 : General discussion 
 
This thesis consisted of two major topics related to pharmacogenetics. The first one 
was to develop methods based on the relatively novel nanopore sequencing for 
application in pharmacogenetics, and the second one was to determine the genetic 
basis of a rare ADR, namely angioedema induced by the commonly used ACEi. Related 
to this ADR, epigenetic involvement via DNA methylation was also explored. 
7.1 Application of nanopore sequencing in pharmacogenetics 
Drug responses are often affected by multiple variants in multiple genes, and 
detection of these variants using conventional approaches like Sanger sequencing or 
single PCR is both laborious and time-consuming. Extensive genotyping panels 
containing a high number of variants can be analysed in advanced instruments like 
next generation sequencers, or multiplex PCR-based technologies with bead-based 
or mass spectrometry detection (Klein et al., 2019; Pratt et al., 2010). However, these 
approaches require high-capital instrument costs, which are not always accessible 
by research/diagnostic laboratories, and many outsource their tests to other 
institutions, leading to delay in result delivery (Harper & Topol, 2012). Moreover, 
customisation of such genotyping panels might be difficult and expensive, as special 
primers or probes are needed. The MinION with its nanopore sequencing technology 
on the other hand is the smallest sequencing device to date. This tool can be 
purchased for only USD 1,000, and can be run using only a laptop, making it highly 
accessible by laboratories of any scale.   
Using this technology, I demonstrated that a targeted sequencing panel of 
pharmacogenetic variants based on multiplex PCR of short fragments was 
achievable, as described in Chapter 3. While the panel of variants included in this 
assay comprised variants associated with response to clopidogrel and warfarin, it can 
be easily accustomed to other panels of variants, as only ordinary primers are 
needed.  
At the time I started the application of nanopore sequencing in this thesis (mid 2016), 




reasonably high accuracy of 94% (Jain et al., 2017). An early experiment with 
reference samples generated accurate genotyping except for one variant. The use of 
1D chemistry with the same bioinformatics tools could not replicate this level of 
accuracy and generated many false genotypes. Without any further substantial 
change in the sequencing chemistry or device in the past three years, the 
improvement of accuracy was driven mainly by the refinement in bioinformatics 
tools available from both ONT and the research community (Table 3.15). Two main 
contributors were the introduction of Albacore v2 as basecalling tool and nanopolish 
as variant calling tool, which achieved the highest accuracy compared to other tools 
trialled in this thesis (Table 3.14). Later, another variant calling tool, Clairvoyante 
showed comparable accuracy with nanopolish, however nanopolish is still preferable 
as the quality score provided an indication of false positive variants.  
The ability of nanopore sequencing to read long single molecule DNA is also 
particularly advantageous in elucidating variants in a complex gene such as CYP2D6. 
CYP2D6 is one of the most important pharmacogenes, but because of extensive 
polymorphism, complex SV, and the presence of pseudogenes, it is technically 
challenging to analyse properly. Most analytical platforms for pharmacogenetics 
simply target panels of common key variants of the genes, and do not consider 
variation throughout the whole gene. Moreover, most methods also do not directly 
phase the variants to provide confident haplotype information. Unless total variation 
throughout CYP2D6 is assessed and phased, it is quite possible to misinterpret the 
haplotypes, and assign incorrect functional scores. 
In Chapter 4, I demonstrated that nanopore sequencing of the whole CYP2D6 gene 
produced reasonably accurate variants, which, most importantly, could be 
confidently phased and haplotypes could be rapidly and accurately assigned (Table 
4.6). False positive variants still existed, but were easily removed from the variant 
calls based on the quality value in nanopolish generated VCF files. These false 
positive variants included variants in homopolymer regions and transition variants. 
False negative variants were also present to a lesser extent, mainly due to variants 
creating a homopolymer string. Recognition of false negatives was less 




introduction of the new pore R10 in late 2019 will likely resolve most of these 
inaccuracies, but this was not tested during this thesis research. 
The determination of the duplicated allele of CYP2D6 is particularly important in 
samples with heterozygote haplotypes of functional and non-functional alleles. Gene 
duplication of functional alleles of CYP2D6 can increase the enzyme activity by two-
fold, while duplication of non-functional alleles has minimum effect, therefore, the 
determination of the duplicated allele is important to provide an accurate phenotype 
prediction. By comparing allele depth, the nanopore sequencing method was capable 
of determining the duplicated allele, which was confirmed by the sequencing of a 8.6-
kb fragment, amplified from the duplicated copy of the gene (Table 4.7). However, 
limitation in sequencing complex SV such as hybrid genes was recognised from this 
work. These hybrid genes will need either amplification using other sets of primers, 
or a novel non-amplification method.  
Recently, targeted nanopore sequencing using CRISPR/Cas (Hafford-Tear et al., 
2019; Slesarev et al., 2019) or computational enrichment (Kovaka et al., 2020; Payne 
et al., 2020) has been demonstrated. The first method cleaves regions of interest 
using CRISPR/Cas and ligates sequencing adapters only to these regions, thus 
enables selective sequencing of regions of interest up to 100 kb (ONT, 2019c). The 
computational enrichment uses a bioinformatic algorithm to reject from the 
nanopores any DNA molecules that do not fall into pre-selected target regions, during 
the sequencing run, thus enriching for pre-defined targeted regions. These two 
approaches can cover an entire gene and detect all variants, and in addition to point 
mutations and small indel, they will also permit interrogation of more complex gene 
rearrangements such as hybrid genes. Moreover, as these methods do not need prior 
amplification, other information including base modification is attainable. Although 
the cost of these approaches are still relatively high due to the inability to include 
multiple samples in one flow cell, strategies to barcode samples might be available in 
the future and these can be an effective methods to sequence genes such as CYP2D6.  
Multi-variant panels or whole gene sequencing based on amplification as shown in 
this thesis were combined with sample barcoding, enabling a cost-effective 
genotyping of up to 96 samples in one run. The introduction of the smaller scale, 




achieve optimal cost-effectiveness. Furthermore, automatic sample preparation such 
as VolTRAX (ONT, 2019e) opens up the opportunity for point-of-care sequencing. 
Further improvement in accuracy as well as simplification in data analysis will be 
essential in realising this approach for clinical use.  
7.2 Genetic analysis of ACEi-A 
ACEi-A is a rare but serious ADR caused by a class of drugs with millions of 
prescriptions every year, leading to a significant number of cases. It was thought to 
have genetic predisposition due to the increased risk in certain populations. 
Moreover, the hereditary form of angioedema with five associated genes has been 
recognised. However, more than 30 years after the first record of this ADR (Jett, 
1984), the genetic causes have yet to be elucidated. Previous genetic reports on this 
ADR were based on either GWAS or small case-control studies with only a handful of 
genes, meaning that investigations have been limited by pre-selected common 
variants. Moreover, none of these previously reported variants were significantly 
enriched in theACEi-A cohort in this thesis. Genetic analysis in 20 cases of ACEi-A by 
WES/WGS was described in Chapter 5 with the aim to find rare variants enriched in 
the samples, thus potentially associated with the ADR.  
The WES/WGS analysis on ACEi-A in this thesis did not find a single strong candidate 
variant that was rare and highly enriched in the ACEi-A samples. However, a number 
of candidate variants moderately enriched in the WGS - ACEi-A dataset (in at least 
three of the ACEi-A samples) were found. Several of the genes bearing the variants 
showed interaction with one another and were enriched in certain biological 
pathways. Given the high number of the shortlisted variants (130 variants in 98 
genes), further research will be required to validate the association of these variants 
with ACEi-A. In addition, due to the limitation of short read-based sequencing in 
deciphering complex genes, this study also has not looked into the potential role of 
different HLA alleles on the risk of ACEi-A. Aspirin induced angioedema/urticaria has 
previously been linked to certain HLA alleles (Kim et al., 2006). Interrogation of HLA 
alleles through other methods such as nanopore sequencing (Liu et al., 2018) or from 
WGS dataset using computational approaches (Bauer et al., 2016) could be 




The results from this thesis suggested that ACEi-A might not arise from a single 
genetic cause. Instead, many other scenarios of genetic contribution to this ADR 
await investigation. These include investigation of this ADR as a multi-genic trait or 
as a diverse group of different phenotypes arising from different genetic causes. 
ACEi-A varies in terms of onset, sites and severity, and these phenotypic diversities 
might arise from different genetic alterations. The small number of samples in this 
study prohibited me from investigating these different phenotypes separately. Also, 
most samples were collected retrospectively, and participants’ phenotypic features 
including the onset of ACEi-A, consumption of other drugs, or other conditions that 
might induce the reactions were based on the participants’ recollection. Such 
information can suffer from recall or perception error. Moreover, for most 
participants, information on the onset of the ADR simply stated that it occurred years 
after the starting of the drug, without any details on the exact time and whether there 
were dose changes or other drugs added prior to the reaction. A more detailed and 
accurate phenotypic information would be valuable to better characterise this ADR 
and to enable group-specific genetic analysis in future studies, preferably with higher 
number of samples.  
Other areas of future investigations include the possibility that the genetic 
contributors lie in the currently non-accessible regions of the genome based on short 
read sequencing or in polymorphisms or mutations other than single point variants, 
such as CNV or other SV, not yet fully investigated in this thesis.  
The recent discovery of many novel SV by long read sequencing (Audano et al., 2019; 
Beyter et al., 2019) offers a new insight on the unexplored impact of structural 
variation on human diseases as well as drug responses. However, the analysis of SV 
is still challenging with short read sequencing and the cost of genome-wide long read 
sequencing still being high. Development of tools to improve comparison of SV in 
multiple samples and large, curated, publicly accessible databases will be helpful to 
drive the exploration of SV in pharmacogenetics and human diseases in general. 
Future studies applying strategies to predict the combination effect of variants in two 
or more genes towards this ADR might also be beneficial. Machine learning tools such 
as Variant Combination Pathogenicity Predictor (VarCoPP) (Papadimitriou et al., 




(ORVAL) (Renaux et al., 2019) to analyse combination effect of more than two 
variants have been described. However, these tools were designed to analyse 
variants in a single patient in relation to genetic diseases, and the application of these 
tools to study ADRs in a cohort of samples needs further investigation. 
Current WES/WGS are done mainly using short read NGS. In this thesis, WES was 
performed on Ion Torrent and WGS on Illumina platform. The high read accuracy 
(>99%) combined with the decreasing cost of these technologies make them a 
preferable method, although several limitations have been identified. Approximately 
10% of the genome is found to be difficult or not reliably sequenced using this 
technology (Laurie et al., 2016), including repetitive sequences and some important 
pharmacogenetic-related genes such as HLA or CYP2D6. For example, during the WGS 
analysis, I found multiple variants in ARSD, which initially looked promising. 
However, the fact that all the variants were present in male samples, and that ARSD 
has a pseudogene in chromosome Y with 91% sequence identity, indicated that these 
were very likely false positive variants. More than 10,000 pseudogenes have been 
reported (Pei et al., 2012), and unlike ARSD pseudogene that can be revealed by the 
sample gender, most of these will potentially cause unrecognised erroneous variants. 
Limitations of short read sequencing in pharmacogenetic applications have been 
reviewed (Schwarz et al., 2019). Some of these limitations can be potentially 
addressed by novel technologies such as nanopore sequencing. However, the overall 
error rates and the current cost of nanopore sequencing for WGS are still relatively 
high compared to the standard NGS. The improving accuracy and decreasing cost of 
nanopore sequencing in the future might drive this technology to complement short 
read sequencing to provide a more comprehensive WGS.  
7.3 Epigenetic analysis of ACEi-A 
In addition to genetic analysis, one approach to investigate epigenetic involvement 
in ACEi-A was explored in Chapter 6. Using data from both clinical samples and an in 
vitro cell culture model, the effect of ACEi on DNA methylation was examined. Data 
from clinical samples showed some putative DNA methylation change in 
chromosome 10, however this was not replicated in the in vitro study. The results 




of other medications. Although ACEi has shown little evidence of modifying DNA 
methylation, this does not exclude the role of epigenetics regulation in ACEi-A. Other 
mechanisms such as the inter-individual difference in DNA methylation level might 
contribute to the occurrence of ACEi-A. Moreover, ACE expression is altered by DNA 
methylation and other factors influencing an individual’s methylation status might 
contribute to alteration in ACE activity level and/or risk of ACEi-A.  
Clinical studies on epigenetic involvement in ADR are still limited. This is partly due 
to the dynamic feature of epigenetics that is subject to changes in physiological, 
pathological, or environmental factors. Therefore, an ADR biobank aiming for genetic 
studies that relies on retrospective sampling of DNA samples may not be well suited 
for epigenetic studies. Unlike genomic sequence that is stable over time, investigation 
of epigenetic regulation will be more effective using clinical sampling in a specific 
time-frame, for example, when the ADR occurs or very soon afterwards. 
An in vitro model can be a good alternative to study epigenetic regulation by drugs. 
The work in this thesis showed that Jurkat cells served the purpose as a model to 
study DNA methylation with the observation of a global decrease in methylation level 
caused by DAC exposure. Although there is little evidence of methylation change by 
the ACEi lisinopril, the cell culture model can be adopted to screen methylation 
changes caused by other drugs of interest. Screening for DNA methylation change by 
EPIC array is a sensitive and reproducible method covering up to ~3% of the total 
~28 million CpG sites in human genome, including promoter and enhancer regions 
(Pidsley et al., 2016). However, the cost of the assay is prohibitive in doing a high-
throughput screening on a panel of drugs. A more affordable method such as mass 
spectrometry of total methylated cytosine might be useful for an initial screening. 
This method can detect down to 5% change in global methylation change, however 
it does not provide information on specific CpG site levels (Kurdyukov & Bullock, 
2016). 
7.4 Concluding remarks and future directions 
The use of the highly accessible nanopore sequencing has proven to be advantageous 
for pharmacogenetic applications. The coming years will likely see increased use of 




future research, development of targeted sequencing using non-amplification 
approach such as CRISPR/Cas or computational enrichment for CYP2D6 to detect all 
possible complex structural variation and at the same time determine accurate 
haplotypes will provide a comprehensive analysis of the gene. This approach is also 
potentially useful to sequence other important pharmacogenes in a multi-target 
approach. It will especially be beneficial in elucidating the range of structural 
variants in other complex genes in pharmacogenetics including HLA, UGT, GST, SULT, 
and other CYP genes. Furthermore, this amplification-free method will also enable 
detection of base modification such as DNA methylation, which might provide further 
insight into the role of epigenetics in regulation of pharmacogenes.  
Application of nanopore sequencing using Flongle is also an area to explore, 
particularly in developing pharmacogenetic tests for clinical application. This smaller 
flow cell will allow for a cost-effective assay using only a small number of samples.  
Genetic analysis on a small cohort of 20 ACEi-A samples generated a list of potentially 
associated variants. Collecting more ACEi-A samples, or collaboration with 
colleagues in other centres who have collected such cases, will be important to 
further shortlist and validate these variants. Additionally, refining the phenotype 
information of the collected cases might shed light on the characteristics of this ADR 
and provide better guidance on the genetic analysis. Genetic analysis of ACEi-A in this 
thesis was based on the hypothesis that ACEi-A arose from a single variant/gene. 
Future study should also consider this ADR as a polygenic trait with more than one 
possible genes responsible for the ADR. Approaches or tools to detect combinations 
of variants/genes that contribute to a single phenotype will likely be beneficial. 
WGS/WES analyses in this thesis were done using short read sequencing, which still 
has limitation in certain regions of the genome (Ebbert et al., 2019). The CNV analysis 
was also limited to candidate genes. Exploration of currently non-accesible regions 
of the genome as well as more comprehensive CNV and other SV using novel 
technologies such as long read sequencing should also be considered.  
Another area to explore is to study the effect of the identified variants in relation to 
ACEi-A, for example the effect of rs4365 variant in ACE activity. This can be done in 
clinical samples from people with and without the variants or in cell culture model 




The work in this thesis did not find any DNA methylation changes upon lisinopril 
treatment. However, studies on other aspects of epigenetic regulation in association 
with ACEi-A or other ADRs are still scarce and should be considered in cases where 
genetic studies have been less successful. The risk of ACEi-A is affected by various 
environmental factors, therefore, future study studying the DNA methylation profile 
of ACEi-A cases at the onset of the reaction in comparison to the DNA methylation 
profile of matched controls might provide some link between environmental factors, 
epigenetics and ACEi-A.  
Lastly, the cell culture model developed in this thesis can be applied to study the DNA 
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Scripts in nanopore sequencing data analysis 
(Chapter 3 and 4) 
 
1. Basecalling  
A. Albacore 
read_fast5_basecaller.py --input /path to MinION raw reads/ --worker_threads 4 --
save_path /path to output directory/ --flowcell FLO-MIN107 --kit SQK-LSK108 --
output fast5 --recursive --barcoding --files_per_batch_folder 0 
B. Guppy 
guppy_basecaller --input /path to Minion raw reads/ --save_path /path to output 
directory/ --config dna_r9.4.1_450bps_flipflop.cfg -t 8 --qscore_filtering --min_qscore 
7 --records_per_fastq 0 --fast5_out --recursive --hp_correct on 
2. Fasta/fastq extraction (poretools) 
A. 2D reads 
poretools fastq --type 2D /path to albacore pass output/ barcode$i >  /path to output 
directory/barcode$i.fastq 
poretools fasta --type 2D /path to albacore pass output/barcode$i >   /path to output 
directory/barcode$i.fasta 
B. 1D reads 
Poretools fastq /path to albacore pass output/barcode$i” > /path to output 
directory/barcode$i.fastq 
poretools fasta /path to albacore pass output/barcode$i” > /path to output 
directory/barcode$i.fasta 
3. Demultiplexing (when using guppy as basecaller) 
porechop-runner.py -i /path to fastq file/ -b /path to output directory/ --
require_two_barcodes 
#this will output a fastq file for each barcode, as well as all non-barcoded one into 
one fastq file.  
#if guppy output more than 1 fastq file, merge all fastq files into one fastq file: 





4. Quality filtering - NanoFilt 
#Gzip fastq file from each barcode 
Gzip /path to fastq file/ > ….fastq.gz 
gunzip -c /path to fastq.gz file/ | NanoFilt -q 7 -l 6000 | gzip >/ path to output fastq.gz 
file/" 
5. Alignment 
A. BWA MEM 
Bwa index /path to Reference file/ 
Bwa mem –x ont2d /path to fasta or fastq directory/barcode$i.fasta or fastq > /path 
to SAM output directory/barcode$i.sam 
bwa mem -x ont2d -t 4 /path to Reference file/ /path to fastq 
directory/barcode$i.fastq | samtools sort -o /path to bam output 
directory/barcode$i.sorted.bam -T /path to fastq directory/barcode$i.tmp – 
B. Graphmap 
graphmap align -r /path to reference file/ -d /path to fasta or fastq 
directory/barcode$i.fasta or fastq -o /path to SAM output directory/barcode$i.sam 
C. Minimap2 
minimap2 -d ref.mmi ref.fa  
minimap2 -ax map-ont -t 4 /path to ref.mmi/ /path to fastq file/ --secondary=no | 
samtools sort -@8 -o /path to bam file/ 
D. NGMLR 
ngmlr –t 4 –r /path to ref.fa/ -q /path to sample.fastq/ -o /path to sample.sam/ -x ont 
E. Samtools 
Samtools view –T /path to reference file/ –bS /path to SAM output 
directory/barcode$i.sam | samtools sort –o /path to bam output 
directory/barcode$i.sorted.bam  
Samtools index /path to bam output directory/barcode$i.sorted.bam 
6. Variant calling 
A. MarginCaller 
/path to MarginAlign Directory/marginCaller /path to SAM output 
directory/barcode$i.sam /path to Reference file /path to VCF output 
directory/barcode$i.vcf --threshold 0.2 --jobTree ./jobTree 
(jobTree file created after the run should be manually deleted before calling the VCF 
file for other sample) 
B. Varscan2 
samtools mpileup -B -f /path to Reference file  /path to BAM 




mpileup2cns --variants --output-vcf --min-var-freq 0.20 --min-freq-for-hom 0.55 > 
/path to VCF directory/barcode$i.vcf" 
vcftools --vcf /path to VCF directory/barcode$i.vcf --positions /path to Text file 
containing SNP position --recode --out /path to filtered VCF 
directory/barcode$i.filtered.vcf" 
C. Nanopolish (version 0.9 and 0.10) 
When using albacore version 1 or older, do an extraction  
nanopolish extract --type any (for 1D) or -- type 2D (for 2D)-d /path to albacore 
output/barcode$i/ > /path to output directory/barcode$i.fasta” 
When using albacore version 2, do an indexing: 
nanopolish index -d /path to Minion Raw Reads/ -s /path to sequencing_summary.txt 
generated by Albacore /path to output directory/barcode$i.fastq” 
nanopolish variants -r /path to output directory/barcode$i.fastq" -b /path to BAM 
directory/barcode$i.bam -g /path to Reference file/ -t 4 --min-candidate-frequency 
0.2 -w Reference_contig --ploidy 2 -o /path to VCF directory/barcode$i.vcf -d 10 
D. Clairvoyante 
/path to pypy/ callVarBam.py --ref.fn /ref.fa/ --bam_fn /sample.bam/ -chkpnt_fn 
/fullv3-ont-ngmlr-hg001-hg19/learningRate1e-3.epoch999.learningRate1e-
4.epoch1499/ --sampleName arg --threshold 0.25 –minCoverage 4 > commands.sh –
pypy /path to pypy/ --call.fn /sample.vcf/ --ctgName Reference_contig 
7. Quality control and statistics 
 
A. NanoOK 
export NANOOK_DIR=/path to your NanoOK directory/ 
#NanoOK Extract (2D) 
nanoOK extract -s /Path to output directory/ -f /path to Fast5 Directory/  -t 4 
#NanoOK Extract (1D) 
nanoOK extract -s /Path to output directory/ -f /path to Fast5 Directory/ -
templateonly -t 4 
NanoOK Align 
nanoOK align -s /Path to output directory/ –r /path to Reference File/-aligner bwa -
t 4 
NanoOK Analysis (2D) 
nanoOK analyse -s /Path to output directory/ –r /path to Reference File/  –passonly 
-aligner bwa -t 4 
NanoOK Analysis (1D) 
nanoOK analyse -s /Path to output directory/ –r /path to Reference File/ –passonly 






qualimap bamqc -bam /path to bam directory/barcode$i.sorted.bam -outfile 
barcode$i.qualimap.pdf 
(output files would be written in bam directory) 
C. MinION QC (R) 
Define the input and output file in the minION_QC.R script 
input.file = /path to albacore sequencing_summary.txt/ 
output.dir = /path to designated output directory/ 
8. Variant phasing (CYP2D6) - WhatsHap 
pip3 install --user whatshap 
#will install in the home directory: .local/bin 
#set the path to the directory 
export PATH=$HOME/.local/bin:$PATH 
whatshap phase --reference /path to reference file/ -o /phased.vcf/ /path to vcf file/ 
/path to bam file/ --tag=PS --ignore-read-groups 
#to include indels; 
whatshap phase --reference "ref.fasta" -o sample.phased.vcf" “sample.vcf" 
"sample.sorted.bam" --tag=PS --ignore-read-groups –indels 
#for visualisation: 
whatshap haplotag -o /haplotag.bam/ --reference /path to ref.fasta/ /path to 
phased.vcf.gz/ /path to bam file/ 
#vcf file has to be in gz format, and indexed using tabix 
#if resulted in error: 
#Found 1 samples in VCF file 
#Samples in BAM file: 
#ERROR: No common samples between VCF and BAM file. Aborting. 
#Do: 
java -jar picard.jar AddOrReplaceReadGroups I=/path to original bam file/ O=/path 
to corrected bam file" RGLB=lib1 RGPU=barcode name (eg. BC10) RGSM=BC10 
RGPL=ONT 
#change sample name in the vcf file into barcode name 
#redo bgzip and tabix of the vcf file 








Scripts in bisulfite amplicon sequencing analysis 
(Chapter 6) 
 
1. Preparation of genome reference  
bismark_genome_preparation --verbose/path to reference directory/           
#reference sequence of each amplicon has to be longer than actual amplicon. Add NN 
to both ends of actual amplicon sequence 
2. Alignment of fastq reads to reference 
perl bismark /path to reference directory/ -q -1 /path to fastq 1/ -2 /path to fastq 2/ 
samtools view -bS /path to unsorted bam/ | samtools sort -o /path to output sorted 
bam/ 
samtools index /path to output sorted bam/ 
3. Extraction of methylation percentage in each CpG site 
bismark_methylation_extractor -p --no_overlap --bedGraph -- zero_based --count 











setwd(/path to working directory/) 
baseDir=(/path to working directory/) 
 











2. Quality control 
#call the detection p-value for the rgSet, and keep those with value >=0.01 
detP <-detectionP(rgSet_all) 
 
# remove poor quality samples 
keep <-colMeans(detP)<0.01 
dim(detP) 
[1] 866091      8 
rgSet_all <- rgSet_all[,keep] 
dim(rgSet_all) 
Features  Samples 





3. Preprocessing/normalisation  
mSetSq <-preprocessIllumina(rgSet_all, bg.correct=TRUE, normalize="controls", 
reference=2) 
# ensure probes are in the same order in the mSetSq and detP objects  
detP <- detP[match(featureNames(mSetSq),rownames(detP)),] 
# remove any probes that have failed in one or more samples  
keep <- rowSums(detP < 0.01) == ncol(mSetSq) 
table(keep) 
keep 
 FALSE   TRUE 
  1684 864407 
mSetSqFlt <- mSetSq[keep,] 
dim(mSetSq) 
Features  Samples 
  864407       16 
 
#Remove cross-reactive probes, etc (based on Pidsley 2016) 
xReactiveProbes <-
read.delim("/media/gsfl/Cen/Epic/EPIC_Working_Directory3/filters/13059_2016_
1066_MOESM1_ESM_crossreactiveprobes.txt",sep=",", head = T) 
> keep <- !(featureNames(mSetSqFlt)%in% xReactiveProbes$PROBE) 
> table(keep) 
keep 
 FALSE   TRUE 
 43127  821280 
mSetSqFlt <- mSetSqFlt[keep,] 
dim(mSetSqFlt) 
[1] 821280      16 
 





head = T) 






 FALSE   TRUE 
   359    820921 
dim(mSetSqFlt) 
[1] 820921      16 
 





> keep <- !(featureNames(mSetSqFlt)%in% OverlappedProbes2$PROBE) 
> table(keep) 
keep 
 FALSE   TRUE 
 10950   809971 
> mSetSqFlt <- mSetSq[keep,] 
> dim(mSetSqFlt) 
[1] 809971     16 
 
#Remove Probes with missing legacy CpG in EPIC array 
removeprobes<- 
read.delim("/media/gsfl/Cen/Epic/EPIC_Working_Directory/MethylationEPICMiss
ingLegacyCpG (v1.0_B3 vs. v1.0_B2).txt",sep="\t",as.is=T) 
keep <- !(featureNames(mSetSqFlt)%in% removeprobes $TargetID)  
table(keep) 
keep 
 FALSE   TRUE 
   204       809767 
mSetSqFlt <-mSetSqFlt[keep,] 
dim(mSetSqFlt) 
Features  Samples 
809767    16 
 
4. Get the M and beta value for the each treatment set 


































5. Make the model matrix, calculate the top100 or any other number 
#scripts below are for lisinopril 1 M. 
#for lisinopril 500 nM, change L1 to L5, for NNK, change to NNK, and for combined 









6. Annotate the top hits 
meth.anno<-
read.delim("/media/gsfl/Cen/Epic/EPIC_Working_Directory/annotation/Methylati






tt100_L1b<-merge(tt100_L1, tt100_L1a, by="row.names",all.x=TRUE, sort=FALSE) 
write.csv(tt100_L1b, file="tt100_L1b.csv") 
 














8. Calculate Global methylation / Average Top 1000 methylation 








 #Calculate average Top 1000 methylation status: 
tt1000_L1<-topTable(ebf_L1,coef=2,number=1000) 


















L1Opt<-mulParOpt(permutation, optimisation, ind=1,th=0.05) 
L5Opt<-mulParOpt(permutation, optimisation, ind=2,th=0.05) 
L1Probes<-mulDiff(betaL1_L5,permutation, m=0.03, t=3, ind=1) 
L5Probes<-mulDiff(betaL1_L5,permutation, m=0.03, t=3, ind=2) 
 
10. Manhattan plot 
R package: qqman 
library(qqman) 
#Controlgroup 
ACE_CONTROL = read.table("Y:/cen/acei-greg 
jones/ACE_control/ACE_Control_AgeCell.txt", header = TRUE, fill = TRUE) 
snpsOfInterest <- c("cg05585149","cg07469445","cg06492112","cg10322879",                   
"cg01459030",                   "cg12875534",                    "cg26344867",                    "cg15363973",                   
"cg12824952",                    "cg05523653",                    "cg16981259",                    "cg03021100",                    
"cg16543090",                    "cg26434653",                    "cg16516888",                    "cg23954066",                    
"cg02681173",                    "cg24443446",                    "cg09015232",                    "cg24816114",                    
"cg02711608",                    "cg00433159",                    "cg04487855",                    "cg01273287",                    




manhattan(ACE_CONTROL, highlight=snpsOfInterest, suggestiveline = -log10(5e-
05)) 
qq(ACE_CONTROL$P, ylim=c(0,10)) 
note: column name CpG has to be changed into “SNP” 
Chr X has to be changed into “Chr23” 
Chr Y has to be changed into “Chr24” 
MAP position has to be changed into “BP” 
Pvalue has to be changed into “P” 
EBF_L5<-read.csv("Y:/Cen/Epic/EPIC_Working_Directory3/EBF_L5.csv", header = 
TRUE, fill = TRUE) 





List of candidate genes for WES, WGS, and CNV analysis 
 
1. Bradykinin and/or substance P metabolism and receptor genes for WES 
and WGS analysis 
No. Gene Role 
1 ACE kinin degrading enzymes 
2 ACE2 kinin degrading enzymes 
3 CPN1 kinin degrading enzymes 
4 DPP4 kinin degrading enzymes 
5 MME kinin degrading enzymes 
6 CTSG kinin degrading enzymes 
7 CTSA kinin degrading enzymes 
8 ECE1 kinin degrading enzymes 
9 CMA1 kinin degrading enzymes 
10 ENPEP kinin degrading enzymes 
11 XPNPEP1 kinin degrading enzymes 
12 XPNPEP2 kinin degrading enzymes 
13 XPNPEP3 kinin degrading enzymes 
14 ANPEP kinin degrading enzymes 
15 CPM kinin degrading enzymes 
16 THOP1 kinin degrading enzymes 
17 LNPEP kinin degrading enzymes 
18 PREP kinin degrading enzymes 
19 PRCP kinin degrading enzymes 
20 BDKRB1 bradykinin receptor 1 
21 BDKRB2 bradykinin receptor 2 
22 TACR1 neurokinin 1 receptor 
23 TACR2 neurokinin 2 receptor 
 
2. Extensive candidate genes for WES and WGS analysis 
No. Gene Role 
1 ETV6 reported in GWAS 
2 PRKCQ reported in GWAS 
3 MME reported in candidate gene study 
4 CRB1 reported in candidate gene study 
5 XPNPEP2 reported variant 
6 BDKRB2 reported variant 
7 DPP4 reported variant 
8 TACR1 neurokinin 1 receptor 
9 TACR2 neurokinin 2 receptor 




11 ACE reported variant 
12 AT2R angiotensin receptor 2 
13 AT1R angiotensin receptor 1 
14 KNG1  Kininogen 
15 F5 reported variant 
16 SERPING1  hereditary angioedema 
17 F12  hereditary angioedema 
18 PLG hereditary angioedema 
19 ANGPT1 hereditary angioedema 
20 KLKB1  Kallikrein B1 
21 ANPEP kinin degrading enzymes 
22 ENPEP kinin degrading enzymes 
23 CTSA kinin degrading enzymes 
24 CTSG kinin degrading enzymes 
25 CMA1 kinin degrading enzymes 
26 CPM kinin degrading enzymes 
27 CPN1 kinin degrading enzymes 
28 ECE1 kinin degrading enzymes 
29 THOP1 kinin degrading enzymes 
30 LnPEP kinin degrading enzymes 
31 PREP kinin degrading enzymes 
32 PRCP kinin degrading enzymes 
33 IL1B regulation of B2R expression 
34 IL6 regulation of B2R expression 
35 IFNG regulation of B2R expression 
36 TNFA regulation of B2R expression 
37 NFKB1 regulation of B2R expression 
38 MAPK14 regulation of B2R expression 
39 JNK regulation of B2R expression 
40 GNAQ signalling pathway of B2R 
41 GNA11 signalling pathway of B2R 
42 GNA12 signalling pathway of B2R 
43 GNA13 signalling pathway of B2R 
44 GNA14 signalling pathway of B2R 
45 GNA15 signalling pathway of B2R 
46 PKC signalling pathway of B2R 
47 MAPK signalling pathway of B2R 
48 PLCB1 signalling pathway of B2R 
49 PLA2 signalling pathway of B2R 
50 NOS3 signalling pathway of B2R 
51 cAMP signalling pathway of B2R 
52 COX2 signalling pathway of B2R 
53 EGFR signalling pathway of B2R 




55 PDGFR signalling pathway of B2R 
56 ITPR3 signalling pathway of B2R 
57 HMOX1 Genes related to vasodilatation 
58 ADRB2 Genes related to vasodilatation 
59 NPPB Genes related to vasodilatation 
60 SMTNL1 Genes related to vasodilatation 
61 GPER1 Genes related to vasodilatation 
62 ADCY6 Genes related to vasodilatation 
63 NPR1 Genes related to vasodilatation 
64 AGTR1 Genes related to vasodilatation 
65 SOD2 Genes related to vasodilatation 
66 ADRB3 Genes related to vasodilatation 
67 ADRB1 Genes related to vasodilatation 
68 CRP Genes related to vasodilatation 
69 NOS2 Genes related to vasodilatation 
70 CALCA Genes related to vasodilatation 
71 CHGA Genes related to vasodilatation 
72 CPS1 Genes related to vasodilatation 
73 EPHX2 Genes related to vasodilatation 
74 PTGDR Genes related to vasodilatation 
75 F2RL1 Genes related to vasodilatation 
76 AGTR2 Genes related to vasodilatation 
77 NOS1 Genes related to vasodilatation 
78 ACE2 Genes related to vasodilatation 
79 SOD1 Genes related to vasodilatation 
80 INS Genes related to vasodilatation 
81 SCPEP1 Genes related to vasodilatation 
82 DENND1B candidate genes in one study' 
83 FCER1A candidate genes in one study' 
84 GSDMB candidate genes in one study' 
85 IL23R candidate genes in one study' 
86 RAD50 candidate genes in one study' 
87 STAT6 candidate genes in one study' 
88 LCEC3_LCECB_del candidate genes in one study' 
89 XPNPEP2 1 iobio genes-angiodema 
90 CPA1 iobio genes-angiodema 
91 KCNN4 iobio genes-angiodema 
92 COL9A3 iobio genes-angiodema 
93 SLC9A3 iobio genes-angiodema 
94 PRSS2 iobio genes-angiodema 
95 SLC7A9 iobio genes-angiodema 
96 COL5A1 iobio genes-angiodema 
97 KCNJ13 iobio genes-angiodema 
98 COL6A2 iobio genes-angiodema 




100 ATP1B4 iobio genes-angiodema 
101 KCNQ1 iobio genes-angiodema 
102 ATP1A4 iobio genes-angiodema 
103 CTRL iobio genes-angiodema 
104 ATP1A3 iobio genes-angiodema 
105 COL5A3 iobio genes-angiodema 
106 CELA3A iobio genes-angiodema 
107 SLC8A1 iobio genes-angiodema 
108 SLC8A2 iobio genes-angiodema 
109 SLC38A2 iobio genes-angiodema 
110 COL12A1 iobio genes-angiodema 
111 CPB1 iobio genes- angiodema 
112 ATP1B3 iobio genes- angiodema 
113 SLC3A2 iobio genes- angiodema 
114 KCNK5 iobio genes- angiodema 
115 COL27A1 iobio genes- angiodema 
116 CPA3 iobio genes- angiodema 
117 COL14A1 iobio genes- angiodema 
118 SLC16A10 iobio genes- angiodema 
119 PGA4 iobio genes- angiodema 
120 PRSS1 iobio genes- angiodema 
121 SLC1A1 iobio genes- angiodema 
122 SLC1A5 iobio genes- angiodema 
123 COL11A2 iobio genes- angiodema 
124 SLC15A1 iobio genes- angiodema 
125 COL7A1 iobio genes- angiodema 
126 CTRB1 iobio genes- angiodema 
127 PGA3 iobio genes- angiodema 
128 COL2A1 iobio genes- angiodema 
129 COL1A2 iobio genes- angiodema 
130 COL5A2 iobio genes- angiodema 
131 COL1A1 iobio genes- angiodema 
132 SLC6A19 iobio genes- angiodema 
133 COL6A5 iobio genes- angiodema 
134 MEP1A iobio genes- angiodema 
135 SLC36A1 iobio genes- angiodema 
136 SLC3A1 iobio genes- angiodema 
137 COL9A1 iobio genes- angiodema 
138 CPB2 iobio genes- angiodema 
139 ATP1B2 iobio genes- angiodema 
140 ATP1B1 iobio genes- angiodema 
141 CELA3B iobio genes- angiodema 
142 CELA2A iobio genes- angiodema 
143 COL6A1 iobio genes- angiodema 




145 SLC8A3 iobio genes- angiodema 
146 ATP1A1 iobio genes- angiodema 
147 FXYD2 iobio genes- angiodema 
148 COL4A3 iobio genes- angiodema 
149 COL22A1 iobio genes- angiodema 
150 COL17A1 iobio genes- angiodema 
151 COL24A1 iobio genes- angiodema 
152 COL21A1 iobio genes- angiodema 
153 PRSS3 iobio genes- angiodema 
154 COL3A1 iobio genes- angiodema 
155 COL11A1 iobio genes- angiodema 
156 COL4A1 iobio genes- angiodema 
157 COL13A1 iobio genes- angiodema 
158 SLC7A7 iobio genes- angiodema 
159 KCNE3 iobio genes- angiodema 
160 COL4A2 iobio genes- angiodema 
161 SLC7A8 iobio genes- angiodema 
162 MEP1B iobio genes- angiodema 
163 COL9A2 iobio genes- angiodema 
164 PGA5 iobio genes- angiodema 
165 COL4A6 iobio genes- angiodema 
166 ATP1A2 iobio genes- angiodema 
167 CELA2B iobio genes- angiodema 
168 COL15A1 iobio genes- angiodema 
169 CPA2 iobio genes- angiodema 
170 COL4A5 iobio genes- angiodema 
171 COL6A6 iobio genes- angiodema 
172 COL6A3 iobio genes- angiodema 
173 COL4A4 iobio genes- angiodema 
174 YBX1 iobio genes- angiodema 
175 RNPEP aminopeptidase-genecards 
176 LAP3 aminopeptidase-genecards 
177 NPEPPS aminopeptidase-genecards 
178 METAP2 aminopeptidase-genecards 
179 ERAP1 aminopeptidase-genecards 
180 DNPEP aminopeptidase-genecards 
181 XPNPEP1 aminopeptidase-genecards 
182 ERAP2 aminopeptidase-genecards 
183 XPNPEP3 aminopeptidase-genecards 
184 METAP1D aminopeptidase-genecards 
185 METAP1 aminopeptidase-genecards 
186 CPQ aminopeptidase-genecards 
187 RNPEPL1 aminopeptidase-genecards 
188 NPEPL1 aminopeptidase-genecards 




190 LTA4H aminopeptidase-genecards 
191 TRHDE aminopeptidase-genecards 
192 DPP6 aminopeptidase-genecards 
193 LVRN aminopeptidase-genecards 
194 BLMH aminopeptidase-genecards 
195 PEPD aminopeptidase-genecards 
196 MIR24-1 aminopeptidase-genecards 
197 CTSH aminopeptidase-genecards 
198 DPP3 aminopeptidase-genecards 
199 OPRPN aminopeptidase-genecards 
200 DPP9 aminopeptidase-genecards 
201 AMZ2 aminopeptidase-genecards 
202 PA2G4 aminopeptidase-genecards 
203 OXT aminopeptidase-genecards 
204 CTSC aminopeptidase-genecards 
205 LOC440434 aminopeptidase-genecards 
206 DPP7 aminopeptidase-genecards 
207 FAP aminopeptidase-genecards 
208 XWNPEP aminopeptidase-genecards 
209 AMZ1 aminopeptidase-genecards 
210 TRABD2B aminopeptidase-genecards 
211 TPP2 aminopeptidase-genecards 
212 DPP10 aminopeptidase-genecards 
213 PGPEP1 aminopeptidase-genecards 
214 SLC2A4 aminopeptidase-genecards 
215 TPP1 aminopeptidase-genecards 
216 PHEX aminopeptidase-genecards 
217 F11 aminopeptidase-genecards 
218 MMP2 aminopeptidase-genecards 
219 LOC100421386 aminopeptidase-genecards 
220 LOC646797 aminopeptidase-genecards 
221 DMTF1 aminopeptidase-genecards 
222 MALT1 aminopeptidase-genecards 
223 GGT1 aminopeptidase-genecards 
224 APP aminopeptidase-genecards 
225 AGT aminopeptidase-genecards 
226 ADPRH aminopeptidase-genecards 
227 KNG1 aminopeptidase-genecards 
228 CXCR1 aminopeptidase-genecards 
229 SCARB2 aminopeptidase-genecards 
230 HLA-B aminopeptidase-genecards 
231 NAGLU aminopeptidase-genecards 
232 AMBP aminopeptidase-genecards 
233 LOC101929950 aminopeptidase-genecards 




235 LAP3P2 aminopeptidase-genecards 
236 LOC100420117 aminopeptidase-genecards 
237 LOC101060212 aminopeptidase-genecards 
238 LOC727713 aminopeptidase-genecards 
239 B2M aminopeptidase-genecards 
240 PDF aminopeptidase-genecards 
241 STX16-NPEPL1 aminopeptidase-genecards 
242 STX16 aminopeptidase-genecards 
243 ABHD11 aminopeptidase-genecards 
244 CCK aminopeptidase-genecards 
245 TRH aminopeptidase-genecards 
246 MMP9 aminopeptidase-genecards 
247 IL7 aminopeptidase-genecards 
248 PYY aminopeptidase-genecards 
249 ZMPSTE24 aminopeptidase-genecards 
250 NTS aminopeptidase-genecards 
251 MAPT aminopeptidase-genecards 
252 CSF2 aminopeptidase-genecards 
253 MMP1 aminopeptidase-genecards 
254 TGFB1 aminopeptidase-genecards 
255 TNFRSF1A aminopeptidase-genecards 
256 TNF aminopeptidase-genecards 
257 TFAP2C aminopeptidase-genecards 
258 IRF2 aminopeptidase-genecards 
259 MYC aminopeptidase-genecards 
260 NCSTN aminopeptidase-genecards 
261 PARP1 aminopeptidase-genecards 
262 TFAP2A aminopeptidase-genecards 
263 KCND3 aminopeptidase-genecards 
264 MMP14 aminopeptidase-genecards 
265 IKZF1 aminopeptidase-genecards 
266 BACE1 aminopeptidase-genecards 
267 QPCT aminopeptidase-genecards 
268 GPI aminopeptidase-genecards 
269 NMT1 aminopeptidase-genecards 
270 IRF1 aminopeptidase-genecards 
271 MAP2 aminopeptidase-genecards 
272 SPI1 aminopeptidase-genecards 
273 IL10 aminopeptidase-genecards 
274 HLA-A aminopeptidase-genecards 
275 CTSB aminopeptidase-genecards 
276 CXCL8 aminopeptidase-genecards 
277 CSF3 aminopeptidase-genecards 
278 DPP8 aminopeptidase-genecards 




280 TAC1 aminopeptidase-genecards 
281 TAC3 aminopeptidase-genecards 
282 EPHX4 aminopeptidase-genecards 
283 ABHD4 aminopeptidase-genecards 
284 ABHD5 aminopeptidase-genecards 
285 CTSV aminopeptidase-genecards 
286 ARPIN aminopeptidase-genecards 
287 ENSG00000257411 aminopeptidase-genecards 
288 ERMP1 aminopeptidase-genecards 
289 PECAM1 aminopeptidase-genecards 
290 KCNA4 aminopeptidase-genecards 
291 FHOD1 aminopeptidase-genecards 
292 HTR3A aminopeptidase-genecards 
293 TMPO aminopeptidase-genecards 
294 MOAP1 aminopeptidase-genecards 
295 PEPB aminopeptidase-genecards 
296 KDR aminopeptidase-genecards 
297 MGAM aminopeptidase-genecards 
298 MLN aminopeptidase-genecards 
299 KLK11 aminopeptidase-genecards 
300 STK39 aminopeptidase-genecards 
301 NR3C1 aminopeptidase-genecards 
302 NRDC aminopeptidase-genecards 
303 GPT aminopeptidase-genecards 
304 MYCN aminopeptidase-genecards 
305 CASP3 aminopeptidase-genecards 
306 PLAU aminopeptidase-genecards 
307 TNKS aminopeptidase-genecards 
308 PDPK1 aminopeptidase-genecards 
309 ELF3 aminopeptidase-genecards 
310 CASP9 aminopeptidase-genecards 
311 CARTPT aminopeptidase-genecards 
312 PFN2 aminopeptidase-genecards 
313 CD84 aminopeptidase-genecards 
314 TSC22D3 aminopeptidase-genecards 
315 ITGB3 aminopeptidase-genecards 
316 TEK aminopeptidase-genecards 
317 ITGA2 aminopeptidase-genecards 
318 AFP aminopeptidase-genecards 
319 OXTR aminopeptidase-genecards 
320 EPCAM aminopeptidase-genecards 
321 ADAM17 aminopeptidase-genecards 
322 TIMM17A aminopeptidase-genecards 
323 ITGAM aminopeptidase-genecards 




325 ALDOA aminopeptidase-genecards 
326 ANG aminopeptidase-genecards 
327 ANK1 aminopeptidase-genecards 
328 TNKS2 aminopeptidase-genecards 
329 TP53 aminopeptidase-genecards 
330 HSPA8 aminopeptidase-genecards 
331 TPO aminopeptidase-genecards 
332 KCNC1 aminopeptidase-genecards 
333 KCND2 aminopeptidase-genecards 
334 NGLY1 aminopeptidase-genecards 
335 TM4SF1 aminopeptidase-genecards 
336 PSME1 aminopeptidase-genecards 
337 ACKR3 aminopeptidase-genecards 
338 REN aminopeptidase-genecards 
339 IL1RN aminopeptidase-genecards 
340 NAALADL1 aminopeptidase-genecards 
341 IL13 aminopeptidase-genecards 
342 ALOX5 aminopeptidase-genecards 
343 ETS1 aminopeptidase-genecards 
344 FCER2 aminopeptidase-genecards 
345 SI aminopeptidase-genecards 
346 ALPP aminopeptidase-genecards 
347 GUSB aminopeptidase-genecards 
348 MYB aminopeptidase-genecards 
349 SCT aminopeptidase-genecards 
350 NEU1 aminopeptidase-genecards 
351 ELANE aminopeptidase-genecards 
352 HP aminopeptidase-genecards 
353 MAP1A aminopeptidase-genecards 
354 FCGR1A aminopeptidase-genecards 
355 FCGR2B aminopeptidase-genecards 
356 FGF2 aminopeptidase-genecards 
357 MPI aminopeptidase-genecards 
358 LGALS3 aminopeptidase-genecards 
359 LTC4S aminopeptidase-genecards 
360 HPX aminopeptidase-genecards 
361 SLC7A5 aminopeptidase-genecards 
362 PSMB8 aminopeptidase-genecards 
363 NF1 aminopeptidase-genecards 
364 LTA aminopeptidase-genecards 
365 SIGLEC1 aminopeptidase-genecards 
366 SH3BGRL aminopeptidase-genecards 
367 IL6R aminopeptidase-genecards 
368 IL4I1 aminopeptidase-genecards 




370 ARAP3 aminopeptidase-genecards 
371 NAA50 aminopeptidase-genecards 
372 PTPN3 aminopeptidase-genecards 
373 FABP12 aminopeptidase-genecards 
374 RECK aminopeptidase-genecards 
375 ACADSB aminopeptidase-genecards 
376 YWHAG aminopeptidase-genecards 
377 PRNP aminopeptidase-genecards 
378 IL4 aminopeptidase-genecards 
379 IL15 aminopeptidase-genecards 
380 SRC aminopeptidase-genecards 
381 RHD aminopeptidase-genecards 
382 APLP2 aminopeptidase-genecards 
383 IL18R1 aminopeptidase-genecards 
384 IL1A aminopeptidase-genecards 
385 GHRH aminopeptidase-genecards 
386 PTPRC aminopeptidase-genecards 
387 ALB aminopeptidase-genecards 
388 SPARC aminopeptidase-genecards 
389 ST6GAL1 aminopeptidase-genecards 
390 S100A4 aminopeptidase-genecards 
391 EGF aminopeptidase-genecards 
392 SST aminopeptidase-genecards 
393 PIK3CB aminopeptidase-genecards 
394 ENPP3 aminopeptidase-genecards 
395 PTPA aminopeptidase-genecards 
396 VEGFA aminopeptidase-genecards 
397 PLCB4 aminopeptidase-genecards 
398 ALOX12 aminopeptidase-genecards 
399 RASA2 aminopeptidase-genecards 
400 ENPP1 aminopeptidase-genecards 
401 ABCB7 aminopeptidase-genecards 
402 WNT5A aminopeptidase-genecards 
403 EEF2 aminopeptidase-genecards 
404 DUSP19 aminopeptidase-genecards 
405 EDN1 aminopeptidase-genecards 
406 CXCR3 aminopeptidase-genecards 
407 CTSL aminopeptidase-genecards 
408 CYCS aminopeptidase-genecards 
409 CASP7 aminopeptidase-genecards 
410 CSN1S1 aminopeptidase-genecards 
411 CXCR4 aminopeptidase-genecards 
412 CDK20 aminopeptidase-genecards 
413 TXN aminopeptidase-genecards 




415 CDH5 aminopeptidase-genecards 
416 CEBPB aminopeptidase-genecards 
417 CTSS aminopeptidase-genecards 
418 CD36 aminopeptidase-genecards 
419 CXCL12 aminopeptidase-genecards 
420 CXCL11 aminopeptidase-genecards 
421 DNTT aminopeptidase-genecards 
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Genes with multiple rare variants (MAF ≤1%) in three or more ACEi-A samples 
Available online at: https://github.com/yusmiatiliau/Thesis_Appendix_E 
 
Appendix F 
Functional enrichment analysis of the 221 genes containing multiple rare 
variants in three or more ACEi-A samples 
Available online at: https://github.com/yusmiatiliau/Thesis_Appendix_F 
 
Appendix G 
Functional modules detected from 221 genes containing rare variants 











Common CNVs as detected by aCGH 
 
Sample CNV type No. of probes 
(size) 
Location Hg19 coordinates Previous report in database* Gene content 
UD53 duplication 11 (125kb) 8p11.22 chr8:39,237,438-39,362,888  TBB, common CNV ADAM5P, ADAM3A  
duplication 14 (80 kb) 17q21.31 chr17:44,194,591-44,275,529  TBB, CNV91 (Nimblegen 
classified benign CNV) 
 
 
duplication 27 (189 kb) 22q11.22 chr22:23,056,562-23,245,889  TBB 
 
 
duplication 12 (101 kb) xp22.33 chrX:3,751,569-3,853,478 CNV82, TBB 
 
  deletion 13 (351 kb) 16p12.2 chr16:21,599,687-21,951,439  TBB, common CNV   
UD59 deletion 7 (160 kb) 10q11.22 chr10:49,980,161-47,140,244 TBB, common CNV    
duplication 6 (396 kb) 14q32.33 chr14:106,335,742-
106,732,386 
TBB, common CNV 
 
 
deletion 19 (109 kb) 6p25.3 chr6:266079-375950 TBB 
 
U68 deletion 5 (36 kb) 1q44 chr1:248,752,348-
248,788,877 
CNV44, TBB    
deletion 28 (167 kb) 10q11.22 chr10:46,980,340-47,148,281 CNV79, TBB 
 
 
duplication 48 (631 kb) 14q32.33 chrs14:106,334,907-
106,966,455 
common CNV, TBB 
 
U69 duplication 11 (125 kb) 8p11.22 chr8:39237438-39362888 common CNV ADAM5P, ADAM3A  
duplication 171 (1.94 Mb) 22q11.22 chr22:23055-24991669 clinically significant 21 genes, from MIR650 to IGL 
UD70  deletion 5 (36 kb) 1q44 chr1:248752348-248788877 CNV44, TBB -  
deletion 19 (109 kb) 6p25.3 chr6:266079-375950 common CNV, TBB 
 
 
deletion 7 (124) 8p11.22 chr8:39246720-39371396 common CNV ADAM5P, ADAM3A  
deletion 7 (160 kb) 10q11.22 chr10:46980161-47140244 common CNV, TBB 
 
 
deletion 48 (631 kb) 14q32.33 chrs14:106334907-
106966455 
common CNV, TBB 
 
 
duplication 12 (101 kb) xp22.33 chrX:3751569-3853478 CNV82, TBB 
 
  deletion 5 (163 kb) 9p21.1 chr9:28600000-28750000 common CNV< TBB   
U105 duplication 18 (104 kb) 6p25.3 chr6:266046-370470 CNV72, TBB    
duplication 16 (631 kb) 14q32.33 chr14:106334907-106966455 common CNV, TBB 
 
 
duplication 13 (351 kb) 16p12.2 chr16:21,599,687-21,951,439  TBB, common CNV 
 
 
duplication 12 (173 kb) 17q21.31 chr17:44171888-44345039 TBB, common CNV 
 
  duplication 26 (189 kb) 22q11.22 chr22:23056562-23245889 TBB, common CNV   
*TBB: thought to be benign 
